



US009043994B2

(12) **United States Patent**
Stern et al.

(10) **Patent No.:** US 9,043,994 B2
(45) **Date of Patent:** Jun. 2, 2015

(54) **CRE-LOX BASED GENE KNOCKDOWN CONSTRUCTS AND METHODS OF USE THEREOF**

(75) Inventors: **Patrick Stern**, Cambridge, MA (US); **Richard Hynes**, Winchester, MA (US)

(73) Assignee: **Massachusetts Institute of Technology**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 787 days.

(21) Appl. No.: 12/076,001

(22) Filed: Mar. 12, 2008

(65) **Prior Publication Data**

US 2009/0187997 A1 Jul. 23, 2009

Related U.S. Application Data

(60) Provisional application No. 60/906,511, filed on Mar. 13, 2007, provisional application No. 60/935,154, filed on Jul. 27, 2007.

(51) **Int. Cl.**

A01K 67/027 (2006.01)
C12N 15/85 (2006.01)

(52) **U.S. Cl.**

CPC A01K 67/0275 (2013.01); A01K 2207/05 (2013.01); A01K 2217/058 (2013.01); A01K 2217/206 (2013.01); A01K 2227/105 (2013.01); C12N 15/8509 (2013.01); C12N 2800/30 (2013.01); C12N 2840/007 (2013.01); C12N 2840/102 (2013.01)

(58) **Field of Classification Search**

USPC 435/6.11, 91.1, 91.31, 455, 375, 6.1, 435/320.1, 350, 477; 514/44; 536/23.1, 536/24.5

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,795,737 A	8/1998	Seed et al.
5,804,387 A	9/1998	Cormack et al.
5,874,304 A	2/1999	Zolotukhin
5,922,687 A	7/1999	Mann et al.
5,985,847 A	11/1999	Carson et al.
6,953,688 B2	10/2005	Ferrick et al.
7,074,611 B2 *	7/2006	Chambon et al. 435/320.1
7,090,976 B2	8/2006	Anderson et al.
7,612,195 B2	11/2009	Grueneberg et al.
2001/0049144 A1	12/2001	Rivera et al.
2005/0075492 A1	4/2005	Chen et al.
2005/0130919 A1	6/2005	Xu et al.
2005/0201991 A1	9/2005	Andrews et al.
2005/0289659 A1	12/2005	Jacks et al.
2007/0044164 A1 *	2/2007	Dickins et al. 800/14
2007/0065912 A1 *	3/2007	Carson et al. 435/69.1
2009/0004668 A1 *	1/2009	Chen et al. 435/6
2009/0187997 A1	7/2009	Stern et al.
2009/0217397 A1	8/2009	Stern et al.
2012/0214242 A1	8/2012	Stern et al.

FOREIGN PATENT DOCUMENTS

WO	WO 9742320	11/1997
WO	WO 9821355	5/1998
WO	WO 0011092	3/2000
WO	WO 0129208 A1 *	4/2001
WO	WO 2004/029219 A2	4/2004
WO	WO 2005/007877 A2	1/2005
WO	WO 2006/003215 A2	1/2006
WO	WO 2007/149246	12/2007

OTHER PUBLICATIONS

- Denning and Priddle. Reproduction, 126:1-11, 2003.*
Pera et al. Journal of Cell Science 113: 5-10 , 2000.*
Stern et al., PNAS, 105(37): 13895-13900, 2008.*
Araki et al. Nucleic Acids Res., 30(19): 1-8, 2002.*
Doench et al., Genes and development, vol. 18, No. 5, pp. 504-511 (2004).*
Opalinska et al., Nature rev., vol. 1, pp. 503-514 (2004).*
Spivak et al, 1991, J. Virol., 65:6800-6810.
N. Sternberg et al, J. Mol. Biol., 187:197-212 (1986).
McGeoch et al., 1988, J. Gen. Virol., 69:1531-1574.
Klamut et al., (1990) Mol. Cell Biol. 163-205.
Buskin and Hauschka, (1989) Mol. Cell Biol. 9:2627.
Mar and Ordahl, (1988) Proc. Natl. Acad. Sci. USA. 85:6404.
Mader, S. and White, J.H. (1993) Proc. Natl. Acad. Sci. USA 90:5603-5607.
Spencer, D.M. et al 1993) Science 262:1019-1024.
Manome, Y. Et al. (1993) Biochemistry 32:10607-10613.
Datta, R. et al. (1992) Proc. Natl. Acad. Sci. USA 89: 1014-10153.
Bennet (1998), infra; Crameri et al. Nature Biotechnol. 14:315-319 (1996).
Lee et al Gene 216:55-65 (1998).
Furth et al. (1992), Anal Biochem 205:365-368.
Chang et al., J. Virol. (2001) 75:3469-3473.
Liu et al., Gene Ther. (1999) 6:1258-1266.
Wolff et al., Science (1990) 247: 1465-1468.
Zhang et al., Hum. Gene Ther. (1999) 10:1735-1737.
Zhang et al., Gene Ther. (1999) 7:1344-1349.
Acsadi et al., New Biot. (1991) 3:71-81.
Hickman et al., Hum. Gen. Ther. (1994) 5:1477-1483.
Hayashi S. and McMahon AP. Dev Biol. Apr. 15, 2002;244(2):305-18.
Tang et al. Nature 356:152-154 (1992).
Qui L. et al. A Construct with fluorescent Indicators for Conditional Expression of miRNA. BMC Biotechnology. Oct. 2008, vol. 8. pp. 1-38, see entire document.
Stegmeier F. et al. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. PNAS. Sep. 2005, vol. 102. No. 37, pp. 13212-13217, see entire document.

(Continued)

Primary Examiner — Jane Zara

(74) *Attorney, Agent, or Firm — Wolf, Greenfield & Sacks, P.C.*

(57) **ABSTRACT**

The present invention relates to vectors, compositions and methods for conditional, Cre-lox regulated, RNA interference. The vectors allow for spatial and temporal control of miRNA expression *in vivo*.

(56)

References Cited**OTHER PUBLICATIONS**

- Horlick and Benfield 1989 Mol. Cell Biol 9:2396.
- International Search Report and Written Opinion dated Sep. 8, 2008 for Application No. PCT/US2007/013601.
- International Preliminary Report on Patentability dated Dec. 16, 2008 for Application No. PCT/US2007/013601.
- International Search Report and Written Opinion dated Nov. 19, 2008 for Application No. PCT/US2008/003225.
- International Preliminary Report on Patentability dated Sep. 15, 2009 for Application No. PCT/US2008/003225.
- [No. Author Listed], RNAi Codex, p53 in *Mus musculus* that targets nucleotides 1224-1245 of NM0116440. Accessed and retrieved from RNAi Codex at <http://codex.cshl.edu/> on Feb. 21, 2013.
- Berezikov et al., Many novel mammalian microRNA candidates identified by extensive cloning and RAKE analysis. *Genome Res.* Oct. 2006;16(10):1289-98. Epub Sep. 5, 2006.
- Chang et al., Lessons from Nature: microRNA-based shRNA libraries. *Nat Methods.* Sep. 2006;3(9):707-14.
- Dickins et al., Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. *Nat Genet.* Nov. 2005;37(11):1289-95. Epub Oct. 2, 2005.
- Donnelly et al., The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. *J Gen Virol.* May 2001;82(Pt. 5):1027-41.
- GenBank Submission; NIH/NCBI, Accession No. AY_445633.1. Delaitre et al., Nov. 19, 2003.
- GenBank Submission; NIH/NCBI, Accession No. NM_011640.3. “*Mus musculus* transformation related protein 53 (Trp53), transcript variant 1, mRNA,” first submitted on Jan. 25, 2000, accessed <http://www.ncbi.nih.gov/> on May 23, 2010, three printout pages are enclosed.
- Grez et al., Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. *Proc Natl Acad Sci U S A.* Dec. 1990;87(23):9202-6.
- He et al., MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet.* Jul. 2004;5(7):522-31.
- Kamanu et al., Exploration of miRNA families for hypotheses generation. *Scientific Reports.* Oct. 15, 2013;3:2940. doi: 10.1038/srep02940.
- Kilby et al., Site-specific recombinases: tools for genome engineering. *Trends Genet.* Dec. 1993;9(12):413-21.
- Mogil et al., Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. *Pain.* Mar. 1999;80(1-2):67-82.
- Monroe et al., RAG2:GFP knockin mice reveal novel aspects of RAG2 expression in primary and peripheral lymphoid tissues. *Immunity.* Aug. 1999;11(2):201-12.
- Pang et al., RN Adb 2.0—an expanded database of mammalian non-coding RNAs. *Nucleic Acids Res.* Jan. 2007;35(Database issue):D178-82. Epub Dec. 1, 2006.
- Rescher et al., Annexins—unique membrane binding proteins with diverse functions. *J Cell Sci.* Jun. 1, 2004;117(Pt 13):2631-9.
- Ritchie et al., RNA stem-loops: to be or not to be cleaved by RNase III. *RNA.* Apr. 2007;13(4):457-62. Epub Feb. 13, 2007.
- Sauer, Site-specific recombination: developments and applications. *Curr Opin Biotechnol.* Oct. 1994;5(5):521-7.
- Schnutgen et al., A directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse. *Nat Biotechnol.* May 2003;21(5):562-5. Epub Mar. 31, 2003.
- Shin et al., A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. *Proc Natl Acad Sci U S A.* Sep. 12, 2006;103(37):13759-64. Epub Aug. 31, 2006.
- Sigmund, Viewpoint: are studies in genetically altered mice out of control? *Arterioscler Thromb Vasc Biol.* Jun. 2000;20(6):1425-9.

* cited by examiner




Figure 1A





Figure 1B

MSCV FLIP vector



pLB2 FLIP vector




Figure 1C




Figure 2A




Fig 2B

Intron splicing




Figure 3




Figure 4




Figure 5

Lenti Transgenics

Cre-regulated RNAi to Study Vascular Development




Figure 6




Figure 7

GFP Fluorescence - e9.5 Embryos




Figure 8



FLIP Vector for Knockdown of 1 or 2 Genes

Figure 9A




PTEN/ p53 Knockdowns in MEFs

Figure 9B

CRE-inducible Pten siRNA Expression Vector

Northern Blot

Figure 9C

CRE-inducible p53 siRNA Expression Vector

Northern Blot

Figure 9D



FLIP Vector for Regulated c-Myc Expression

Figure 9E



Northern Blot

Figure 9F




Figure 10A




Figure 10B




Figure 10C




Figure 10D




Figure 11A




Figure 11B

1
**CRE-LOX BASED GENE KNOCKDOWN
CONSTRUCTS AND METHODS OF USE
THEREOF**
**CROSS REFERENCE TO RELATED
APPLICATIONS**

This application claims priority of U.S. Provisional Application Ser. No. 60/906,511, filed Mar. 13, 2007, and U.S. Provisional Application Ser. No. 60/935,154, filed Jul. 27, 2007, which are hereby incorporated by reference, in their entirety.

GOVERNMENT INTEREST STATEMENT

This invention was made in whole or in part with government support under grant number U54-CA112967, awarded by the National Institutes of Health. The government may have certain rights in the invention.

FIELD OF THE INVENTION

The present invention relates to improved vectors and their use in a cre-lox based method for conditional RNA interference.

BACKGROUND OF THE INVENTION

RNA interference (RNAi) is an extremely versatile tool for inhibition of gene expression. RNAi is based on the introduction of double stranded RNA (dsRNA) molecules into cells, whereby one strand is complementary to the coding region of a target gene. Through pairing of the specific mRNA with the introduced RNA molecule, the mRNA is degraded by a cellular mechanism. Short (30 bp) interfering RNA duplexes (siRNA) have been shown to be effective, and do not provoke an immune response, extending the application to mammalian cells. Small hairpin RNAs (shRNAs) transcribed in vivo, are able to trigger degradation of corresponding mRNAs similar to the siRNAs. Micro RNAs (miRNAs) are the endogenous form of shRNAs that carry out the gene silencing function in vivo.

shRNA expression has been accomplished using gene expression vectors, with RNA polymerase III (Pol III) or Polymerase II (Pol II) promoters, with expression occurring in mice injected with the shRNA expression vectors, however, gene inhibition was temporally and spatially restricted. Moreover stable integration of the construct is not readily accomplished or validated in current systems.

SUMMARY OF THE INVENTION

In one embodiment, this invention provides a vector comprising:

- i. a first pair of loxP sequences, inverted in orientation, with respect to each other;
- ii. a first nucleic acid encoding a first selectable marker in sense orientation, wherein said nucleic acid is positioned between said first pair of loxP sequences;
- iii. a second nucleic acid encoding a second selectable marker, fused in frame to an miRNA sequence of interest in antisense orientation, said miRNA sequence of interest being flanked by splice donor and splice acceptor sequences, said second nucleic acid is positioned between said first pair of loxP sequences, and said second nucleic acid is 3' with regard to said first nucleic acid;

2

iv. a second pair of loxP sequences, inverted in orientation, with respect to each other, wherein said first loxP sequenced of said second pair is positioned between said first and said second nucleic acid, and said second loxP sequence in said second pair is positioned 3' with respect to said first pair of loxP sequences, and said second pair of loxP sequences differs from that of said first pair of loxP sequences.

In one embodiment, the first pair of loxP sequences comprises the wildtype sequence, and in another embodiment, the second pair of loxP sequences comprises a mutated loxP. In one embodiment, the first pair of loxP sequences comprises the loxP 5171 sequence and in another embodiment, the second pair of loxP sequences comprises the loxP 2272 sequence.

In one embodiment, the first nucleic acid encodes two selectable markers fused in-frame with respect to each other, which in one embodiment, comprise a first antibiotic resistance cassette fused in frame to a sequence encoding a cell surface marker, which in one embodiment is a c-terminal sequence encoding a Foot-and-mouth-disease virus (FMDV) 2A peptide. In one embodiment, the two selectable markers localize to different cellular compartments, when expressed.

In another embodiment, the vector comprises a promoter operatively linked to the first nucleic acid, and in one embodiment, the promoter is tissue specific, or in another embodiment, the promoter is inducible.

In one embodiment, the miRNA agent is an shRNA. In one embodiment, the miRNA specifically inactivates p53 gene expression or PTEN gene expression, or a combination thereof. In one embodiment, according to this aspect of the invention, the vector comprises a nucleotide sequence corresponding to, or homologous to SEQ ID Nos: 22, 23, 25, 26 or 27.

In another embodiment, the miRNA specifically inactivates α4 integrin gene expression, and in one embodiment, comprises a nucleotide sequence corresponding to, or homologous to SEQ ID NO: 2, or in another embodiment, the vector has a nucleotide sequence corresponding to, or homologous to SEQ ID NO: 8

In one embodiment, the second nucleic acid further comprises an oncogene fused in frame to the miRNA sequence of interest in antisense orientation. In another embodiment the vector has a nucleotide sequence corresponding to or homologous to SEQ ID NO: 21.

In one embodiment, the vector backbone is derived from a retrovirus.

In another embodiment, the vector further comprises a first regulatory sequence operationally linked to the first nucleic acid, and being in an antisense orientation, which in one embodiment is a UbiquitinC promoter sequence. In another embodiment, the vector further comprises a second regulatory sequence, located 5' to said first regulatory sequence, wherein the second regulatory sequence is in a sense orientation. In another embodiment, the vector further comprises a Bovine Growth Hormone polyadenylation signal positioned 3' to said second pair of loxP sites. In another embodiment, the vector further comprises a modified U3 LTR positioned 5' to the polyadenylation signal.

In another embodiment, the vector further comprises a second miRNA sequence of interest in antisense orientation fused to the miRNA sequence of interest. In one embodiment, the second miRNA sequence of interest modulates expression of a gene whose activity is cooperative with that of a gene modulated by the first miRNA sequence of interest. In another embodiment, the second miRNA sequence of interest modulates expression of a gene whose activity antagonizes that of

a gene modulated by said first miRNA sequence of interest. In another embodiment, the vector further comprises a third nucleic acid in antisense orientation, positioned between said first pair of loxP sequences, wherein said third nucleic acid encodes a protein of interest. In one embodiment, the first miRNA sequence of interest specifically interacts with a sequence encoding said protein of interest or a homologue thereof. In another embodiment, the vector may be expressed in a mammalian host, and the homologue thereof is an endogenous protein in the host, which in one embodiment is associated with a disease or disorder in said host.

In one embodiment, the miRNA sequence of interest is flanked by restriction endonuclease sites, which are flanked by splice donor and splice acceptor sequences. In one embodiment, the miRNA specifically inactivates firefly luciferase gene expression, and in one embodiment comprises a sequence corresponding to, or homologous to SEQ ID NO: 1. In one embodiment, the vector comprises a nucleotide sequence corresponding to SEQ ID NO: 3.

In one embodiment, this invention provides a composition or cell comprising a vector of this invention. In one embodiment, this invention provides a kit comprising a vector of this invention.

In one embodiment, the vector in the kits of this invention comprise an miRNA sequence of interest flanked by restriction endonuclease sites, which are flanked by splice donor and splice acceptor sequences. In one embodiment, according to this aspect, the miRNA specifically inactivates firefly luciferase gene expression. In one embodiment, the miRNA comprises a sequence corresponding to, or homologous to SEQ ID NO: 1, or in one embodiment, the vector comprises a nucleotide sequence corresponding to SEQ ID NO: 3. In one embodiment, according to this aspect, the kit further comprises restriction endonucleases, which are capable of specifically cleaving such sites.

In one embodiment, this invention provides a method of producing an animal genetically inactivated for a coding sequence, the method comprising:

- a. contacting an embryonic stem cell with a vector as herein described;
- b. injecting the embryonic stem cell in (a) to a blastocyst of said animal; and
- c. obtaining an animal in (b) expressing said vector whereby, following Cre-mediated recombination in the animal, the miRNA agent is expressed and reduces expression of the coding sequence, thereby being a method of producing an animal genetically inactivated for a coding sequence.

In one embodiment, the second selectable marker is expressed in a plurality of cells of said animal following Cre-mediated recombination, or in another embodiment, the first selectable marker is lost in a plurality of cells of said animal, following Cre-mediated recombination. In another embodiment, Cre-mediated recombination is tissue-specific in said animal.

In another embodiment, this invention provides a method of conditionally reducing expression of a coding sequence in a target cell, the method comprising contacting the target cell with a vector comprising:

- a. a first pair of loxP sequences, inverted in orientation, with respect to each other;
- b. a first nucleic acid encoding a first selectable marker in sense orientation, wherein said nucleic acid is positioned between said first pair of loxP sequences;
- c. a second nucleic acid encoding a second selectable marker, fused in frame to an miRNA sequence of interest in antisense orientation, said miRNA sequence of inter-

est being flanked by splice donor and splice acceptor sequences, said second nucleic acid is positioned between said first pair of loxP sequences, and said second nucleic acid is 3' with regard to said first nucleic acid;

d. a second pair of loxP sequences, inverted in orientation, with respect to each other, wherein said first loxP sequenced of said second pair is positioned between said first and said second nucleic acid, and said second loxP sequence in said second pair is positioned 3' with respect to said first pair of loxP sequences, and said second pair of loxP sequences differs from that of said first pair of loxP sequences.

In one embodiment, according to this aspect of the invention, the cell is engineered to express a Cre recombinase, or in another embodiment, the cell endogenously expresses a Cre recombinase. In one embodiment, the target cell is contacted with said vector in vivo, in vitro or ex-vivo, and in one embodiment, contact is in vivo, and the Cre recombinase is expressed at specific times during development.

In one embodiment, the miRNA specifically inactivates firefly luciferase gene expression and the method further comprises excising said miRNA which specifically inactivates firefly luciferase gene expression and inserting a second miRNA which specifically inactivates a gene of interest.

In another embodiment, the vector further comprises a second miRNA sequence of interest in antisense orientation fused to the miRNA sequence of interest. According to this aspect, and in one embodiment, the second miRNA sequence of interest modulates expression of a gene whose activity is cooperative with that of a gene modulated by said first miRNA sequence of interest, or in another embodiment, the second miRNA sequence of interest modulates expression of a gene whose activity antagonizes that of a gene modulated by the first miRNA sequence of interest. In one embodiment, the first and second miRNA sequence of interest regulate expression of a tumor suppressor.

In another embodiment, the vector further comprises a third nucleic acid in antisense orientation, positioned between the first pair of loxP sequences, wherein said third nucleic acid encodes a protein of interest. According to this aspect, and in one embodiment, the third nucleic acid encodes an oncogene.

According to this aspect, and in another embodiment, the first miRNA sequence of interest specifically interacts with a sequence encoding an endogenous form of the protein of interest, and in one embodiment, the endogenous form is associated with a disease or disorder in the host.

In another embodiment, this invention provides a non-human animal with reduced expression of a coding sequence, wherein reduced expression is produced according to a method of this invention.

In another embodiment, this invention provides a mammalian cell with reduced expression of a coding sequence, wherein reduced expression is produced according to a method of this invention.

In another embodiment, this invention provides a method of assessing neoplasia in an animal model, said method comprising:

- i. contacting a target cell in a subject animal with a vector comprising:
- first pair of loxP sequences, inverted in orientation, with respect to each other;
- a first nucleic acid encoding a first selectable marker in sense orientation, wherein said nucleic acid is positioned between said first pair of loxP sequences;

a second nucleic acid encoding a second selectable marker, fused in frame to an miRNA sequence of interest with a suspected role in neoplasia or suppression thereof in antisense orientation, said miRNA sequence of interest being flanked by splice donor and splice acceptor sequences, said second nucleic acid is positioned between said first pair of loxP sequences, and said second nucleic acid is 3' with regard to said first nucleic acid;

second pair of loxP sequences, inverted in orientation, with respect to each other, wherein said first loxP sequenced of said second pair is positioned between said first and said second nucleic acid, and said second loxP sequence in said second pair is positioned 3' with respect to said first pair of loxP sequences, and said second pair of loxP sequences differs from that of said first pair of loxP sequences; and

ii. evaluating neoplasia or development thereof in said animal;

whereby said method assesses development of neoplasia or suppression thereof in said subject animal as opposed to a control subject.

In some embodiments, the Cre recombinase is expressed in a cell- or tissue-specific manner.

In some embodiments, the first pair of loxP sequences comprises the wildtype sequence, and in some embodiments, the second pair of loxP sequences comprises a mutated loxP. In some embodiments, the first pair of loxP sequences comprises the loxP 5171 sequence and in some embodiments, the second pair of loxP sequences comprises the loxP 2272 sequence.

In some embodiments, the vector comprises a first regulatory sequence operatively linked to said second nucleic acid and said regulatory sequence is in antisense orientation and in some embodiments, the first regulatory sequence is a UbiquitinC promoter sequence. In some embodiments, the vector further comprises a second regulatory sequence, located 5' to said first regulatory sequence, wherein said second regulatory sequence is in sense orientation.

In some embodiments the vector further comprises a Bovine Growth Hormone polyadenylation signal positioned 3' to said second pair of loxP sites and in some embodiments, the vector further comprises a modified U3 LTR positioned 5' to said polyadenylation signal. In some embodiments, the first regulatory sequence is tissue specific or in some embodiments, the first regulatory sequence is inducible.

In some embodiments, the miRNA agent is an shRNA.

In some embodiments, the miRNA specifically inactivates p53 or PTEN gene expression.

In some embodiments, the vector further comprises a second miRNA sequence of interest in antisense orientation fused to the miRNA sequence of interest. In some embodiments, the second miRNA sequence of interest modulates expression of a gene whose activity is cooperative with that of a gene modulated by said first miRNA sequence of interest. In some embodiments, the first and second miRNA sequence of interest regulate expression of a tumor suppressor.

In some embodiments, the first miRNA sequence of interest specifically inactivates one of p53 or PTEN gene expression and said second miRNA sequence of interest specifically inactivates the other.

In some embodiments, the vector comprises a sequence corresponding to or homologous to SEQ ID No: 27.

In some embodiments, the second miRNA sequence of interest modulates expression of a gene whose activity antagonizes that of a gene modulated by said the miRNA sequence of interest.

In some embodiments, the second nucleic acid encodes an oncogene.

In some embodiments, the vector comprises a third nucleic acid in antisense orientation, positioned between the first pair of loxP sequences, wherein the third nucleic acid encodes a protein of interest.

In some embodiments, the third nucleic acid encodes an miRNA specifically inactivating a tumor suppressor.

In some embodiments, the third nucleic acid encodes an miRNA specifically inactivating p53, PTEN or a combination thereof.

In some embodiments, the vector comprises a nucleic acid sequence corresponding to or homologous to SEQ ID NO: 21.

15 BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts one embodiment of the organization and expression of constructs of this invention. A. Schematic representation of an embodiment of the pFLIP inserts of this invention. Two pairs of mutated loxP sites and their orientation are depicted, as well as the positioning of the positioning of the selectable marker sequences and miRNA sequence, with respect thereto. Schematic shows elements prior to and following Cre-mediated recombination. B. Schematic depiction of differences in the pLB2 versus pLB vector. C. Schematic depiction of MSCV and pLB2 constructs.

FIG. 2A depicts placement of the miR30 in an artificial intron by flanking the miR30 with consensus splice donor and splice acceptor sequences (in red) (SEQ ID NO: 28). FIG. 2B is a schematic depiction of the FLIP vector comprising an miRNA in an intron.

FIG. 3 demonstrates efficient intron splicing from the vector assayed by reverse transcription of cellular mRNA and subsequent PCR, compared to PCR of genomic DNA. The PCR amplified only the transcript derived from the vectors that have been reversed by Cre activity. As is evident from the gel, in constructs without the intron, band sizes are similar, however in constructs with the intron, the band is significantly smaller than that of genomic DNA (genomic amplifies as doublet, an irrelevant finding).

FIG. 4 demonstrates results of FACS analysis of constructs exposed to Cre, for GFP+ cells (all equal number of GFP+ cells). Numbers are Mean Fluorescent Intensity. The Figure indicates that inclusion of the intron increased expression.

FIG. 5 demonstrates results of FACS analysis for alpha-4 integrin surface expression in DC2.4 cells transduced with a vector comprising a miR30 targeting the integrin, with and without Cre. Cre-mediated reduction of expression was roughly 6-fold.

FIG. 6 schematically depicts the generation of mice transgenic for the vectors of this invention, with tissue-specific expression of such constructs. Embryonic Stem cells that express Cre from the VEGF-R2 (Flk1) locus, which turns on Cre expression about embryonic day 8 are infected with a vector of this invention and selected with puromycin. Using tetraploid complementation, the vector-infected ES cells are injected to blastocysts to generate embryos derived exclusively from the transduced ES cells. Fluorescence in the figure is background fluorescence, not Cre regulated.

FIG. 7 demonstrates GFP expression in the yolk sacs of e8.5 embryos representing “blood islands”, which are endothelial precursor cells and express Flk1 (and hence Cre) about 1 day before embryos were removed.

FIG. 8 demonstrates fluorescence in embryos derived at stage e9.5 from adult pLB2-FLIP transgenic males crossed to Mox-Cre females. Mox-Cre is expressed very early in embryos (e2 or e3). Embryos inheriting both the pLB2 vector

and Cre exhibited GFP+ throughout (panel 1), as compared to embryos lacking Cre (panel 2).

FIG. 9 presents multiple gene knockdowns. 9A schematically depicts how the miR30s can be concatamerized to knockdown more than 1 gene with a single vector. FIG. 9B demonstrates immunoblot results of targeted knockdown of p53 and PTEN tumor suppressors using the scheme of FIG. 9A. FIGS. 9C and 9D demonstrate Northern blot results of targeted knockdown of p53 and PTEN tumor suppressors. FIG. 9E is a schematic depiction of a pFLIP construct in which GFP was replaced with the oncogene c-Myc. FIG. 9F demonstrates immunoblot results of Cre-regulated expression of a c-Myc transgene. c-Myc expression was combined with targeted knockdown of p53, or PTEN expression, or p53/PTEN expression in an intron, which in turn allowed for the examination of oncogene-tumor suppressor interactions.

FIG. 10A plots results of a FACS analysis of PBLs detecting changes in surface marker expression following knockdown. FIG. 10B presents immunoblots of spleen cells from mice reconstituted with Cre-ER donor marrow infected with FLIP vector puro2AGFP/Thy1.1+miRNA(s). Lane 1—FF luc knockdown, 2-p53 KD, 3—PTEN KD, 4-p53/PTEN KD. FIG. 10C is a photograph of tails of siblings of Lenti FLIP-p53 transgenic mouse crosses to Mox-Cre (early embryonic Cre). FIG. 10D plots the percent GFP positive B cells in doxorubicin treated versus untreated B cells in progeny of Lenti FLIP-p53 transgenic crossed to Tie2-Cre (hematopoietic Cre).

FIG. 11A plots results of a FACS analysis showing spleen and lymph node marker expression, from mice reconstituted with CD19-Cre (B cell Cre) donor marrow infected with FLIP vector puro2AGFP/c-Myc+miR-p53. Results are of samples isolated fourteen weeks post-transfer. FIG. 11B shows immunoblot results of the spleen and lymph node cells probed for c-Myc expression.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides, in one embodiment, constructs and enhanced methods for conditionally reducing expression of a coding sequence in a cell or animal, comprising contacting the cell with a vector comprising a first selectable marker in sense orientation, and a second selectable marker fused in frame to an miRNA sequence, in antisense orientation, wherein the miRNA sequence is flanked by splice donor and acceptor sequences, and wherein the marker sequences are flanked by two pairs of loxP sites, which sites are initially inverted in orientation, in cells capable of expressing a Cre recombinase.

Conditionally reduced expression of a coding sequence was demonstrated herein, with the use of a retroviral vector pLB2, which comprises, in some embodiments, a first pair of loxP sequences, inverted in orientation, with respect to each other, a first nucleic acid encoding a first selectable marker in sense orientation, wherein the first nucleic acid is positioned between the first pair of loxP sequences, a second nucleic acid encoding a second selectable marker, fused in frame to an miRNA sequence of interest in antisense orientation, wherein the second nucleic acid is positioned between the first pair of loxP sequences, and the second nucleic acid is 3' with regard to the first nucleic acid, a second pair of loxP sequences, inverted in orientation, with respect to each other. The first loxP sequence of the second pair is positioned between the first and second nucleic acid, and the second loxP sequence of the second pair is positioned 3' with respect to the first pair of loxP sequences, and the second pair of loxP sequences differs from that of said first pair of loxP sequences. In addition, the

miRNA sequence of interest is flanked by splice donor and acceptor sites, to comprise an artificial intron.

FIG. 3 demonstrates one embodiment of a pLB2 vector of this invention, showing splicing of the intron, and FIG. 4 shows greater expression of the sequence when flanked by splice donor and acceptor sites, following Cre expression. FIG. 5 demonstrates about a 6-fold knockdown of α4-integrin expression in DC2.4 cells transduced with pLB2, upon expression of Cre.

In one embodiment, this invention provides a method of conditionally reducing expression of a coding sequence in a target cell, said method comprising contacting said target cell with a vector comprising: contacting the target cell with a vector comprising:

- 15 a. a first pair of loxP sequences, inverted in orientation, with respect to each other;
- b. a first nucleic acid encoding a first selectable marker in sense orientation, wherein said nucleic acid is positioned between said first pair of loxP sequences;
- c. a second nucleic acid encoding a second selectable marker, fused in frame to an miRNA sequence of interest in antisense orientation, said miRNA sequence of interest being flanked by splice donor and splice acceptor sequences, said second nucleic acid is positioned between said first pair of loxP sequences, and said second nucleic acid is 3' with regard to said first nucleic acid;
- d. a second pair of loxP sequences, inverted in orientation, with respect to each other, wherein said first loxP sequenced of said second pair is positioned between said first and said second nucleic acid, and said second loxP sequence in said second pair is positioned 3' with respect to said first pair of loxP sequences, and said second pair of loxP sequences differs from that of said first pair of loxP sequences.

In one embodiment, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. In one embodiment, the vector is a genomic integrated vector, or “integrated vector”, which can become integrated into the chromosomal DNA of the host cell. In another embodiment, the vector is an episomal vector, i.e., a nucleic acid capable of extra-chromosomal replication in an appropriate host, such as, for example a eukaryotic host cell. The vector according to this aspect of the present invention may be, in other embodiments, a plasmid, a bacmid, a phagemid, a cosmid, a phage, a virus or an artificial chromosome.

A nucleic acid of the present invention will generally contain phosphodiester bonds in one embodiment, or in another embodiment, nucleic acid analogs are included, that may have alternate backbones, comprising, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzel et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al., Chem. Lett. 805 (1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986), phosphorothioate, phosphorodithioate, O-methylphosphoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incorporated by reference). These modifications of the ribose-phosphate backbone or bases may be done to facilitate the addition of other moieties such as chemical constitu-

ents, including 2'O-methyl and 5' modified substituents, or to increase the stability and half-life of such molecules in physiological environments.

The nucleic acids may be single stranded or double stranded, or contain portions of both double stranded or single stranded sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid contains any combination of deoxyribo- and ribo-nucleotides, and any combination of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthanine and hypoxanthanine, etc. Thus, for example, chimeric DNA-RNA molecules may be used such as described in Cole-Strauss et al., Science 273:1386 (1996) and Yoon et al., PNAS USA 93:2071 (1996).

The vectors of this invention comprise, inter alia, an miRNA agent specific for a coding sequence.

The term "miRNA agent" refers, in one embodiment, to an agent that modulates expression of a target gene by an RNA interference mechanism. Micro-RNAs are a very large group of small RNAs produced naturally in organisms, which in one embodiment, regulates the expression of target genes. Founding members of the micro-RNA family are let-7 and lin-4. The let-7 gene encodes a small, highly conserved RNA species that regulates the expression of endogenous protein-coding genes during worm development. The active RNA species is transcribed initially as an ~70 nt precursor, which is post-transcriptionally processed into a mature ~21 nt form. Both let-7 and lin-4 are transcribed as hairpin RNA precursors, which are processed to their mature forms by Dicer enzyme.

In one embodiment the miRNA agent comprises double-stranded RNA, which can form a hairpin structure. The miRNA agents employed, in another embodiment, are small ribonucleic acid molecules, or oligoribonucleotides, that are present in duplex structures, such as, in one embodiment, two distinct oligoribonucleotides hybridized to each other, or in another embodiment, a single ribooligonucleotide that assumes a hairpin structure to produce a duplex structure.

In one embodiment, miRNA agent does not exceed about 100 nt in length, and typically does not exceed about 75 nt length, where the length in certain embodiments is less than about 70 nt. In one embodiment, the miRNA agent of this invention has a length about 15 to 40 bp, or in another embodiment, about 20 and 29 bps, or in another embodiment, 25 and 35 bps, or in another embodiment, about 20 and 35 bps, or in another embodiment, about 20 and 40 bps, or in another embodiment, 21 bp, or in another embodiment, 22 bp.

In one embodiment, the nucleic acids/oligonucleotides comprising the miRNA agent may be synthesized on an Applied Bio Systems oligonucleotide synthesizer according to specifications provided by the manufacturer. In another embodiment, the nucleic acids/oligonucleotides or modified oligonucleotides may be synthesized by any number of means as is generally known in the art, and as is described hereinbelow.

In one embodiment, the miRNA agent encodes an interfering ribonucleic acid. In one embodiment, the miRNA agent is a transcriptional template of the interfering ribonucleic acid. According to this aspect of the invention, and in one embodiment, the transcriptional template is typically a DNA that encodes the interfering ribonucleic acid. The DNA may be present in a vector, such as, and in one embodiment, a plasmid vector, or in another embodiment, a viral vector, or any other vector, as will be known to one skilled in the art.

In one embodiment, the term "coding sequence" refers to a nucleic acid sequence that "encodes" a particular polypeptide or peptide. In one embodiment, the coding sequence is a

nucleic acid sequence that is transcribed (in the case of DNA) and is translated (in the case of mRNA) into a polypeptide in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence will usually be located 3' to the coding sequence.

In one embodiment the term "coding sequence", includes DNA sequences that encode a polypeptide, as well as DNA sequences that are transcribed into inhibitory antisense molecules.

In one embodiment, the term "reducing expression", as it refers to vectors and their use according to the methods of this invention, refers to a diminishment in the level of expression of a gene when compared to the level in the absence of the miRNA agent.

In one embodiment, reduced expression may be affected at the transcriptional or translational level, or a combination thereof. In one embodiment, this invention provides vectors and methods for greater reduction of expression of a coding sequence, as a consequence of greater expression of the miRNA sequence, greater stability of the miRNA sequence, or a combination thereof.

According to this aspect of the invention, reduced expression using the vectors, and/or according to the methods of this invention, is specific. In one embodiment, the reduction in expression is via an ability to inhibit a target gene without manifest effects on other genes of the cell. The consequences of inhibition can be confirmed, in other embodiments, by examination of the outward properties of the cell or organism or by biochemical techniques such as RNA solution hybridization, nuclease protection, Northern hybridization, gene expression monitoring with a microarray, antibody binding, enzyme linked immunosorbent assay (ELISA), Western blotting, radioimmunoassay (RIA), other immunoassays, and fluorescence activated cell analysis (FACS).

In one embodiment, the miRNA agent is an shRNA, which specifically inactivates p53, alpha-4 integrins, or others, as exemplified and described herein.

In one embodiment, the vectors and methods of utilizing the same for reducing expression of a target gene may result in inhibition of target gene expression of greater than 10%, 33%, 50%, 75%, 80%, 85%, 90%, 95% or 99% as compared to a cell subjected to a vector as herein described.

It is to be understood that the term vector refers to any vector as herein described, or any variation thereof, comprising an element of such a vector as herein described, as will be appreciated to one skilled in the art. For example, and in some embodiments, the term vector may be considered to comprise a pLB, pLB2, MSCV or pFLIP vector, or components thereof.

In one embodiment, this invention provides for a method of conditionally reduced expression of a coding sequence in a target cell. In one embodiment, the term "conditionally reduced expression" refers to the flexibility inherent in the methods/vectors of this invention, which enable regulation of reducing expression of a coding sequence in a target cell. In one embodiment, reducing expression via the vectors/methods of this invention is controlled over time, or in a cell or tissue-specific manner, such that production of the miRNA agent is not constant.

Expression of the miRNA agent within a target cell, in one embodiment of this invention, takes advantage of a lox/cre

11

system. In one embodiment, miRNA agent expression is dependent upon the presence of a Cre recombinase. According to this aspect of the invention, Cre recombinase inverts the second nucleic acid from antisense to sense orientation, such that a functional miRNA agent is expressed, and whereby splicing of the miRNA occurs, uncoupling miRNA from reporter expression, in some embodiments.

In one embodiment, the cre recombinase, is derived from a P1 bacteriophage (Abremski and Hoess, J. Biol. Chem. 259 (3):1509-1514 (1984)) which acts on a specific 34 base pair DNA sequence known as "loxP" (locus of crossover), which is, in turn, comprised of two 13 base pair inverted repeats (serving as the recombinase binding sites) flanking an 8 base pair core sequence (Current Opinion in Biotechnology 5:521-527 (1994)). Cre catalyzes the rearrangement of DNA sequences that contain loxP sites. Recombination between two loxP sites (catalyzed by the cre protein) causes, in certain cases, the loss of sequences flanked by these sites [for a review see N. Kilby et al, Trends Genet., 9:413-421 (1993)].

In one embodiment, the cre recombinase, is expressed in hematopoietic cells, for example, as described in Zhang CC, et al. Nat. Med. 2006 February; 12(2):240-5. In some embodiments, Cre is estrogen, or estrogen agonist or antagonist induced, for example as described in Hayashi S, McMahon AP. Dev Biol. 2002 Apr. 15; 244(2):305-18. It is to be understood that any Cre Recombinase, or other appropriate recombinase, which can generate the desired expressed products of the vectors of this invention are to be considered a part of this invention.

In some embodiments, the loxP WT has a sequence as follows:

ATAACTTCGTATAGCATACATTATACGAAGTTAT (SEQ ID NO:11)

In some embodiments, this invention utilizes two sets of loxP sites, whose sequences differ. In one embodiment, one pair of the loxP sites may be WT, while the other may be mutated, or in another embodiment, both are mutated.

In one embodiment, mutated loxP sites inclusive of any known in the art, or homologues thereof may be employed in the constructs, materials and/or methods of this invention, for example, mutant sequences exemplified by loxP2272, loxP5171, loxP2271, loxP3171, loxP5272 or loxP5372 as described in Lee et al., Gene, 216:55-65 (1998).

In one embodiment, the loxP sets are oriented initially with inverted orientation, such that regions of the vector undergo inversion, following exposure to a Cre-recombinase. Following such inversion, one of the pairs of loxP sites are co-aligned, thus in the presence of a Cre-recombinase, excision can occur.

In one embodiment, the two pairs of loxP sites are chosen so as to minimize recombination therebetween, as exemplified herein.

Cre works in simple buffers, such as, in one embodiment, with magnesium or, in another embodiment, spermidine as a cofactor, as is well known in the art. The DNA substrates acted on by Cre may be, in one embodiment, in linear, or, in another embodiment, in a supercoiled configuration.

In one embodiment, the Cre sequence is as that described in N. Sternberg et al, J. Mol. Biol., 187:197-212 (1986). In another embodiment, the Cre recombinase may be obtained from commercial sources (for example from Novagen, Catalog No. 69247-1).

In one embodiment, cre recombinase will be expressed in a target cell of this invention. In another embodiment, the

12

target cell will be engineered to express Cre by any means as will be known to one skilled in the art.

In one embodiment, the terms "homology", "homologue" or "homologous", refer to a, which exhibits, in one embodiment at least 70% correspondence with the indicated sequence. In another embodiment, the sequence exhibits at least 72% correspondence with the indicated sequence. In another embodiment, the sequence exhibits at least 75% correspondence with the indicated sequence. In another embodiment, the sequence exhibits at least 80% correspondence with the indicated sequence. In another embodiment, the sequence exhibits at least 82% correspondence with the indicated sequence. In another embodiment, the sequence exhibits at least 85% correspondence with the indicated sequence. In another embodiment, the sequence exhibits at least 87% correspondence with the indicated sequence. In another embodiment, the sequence exhibits at least 90% correspondence with the indicated sequence. In another embodiment, the sequence exhibits at least 92% correspondence with the indicated sequence. In another embodiment, the sequence exhibits at least 95% or more correspondence with the indicated sequence. In another embodiment, the sequence exhibits at least 97% correspondence with the indicated sequence. In another embodiment, the sequence exhibits at least 99% correspondence with the indicated sequence. In another embodiment, the sequence exhibits 95%-100% correspondence with the indicated sequence. Similarly, as used herein, the reference to a correspondence to a particular sequence includes both direct correspondence, as well as homology to that sequence as herein defined.

Homology, as used herein, may refer to sequence identity, or may refer to structural identity, or functional identity. By using the term "homology" and other like forms, it is to be understood that any molecule, that functions similarly, and/or contains sequence identity, and/or is conserved structurally so that it approximates the reference sequence, is to be considered as part of this invention. Homology may be determined in the latter case by computer algorithm for sequence alignment, by methods well described in the art. For example, computer algorithm analysis of nucleic acid sequence homology may include the utilization of any number of software packages available, such as, for example, the BLAST, DOMAIN, BEAUTY(BLAST Enhanced Alignment Utility), GENPEPT and TREMBL packages.

An additional means of determining homology is via determination of candidate sequence hybridization, methods of which are well described in the art (See, for example, Nucleic Acid Hybridization, Hames and Higgins, Eds. (1985); Molecular Cloning, Sambrook and Russell, eds. (2001), and Current Protocols in Molecular Biology, Ausubel et al. eds, 1989). For example, methods of hybridization may be, in one embodiment, carried out under moderate to stringent conditions, to the complement of a DNA encoding a native peptide or protein of interest. Hybridization conditions may be, for example, overnight incubation at 42° C. in a solution comprising: 10-20% formamide, 5×SSC (150 millimolar (mM) NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 micrograms (μ g)/milliliter (ml) denatured, sheared salmon sperm DNA. Each method represents a separate embodiment of the present invention. In some embodiments, this invention provides a nucleic acid or a vector or composition or cell comprising the same, with a sequence corresponding to or homologous to any of those set forth in SEQ ID NO: 1-27.

In another embodiment, mutated loxP sites, may be employed in the vectors and/or methods of this invention.

13

In one embodiment of this invention, a modified pLB vector was constructed, resulting in greater expression, the vector being schematically depicted in FIG. 1B, and referred to herein as pLB2.

In this embodiment of the modified vector (pLB2), the promoter driving the RNA genome was derived from. The packaging signal (Psi), central polypurine tract (cPPT), anti-repressor (Element #40) and scaffold attached region (SAR) were similar to those used in previously described pLB vectors, representing one embodiment of the invention.

In one embodiment, the pLB2 has an internal Ubiquitin-C promoter, driving expression of the FLIP cassette. The FLIP cassette maintains GFP-miR30, or other miR30 fused sequences as herein described in the antisense orientation until reversed by Cre activity.

In some embodiments, pLB2 comprises a modified 3'LTR, as well. In some embodiments, such modification comprises deletions of the U3 to produce self-inactivating vectors (SIN). In some embodiments, pLB2 will comprise from ~200 to a ~420 nucleotide deletion, or in some embodiments, up to the minimum required for integration (~25 nt) and another 20 nt that significantly improved polyadenylation of the integrated viral transcript.

In some embodiments, these untranslated regions aid in protecting the miRNA from rapid breakdown.

In some embodiments, pLB2 will comprise a Bovine Growth Hormone Polyadenylation signal. In another embodiment, the Bovine Growth Hormone polyadenylation signal is positioned 3' to the second pair of loxP sites.

In some embodiments of this invention, pLB2, or the vectors/compositions/kits of this invention comprise, and methods make use of splice donor and splice acceptor sequences flanking at least one miR30, such that the miR30 is contained within an artificial intron.

In some embodiments, such introns may comprise any known in the art, whose use herein results in enhanced miR30 expression, following Cre exposure. In some embodiments, a consensus sequence is utilized, as herein described. In some embodiments, splice donor and acceptor sequences are optimized to yield the greatest fold reduction in gene expression.

In some embodiments, the intron may comprise, or be derived from the 2.0 kb LAT of Herpes Simplex Virus, type I (HSV-1), strain 17. The sequence of this LAT is reported in McGeoch et al., 1988, J. Gen. Virol., 69:1531-1574; the sequence of the 2.0 kb LAT of HSV-1 strain F is reported in Spivak et al., 1991, J. Virol., 65:6800-6810, both of which are incorporated by reference herein.

In some embodiments, the splice donor sequence, is located 5' to the miR30 in the constructs of this invention, may span from about 2 to about 25 nucleotides, and the splice acceptor sequence, located 3' to the miR30 in the constructs of this invention, may span from about 2 to about 25 nucleotides. Corresponding sequences may be obtained from other introns by conventional methods which follow the teachings herein.

In some embodiments, the miR30 will be flanked by restriction endonuclease sites, which in turn are flanked by the splice donor and splice acceptor sequences, respectively. In some embodiments, such restriction endonuclease sites allow for the ready exchange of miR30 sequences in a given vector/construct of this invention.

In some embodiments, the constructs/kits/compositions of this invention may comprise and methods make use of the same, whereby such constructs comprise one or more introns, or hybrids thereof. In one embodiment, multiple miR30s may be flanked by multiple introns and attached in tandem, or in some embodiments, an intron may be optimized, derived

14

from two or more native introns, whereby expression for a particular tissue or sequence is optimally derived.

In some embodiments, the term "intron" as used herein, refers to a non-coding nucleotide sequence of varying length, normally present within many eukaryotic genes, which is removed from a newly transcribed mRNA precursor by the process of splicing. In general, the process of splicing requires that the 5' and 3' ends of the intron be correctly cleaved and the resulting ends of the mRNA be accurately joined, such that a mature mRNA having the proper reading frame for protein synthesis is produced.

Introns have highly conserved sequences at or near each end of the intron which are required for splicing and intron removal. In some embodiments, the term "splice donor site" or "SD" or "5' splice site" refers to the conserved sequence immediately surrounding the exon-intron boundary at the 5' end of the intron, where the exon comprises the nucleic acid 5' to the intron. In some embodiments, the term "splice acceptor site" or "SA" or "3' splice site" herein refers to the sequence immediately surrounding the intron-exon boundary at the 3' end of the intron, where the exon comprises the nucleic acid 3' to the intron. In some embodiments, the term "intron" refers to a nucleic acid comprising a splice donor site and a splice acceptor site including intervening sequences, such as an miRNA as herein described and the presence of restriction endonuclease sites. Many splice donor and splice acceptor sites have been characterized and Ohshima et al., J. Mol. Biol., 195:247-259 (1987) provides a review of these. Examples of efficient splice donor sequences include the wild type (WT) ras splice donor sequence and the GAC:GTAAGT (SEQ ID NO: 12) sequence. In some embodiments, the splice donor site is a "consensus splice donor sequence" and in some embodiments, the splice acceptor site is a "consensus splice acceptor sequence"; these consensus sequences are evolutionarily highly conserved. The consensus sequences for both splice donor and splice acceptor sites in the mRNAs of higher eukaryotes are shown in Molecular Biology of the Cell, 3.sup.rd edition. Alberts et al. (eds.), Garland Publishing, Inc., New York, 1994, on page 373, FIG. 12-53. The consensus sequence for the 5' splice donor site is C/A (C or A) AG:GUAAGU (wherein the colon denotes the site of cleavage and ligation) (SEQ ID NO: 13). The 3' splice acceptor site occurs within the consensus sequence (U/C).sub.11NCAG:G (SEQ ID NO: 14). Other efficient splice donor and acceptor sequences can be readily determined using the techniques for measuring the efficiency of splicing.

In some embodiments, such introns used in the vectors/kits/compositions/methods of this invention provide a splicing efficiency of at least about 75%, or in another embodiment, at least about 80%, or in another embodiment, at least about 85%, or in another embodiment, at least about 90%, or in another embodiment, at least about 95%.

In some embodiments, the term "about" when in reference to a value as described herein is to be understood to encompass the indicated value +/-1%, or in some embodiments, +/-3%, or in some embodiments, +/-5%, or in some embodiments, +/-7%, or in some embodiments, +/-10%, or in some embodiments, +/-15%, or in some embodiments, +/-20%, or in some embodiments, +/-25%.

Intron splicing efficiency is readily determined by quantifying the spliced transcripts versus the full-length, unspliced transcripts that contain the intron, using methods known in the art such as by quantitative PCR or Northern blot analysis, using appropriate probes for the transcripts. See, e.g., Sambrook et al., supra, and other general cloning manuals. Reverse transcription-polymerase chain reaction (RT-PCR)

15

can be used to analyze RNA samples containing mixtures of spliced and unspliced mRNA transcripts. For example, fluorescent-tagged primers designed to span the intron are used to amplify both spliced and unspliced targets. The resultant amplification products are then separated by gel electrophoresis and quantitated by measuring the fluorescent emission of the appropriate band(s). A comparison is made to determine the amount of spliced and unspliced transcripts present in the RNA sample.

In some embodiments, this invention provides a vector comprising any desired grouping of elements, which at least consists of an miR30 and flanking splice donor and splice acceptor sites, in antisense orientation, situated between two sets of loxP sites as herein described, such that upon exposure to a Cre recombinase, or other appropriate recombinase, inversion and excision occurs and expression of the miR30 is accomplished.

In some embodiments, such vectors/compositions/kits of this invention may be said to consist essentially of at least one miR30 contained within an artificial intron, wherein the phrase "consist essentially of" is to convey that other sequences may be incorporated into the vectors/compositions/kits of this invention, including marker sequences, regulatory sequences, including promoter and enhancers, other coding sequences, which may be in antisense orientation, and juxtaposed between loxP sites as herein described, or such sequences may be in sense orientation, and are Cre-independent for their expression.

In one embodiment, the constructs of this invention will comprise a promoter, operatively linked to the first nucleic acid sequence encoding a selection marker. In one embodiment, the term "promoter" refers to a nucleic acid sequence, which regulates expression of a nucleic acid, operably linked thereto. Such promoters are known to be cis-acting sequence elements required for transcription as they serve to bind DNA dependent RNA polymerase, which transcribes sequences present downstream thereof.

The term "operably linked", in one embodiment, refers to a relationship permitting the sequences to function in their intended manner. A vector comprising a regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the nucleic acid sequence is achieved under conditions compatible with the control sequences. "Operably linked" refers, in some embodiments, to a juxtaposition of two or more components, wherein the components so described are in a relationship permitting them to function in their intended manner. For example, a promoter and/or enhancer is operably linked to a coding sequence if it acts in *cis* to control or modulate the transcription of the linked sequence. Generally, but not necessarily, the DNA sequences that are "operably linked" are contiguous and, where necessary to join two protein coding regions or in the case of a secretory leader, contiguous and in reading frame. However, although an operably linked promoter is generally located upstream of the coding sequence, it is not necessarily contiguous with it. Enhancers do not have to be contiguous. An enhancer is operably linked to a coding sequence if the enhancer increases transcription of the coding sequence. Operably linked enhancers can be located upstream, within or downstream of coding sequences and at considerable distances from the promoter. A polyadenylation site is operably linked to a coding sequence if it is located at the downstream end of the coding sequence such that transcription proceeds through the coding sequence into the polyadenylation sequence. Linking is accomplished by recombinant methods known in the art, e.g., using PCR methodology, by annealing, or by ligation at convenient restriction sites. If convenient

16

restriction sites do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.

In one embodiment, the promoter will be an RNA polymerase III promoter.

In one embodiment, a promoter, including an engineered promoter used in the vectors and methods of this invention, may be one known to confer cell-type specific expression of a sequence operatively linked to thereto. For example, and in one embodiment, a promoter specific for myoblast gene expression can be operatively linked to an miRNA for a coding sequence of interest, a reporter gene, or a coding sequence of interest, to confer muscle-specific expression thereof. Muscle-specific regulatory elements which are known in the art include upstream regions from the dystrophin gene (Klamut et al., (1990) Mol. Cell Biol. 10:193), the creatine kinase gene (Horlick and Benfield (1989) Mol. Cell Biol. 9:2396; Buskin and Hauschka, (1989) Mol. Cell Biol. 9:2627) and the troponin gene (Mar and Ordahl, (1988) Proc. Natl. Acad. Sci. USA. 85:6404).

In another embodiment, promoters used in the vectors and methods of this invention, specific for other cell types known in the art (e.g., the albumin enhancer for liver-specific expression; insulin regulatory elements for pancreatic islet cell-specific expression; various neural cell-specific regulatory elements, including neural dystrophin, neural enolase and A4 amyloid promoters) may be used, and represent an embodiment of this invention. In another embodiment, a promoter or regulatory element, which can direct constitutive expression of a sequence operatively linked thereto, in a variety of different cell types, such as a viral regulatory element, may be used. Examples of viral promoters commonly used to drive gene expression include those derived from polyoma virus, Adenovirus 2, cytomegalovirus and Simian Virus 40, and retroviral LTRs.

In another embodiment, a regulatory element, which provides inducible expression of a gene linked thereto, may be used. The use of an inducible promoter may allow, in another embodiment, for an additional means of modulating the product of the coding sequence in the cell. Examples of potentially useful inducible regulatory systems for use in eukaryotic cells include hormone-regulated elements (e.g., see Mader, S, and White, J. H. (1993) Proc. Natl. Acad. Sci. USA 90:5603-5607), synthetic ligand-regulated elements (see, e.g., Spencer, D. M. et al 1993) Science 262:1019-1024) and ionizing radiation-regulated elements (e.g., see Manome, Y. Et al. (1993) Biochemistry 32:10607-10613; Datta, R. et al. (1992) Proc. Natl. Acad. Sci. USA 89: 1014-10153). Additional tissue-specific or inducible regulatory systems may be developed for use in accordance with the invention.

In another embodiment, the vector further comprises a first regulatory sequence operationally linked to the first nucleic acid, and being in an antisense orientation, which in one embodiment is a UbiquitinC promoter sequence. In another embodiment, the vector further comprises a second regulatory sequence, located 5' to said first regulatory sequence, wherein the second regulatory sequence is in a sense orientation.

In one embodiment, the term "capable of expressing a Cre recombinase" refers to a cell that endogenously expresses the Cre recombinase, or in another embodiment, is engineered to express a Cre recombinase.

In one embodiment, the cell is in a culture system, or in another embodiment, in a body of a subject, or in another embodiment, is ex-vivo cultured, and following transfection or transduction with a vector of this invention, is reintroduced to the subject from which the cell was taken. In one embodi-

ment, the cell is a stem or progenitor cell. In another embodiment, the cell is a mature, differentiated cell. In one embodiment, the cell is a human cell in origin, or in another embodiment, the cell is murine in origin.

In one embodiment, the terms "cells," "host cells" or "target cells" are used interchangeably, and refer, in one embodiment, not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

In another embodiment, the cell is a diseased cell. In one embodiment, the cell is infected, or in another embodiment, the cell is transformed or neoplastic. In another embodiment, the cell is obtained from a subject with a disease whose etiology is associated with a genetic mutation. In another embodiment, the cell is obtained from a subject with a disease, where an inappropriate immune or inflammatory response has been initiated.

In one embodiment, the target cell of any method of the present invention may be a cancer cell or neoplastic cell. "Neoplastic cell" refers, in one embodiment, to a cell whose normal growth control mechanisms are disrupted (typically by accumulated genetic mutations), thereby providing potential for uncontrolled proliferation. Thus, "neoplastic cell" can include, in one embodiment, both dividing and non-dividing cells. In one embodiment, neoplastic cells may include cells of tumors, neoplasms, carcinomas, sarcomas, leukemias, lymphomas, and others. In another embodiment, "neoplastic cells" may include central nervous system tumors, such as, for example brain tumors. These may include, in other embodiments, glioblastomas, astrocytomas, oligodendroglomas, meningiomas, neurofibromas, ependymomas, schwannomas or neurofibrosarcomas. In another embodiment, "neoplastic cells" can include either benign or malignant neoplastic cells. In another embodiment, "neoplastic cells" can include any other type of cancer known in the art.

In one embodiment, the target cell may be an infected cell. In another embodiment, the target cell may be a pathogenic cell. In another embodiment, the target cell may mediate autoimmunity or another disease state. In another embodiment, the target cell may comprise a mutated cellular gene necessary for a physiological function. In one embodiment, the mutated product results in disease in the subject. According to this aspect of the invention, the vectors/methods of this invention may be employed to silence a defective gene, and may further be followed by delivery of a wild-type copy of the desired gene.

It is to be understood that any cell comprising a vector of this invention, or utilized for the methods of this invention, is to be considered as part of this invention, and represents an embodiment thereof.

According to this aspect of the invention, and in one embodiment, following Cre-mediated recombination in the target cell, the miRNA agent is expressed and reduces expression of the coding sequence, thereby conditionally reducing expression of a coding sequence in the target cell.

In another embodiment, the vector is a retroviral vector. In one embodiment, the retroviral vector of this invention may correspond to one as exemplified herein.

A retroviral or retrovirus vector, as used herein, is a vector, which comprises at least one component part derivable from a retrovirus. In one embodiment, the component part is involved in the biological mechanisms by which the vector infects cells, expresses genes or is replicated. The term "derivable", in one embodiment, refers to the fact that the

sequence need not necessarily be obtained from a retrovirus but instead could be derived therefrom. By way of example, the sequence may be prepared synthetically or by use of recombinant DNA techniques.

5 The retroviral vectors of this invention may be derived from any member of the family of retroviridae.

In one embodiment, the vectors of this invention are lentivirus, and may be derived from any member of the family of lentiviridae.

10 In one embodiment, the retroviral vectors of this invention comprise sufficient retroviral genetic information to allow packaging of an RNA genome, in the presence of packaging components, into a viral particle capable of infecting a target cell. In one embodiment, infection of the target cell includes

15 reverse transcription and integration into the target cell genome. The retroviral vectors of this invention may carry, in one embodiment, non-viral coding sequences which are to be delivered by the vector to the target cell. In one embodiment, the retroviral vectors of this invention are incapable of independent replication to produce infectious retroviral particles

20 within the final target cell. In one embodiment, the retroviral vectors of this invention will lack a functional gag-pol and/or env gene and/or other genes essential for replication.

In some embodiments, the vectors of this invention may be 25 integrated into the genome (germ line) of a host mammal, thereby forming a transgenic animal. In some embodiments, such integration into the germ line is desired for the transmission of the construct to offspring, and thus, a strain of mammals containing the constructs can be maintained, as exemplified in an embodiment herein.

30 Depending upon the characteristics of the miR30 employed, or the intron, for example, a variety of screening procedures are available, which may comprise probe analysis, mRNA analysis, enzyme analysis, functional assays, antibody screens and protein, carbohydrate and lipid analysis, to ascertain, for example gene knockdown, or construct incorporation, as will be appreciated by one skilled in the art.

As exemplified herein, transgenic animals expressing the constructs of this invention may be prepared, representing 40 another embodiment of the invention. In some embodiments, such procedures entail injection of the constructs into early embryos, which may be accomplished by means well known in the art, for example, embryos are placed in a drop of medium (see Quinn, J. Reprod. Fert. 66:161-168 (1982) the disclosure of which is incorporated by reference). The drop of

45 medium is covered with paraffin oil and the embryos are viewed with an inverted microscope using Hoffman optics. Injection of the vectors of this invention may be accomplished by positioning a one cell embryo, or blastula with a holding micropipette and injecting the vector thereto with a finely pulled injection micropipette. The control of the fluid flow through the micropipettes may be accomplished by art-recognized means, for example, the entire system may be filled with paraffin oil allowing positive pressure for injection and negative pressure for holding the embryo to be injected under fine control. Embryo survival after injection may be assessed morphologically.

The embryos surviving microinjection may be placed in HT6 medium in preparation for transfer to the oviducts of 6-60 to 8-week old female mice. The recipient may be administered PMS i.p. followed later by hCG and placed with a vasectomized male mouse. To aid the recipient in accepting the microinjection embryos the gonadotropic administration and mating may coincide with the schedule of the donor mouse.

65 The success of the embryo transfer is, in some embodiments judged by the birth of mice about 19-21 days after

transfer. Success of the microinjection may be assessed by Southern hybridization analysis of DNA isolated from mouse tail biopsies.

In one embodiment, the vectors and methods of this invention may employ the use of enhancer sequences. In one embodiment, the term "enhancer" refers to a DNA sequence, which binds to other protein components of the transcription initiation complex and may thus facilitate the initiation of transcription directed by its associated promoter.

In another embodiment, the vectors and their use according to the present invention include at least two selectable markers, which may serve to indicate inversion and excision mediated by a Cre-recombinase, as described herein. In one embodiment, the selectable marker comprises an antibiotic resistance cassette, by means well known to one skilled in the art. In one embodiment, the resistance cassette is for conferring resistance to ampicillin, bleomycin, chloramphenicol, gentamycin, hygromycin, kanamycin, lincomycin, methotrexate, phosphinothricin, puromycin, or tetracycline, or derivatives thereof.

In another embodiment, the selectable marker may comprise nucleic acid sequences encoding for a reporter protein, such as, for example, green fluorescent protein (GFP), DS-Red (red fluorescent protein), acetohydroxyacid synthase (AHAS), beta glucuronidase (GUS), secreted alkaline phosphatase (SEAP), beta-galactosidase, chloramphenicol acetyl-transferase (CAT), horseradish peroxidase (HRP), luciferase, nopaline synthase (NOS), octopine synthase (OCS), or derivatives thereof, many known in the art, or any number of other reporter proteins known to one skilled in the art.

In some embodiments, the invention provides vectors/kits/compositions and the use of any form or derivative of GFP that emits sufficient fluorescence to enable fluorescence detection of intracellular GFP by flow cytometry using a fluorescence-activated cell sorter (FACS), or by fluorescence microscopy. GFP usable in the invention include wild-type as well as naturally occurring (by spontaneous mutation) or recombinantly engineered mutants and variants, truncated versions and fragments, functional equivalents, derivatives, homologs and fusions, of the naturally occurring or wild-type proteins. A range of mutations in and around the chromophore structure of GFP (around amino acids 64-68) have been described. These mutations result in modifications of the spectral properties, the speed of chromophore formation, the extinction coefficient, and the physical characteristics of the GFP. These forms of GFP may have altered excitation and emission spectra as compared to the wild-type GFP, or may exhibit greater stability. The mutant GFPs may fluoresce with increased intensity or with visibly distinct colors than the wild-type protein, e.g., blue, yellow or red-shifted fluorescent proteins, the DNA containing these genes of which are available commercially (Clontech, Palo Alto, Calif.; Quantum Biotechnologies, Montreal, Canada). Mutants with increased fluorescence over the wild-type GFP provide a much more sensitive detection system. Mutants may have a single excitation peak as opposed to 2 peaks characteristic of the native protein, may be resistant to photobleaching or may exhibit more rapid oxidation to fluorophore. For example, the *Aequorea* GFP mutant, S65T (Heim et al. *Nature* 373: 663-664 (1995)), in which Ser65 has been replaced by Thr, offers several advantages over the wild-type GFP in that the mutant provides six-fold greater brightness than wild-type, faster fluorophore formation, no photoisomerization and only very slow photobleaching. Modifications of Ser65 to Thr or Cys result in GFPs that continue to emit maximally at approximately 509 nm but which have a single excitation peak red-shifted to 488 nm and 473 nm respectively. This has several

advantages in that it brings the excitation peaks more in line with those already used with fluorescent microscopes and fluorescence-activated cell sorters (FACS) for FITC. Furthermore, chromophore formation of these mutants is more rapid

and the extinction coefficient is greater than that of wtGFP (wild-type GFP), which results in a stronger fluorescent signal (Heim et al., 1995, *supra*). Other GFP mutants have codons optimized for mammalian cell expression as well as exhibiting greater fluorescence than the original GFP gene (see Bennet (1998), *infra*; Crameri et al. *Nature Biotechnol.* 14:315-319 (1996)). "Humanized" or otherwise modified versions of GFP, including base substitution to change codon usage, that favor high level expression in mammalian cells, are suitable for use in the constructs of the invention (see, e.g., Hauswirth et al., U.S. Pat. No. 5,874,304; Haas et al. U.S. Pat. No. 5,795,737). GFP mutants that will fluoresce and be detected by illumination with white light are described in WO 9821355. Still other mutant GFPs are described in U.S. Pat. No. 5,804,387 (Cormack et al.) and WO 9742320 (Gaitanaris et al.).

In another embodiment, the vector may further include an origin of replication, and may be a shuttle vector, which can propagate both in bacteria, such as, for example, *E. coli* (wherein the vector comprises an appropriate selectable marker and origin of replication) and be compatible for propagation in vertebrate cells, or integration in the genome of an organism of choice.

The nucleic acids may be introduced into tissues or host cells by any number of routes, including viral infection, microinjection, or fusion of vesicles. Jet injection may also be used for intramuscular administration, as described by Furth et al. (1992), *Anal Biochem* 205:365-368. The nucleic acids may be coated onto gold microparticles, and delivered intradermally by a particle bombardment device, or "gene gun" as described in the literature (see, for example, Tang et al. (1992), *Nature* 356:152-154), where gold microprojectiles are coated with the DNA, then bombarded into skin cells. Expression vectors may be used to introduce the nucleic acids into a cell.

In one embodiment, the vectors of this invention may be fed directly to, injected into, the host organism containing the target gene. The vectors of this invention may be directly introduced into the cell (i.e., intracellularly); or introduced extracellularly into a cavity, interstitial space, into the circulation of an organism, introduced orally, etc. Methods for oral introduction include direct mixing of the vector with food of the organism. Physical methods of introducing the vectors include injection directly into the cell or extracellular injection into the organism of a solution comprising the vector. The vectors may be introduced in an amount, which allows delivery of at least one copy per cell. Higher doses (e.g., at least 5, 10, 100, 500 or 1000 copies per cell) of the vectors may yield more effective inhibition; lower doses may also be useful for specific applications.

In other embodiments, a hydrodynamic administration protocol is employed, and may be as described in Chang et al., *J. Virol.* (2001) 75:3469-3473; Liu et al., *Gene Ther.* (1999) 6:1258-1266; Wolff et al., *Science* (1990) 247: 1465-1468; Zhang et al., *Hum. Gene Ther.* (1999) 10:1735-1737; and Zhang et al., *Gene Ther.* (1999) 7:1344-1349, each of which represents an embodiment of this invention.

In other embodiments, delivery protocols of interest may include, but are not limited to: those described in U.S. Pat. No. 5,985,847, or 5,922,687, WO/11092; Acsadi et al., *New Biol.* (1991) 3:71-81; Hickman et al., *Hum. Gen. Ther.* (1994) 5:1477-1483; or Wolff et al., *Science* (1990) 247: 1465-1468, and others, as will be appreciated by one skilled in the art.

The methods of this invention comprise the step of contacting a target cell with a vector of this invention. In one embodiment, the terms “contacting”, “contact” or “contacted” indicate, direct or, in another embodiment, indirect exposure of the cell to a vector, compound or composition comprising the vectors of this invention. It is envisaged that, in another embodiment, indirect supply to the cell may be via provision in a culture medium that surrounds the cell, or via parenteral administration in a body of a subject, whereby the vector ultimately contacts a cell via peripheral circulation (for further detail see, for example, Methods in Enzymology Vol. 1-317, Rubin and Dennis, eds., (1955-2003) and Current Protocols in Molecular Biology, Ausubel, et al, eds (1998), Molecular Cloning: A Laboratory Manual, Sambrook and Russell, eds., (2001), or other standard laboratory manuals). It is to be understood that any direct means or indirect means of intracellular access of a vector, or composition comprising the same of this invention represents an embodiment thereof.

In one embodiment, the target cell is contacted with a vector/composition comprising the same, of this invention, *in vivo*, *in vitro* or *ex-vivo*. In one embodiment, cells may be procured from a subject, contacted with a vector of this invention, and reintroduced into the subject. In one embodiment, the cell is a stem or progenitor cell, and reintroduction into the subject may be followed, in another embodiment, by stimulation of differentiation of the contacted cell, *in vivo*.

In another embodiment, Cre recombinase is expressed at specific times during development.

In another embodiment, this invention provides for the generation of a non-human animal with reduced expression of a coding sequence, wherein the reduced expression is produced according to the methods, and/or utilizing the vectors of this invention.

Transgenic mice, may, in one embodiment, be derived using the vectors/methods of this invention, according to Hogan, et al., “Manipulating the Mouse Embryo: A Laboratory Manual”, Cold Spring Harbor Laboratory (1988) which is incorporated herein by reference. Embryonic stem cells may, in another embodiment, be manipulated according to published procedures (Teratocarcinomas and embryonic stem cells: a practical approach, E. J. Robertson, ed., IRL Press, Washington, D.C., 1987; Zjilstra et al., *Nature* 342: 435-438 (1989); and Schwartzberg et al., *Science* 246:799-803 (1989), each of which is incorporated herein by reference). Zygotes may be manipulated, in another embodiment, according to known procedures; for example see U.S. Pat. No. 4,873,191, Brinster et al., *PNAS* 86:7007 (1989); Suslic et al., *J. Biol. Chem.* 49:29483 (1995), and Cavad et al., *Nucleic Acids Res.* 16:2099 (1988), hereby incorporated by reference. Tetraploid blastocyst complementation may also be utilized to achieve non-human animals, which express the vectors of this invention, according to methods as exemplified herein, or, as are well known in the art.

In one embodiment, this invention provides a method of producing an animal genetically inactivated for a coding sequence, the method comprising contacting an embryonic stem cell with a vector of this invention which may be used for gene silencing, injecting the contacted embryonic stem cell to a blastocyst of an animal and obtaining an animal expressing the vector, whereby, following Cre-mediated recombination in the animal, the miRNA agent is expressed and reduces expression of the coding sequence, thereby being a method of producing an animal genetically inactivated for a coding sequence.

In another embodiment, the method of conditionally reducing expression of a coding sequence, as described and exemplified herein, may be therapeutic. In one embodiment,

the term “therapeutic” refers to the fact that when in contact with a cell in a subject in need, provides a beneficial effect.

In one embodiment, the compositions/vectors and methods of conditionally reducing expression of a coding sequence of this invention prevent inappropriate expression of an encoded protein in a subject. Some examples include endogenous proteins which are mutated, and produces a non-functional protein, or an over-expressed protein, which in another embodiment, may be non-functional, or in another embodiment, pathogenic.

In one embodiment, the encoded protein may include cytokines, such as interferons or interleukins, or their receptors. According to this aspect of the invention, and in one embodiment, inappropriate expression patterns of cytokines may be altered to produce a beneficial effect, such as for example, a biasing of the immune response toward a Th1 type expression pattern, or a Th2 pattern in infection, or in autoimmune disease, wherein altered expression patterns may prove beneficial to the host. In these cases, and in one embodiment, conditionally reducing expression of the inappropriate or non-protective cytokine/receptor may be followed by delivery of an appropriate cytokine, or a vector/nucleic acid for expressing the same.

In another embodiment, the encoded protein may include an enzyme, such as one involved in glycogen storage or breakdown. In another embodiment, the encoded protein may include a transporter, such as an ion transporter, for example CFTR, or a glucose transporter, or other transporters whose inappropriate expression results in a variety of diseases. As described hereinabove, and in another embodiment, conditionally reducing expression of the encoded proteins, according to this aspect of the invention, may be followed by delivery of a wild-type protein, or a plasmid encoding same, or a mutated protein, which results in a therapeutic effect in the subject.

In another embodiment, the encoded protein may include a receptor, such as one involved in signal transduction within a cell. Some examples include as above, cytokine receptors, leptin receptors, transferring receptors, etc., or any receptor wherein altered expression results in inappropriate or inadequate signal transduction in a cell.

It is to be understood that any encoded protein, wherein conditionally reducing expression of the product is therapeutic to a subject is to be considered as part of this invention, and methods/vectors to provide wild-type or otherwise therapeutic versions of the encoded protein to the subject, following conditional reduction of expression of the mutated version, is to be considered as part of this invention, and embodiments thereof.

In another embodiment, the vectors/methods of this invention may be utilized to conditionally reduce expression of an oncogene, whose expression promotes cancer-related events. In one embodiment, the conditionally reduced expression of oncogenes comprising ABL1, BCLI, BCL2, BCL6, CBFA2, CBL, CSFIR, ERBA, ERBB, EBRB2, ETS1, ETS1, ETV6, FOR, FOS, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, MYB, MYC, MYCLI, MYCN, NRAS, PIM 1, PML, RET, SRC, TALI, TCL3, YES, or any form thereof, or combinations thereof, may be effected via the vectors/compositions/methods of this invention. In another embodiment, vectors/methods of this invention may be utilized to conditionally reduce expression of a Prostate Tumor Inducing Gene, which may comprise in one embodiment, PTI-1, PTI-2, PTI-3 or combinations thereof.

In one embodiment, the vectors/methods of this invention may be utilized to conditionally reduce expression of genes whose products promote angiogenesis, such as, for example,

and in one embodiment, VEGF, VEGF receptor, erythropoietin, or combinations thereof. In another embodiment, the coding sequence for which conditional reducing expression is desired may comprise a matrix metalloproteinase, wherein reduction of expression prevents, in one embodiment, metastasis of cancerous cells, or, in another embodiment, tissue necrosis in infectious or inflammatory diseases.

In another embodiment, the vectors/compositions/methods of this invention may be utilized to conditionally reduce expression of a mutated rhodopsin gene. Autosomal dominant retinitis pigmentosa (ADRP) is characterized by the substitution of histidine for proline at codon 23 (P23H) in their rhodopsin gene, resulting in photoreceptor cell death from the synthesis of the abnormal gene product. In one embodiment, P23H mutant mRNAs may be targeted for conditional reduction of expression.

In another embodiment, the vectors/compositions/methods of this invention may be utilized to reverse effects of high glucose on progression of diabetic retinopathy. High glucose environments can result in chronically increased nitric oxide (NO) activity, which leads to endothelial cell dysfunction and impaired blood retinal barrier integrity characteristic of diabetic retinopathy.

In one embodiment, NOS synthesis may be conditionally reduced, in a tissue specific manner, in another embodiment, via the use of miRNAs targeted against VEGF, iNOS, or eNOS using the vectors/compositions and methods, as described hereinabove. In another embodiment, glucose transporters may be similarly targeted for therapeutic purposes in diabetic retinopathy.

In another embodiment, the vectors/compositions and methods for reducing expression of a coding sequence may be applied in a subject with a disease, where the disease may comprise, but is not limited to: muscular dystrophy, cancer, cardiovascular disease, hypertension, infection, renal disease, neurodegenerative disease, such as alzheimer's disease, parkinson's disease, huntington's chorea, Creutzfeld-Jacob disease, autoimmune disease, such as lupus, rheumatoid arthritis, endocarditis, Graves' disease or ALD, respiratory disease such as asthma or cystic fibrosis, bone disease, such as osteoporosis, joint disease, liver disease, disease of the skin, such as psoriasis or eczema, ophthalmic disease, otolaryngeal disease, other neurological disease such as Turret syndrome, schizophrenia, depression, autism, or stroke, or metabolic disease such as a glycogen storage disease or diabetes. It is to be understood that any disease whereby reduced expression of a particular protein, which can be accomplished via the use of the vectors or cells or compositions, or via the methods of this invention, is to be considered as part of this invention.

In one embodiment, the vectors and/or methods of this invention inactivate a gene whose product expression results in a disease, disorder or condition. In some embodiments, such vectors may further a second sequence of interest, which are in antisense orientation, as well, and may in some embodiments, be fused to the miRNA sequence as herein described. In some embodiments, the second sequence of interest may itself be flanked by restriction endonuclease sites, splice donor and acceptor sites, or combinations thereof, or in some embodiments, a splice acceptor sequence is positioned 3' to the second sequence, while a splice donor sequence is positioned 5' to the first sequence, such that the splice sequences (and/or restriction endonuclease sites) flank fused miRNAs.

In some embodiments, such second sequences may comprise sequences encoding a therapeutic protein, for example where the sequence which is inactivated is a mutated product, which results in disease, the second sequence may encode the same product, in a therapeutic form, which in turn prevents or

treats the disease. For example, in subjects with a mutated CFTR, as herein described, the second sequence may encode a wild type CFTR, or one which restores therapeutic activity in a subject.

5 In some embodiments, the first miRNA sequence of interest specifically interacts with a sequence encoding an endogenous form of the protein of interest, and in one embodiment, the endogenous form is associated with a disease or disorder in the host.

10 According to this aspect, and in one embodiment, the second sequence may be another miRNA sequence of interest, which modulates expression of a gene whose activity is cooperative with that of a gene inactivated by the first miRNA sequence of interest. For example, multiple oncogenes may 15 be inactivated in a subject with a particularly aggressive neoplasia, or, in another embodiment, multiple mediators of inflammation may be inactivated in a subject with severe inflammatory disease, or autoimmune disease, or others, as will be appreciated by one skilled in the art.

20 In another embodiment, the second miRNA sequence may modulate expression of a gene whose activity antagonizes that of a gene modulated by the first miRNA sequence of interest.

25 In another embodiment, two or more miRNA sequences are expressed in such subjects/are found within the vectors of this invention, and in some embodiments, the vector may further comprise a third nucleic acid in antisense orientation, positioned between the first pair of loxP sequences, wherein the third nucleic acid encodes a protein of interest, which 30 may, in some embodiments be directly related to the products of genes being inactivated, for example, when oncogenes are being inactivated, the third sequence may encode a tumor suppressor. In some embodiments, the encoded protein of interest may be indirectly related, for example, a molecule

35 known to activate the immune response in the subject. In some embodiments, other products may be co-expressed, for example tumor vaccines or antigens directed against/derived from the tumor or neoplasia being treated. In other embodiments, such products may be co-administered, or staggered in 40 administration, or administered at a site distal to delivery of the vectors of this invention, whose therapeutic effect is cooperative.

45 In another embodiment, the vector will comprise a third sequence, and the methods of this invention make use of the same, or of administration of additional protein/polypeptide/nucleic acids/vectors, which comprise/express any desired protein, for example a therapeutic protein, for example insulins, amylases, proteases, lipases, kinases, phosphatases, glycosyl transferases, trypsinogen, chymotrypsinogen, carboxypeptidases, hormones, ribonucleases, deoxyribonucleases, triacylglycerol lipase, phospholipase A2, elastases, amylases, blood clotting factors, UDP glucuronyl transferases, ornithine transcarbamoylases, cytochrome p450 enzymes, adenosine deaminases, serum thymic factors, thymic

55 humoral factors, thymopoietins, growth hormones, somatomedins, costimulatory factors, antibodies, colony stimulating factors, erythropoietin, epidermal growth factors, hepatic erythropoietic factors (hepatopoietin), liver-cell growth factors, interleukins, interferons, negative growth factors, fibroblast growth factors, transforming growth factors of the α family, transforming growth factors of the β family, gastrins, secretins, cholecystokinins, somatostatins, serotonin, substance P and transcription factors and enzymes (e.g., ACC synthases and oxidases, ACP desaturases and

60 hydroxylases, ADP-glucose pyrophorylases, ATPases, alcohol dehydrogenases, amyloglucosidases, catalases, cellulases, chalcone synthases, chitinases, cyclooxygenases,

25

decarboxylases, dextrinases, DNA and RNA polymerases, galactosidases, glucanases, glucose oxidases, granule-bound starch synthases, GTPases, helicases, hemicellulases, integrases, inulinases, invertases, isomerasases, kinases, lactases, Upases, lipoxygenases, lysozymes, nopaline synthases, octopine synthases, pectinesterases, peroxidases, phosphatases, phospholipases, phosphorylases, phytases, plant growth regulator synthases, polygalacturonases, proteinases and peptidases, pullanases, recombinases, reverse transcriptases, RUBISCOs, topoisomerases, and xylanases); chemokines (e.g. CXCR4, CCR5), the RNA component of telomerase, vascular endothelial growth factor (VEGF), VEGF receptor, tumor necrosis factors nuclear factor kappa B, transcription factors, cell adhesion molecules, Insulin-like growth factor, transforming growth factor beta family members, cell surface receptors, RNA binding proteins (e.g. small nucleolar RNAs, RNA transport factors), translation factors, telomerase reverse transcriptase), or combinations thereof.

In another embodiment, expression of a tumor suppressor gene is desired, such as, for example, APC, BRCA 1, BRCA2, MADH4, MCC, NF 1, NF2, RB 1, TP53, WTI, or combinations thereof, and vectors of this invention comprising and methods making use of such sequences, may in one embodiment, suppress, or in another embodiment, diminish severity, or in another embodiment, prevent metastasis of a cancer, and represent an embodiment of this invention.

In another embodiment, expression of an immunomodulating protein is desired, such as, for example, cytokines, chemokines, complement components, immune system accessory and adhesion molecules or their receptors, such as, for example, GM-CSF, IL-2, IL-12, OX40, OX40L (gp34), lymphotactin, CD40, and CD40L, interleukins 1 to 15, interferons alpha, beta or gamma, tumour necrosis factor, granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF), chemokines such as neutrophil activating protein (NAP), macrophage chemoattractant and activating factor (MCAF), RANTES, macrophage inflammatory peptides MIP-1 α and MIP-1 β , complement components and their receptors, or an accessory molecule such as B7.1, B7.2, TRAP, ICAM-1, 2 or 3, cytokine receptors, OX40, OX40-ligand (gp34), or combinations thereof.

In another embodiment, expression of a protein, which suppresses angiogenesis is desired, and vectors comprising same and uses thereof to treat disease states, including cancer, hemangiomas, glaucoma, and other diseases, as will be well known to one skilled in the art, represent embodiments of this invention. In one embodiment, suppression of angiogenesis is accomplished via expressing an endostatin.

In another embodiment, the method of conditionally reducing expression of a coding sequence, as described and exemplified herein, may be for the evaluation of interacting proteins or endogenous mechanisms or interaction of substances therewith. For example, and in one embodiment, reduced expression of a specific tumor suppressor, or multiple suppressors is evaluated in an animal subject, for the creation of an experimental model. According to this aspect and in some embodiments, knockdown of such suppressors may be cell or tissue specific. In some embodiments, according to this aspect, the model may further comprise expression of an oncogene. In some embodiments, the model may further comprise the evaluation of therapies and/or treatment regimens, as a model for appropriate therapeutics.

In another aspect, the reduced expression may be of a specific oncogene in an established animal model of cancer, or multiple oncogenes, for the creation of an experimental model of cancer therapy. According to this aspect and in some

26

embodiments, knockdown of such oncogenes may be cell or tissue specific, and evaluation thereof may provide a mechanism for therapy of a particular cancer, or cancers in general. In some embodiments, according to this aspect, the model may further comprise expression of a tumor suppressor. In some embodiments, the model may further comprise the evaluation of therapies and/or treatment regimens, as a model for appropriate therapeutics, or in some embodiments, evaluation of certain agents, or lifestyle changes which prevent therapy, reduce efficacy thereto, or exacerbate disease.

Similarly, animal models of diseases, such as suspected multi-genic dependent diseases may be evaluated with the vectors, nucleic acids, compositions and methods of this invention, as will be appreciated by one skilled in the art.

In another embodiment, this invention provides a method of assessing neoplasia in an animal model, said method comprising:

- i. contacting a target cell in a subject animal with a vector comprising:
 - first pair of loxP sequences, inverted in orientation, with respect to each other;
 - a first nucleic acid encoding a first selectable marker in sense orientation, wherein said nucleic acid is positioned between said first pair of loxP sequences;
 - second nucleic acid encoding a second selectable marker, fused in frame to an miRNA sequence of interest with a suspected role in neoplasia or suppression thereof in antisense orientation, said miRNA sequence of interest being flanked by splice donor and splice acceptor sequences, said second nucleic acid is positioned between said first pair of loxP sequences, and said second nucleic acid is 3' with regard to said first nucleic acid;
 - second pair of loxP sequences, inverted in orientation, with respect to each other, wherein said first loxP sequenced of said second pair is positioned between said first and said second nucleic acid, and said second loxP sequence in said second pair is positioned 3' with respect to said first pair of loxP sequences, and said second pair of loxP sequences differs from that of said first pair of loxP sequences; and
- ii. evaluating neoplasia or development thereof in said animal;

whereby said method assesses development of neoplasia or suppression thereof in said subject animal as opposed to a control subject.

In some embodiments, the Cre recombinase is expressed in a cell- or tissue-specific manner.

In some embodiments, the first pair of loxP sequences comprises the wildtype sequence, and in some embodiments, the second pair of loxP sequences comprises a mutated loxP. In some embodiments, the first pair of loxP sequences comprises the loxP 5171 sequence and in some embodiments, the second pair of loxP sequences comprises the loxP 2272 sequence.

In some embodiments, the vector comprises a first regulatory sequence operatively linked to said second nucleic acid and said regulatory sequence is in antisense orientation and in some embodiments, the first regulatory sequence is a UbiquitinC promoter sequence. In some embodiments, the vector further comprises a second regulatory sequence, located 5' to said first regulatory sequence, wherein said second regulatory sequence is in sense orientation.

In some embodiments the vector further comprises a Bovine Growth Hormone polyadenylation signal positioned 3' to said second pair of loxP sites and in some embodiments, the vector further comprises a modified U3 LTR positioned 5'

27

to said polyadenylation signal. In some embodiments, the first regulatory sequence is tissue specific or in some embodiments, the first regulatory sequence is inducible.

In some embodiments, the miRNA agent is an shRNA.

In some embodiments, the miRNA specifically inactivates p53 or PTEN gene expression.

In some embodiments, the vector further comprises a second miRNA sequence of interest in antisense orientation fused to the miRNA sequence of interest. In some embodiments, the second miRNA sequence of interest modulates expression of a gene whose activity is cooperative with that of a gene modulated by said first miRNA sequence of interest. In some embodiments, the first and second miRNA sequence of interest regulate expression of a tumor suppressor.

In some embodiments, the first miRNA sequence of interest specifically inactivates one of p53 or PTEN gene expression and said second miRNA sequence of interest specifically inactivates the other.

In some embodiments, the vector comprises a sequence corresponding to or homologous to SEQ ID No: 27.

In some embodiments, the second miRNA sequence of interest modulates expression of a gene whose activity antagonizes that of a gene modulated by said the miRNA sequence of interest.

In some embodiments, the second nucleic acid encodes an oncogene.

In some embodiments, the vector comprises a third nucleic acid in antisense orientation, positioned between the first pair of loxP sequences, wherein the third nucleic acid encodes a protein of interest.

In some embodiments, the third nucleic acid encodes an miRNA specifically inactivating a tumor suppressor.

In some embodiments, the third nucleic acid encodes an miRNA specifically inactivating p53, PTEN or a combination thereof.

In some embodiments, the vector comprises a nucleic acid sequence corresponding to or homologous to SEQ ID NO: 21

In some embodiments, animal models, and/or treatment strategies for the following neoplasias are to be considered as part of this invention, when applying the vectors, nucleic acids, compositions and methods of this invention to create a model and/or treatment for a cancer which may comprise: comprise adrenocortical carcinoma, anal cancer, bladder cancer, brain tumor, brain stem glioma, brain tumor, cerebellar astrocytoma, cerebral astrocytoma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal, pineal tumors, hypothalamic glioma, breast cancer, carcinoid tumor, carcinoma, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, extrahepatic bile duct cancer, ewings family of tumors (Pnet), extracranial germ cell tumor, eye cancer, intraocular melanoma, gallbladder cancer, gastric cancer, germ cell tumor, extragonadal, gestational trophoblastic tumor, head and neck cancer, hypopharyngeal cancer, islet cell carcinoma, laryngeal cancer, leukemia, acute lymphoblastic, leukemia, oral cavity cancer, liver cancer, lung cancer, small cell lung cancer, non small cell lung cancer, lymphoma, AIDS-related lymphoma, central nervous system (primary), lymphoma, cutaneous T-cell, lymphoma, Hodgkin's disease, non-Hodgkin's disease, malignant mesothelioma, melanoma, Merkel cell carcinoma, metastatic squamous carcinoma, multiple myeloma, plasma cell neoplasms, mycosis fungoides, myelodysplastic syndrome, myeloproliferative disorders, nasopharyngeal cancer, neuroblastoma, oropharyngeal cancer, osteosarcoma, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, exocrine, pancreatic cancer, islet cell carcinoma, paranasal sinus and nasal cavity cancer, parathyroid

28

cancer, penile cancer, pheochromocytoma cancer, pituitary cancer, plasma cell neoplasm, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell cancer, salivary gland cancer, Sezary syndrome, skin cancer, cutaneous T-cell lymphoma, skin cancer, Kaposi's sarcoma, skin cancer, melanoma, small intestine cancer, soft tissue sarcoma, soft tissue sarcoma, testicular cancer, thymoma, malignant, thyroid cancer, urethral cancer, uterine cancer, sarcoma, unusual cancer of childhood, vaginal cancer, vulvar cancer, Wilms' tumor, or any combination thereof. It is to be understood that the animal models, and/or treatment strategies for the neoplasias listed herein, and in reference thereto in applying the vectors, nucleic acids, compositions and methods of this invention to create a model and/or treatment for such neoplasias are to be considered for application to preneoplastic or hyperplastic lesions thereof, as well, and represent other embodiments of this invention.

In another embodiment, the methods/vectors/compositions of this invention do not exhibit the limitation of causing constitutive gene silencing or gene expression, in all tissues.

According to this aspect of the invention, the methods of this allow for regulated expression of miRNA and thereby regulated expression of a desired coding sequence.

In another embodiment, this invention provides for kits for conditional reduction of expression, or conditional expression of a coding sequence, comprising one or more containers filled with one or more of the ingredients of the aforementioned vectors, or compositions of the invention.

The vectors of the invention may be employed, in another embodiment, in combination with a non-sterile or sterile carrier or carriers for administration to cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to an individual. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a recombinant virus of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, and combinations thereof. The formulation should suit the mode of administration.

The vectors or compositions of the invention may be employed alone or in conjunction with other compounds, such as additional therapeutic compounds.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by intravascular (i.v.), intramuscular (i.m.), intranasal (i.n.), subcutaneous (s.c.), oral, rectal, intravaginal delivery, or by any means in which the recombinant virus/composition can be delivered to tissue (e.g., needle or catheter). Alternatively, topical administration may be desired for insertion into epithelial cells. Another method of administration is via aspiration or aerosol formulation.

For administration to mammals, and particularly humans, it is expected that the physician will determine the actual dosage and duration of treatment, which will be most suitable for an individual and can vary with the age, weight and response of the particular individual.

The following examples are presented in order to more fully illustrate some embodiments of the invention. They should, in no way be construed, however, as limiting the scope of the invention.

EXAMPLES

Materials and Methods

Generation of Constructs

pLB2 was generated by modification of pLB [Kissler S, et al. Nat. Genet. 2006 April; 38(4):479-83] to introduce the FLIP insert, followed by insert fill in and ligation.

29

The FLIP insert comprises loxP 5171 and loxP 2272 genes, a modified puromycin resistance cassette incorporating the foot-and-mouth-disease virus (FMDV) 2A encoding sequence at its C-terminus, fused in frame to a gene encoding the Thy1.1 surface marker (See Schnutgen F, et. al., Nat. Biotechnol. 2003 May; 21(5):562-5 for methods), and nucleic acids encoding the indicated miR30 and GFP, as outlined in FIG. 1.

An miR30 following GFP was placed in an artificial intron by flanking the miR30 with consensus splice donor and splice acceptor sequences (underlined). The restriction sites NotI-PmeI (in bold) flanked a miR30 specific for firefly luciferase.

(SEQ ID NO: 1)
 agtaGCGGCCATTGCAGGTGAGTGG**gcggccgca**aggcttgttaagt
 ctcgttccggcagcacatatactatgtttgaatgaggcttcgacttta
 cagaatcggtgcctgcacatcttggaaacacttgctggattacttctt
 aggttaacccaaacagaaggctcgagAAGGTATATTGCTGTTGACAGTGAG
 CGAGCCTCCGTGAATTGGAATCCTAGTGAAGCCACAGATGTAGGATTCCA
 ATTTCAGCGGGAGCCTGCCTACTGCCTCGgaattcaagggctactttagg
 agcaatttatcttggtaactaaactgaataccttgctatctttgatac
 attttacaaaagctgaattaaaatggtataaattaaatcacttttcaa
tggaaagactaatgcgtttaaacCCCTGACTCTCCCCTTTTTTCCT
CTCAGGTATGCATAaac.

A similar construct was prepared, comprising a miR30 specific for $\alpha 4$ integrin:

(SEQ ID NO: 2)
 agtaGCGGCCATTGCAGGTGAGTGG**gcggccgca**aggcttgttaagt
 ctcgttccggcagcacatatactatgtttgaatgaggcttcgacttta
 cagaatcggtgcctgcacatcttggaaacacttgctggattacttctt
 caggttaacccaaacagaaggctcgagAAGGTATATTGCTGTTGACAGTGAG
 GCGCCGACATTCAACCATCATTAGTGAAGGCCACAGATGTAAATAAT
 GATGGTGAATGTCGTTGCCTACTGCCTCGGAattcaagggctacttta
 ggagcaatttatcttggttactaaactgaataccttgctatctttgat
 acattttacaaaagctgaattaaaatggtataaattaaatcacttttca
aattggaaagactaatgcgtttaaacCCCTGACTCTCCCCTTTTTTC
CTCAGGTATGCATAaac

It is noted that the preceding sequences represent sense orientation.

A pLB2 construct comprising the FLIP cassette containing miR30 targeting FireFly luciferase was constructed, with the following sequence:

(SEQ ID NO: 3)
 GTCGACGGATCGGGAGATCTCCGATCCCCTATGGTGCACTCAGTACA
 ATCTGCTCTGATGCCGATAGTTAAGCCAGTATCTGCTCCCTGCTGTG
 GTTGGAGGTGCTGAGTAGTGCGCGAGCAAAATTAAAGCTACAACAAAGGC
 AAGGCTTGACCACATTCAGAAGAATCTGCTTAGGGTAGGCGTTT

30

-continued

GGCTGCTTCGCGATGTACGGGCAGATAACGCCTGACATTGATTATT
 GACTAGTcatgttcttctgcgttatccccgtattctgtggataaccgt
 5 attaccgcctttaggctgagctgataccgcgcgcgaaaccgcacgca
 gcgcagcgcgatcagtgcggagaaagcggaaagagcggcaatacgcaaaac
 cgccctccccgcgttggccgattatgcgttgtgacacagg
 10 tttcccgcactggaaagcgcccgcaggctggatctgttagtta
 gtcactcattaggcaccgcggcttacactttatgttccggtcgta
 tgggtgtggaaattgtgagcggataacaatccacacaggaaacagctat
 15 gaccatgattacgccaaggcgcaattaaccctagcttaatgttagtcta
 tgcaatactctgttagtctgcacatggtaacgttagttagcaacatg
 ccttacaaggagagaaaaagcaccgtcatgcgttgcgattggggatgg
 20 tggtagatcgtgccttatttaggaaaggcaacacagacgggtctgacatggat
 tggacgaaccactgaattgcgcattgcagagatattttataggcc
 tagctcgatacaataaaccgggtctctggttagaccagatctgagcctg
 ggagctctggtaacttagggaaaccactgttaagcctcaataaaagct
 25 tgccttagttcttgcattacttggtgttagtgcgttgcggactctgg
 aactagagatccctcagaccctttactgttttttttttttttttttttttt
 tggcggccgaacaggacttgaaAGCGAAAGGGAAACCAGAGGAGCTC
 30 TCGACGCAGGACTCGGTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGC
 GGCGACTGGTGAGTACGCCAAAAATTGACTAGCGGAGGCTAGAAGGAG
 AGAGATGGGTGCGAGAGCGTCAGTTAACGGGGAGAATTAGATCGC
 35 ATGGGAAAAAATTGGTTAAGGCCAGGGGAAAGAAAAAATAAATTAA
 AACATATAGTATGGCGAACAGCAGGGAGCTAGAACGATTGCACTTAACTC
 GGCCTGTTAGAACATCAGAAGGCTGAGACAAATACTGGACAGCTACA
 40 ACCATCCCTTCAGACAGGATCAGAAAGAACTTAGATCATTATAAACAG
 TAGCAACCCCTATTGTTGCATCAAAGGATAGAGATAAAAGACACCAAG
 GAAGCTTAGACAAGATAGAGGAAGAGCAAACAAAAGTAAGACCCACCGC
 45 ACAGCAAGCGGCCGCGCGTGTATCTCAGACCTGGAGGGAGATATG
 AGGGACAATTGGAGAAGTGAATTATAAAATATAAAAGTAGTAAAATTGA
 ACCATTAGGAGTAGCACCACCAAGGCAGAGAGATGGTGAGAGAG
 50 AAAAAGAGCAGTGGGAAATAGGAGCTTGTCTGGTTCTGGGCA
 GCAGGAAGCACTATGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAG
 ACAATTATTGCTGGTATAGTGCGCAGCAGACAATTGCTGAGGGCTA
 TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGCATCAAGCAG
 55 CTCCAGGCAAGAATCTGGCTGTGAAAGATACCTAAAGGATCAACAGCT
 CCTGGGGATTGGGTTGCTCTGGAAAACCTATTCGACCACTGCTGTC
 CTTGGAAATGCTAGTTGAGTAATAATCTCTGGAAACAGATTGGAATCAC
 60 ACGACCTGGATGGAGTGGGACAGAGAATTAACAATTACACAAGCTTAAT
 ACACCTCTTAATTGAAAGAATCGCAAAACAGCAAGAAAAGAATGAACAAG
 AATTATTGAAATTAGATAAATGGCAAGTTGTTGGAATTGGTTAACATA
 65 ACAAAATTGGCTGTTGATATAAAATTATTCAATGATAGTAGGAGGCTT

US 9,043,994 B2

31

-continued

GGTAGGTTAAGAATAGTTTGCTGTACTTCTATAGTGAATAGAGTTA
 GCCAGGGATATTCAACCATTATCGTTTCAGACCCACCTCCAAACCCGAGG
 GGACCCGACAGGCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGACAG
 AGACAGATCCATTGATTAGTAGAACGGATCGGCACTGCGTGCGCAATT
 TCGAGACAAATGGCAGTATTCATCCACAATTAAAAAGAAAAAGGGGGAT
 TGGGGGTACAGTGCAGGGAAAGAATAGTAGACATAATAGCAACAGACA
 TACAAACTAAAGAATTACAAAACAAATTACAAAATTCAAATTTCGG
 GTTTATTACAGGGACAGCAGAGATCCAGTTGTTAGTACCGGGCCGGT
 GCTTGCTCTGAGCCAGCCCACCAAGTTGGAATGACTCCTTTATGACT
 TGAATTTCAAGTATAAAAGTCTAGTGTCAAATTAAATTGAAACAATGTA
 TAGTTTGCTGGTTGGGGAAAGGAAAAAAATGGTGGCAGTGT
 CAGAATTAGAAGTGAATGAAAATCTGTTGTGTGAGGATTCTAATGA
 CATGTGGTGTTGCATACTGAGTGAAAGCCGTGAGCATTCTGCCATGTCA
 CCCCCCTGCTCAGTAATGTACTTTACAGAAATCCTAAACACTCAGCCT
 GCATTCTGCCAGGGCCCGCTCTAGATCTAGACGGTTGATCTggcctccg
 cgccgggttttggcgtcccgccggcccccttcacggcagcgc
 tgccacgtcagacgaaggcgcaggagcgttcgtatccggccgg
 cgctcaggacagcggccgcgtcataagactcgccattagaaccccag
 tatcagcagaaggacatttaggacggacttggtgactctagggact
 ggtttttccagagagcggAACAGGCGAGGAAAGTAGTCCTTC
 gcgattctcgaggagatctctgtggggcggtgaacgcggatgattata
 taaggacgcgggggttggtggcagactgttcgtcgccggggattt
 ggtcgeggttttgttggtggatcgctgtatcgtaacttggtgagtgc
 gggctgtgggtggccggggcttcgtggccggggccgtcggtgg
 acggaaaggcgttgagagaccgccaaggctgtatgtctgggtccgcgc
 aagggtgcctgaactgggggtggggggagcgcacaaaatggggctgt
 tcccgagtcttgaatggaagacgcgttgtaaggcgggtgtgaggctgt
 aaacaagggtggggcatggtggccgcagaaggacttgcaggcc
 ttcgctaattcgccggaaaggcttattcggttgaggatggctggggcaca
 tctggggaccctgcgtgaagttgtcaactgcggagaactcgggttt
 tcgtctgggttggggggccggcagttatcggttgccgttgccgtgcacc
 cgtaccccttggagcgcgcgcctcgtgtgtgcgtacgcacccgttctg
 ttggcttataatgcagggtggggccacccgtggtaggtgtccgttaggc
 tttctccgtgcaggacgcagggttcggccattaggtaggtaggcttcc
 atcgacaggccggcgcacccgtggtagggggaggataagtggggcgtcg
 tttcttggtcggtttatgtacctatctttaagttagtgcaggactcc
 gtttgaactatgcgtcggttggcagtggtgtttgtgaagtttt
 aggcacctttaatgtaatcatgggtcaatatgtaaatttgcgt
 tagacttagtaattgcgtcaatttcggccgttttggttgcgttttgc
 agacGAAGTACCGCCTAGCCGTTAATAAGCCTCGATGCggatccataact

32

-continued

tgcgtataggataacctatacgaaagtatctcgaggtaaccgcaccatgacc
 gagtacaaggccacggcgccctcgccacccgcgcacgcgtccccagggc
 5 cgtacgcaccctcgcccgccgttcgcgcactaccgcgcacgcgcaca
 ccgtcgatccggaccgcacatcgagcgggtcaccgcgcacgcgtcaagaactc
 ttccctacgcgcgtcggtcgacatcgcaagggtgtggtgcggacga
 10 cggccgcgggtggcgttgcgcaccacgcggagagcgtcgaaagcgggggg
 cgggttcgcgcagatcgccgcgcatggccgcgttgcggatcgccgttcccg
 ctggccgcgcgcacacagatggaaaggcttgcgcgcgcaccgcggccaa
 15 ggagccgcgtggttctggccaccgcgtcgccgttcgcgcaccagg
 gcaagggtctgggcagcgcgcgtgtgcgcgtcccgaggatggaggccggccag
 cgcgcgggggtgcccgccttcggagacccgcgcgcgcaccctccc
 20 ctcttacgcgcgcgtccgcgttcaccgcgcacgcgtcgagggtgc
 aaggaccgcgcacccgtggcgtatgcgcgcgcgcgcgcgcgcgc
 aaacagaaaattgtggcaccactgtaaacagacttgcaccc
 caagtttgcggagacgtcgacttgcgcgcgcgcgcgc
 25 tcagcgtcgctccgtctcgatcttcgcgcgcgcgcgcgcgc
 gtgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc
 ccgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc
 30 tgacccgcggagacgtcgacttgcgcgcgcgcgcgc
 gagcacacgttccgcgcgcgcgcgcgcgcgc
 ggtccttaccctagccaaacttccaccacaaggatgcggcgc
 35 gtgagcttcgcgttgcggcgcgcgcgcgcgc
 agtgtgtatagagacaaactgtgtgcgcgcgcgcgcgc
 tcagaacacatctggatgtgtgtgtgtgtgt
 40 aaggccctggacttcatttcgtgtatctagaaggccataacttcgtatag
 tacacattatacgaaaggatgttaacgcattacttccaaattgaaaa
 aagtgtttaatttataccatttataattcgcatttgc
 45 agagatagcaaggatttgcgttgcgcgcgc
 tagcccccttgcatttcgcggcgttgcgcgcgcgc
 CTACATCTGTGGCTTCACTAGGATTCCAATTACGGGAGCTCGCTACTG
 50 TCAACAGCAATATACCTTtcgcgccttcgtgggttaacctgt
 taatcccgcaagtgttccaaagatgtgcaggcaacgattctgt
 ctgcgcgcgcgcgcgcgc
 55 caaggcgttgcggccgcgcgcgcgcgcgcgcgc
 cggccggccgcgcgcgcgcgcgc
 gggctttgcgtcggttgcgcgcgcgcgc
 cagcaggccgcgcgcgcgcgc
 60 gctgcacgcgtccgttcgtgcgttgcgcgcgc
 atgcgcgttgcgttcgtgcgcgcgcgcgc
 gttgtactccaggccaggatgtggccgttgcgcgc
 tgcgcgttgcgttcaccagggtgcgcgc
 65 tgcgcgttgcgttcaccagggtgcgcgc
 tgcgcgttgcgttcaccagggtgcgcgc

33

-continued

tccggcgccgggttttagttgcgcgtcgccttgaagaagatggcgctc
 ctggacgtageccctcgggcatggcgacttgaagaagtcgtgtcgctca
 tggcgccggtagcggtgaagcactgcacggcgtaggtcagggtggc
 acggggtgcccggccaggccacggcgacttgcgggtggcagatgaaactt
 cagggtcagttgcgttaggtggcatgcgcctgcgcctgcggcacacgc
 tgaacttgcgcgtttacgtgcgcgtccagtcgaccaggatggcacc
 accccggtaaacagctcgcctgtctaccatggtgccgaccggat
 aacttcgtataaggatccatatacgaagttatccattcaggctgtctag
 catcaatggcatggcacaaagcttagccataacttcgtataatgtgtact
 atacgaagttatccTGTTAAAGGGTTCGGTCACTAGGTACAATTG
 ATATCAAGCTTACGATAATCAACCTCTGGATTACAAAATTGTGAAAGA
 TTGACTGGTATTCTTAATCATGTTGCTCCTTACGCTATGTTGACCG
 TGCTTAAATGCCCTTGATCATGCTATTGCTCCGTATGCCCTCATTT
 TCTCCCTTGATAAACCTGGTGTGCTCTTATGAGGAGTTG
 CCCGTTGTCAGGCAACGTGGCGTGTGCACGTGTTGCTGACGCAAC
 CCCCACGGTGGGGATTGCCACCACCTGTCAGCTCCTTCGGGACTT
 TCGCTTCCCCCTCCATTGCCACGGCGGAACTCATGCCGCTGCC
 GCCGCTGCTGGACAGGGCTGGACTGACAATTCCGTGGT
 GTTGTGGGAAATCATGTCCTTCCCTGGCTGCTCGCCTGTTG
 CCTGGATTCTGCGCGGACGTCCTCTGCTACGTCCTTCGGCCCTCAAT
 CCAGCGGACCTCCCTCCCGGCCCTGCTGCCGCTCTGCC
 GCGTCTCGCCTCGCCCTCAGACGAGTCGGATCTCCCTTGGCGCCT
 CCCCACGATCGATACCGTCGACCTCGATCGAGACCTAGAAAACATGGAGC
 AATCACAAAGTAGCAACACGAGCTACCAATGCTATTGTGCTGGTAG
 AAGCACAAAGAGGAGGAGGAGGTGGGTTTCCAGTCACACCTCAGGTACCA
 AGCATGGGTAAGTACTGTTCTCATCACATCATCAAGGTTATATACC
 ATCAATATTGCCACAGATGTTACTTAGCCTTTAATATTCTCAATT
 GTGTATATGCAATGATAGTTCTCTGATTCTGAGATTGAGTTCTCATGT
 GTATGATTATTAGAGTTCTCTTCAATGTTCTGAAACTTCTTCTG
 TTTTCTTACTGATTGTAAGACTTCTTTATAATCTGCATATTACA
 ATTCTCTTACTGGGTGTTGCAAATATTTCTGTCATTCTATGCC
 CTTTCTTAATGGTTTTAATTTAAAATAAGTCTTAATATT
 ATCTAATTAAACATCTTCTTGTTGAGACTTGTGAGTCATAAGAAA
 TTTTCTCTACAGTGAAGTCATGATGGCATGCTTCTATATT
 AAGATTAAAGTTGCCTCTCCATTAGACTTATAATTCACTGGATT
 TTTTGTGTATGGTATGACATATGGTCCCTTTATTACATAT
 AAATATTTCCCTGTTTCTAAAAAAGAAAAGATCATCTTCCA
 TTGTAATGCCATATTTCTCATAGGTCACTTACATATATCAATGGGT
 CTGTTCTGAGCTACTCTATTATCAGCCTCACTGTCATCCCCACA
 CATCTCATGCTTGCTAAATCTGATATTAGTGGAACATTCTTCC

34

-continued

ATTTGTTCTACAAGAATATTTTGTTATTGCTTTGGGCTCTATATA
 CATTTTAGAATGAGGTTGGCAAGGTACCTTAAGACCAATGACTTACAAG
 5 GCAGCTGTAGATCTAGCCACTTTAAAAGAAAAGGGGGACTGGAAGG
 GCTAATTCACTCCAGGTGCTTTCGCTGTACTGGTCTCTGGTAG
 ACCAGATCTGAGCCTGGAGCTCTGGCTAACTAGGGAAACCACTGCTT
 10 AAGCCTCATAAAGCTCGACTGTGCCTCTAGTTGCCAGCCATCTGTTGTT
 TGCCCTCCCCGTGCCTTCCTGACCTGGAAGGTGCCACTCCACTGT
 CCTTCTCTAATAAAATGAGGAAATTGATCGCATTGCTGAGTAGGTGTC
 15 ATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGAGGATTGG
 GAAGACAATAGCAGGCATGCTGGGATGCGGTCCGACTGTACTGGTCT
 CTCTGGTAGACCGAGATCTGAGCCTGGAGCTCTGGCTAACTAGGGAA
 20 CCCACTGCTTAAGCCTAATAAGCTGCTTGTGAGTGCTCAAGTAGTGT
 GCGCGTCTGTTGACTCTGGTAACTAGAGATCCCTCAGACCCCTTA
 GTCAAGTGTGAAAATCTAGCAGCATGTGAGCAGGAAAGCCAGCAAAGG
 25 CCAGGAACGTTAAAGGCCGCGTTGCTGGCTTTCCATAGGCTCCGC
 CCCCCGACGAGCATCACAAAATCGACGCTCAAGTCAGAGTGGCGAAA
 CCCGACAGGACTATAAAAGATACCAGGCGTTCCCTGGAAGCTCCCTCG
 TGCGCTCTCTGTTCCGACCCCTGCCGTTACCGGATACCTGTCGCC
 30 CTCCCTCGGAAGCGTGGCGCTTCTCATAGCTCACGCTGTAGGTATCT
 CAGTCGGTAGGTCGTTGCTCCAAGCTGGCTGTCAGAACCCC
 CGTTCAAGCCGACCGCTGCCGCTTACCGGTAACATCGCTTGAGTCC
 35 AACCCGTAAGACACGACTATGCCACTGGCAGCAGCCACTGGTACAG
 GATTAGCAGAGCAGGTATGAGCGGTGCTACAGAGTTCTGAAGTGGT
 GGCTTAACACTGGCTACACTAGAAGACAGTATTGGTATCTGCGCTCG
 40 CTGAAGGCACTTACCTCGAAAAAGAGTGGTAGCTTGTGATCCGGAA
 ACAAAACACCGCTGGTAGCGGTGGTTTTGTTGCAAGCAGCAGATTA
 CGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTGATCTTCTACGGG
 45 TCTGACGCTCAGTGGAACGAAACTCACGTTAAGGGATTTGGTCAG
 ATTATCAAAAGGATCTCACCTAGATCCTTTAAATTAAAATGAAGT
 TTAAATCAATCTAAAGTATATGAGTAAACTGGCTGACAGTTACCAA
 50 TGCTTAATCAGTGGACCTATCTCGCAGTCGTCTATTGCTCATC
 CATAGTTGCCGACTCCCCGTCGTAGATAACTACGATAACGGGAGGGCT
 TACCATGCGCCAGTGTGCAATGATACCGCGAGACCCACGCTCACCG
 55 GCTCCAGATTATCAGCAATAACCGCCAGCCGGAGGGCGAGCGCAG
 AAGTGGCTCGCAACTTATCCGCCCTCATCCAGTCTATTAAATTGTC
 GGGAGCTAGAGTAAGTAGTCGCCAGTTAATAGTTGCGCAACGTTGTT
 GCCATTGCTACAGGCACTGTTGTCAGCCTGCTGTTGGTATGGCTC
 60 ATTCAGCTCCGGTCCCAACGATCAAGGCGAGTTACATGATCCCCATGT
 TGTGCAAAAGCGGTTAGCTCCTCGGTCTCCGATCGTTGTCAGAAGT
 AAGTTGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAATT
 65 TCTTACTGTCATGCCATCCGTAAGATGCTTTCTGACTGGTAGTACT

US 9,043,994 B2

35

-continued

```

CAACCAAGTCATTCTGAGAATAGTGTATGCCGCACCGAGTTGCTCTTGC
CCGGCGTCAATACGGATAAACCGCGCCACATAGCAGAACTTAAAAGT
GCTCATCTGGAAACGTTCTCGGGCGAAAACTCTCAAGGATCTTAC
CGCTGTTGAGATCCAGTCGATGTAACCCACTCGCACCCAACGTGCT
TCAGCATCTTTACTTACCCAGCCTTCTGGGTGAGCAAAACAGGAAG
GCAAAATGCCGAAAAAGGGATAAGGGCAGACGGAAATGTTGAATAC
TCATACTCTCCCTTTCAATATTATTGAAGCATTATCAGGGTTATTGT
CTCATGAGCGGATACATATTGAATGTATTAGAAAAATAACAAATAGG
GGTCCCGCACATTCCCCGAAAGTGCCACCTGAC

```

The pFLIP insert comprising an RNAi to p53 (not in an intron) has a nucleic acid sequence as follows (microRNA-short hairpin to p53 in upper case):

(SEQ ID NO: 4)

```

tccataacttcgtataggataacctatacgaagttatctcaggtaaccgc
accatgacggagtacaagccacggtgcgccctcgccacccgcacgacgt
ccccagggccgtacgacccctcgccgcggcgtcggcactacccgcga
cgccacaccgcgtcgatccggaccgcacatcgagcgggtcaccgagctg
caagaactttctcacgcgcgtcggcgtcgacatcgcaagggtgtgggt
cgccggacgacggccggcggtggcggtctggaccacgcggagagcgctg
aagcgggggcggtttcgcccgagatcgcccgccatggcccgagttgagc
ggttcccggtcgcccgccgacaaacagatggaaaggccctcgccgcgc
ccggccaaaggagcccggtggccctggccaccgtcgccgtctgcggcc
accaccaggcgcaagggtctggcagcgccgtcggtctcccgagttggag
ggggcccgagcgccgggggtgcccgcgttctggagaccccgccggcc
caaccccccctctaegagcggtcggttcaccgtcacccgcacgtcg
aggtgecccgaaaggacccgcacccgtgtcgatgaccggcaagccgggt
ctgtacaagaaaacagaaaatttgtggcaccagtggaaacagacttgtaa
tgaccttcgtatggcggagacgtcgagtccaaacctggggcatga
accaggccatcagcgctctctgtctcgatcttcgtcgagggtgtcccg
ggcagaagggtgaccacgcgtacacgcgtcgccgtgaacccaaaccc
cctggactgcgcctgagaataacaccaaggataactccatccacgtcg
atgtcagccgtaccggagagaagaggaagcgtgtcgatcccgcc
ggataccggacacacgtaccgcgtcccggtcaccctctccaaaccc
ctatatcaaggcccttagccaacttcaccaccaaggatggggcg
actactttgtgagttcgagtctcgccggcgaaatccatgagctccat
aaaagtatcgtgtatagagacaaactggtcaagtgtggccgataag
cctgtgggttcaagacacatccgttatcgatctgtgtgtcttccct
ccctccccaagccctggacttcattctctgtatctagaaggcataac
ttcgatagtagacattatacgaaagtatGTTAACGCATTAGTCTTCC
AATTGAAAAAAAGTGTATTAAATTATACCATTTAATTCAAGCTTGTAAAA
ATGTATCAAAGAGATAGCAAGGTATTCAGTTTAGTAAACAAGATAATTG

```

36

-continued

```

CTCCTAAAGTAGCCCCTGAAATCCGAGGCAGTAGGCATCCACTACAAGT
ACATGTGTAATACATCTGGCTTCACTATTACACATGACTTGTAGTGG
5 GCGCTCACTGTCAACAGCAATATACCTCTCGAGCCTCTGTTGGTTAA
CCTGAAGAAGTAATCCCAGCAAGTGTTCAGATGTGCAGGCAACGATT
CTGTAAAGTACTGAAGCCTCATCAACATAGTATATGTGCTGCCGAGC
10 GAGCACTTAACAAGGCTTGCGGCCGtaacttgtacagctgtccatgcgc
agagtgtatccggcgccgtcagcaactccagcaggaccatgtgatcg
cttctcggtgggtcttgcgtggccggactgggtgtcaggtagtgg
15 tgcggcagcagcacggggccgtcgccgtatgggtgttctgtgtggtag
tggtcggcgagctgcacgctgcgtcgatgtgtggccgtatctggtag
gttcacccgtatgcgttctgtgtgtccatgtatagacgttgt
20 ggcgtgtgttagtgtactccagttgtgtccccaggatgtgtccgtctcc
ttgaagtcgtatgccttcagctcgatcggttccaccagggtgtccctc
gaacttcacccgtcgccgggtcttgcgtatgtgtccgtccctgaagaaga
25 tggtgcgtccctggacgttagccctcgccatggccgtatggccgttgaagaagtcg
tgcgtccatgtgtgtccgggttagccgtgaagcactgcacccgttaggt
cagggtgtcagcagggtggccaggccacggcagcttgcgggtgtgc
30 agatgaacttcagggtcagttgtccgttaggtgtccatccctcgccctcg
ccggacacgctgaacttgtggccgttacgtcgccgtccagctcgaccag
gtggcaccaccccggtgaacagctccctgcctgtcaccatgttgg
35 cgaccggataacttcgtataaggatccatcgtacgttatccattcg
gtgtgttagcatcaatggcatggcacaagcttagccataacttcgtat
aatgtgtactatacgaaagtatcccggtt.

```

GFP-miR30 flanked by a single loxP site, as FLIP would look after Cre-mediated recombination, has a sequence as follows:

(SEQ ID NO: 5)

```

45 atggATAACTTCGTATAAgataacctTATACGAAGTTAaccgggtcgccac
catggtagcaaggccggaggagctgttccaccgggtgggtccatctgg
tcgagctggacggcgtaaacggccacaagttcagctgtccggcgag
50 ggcggaggccgtgccacccgtccacggcaagctgaccctgtcaagttcatctgcac
caccggcaagctgcccgtggccaccctcggtaccaccctgcac
acggcggtcagtgttcagccgttccaccggaccacatgaagcagcagac
55 ttcttcgtatccgtccatgtcccgaaagggtacgtccaggagcgtaccatctt
cttcaaggacgcggcaactacaagacccgcggccagggtgaagttcgagg
gcgcacccctggtaacccgtcgacgtgaagggcatcgacttcaaggag
60 gacggcaacatctggccacaagctgggttacactacaacacggccaca
cgtctatcatggccacaaggcacaacggcatcaaggtaacttca
agatccgcacaacatcgaggacggcgtcagctgcgtccgaccactac
cagcagaacaccccatcgccgtccggccggccgtgtgtccggacaacca
65 ctacctgagcaccctgtccgtccatgtccggccaccactac

```

US 9,043,994 B2

37

-continued

atcacatggctctgctggagttcgtagccgcggggatcaacttcggc
atggacgagctgtacaaga taCGGGCGCAAGCCTTGTAAAGTGCTCGTT
CGGCAGCACATATACTATGTTGAATGAGGCTTCAGTACTTACAGAATC
5 GTTGCTGCACATCTGGAAACACTGCTGGATTACTTCTTCAGGTTAA
CCCAACAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGGCCAC
TACAAGTACATGTGTAATAGTGAAGCCACAGATGTATTACACATGACTT
10 GTAGTGGATGCCTACTGCCTCGGAATTCAAGGGCTACTTAGGAGCAAT
TATCTGTTACTAAAATGTAATACCTGCTATCTCTTGATACATTTT
ACAAAGCTGAATTAAATGGTATAAATTAAATCACTTTTCATGGAA
15 GACTAATGCGTTAACATAACTCGTATAatgtgtactATACGAAGTTA
Tggc.

pLB2 comprising the FLIP cassette comprising an intron with restriction sites NotI-PmeI and has a sequence as follows:

(SEQ ID NO: 6)
GTCGACGGATCGGAGATCTCCGATCCCCTATGGTGCACTCTCACTACA
ATCTGCTCTGATGCCGATAGTTAACGGCAGTACTGCTCCCTGCTGTGT
GTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTAAAGCTACAACAGC
AAGGCTTGACGACAATTGATGAAGAACATGCTTAGGGTTAGGGCTTT
GCGCTGCTTCGCGATGTACGGCCAGATATACCGCTTGACATTGATTATT
GACTAGTcatgttcttcgttatcccctgattctgtggataaccgt
attaccgccttgagttagtgcataccgcgtcgccgcagccgaacgaccga
goggcagcggatcgttagcgccggaaaggccggaaatcgcggccaaac
cgccctccccggcggtggccgattcattaatgcggctggccacgacagg
tttcccgactggaaaggccggcgttagcgccaaatgtggat
gtctcaactcattaggccacccaggcttacactttatgcctccggctcgta
tgttggatgtggatattgtggccgataacaatttcacacaggaaacagctat
gaccatgattacgccaaggccggcaattaccctagcttaatgttagtctta
tgcaataactcttgcgttgcacatggtaacgtatgttagcaacatg
ccttacaaggagagaaaaaccggccatgcggatggggatggggatagg
tggtaatcgatcgccatttaggaaggcaacacgggtctgacatggat
tggacgaaaccactgaaattggccattgcggatattgtttaatgtgg
tagctcgatcaaataacgggtctctggtagaccatgtggcc
ggagctctggtaacttagggaaaccactgcttaacgctcaataagct
tgccttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc
aactagagatccctcagacccttttagtgcgttgcgttgcgttgcgttgc
tggcccccggaaacaggacttggaaaggcaaggccggatggggatgggg
TCGACGCAGGACTCGGCTTGCTGAAGCGCGACGGCAAGAGGGGAGGGC
GGCGACTGGTGAGTACGCCAAAATTGACTAGCGGAGGCTAGAAGGAG
AGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGAGAATTAGATCGCG
ATGGGAAAAAAATTGGTTAAGGCCAGGGGAAAGAAAAAAATTAAATTAA

38

-continued

AACATATAGTATGGCAAGCAGGGAGCTAGAACGATTGCAAGTTAACCT
GGCCTGTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACA
5 ACCATCCCTCAGACAGGATCAGAAGAACTTAGATCATTATATAATACAG
TAGCAACCCCTCTATTGTGTGATCAAAGGATAGAGATAAAAGACACCAAG
GAAGCTTAGACAAGATAGAGGAAGAGCAAAACAAAGTAAGACCACCGC
10 ACAGCAAGCGGCCGCGCCTGATCTCAGACCTGGAGGAGGAGATATG
AGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAATTGA
ACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAG
15 AAAAAGAGCAGTGGGAATAGGAGCTTGTCTGGTTCTGGAGCA
GCAGGAAGCACTATGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAG
ACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAATTGCTGAGGGCTA
20 TTGAGGCCAACAGCATCTGTTGCAACTCACAGTCTGGGCATCAAGCAG
CTCCAGGAAGAATCTGGCTGTGGAAAGATACTAAAGGATCAACAGCT
CCTGGGATTGGGTTGCTCTGGAAACTCATTTGACCAACTGCTGTGC
25 CTTGGAATGCTAGTTGGAGTAATAATCTCTGGAACAGATTGGAATCAC
ACGACCTGGATGGAGTGGACAGAGAAATTAAACAATTACACAAGCTTAAT
ACACTCCTTAATTGAAGAATCGAAAACCAGCAAGAAAAGAATGAACAAG
30 AATTATTGGAATTAGATAAATGGCAAGTTGTGGATTGGTTAACATA
ACAAATTGGCTGTGGTATATAAATTATTCTATAATGATAGTAGGAGGCTT
GGTAGGTTAAAGAATAGTTTGTGTACTTTCTATAGTGAATAGAGTTA
35 GGCAGGGATATTACCAATTATCGTTAGACCCACCTCCAACCCCGAGG
GGACCCGACAGGCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAG
AGACAGATCCATTGATTAGTGAACGGATCGGACTCGTGCGCCATT
TGCAGACAAATGGCAGTATTCTCCAAATTAAAAGAAAAGGGGGGAT
40 TGGGGGGTACAGTGCAGGGAAAGAATAGTAGACATAATAGCAACAGACA
TACAAACTAAAGAATTACAAAACAAATTACAAAATTCAAAATTTCGG
GTTCATTACAGGGACAGCAGAGATCCAGTTGGTTAGTACCGGCCGGT
45 GCTTGTCTGAGCCAGCCCACAGTTGGAAATGACTCCTTTATGACT
TGAATTTCAGTATAAAAGTCTAGTGTAAATTAAATTGAACAACGTGA
TAGTTTTGCTGGTGGGGAAAGGAAAAAAATGGTGGCAGTGTGTTTT
50 CAGAATTAGAAGTGAATGAAAATTGTTGTGTGAGGATTCTAATGA
CATGTGGTGGTGCATACTGAGTGAAGCGGGTGGCAGTGTGTTTT
CCCCCTCGTGCAGTAATGTACTTACAGAAATCTAAACTCAAAGAT
55 TGATATAAAACATGCTCTTGTGTATACCGGTCTCTCTGGTAGTC
TCACTCAGCCTGCATTCTGCCAGGGCCGCTAGATCTAGACGGTTGA
TCTggccctccggccgggtttggccctccggccggccccccctcc
60 acggcgacgcgtccacgtcagacgaaaggccggcggccgttgcgttgc
ttccggccggacgcgtcaggacagccggccgtgcataagactccggcc
tagaaccctcgtatcggcggccatattttggacggacttggtgac
65 tctaggcactggttttccagagagcggaaacaggcggaggaaaagta

US 9,043,994 B2

39

-continued

gtcccttcggcgattctcgaggatctccgtgggggggtgaacgcc
 gatgattataaggacgcgcgggtgtggcacagctagttcgcgcag
 cgggatttgggtcgcggtttgttgatcgctgtgatcgactt
 ggtgagttcggtgtgtgggtggccgggtttcggtggccggggcc
 gtcgggtgggacggaagcgtgtggagagaccgcaaggctgttagtctgg
 gtccgcgagcaagggtggccctgaactgggggttggggggagcgcacaaaa
 tggcggtgttcccgagtctgaatggaaagacgctgttaaggcggtgt
 gaggtcggtgaaacaagggtggggcatgtggggcggcaagaacccaagg
 tcttgggccttcgtaatgcgggaaagctttatcggttagatggc
 tggggcaccatctgggaccctgacgtgaagttgtcactgactggagaa
 ctgggtttgtctgtttggggggggcggcagttatcggtggccgttgg
 gcagtgcacccgtaccttgggagcgcgcgcctcgctgtgacgtc
 acccgttctgtggctataatgcgggtggggcacctgcccgttaggt
 tgccgtaggcttctccgtcgcaggacgcagggttcggccttaggttag
 gctctctgaatcgacaggcgccggacctcggttaggggggggataagt
 gaggcgtcagttttttgtcggtttatgtacatatcttaagtac
 tgaagctccgtttgaactatgcgtcggtggcgagttgtgtttgt
 gaagtttttaggcacctttgaaatgtaatcattggtaaatatgtaa
 ttttcagtgttagacttagtaattgtccgttaattctggcgttttgg
 ctttttgttagacGAAGTACCGCCTAGCCGTTAATAAGCCTCGATGCgg
 atccataacttcgtataggataccttatacgaagttatctcaggtaccgc
 caccatgaccgagtacaagccacggtgccgcctcgccacccggcagacg
 tccccaggccgtacgcaccctcgccgcgttgcgcactacccggc
 acggccacacccgtcgatccggaccggccacatcgagcgggtcaccgagct
 gaaagaactttccacgcgcgtcggtcgacatcgcaagggtgtgg
 tcgcggacgacggcgecgccgggtcggtctggaccacccggagacgc
 gaaggccgggggggtgttcggcagatcgcccgccgtcgatggccgagttgag
 cggttccggcggtggccgcgcagcaacagatggaaaggctctggcgccgc
 accggcccaaggagcccgctgtgttctggccacccgtcgccgtctcgcc
 gaccaccagggoaagggtctggcagcgcgtcgatccccggagtgga
 ggccggcgcgcgggggtggccgccttcctggagacccgtcgccgc
 gcaaccccttcacgcgcgtcggttcacccgtcaccggcgcacgtc
 gaggtgcggcgaaggacccgcgcacccgtcgatgaccggcaaggccgggtgc
 cctgtacaagaaacagaaaattgtggcaccagtgaaacagacattgt
 ttgacccatcagcgtcgctctctgtcagttcgagggtgtcc
 aacccagccatcagcgtcgctctctgtcagttcgagggtgtcc
 agggcagaaggtgaccagccgtgcacacccgtcgccgtgtgaaccaaacc
 gcctggactgcgcgcgtgagaataacaccaaggataactccatcc
 gagttcagccgtaccggagagaagagaaacgcgtctcgaggacc
 cgggatacccgagcacacgtaccgcgtcccgcggtcaccctctca
 cctatatcaaggccttaccctagccaaattcaccaccaaggatgaggc

40

-continued

gactactttgtgagcttcgagtcgtcgatccatgagctcaa
 taaaagtatcagtgttatagagacaaactgtcaagtgtggccgataaa
 5 gctgtcggttgcagaacacatcctggatgcgtgtgtgtgtgtttcc
 tccttcctccaagccctggacttcatttcctgtgtatagaagccataa
 cttcgtatagtagtacacattatacgaagttatgtttATGCATACCTGGAGGA
 10 AAAAAAAAAGGGGAGAGTCAGGGTTAACCTGGAATGAAAGGTCAAGGT
 GTGACGTCAGCTGGCGGCCACTCACCTGCAATTGGCCGtact
 tgtacagctgtccatgcgcagagtgatcccgccgggtcacaactcc
 15 agcaggaccatgtgatcgccgttctcggtgggtcttgcagggcga
 ctgggtgtcaggtagtgggtcgccgcagcgcacggggccgtcgcc
 tgggggtgtctgtgttagtggtcggcagctgcacgctgcgttgc
 20 atgttgcggatcttgcgttttttttttttttttttttttttttttt
 ggcattatagacgttgcgtgttttttttttttttttttttttttt
 ccaggatgttgcgttcccttgcgttttttttttttttttttttt
 25 ttaccagggtgtccgcctcgaaacttacccctcgccgggttttt
 gccgtgccttgcgttttttttttttttttttttttttttttttt
 tggccgacttgcgttttttttttttttttttttttttttttttt
 30 aacactgcacccgttaggtcagggtgtcaagggtggccaggac
 gggcagttgcgggtggtcagatgaaacttcagggtcagttgcgtt
 tggcatgcctcgccctcgccggacacgctgaacttgcgttgc
 35 tcgcgcgtccagctcgaccaggatggcaccaccccggtgaac
 ggccttgccttgcaccatggggccggatataacttcgtataagg
 atacgaagttatccattcaggctgtgttagatcaatggcatgg
 40 ctttgcataacttcgtataatgtgtactatacgaattatccTGTT
 AAGGGTTCGGTCCACTAGGTACAATTGATATCAAGCTTATCGATAAT
 CAACCTGGATTACAAAATTGTGAAAGATTGACTGGTATTCTTA
 TGTTGCTCTTTACGCTATGTGGATACGCTGCTTAAAGCCTTGATC
 45 ATGCTATTGCTTCCGTATGGCTTCATTTCCTCCTTGTATAAATCC
 TGTTGCTGTCTCTTATGAGGAGTTGCTGGCCCGTTGTCAGGCAACCTGG
 CGTGGTGTGCACTGTGTTGCTGACGCAACCCCCACTGGTGGGGCATTG
 50 CCACCCACTGTCACTCCCTTCGGGACTTTGCTTCCCTCCCTATT
 GCCACGGCGGAACCTCATGCCGCCTGCCCTGCCGCTGCTGGACAGGGC
 TCGGCTGTTGGCACTGACAATTCCGTGGTGTGTCGGGAAATCATCGT
 55 CCTTCTGCTACGTCCCTCGCCCTCAATCCAGCGGACCTCCCTCC
 CGGCGCTGCGCCCTCGCCCTCTCCGCGTCTCGCCTTCGCCCT
 60 AGACGAGTCGGATCTCCCTTGCCCGCTCCCGCATCGATACCGTGA
 CCTCGATCGAGACCTAGAAAAACATGGAGCAATCACAAGTAGCAATACAG
 CAGCTACCAATGCTGATTGTGCTGGCTAGAAGCACAAGAGGAGGAG
 65 GTGGGTTTCCAGTCACACCTCAGGTACCAAGCATGGGTAAAGTACTGT

US 9,043,994 B2

41

-continued

TCTCATCACATCATATCAAGGTATAACCATCAATATTGCCACAGATGT
 TACTTAGCCTTTAATATTCTAATTAGTGTATGCAATGATAGTT
 CTCTGATTCTGAGATTGAGTTCTCATGTAATGATTATTAGAGTT
 5 CTCTTCATCTGTTCAAATTGGTCTAGTTTATTACTGATTGTT
 AAGACTCTTTATAATCTGCATATTACAATTCTCTTACTGGGTGTT
 GCAAATTTCTGTCATTCTATGGCTGACTTTCTTAATGGTTTTA
 ATTTAAAAATAAGCTTAATATTCACTGAATCTAATTAAACATTTTC
 TTGTTAGGACTTGAGTCATAAGAAATTCTACTGAAGTC
 ATGATGGCATGCTCTATATTCTAAAAGATTAAAGTTGGCCTT
 CTCCATTAGACTTATAATTCACTGAAATTGGTGTATGGTATGA
 CATATGGTCCCTTTATTTACATATAAATATTCCGTTTT
 CTAAAAAAGAAAAGATCATCTTCCCATTGAAAATGCCATTTTT
 TTCATAGGTCACTTACATATATCAATGGGTCTGTTCTGAGCTCTACTCT
 ATTTATCAGCCTCACTGCTATCCCCACACATCTCATGCTTGTCTAA
 ATCTTGATATTAGTGGAACATTCTTCCCATTGTTCTACAAGAATAT
 TTTGTTATTGCTTTGGGCTCTATATACATTAGAATGAGGTTGGC
 AAGGTACCTTAAGACCAATGACTTACAAGGAGCTGTAGACTTAGCCA
 CTTTTAAAAGAAAAGGGGGACTGGAAGGGCTAATTCACTCCAGCTGC
 TTTTGCGCTGACTGGGCTCTCTGGTTAGACAGATCTGAGCTGGGAG
 CTCTCTGGCTAACTAGGAACCCACTGCTTAAGCCTATAAGCTCGACT
 GTGCCCTCTAGTGCAGGCCATCTGTTGCCCTCCCCGTGCTTC
 CTTGACCCTGGAAGGTGCCACTCCACTGCTCTTCTAATAAAATGAGG
 AAATTGCATCGATTGCTGTAGTAGGTCTATTCTGGGGGGGG
 GTGGGGCAGGACAGCAAGGGGAGGATTGGGAGACAATGAGGAGCATGC
 TGGGATGCGTCCGACTGTACTGGGCTCTCTGGTTAGACAGATCTG
 AGCCTGGGAGCTCTGGCTAACTAGGAACCCACTGCTTAAGCCTCAAT
 AAAGCTGCCTTGAGTGTCAAGTAGTGTGTGCCGCTGTGTGTGAC
 TCTGGTAACTAGAGATCCCTCAGACCCCTTGTAGTCAGTGTGGAAATCTC
 TAGCAGCATGTGAGCAAAGGCCAGCAAAGGCCAGGAAACCGTAAAAGG
 CCGCGTTGCTGGCTTTCCATAGGCTCCGCCCTGACGAGCATCAC
 AAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAG
 ATACCAAGGCCTTCCCTGGAGGCTCCCTGCGCTCTCTGTCCGA
 CCTGCGCTTACCGGATACCTGTCGCCCTTCTCCCTGGGAAGCGTG
 GCGCTTCTCATAGCTCACGCTGTAGGTATCTCAGTTGGTAGGTGCT
 TCGCTCCAAGCTGGCTGTGTCAGCAACCCCCGTTAGCCGACCGCT
 GCGCCTTATCGGTAATATCGTCTTGAGTCCAACCCGGTAAGACACGAC
 TTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGT
 TGAGGCGGTGCTACAGAGTTCTGAGTGGCCTAATACGGCTACA
 CTAGAAGAACAGTATTGGTATCTGCGCTGCTGAAGCCAGTTACCTTC
 GGAAAAAGAGTTGGTAGCTCTGATCGGCAAACAAACCACCGCTGGTAG
 CGGTGGTTTTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGAT

42

-continued

CTCAAGAAGATCCTTGATCTTCTACGGGTCTGACGCTCAGTGGAAC
 GAAAACCTACGTTAAGGGATTGGTCTGAGATTATCAAAAGGATCTT
 5 CACCTAGATCCTTTAAATTAAAATGAAGTTAAATCAATCTAAAGTA
 TATATGAGTAAACTGGTCTGACAGTACCAATGCTTAACTAGTGAGGCA
 CCTATCTCAGCGATCTGCTATTCTGTCATCCATAGTTGCCTGACTCCC
 10 CGTCGTAGATAACTACGATACGGAGGGCTTACCATCTGGCCCGAGTG
 CTGCAATGATACCGCGAGACCCACGCTCACCGCTCCAGATTATCAGCA
 ATAAACCCAGGCCAGCGGAAGGGCCAGCGCAGAAGTGGTCTGCAACTTT
 15 ATCCGCCTCCATCCAGCTATTAAATTGTCGGGGAAAGCTAGAGTAAGTA
 GTTCGCCAGTTAATAGTTGCGCAACCTGTTGCTACAGGCATC
 GTGGGTACGCTCGTGTGGTATGGCTTCATTCACTCCGGTCCCA
 20 ACGATCAAGGCGAGTTACATGATCCCCATGTTGCAAAAAAGCGGTTA
 GCTCCCTCGGTCTCCGATCGTGTAGAAGTAAGTGGCCGAGTGTAA
 TCACTCATGGTTATGGCAGCACTGCTACATTCTTACTGTATGCCATC
 25 CGTAAGATGCTTCTGTGACTGGTAGTACTCAACCAAGTCATTCTGAG
 AATAGTGTATGCGCGACCGAGTTGCTCTGCCGGTCAATACGGGAT
 AATACCGGCCACATAGCAGAACTTTAAAGTGTCTCATATTGAAAACG
 30 TTCTCGGGCGAAAACCTCAAGGATCTTACCGCTGGTAGATCCGTT
 CGATGTAACCCACTCGTCACCCAACTGATCTCAGCATCTTACTTTC
 ACCAGCGTTCTGGTAGCAGGAAACAGGAAAGGCAATGCCGAAAAAAA
 35 GGGATAAGGGCACACGGAATGTTAATCTCATACTCTCTTTTC
 AATATTATTGAAGCATTATCAGGGTATTGTCTCATGAGCGGATACATA
 TTTGAATGTATTAGAAAATAACAAATAGGGTCCGCGACATTCC
 CCGAAAAGTGCCACCTGAC .

PLB2 comprising the FLIP cassette with the miR30 targeting FireFly luciferase in the antisense orientation was constructed, with a sequence as follows:

45 (SEQ ID NO: 7)
 GTGACGGATCGGGAGATCTCCGATCCCTATGGTCACTCTCAGTACA
 ATCTGCTCTGATGCCCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTG
 50 GTTGGAGGTGCTGAGTAGTGCAGCAGCAAAATTAAAGCTACAAACAGGC
 AAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCCTT
 GCGCTGCTCGCGATGTACGGCCAGATAACGCTTACATTGATTATT
 55 GACTAGTcatgttctttctgcttgcgttatccccgtattctgtggataaccgt
 attaccgccttttgagttagtgcataccgcctcgccgcacgcacgcga
 ggcgcaggcaggcactgcaggcaggaaagcggaaagcgcaccaatgcacaaac
 cgcctctcccgccgtggccattatgcacgtggcacgcacagg
 60 tttccgcactggaaagcggcaggcactgcaggcataaccgcacacaggat
 gtcactcattggcaccaggcattacactttatgcctccggctcgta
 tggtgtggaaattgtgagcggataacaatttcacacaggaaacagctat
 65 gaccatgattacgcacccaggcattacactttatgcctccggctcgta

43

-continued

tgcaatactttgttgttgcacatggtaacatggatgttagcaacatg
 ccttacaaggagaaaaaaagcaccgtgcacgcggatggtaaggatgg
 tggtacgatcgtgcatttaggaaggcaacacagacgggtctgacatgg
 tggacgaaccactgaattggccgtatgcagagatattgtatattaatgt
 tagctcgatataaaacgggtctctgttagaccagatctgacgcctg
 ggagctctggtaacttagggaaaccactgtctaagcctcaataaagct
 tgccttgagtgtttcaagtagtgtgtgcccgtctgtgtgactctgt
 aactagagatccctcagacccttttagtcgtgtggaaaatctctagcag
 tGGCGCCCGAACAGGGACTTGAAAGCGAAAGGAAACCAAGAGGGAGCTC
 TCAGCGCAGGACTCGCGTTGCTGAAGCGCAGCGCAAGAGGGAGGGC
 GGCAGTGGTAGTACGCCAAAATTTGACTAGCGGAGGCTAGAAGGAG
 AGAGATGGGTGAGAGCGTCAGTATTAGCGGGGAGAATTAGATCGCG
 ATGGGAAAAAAATCGGTTAAGGCCAGGGGAAAGAAAAATATAAATTAA
 AACATATAGTATGGCAAGCAGGGAGCTAGAACGATTGCAAGTTAAC
 GGCTGTTAGAACATCAGAAGGCTGTAGACAAATACTGGACAGCTACA
 ACCATCCCTCAGACAGGATCAGAAGAACTTAGATCATTATAATACAG
 TAGCAACCCCTTATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAG
 GAAGCTTAGACAAGATAGAGGAAGAGCAGAACAAAGTAAGACCACCGC
 ACAGCAAGCGGCCGGCGCTGATCTCAGACCTGGAGGGAGATATG
 AGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAATTG
 ACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGTGCAGAGAG
 AAAAAAGAGCAGTGGGAATAGGAGCTTGTCTGGTTCTGGAGCA
 GCAGGAAGCACTATGGCGCAGCGTCATGACGCTGACGGTACAGGCCAG
 ACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAATTGCTGAGGGCTA
 TTGAGGCGCAACAGCATCTGTCACACTCACAGTCTGGGCATCAAGCAG
 CTCCAGGCAAGAATCTGGCTGAGGAAAGATACCTAAAGGATCAAGCCT
 CCTGGGATTGGGGTGTCTGGAAAACCTATTGCACCACTGCTGTGC
 CTTGGAAATGCTAGTTGGAGTAATAATCTCTGGAACAGATTGGAAATC
 ACAGACCTGGATGGAGTGGGAGAGAAATTAAACAATTACACAAGCTTAAT
 ACACCTTAATTGAAGAATCGAAAAACCAGCAGAACAAAAGATGAACAAAG
 ATTATGGAAATTAGATAAATGGCAAGTTGTGAAATTGGTTAACATA
 ACAAAATTGGCTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTT
 GGTAGGTTAAGAATAGTTTGCTGTACTTCTATAGTGAATAGAGTTA
 GGCAGGGATATTCAACATTATCGTTTCAGACCCACCTCCACCGAGG
 GGACCCGACAGGCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAG
 AGACAGATCCATTGATTAGTGAACGGATCGGCACACTGCGTGCGCCAATT
 TGCAGACAAATGGCAGTATTCAACAAATTAAAAGAAAAGGGGGGAT
 TGGGGGGTACAGTGCAGGGAAAGAATAGTAGACATAATGAAACAGACA
 TACAAACTAAAGAATTACAAAACAAATTACAAAATTCAAAATTTC
 GTTTATTACAGGGACAGCAGAGATCCAGTTGGTTAGTACCGGGCCGGT

44

-continued

GCTTGCTCTGAGCCAGCCCACAGTTGGAAATGACTCCTTTTATGACT
 TGAATTTCAGTATAAAGTCTAGTGTAAATTAAATTGAACAACTGTA
 5 TAGTTTTGCTGGGGAGGAAAAAAATGGTGGCAGTGTGTTTT
 CAGAATTAGAAGTGAATGAAAACCTGTTGTGTGAGGATTCTAATGA
 CATGTGGTGGTTGCATACTGAGTGAAGCCGGTGAGCATTCTGCCATGTCA
 10 CCCCTCGTGCAGTAATGTAACCTAACCTAAAGAT
 TGATATAAACCATGCTCTGTGTATATCCGGTCTCTCTGGTAGTC
 TCACTCAGCCTGCATTCTGCCAGGGCCGCTAGATCTAGACGGTTGA
 15 TCTggccctccgcgcggggtttggccctccgcggggccccccctcc
 acggcgagcgctgccacgtcagacgaaggcgccaggagcggtccatgc
 ttccggccggacgctcaggacacgcggccgctgtcataagactcggcc
 tagaaccctcagttttttccagagacggccacaggcgccggaaaatga
 20 tctagggactgggtttccagagacggccacaggcgccggaaaatga
 gttcccttcggccatttcgtggagggatctccgtggggccgtgaacgcc
 gtatgttatataaggacgcgcgggtgtggccacagctgtttccgtcc
 25 ccgggattttgggtcgccgttctgtttgtggatcgtgtgtactcgtact
 ggtgagttccggcgtgtgggtcgccgggtttcgtggccggccggcc
 gtcggggacggaaacgtgtggagagacccccaaggctgttagtctgg
 30 gtccgcgcggccatgcggaaagcttattccgtggggggagcgcacaaaa
 tggcggtgttcccgagtcttgaatggaaagacgcgttgcggccggcgt
 gaggtcggttgcggccatggggggatcgtggccggccagaacccaaagg
 35 tcttggggccatgcggaaagcttattccgtggggggagcgcacaaaa
 tggcggtgttcccgagtcttgaatggaaagacgcgttgcggccggcgt
 ctgggggttgcgtctgggtcgccggccatggggggatcgtggccggcc
 40 gcgtgcacccgtaccttggagcgccgcgcctcgctgtgtgcgtgc
 acccggttgcgttgcggccatgcggccatgcggccatgcggccatgc
 tgggggttgcgtctgggtcgccggccatggggggatcgtggccggcc
 45 gctctctgaatcgacaggcgccggccatgcggccatgcggccatgc
 gaggtcggttgcgttgcggccatggggggatcgtggccggccatgggg
 tgaagctccgggtttgaactatgcgtcgccgtgggggtggggggatc
 50 gaagtttttaggcaccccttggaaatgtaatcatgtttgggtcaatgt
 ttttcgttttagacttagaaattgtccgttatttttttttttttttt
 cttt
 55 atccataacttcgtataggataccttatacgaagttatctcaggta
 cccatgaccggatcacaaggccacccgcgtccgcgcgcgcac
 tccccaggccgtacgcacccctcgccgcgcgttgcgcactacccgc
 acgcgcacccgcgtacccgcgtccgcgcgcgcac
 60 gcaagaacttttttttttttttttttttttttttttttttttttttt
 tccggccacggccgcggccgtggccgttgcgttgcgttgcgttgc
 gaagcggggggccgttgcgttgcgttgcgttgcgttgcgttgc
 65 cggttccggctggccgcgcacatggaaaggcccttgcgttgcgttgc

US 9,043,994 B2

45

-continued

accggcccaaggagccgcgtggttctggccaccgtcgccgtctcgccc
 gaccaccagggaagggtctggcagcgcgtcggtccccggagtggaa
 ggccgcccagegcgcgggtgcccgccttcggagacccgcggcccc
 gcaacctcccttctacgagcggctcggttcaccgtcacccgcacgtc
 gaggtgcccgaaggaccgcacccgtgtcatgaccgcagccccgtgc
 cctgtacaagaaaacagaaaaattgtggcaccagtgaacagactttgaatt
 ttgaccttctcaagttggcggagacgtcgagtccaaacctggccatg
 aacccagccatcagcgtcgctccgtctcagtcgtcccgaggatcg
 gggcagaagggtgaccaggctgacagectgcgtgtgaacccaaaccc
 cctggactccgcctatgagaataacaccaaggataactccatccgcatg
 agttcagccgtacccgagagaagaggaagcgtctcaggcaccctc
 ggataccgcacacgtaccgcgtcccggtcacccctctccaaaccc
 ctatatacaggcccttaccctagccaacttcaccaccaaggatgggc
 actactttgtgagcttcgagtcgtccggcgcgaatccatgagctccat
 aaaagtatcagtggtatagagacaaacttgtcaagtgtggccgataag
 cctgctggcagaacacatccgttgcgtctgtgtcttccctct
 ccctccccaagccctggacttcattctctgtatcagaagccataac
 ttcgtatagtacacattatacgaagttatgttATGCATACTGGAGGAA
 AAAAAAAAGGGAGAGTCAGGGtttaacgcattagtcttccaattgaa
 aaagtatcattatcattatcattatcattatcattatcattatcatt
 aagatagcaaggattcattatcattatcattatcattatcattatcatt
 atgatcccttgcatttcGAGGGAGTAGGCAGGCTCCCGTGAATTGGAA
 TCCTACATCTGTGGCTTCACTAGGATTCCAATTCAACGGGAGCTCGCTCAC
 TGTCAACAGCAATAACCTTctcgagcctctgtggtaacctgaaga
 agtaatcccgcaagtgtttcaagatgtcaggcaacgcattctgtaaag
 tactgaagcccttgcattcaaacatagtatgtctgcgtccgaagccgactt
 aacaaggcttgcggccgcCCACTCACCTGCAATTGGGCCGtacttgtac
 agctcgccatgcgcagagtgtccggccgggtcacgaactccagcag
 gaccatgtgtcgccgttgcgttgcgttgcgtccggactgg
 tgctcaggtagtgggtcgccgcagcgcacggggccgtcgccgtatgggg
 gtgttctgtgttagtgggtcgccgcagctgcacgtcgccgtatgggg
 gtggccgatcttgcattgcgttgcgttgcgtccggatgggg
 tgatatagacgttgtgttagtgcgttgcgtccatgtgtgtccagg
 atgttgcgtcccttgcattgcgttgcgtccatgtgtgtccagg
 cagggtgtcgccctcgaaacttccatgcgtccgggttgcgtatgggg
 cgtcccttgcattgcgtccgttgcgtccggatgggttgcgtatgggg
 gacttgcattgcgtccgttgcgtatgtgtgggttgcgtatgggg
 ctgcacgcgttaggtcagggtggtcacgcgggtggccaggccacgg
 gcttgcgttgcgtatgggttgcgtatgtgtggccatggccatggcc
 tcgcctcgcctcgccggacacgcgttgcgtatgtgtggccatggcc

46

-continued

gtcagctcgaccaggatggcaccaccccggtgaacagctctcgccct
 tgctcaccatggtggcaccggataacttcgtataaggatcctatacg
 5 aagttatccattcaggctgtgtcatcaatggcatggcacaagcttca
 gccataacttcgtataatgtgtactatacgaaggatccTGTTAAAGGG
 TTCCGGTCCACTAGGTACAATTGATATCAAGCTTATCGATAATCAACC
 10 TCTGGATTACAAAATTGTGAAAGATTGACTGGTATTCTTAATATTTG
 CTCCTTTACGCTATGTGGATACGCTGTTAATGCCTTGTATCATGCT
 ATTGCTTCCCGTATGGCTTCATTCTCCTCTGTATAAACTGGTGG
 15 GCTGTCTTTATGAGGAGTTGTGGCCGTTGTCAGGCAACGTGGCGTGG
 TGTGCACTGTGTTGCTGACGCAACCCCCACTGGTTGGGCATTGCCACC
 ACCTGTCAGCTCTTCCGGACTTCGCTTCCCTCCCTATTGCCAC
 GGCGGAACCTCATGCCGCCTGCCCTGGCCGCTGCTGGACAGGGCTCGC
 20 TGTTGGCACTGACAATTCCGTGGTGTGTCGGGAAATCATGTCCTT
 CCTTGGCGTGCCTGCTGTGTTGCCACCTGGATTCTGCGCGGACGTCTT
 CTGCTACGTCCTTCGCCCTCAATCCAGCGAACCTCCCTCCGCGGCC
 25 TGCTGCCGCTCTGCCCTCTCCCGCTTCCGCTTCGCCCTCGCCCTCAGACG
 AGTCGGATCTCCCTTGGCGCTCCCGCATCGATACGTCAGACCTCG
 ATCGAGACCTAGAAAACATGGAGCAATCACAAGTAGCAATACAGCAGCT
 30 ACCAATGCTGATTGTGCCCTGGCTAGAAGCACAAGAGGAGGAGGAGTGG
 TTTCCAGTCACACCTCAGGTACCAAGCATGGGTAAGTCTGTTCTCAT
 CACATCATATCAAGGTTATATACCATATAATTGCCACAGATGTTACTTA
 35 GCCTTTAAATTTCTTAATTAGTGTATATGCAATGATAGTTCTGTA
 TTTCTGAGATTGAGTTCTCATGTGTAATGATTAGTTAGGTTCTCTTT
 CATCTGTTCAAATTGTCTAGTTTATTTTACTGATTGTAAGACT
 40 TCTTTTATAATCTGCATATTACAATTCTTTACTGGGTGTTGCAAT
 ATTTCTGTCATTCTATGCCCTGACTTTCTTAATGGTTTTAATT
 AAAATAAGCTTAAATTCTGCAATCTAATTAAACATTTCTTTGTG
 45 GTTGGACTTTGAGTCATAAGAAATTTCCTACACTGAAGTCATGATG
 GCATGCTCTATATTATTCTAAAGATTTAAGTTGCGCTTCCCAT
 TTAGACTTATAATTCACTGGAATTGGTGTATGGTATGACATATG
 50 GGTTCCCTTTATTTTACATATAAAATATTCCTGTTCTAA
 AAGAAAAGATCATCTTCCATTGTAAGGCTATTTCTATA
 GGTCACTACATATATCAATGGGTCTGTTCTGAGCTACTCTATT
 55 TCAGCCTCACTGTCATCCCCACACATCTCATGCTTGTCTAAATCTG
 ATATTAGTGGAACATTCTCCATTGTTCTACAGAATATT
 TATTGTTGGCTCTATATACATTAGAATGAGGTTGGCAAGGTA
 CCTTTAAAGCCAATGACTTACAAGGCAGCTGTAGATCTAGCCACTTT
 60 AAAAGAAAAGGGGGACTGGAAGGGCTAATTCACTCCAGCTGCTTTG
 CCTGTACTGGGTCTCTGGTTAGACAGATCTGAGCCTGGAGCTCT
 GGCTAACTAGGGAACCCACTGCTTAAGCCTCATAAAGCTGACTGTGCT
 65 TCTAGTTGCCAGCCATCTGTTGCTTGCCTCCCTGCTCCTTGAC

US 9,043,994 B2

47

- continued

CCTGGAAAGGTGCCACTCCCCTGCTCCTTCTAATAAAATGAGGAAATTG
 CATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGGGGGGGGG
 CAGGACAGCAAGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGA
 TCGGGTCCGGACTGTACTGGGCTCTCTGGTAGACCAGATCTGAGCTG
 GGAGCTCTCGCTAACTAGGGAACCCACTGCTTAAGCCTAATAAGCT
 TGCTTGAGTGCTCAAGTAGTGTGCCCCGCTGTTGTGACTCTGGT
 AACTAGAGATCCCTCAGACCCTTTAGTCAGTGTGGAAAATCTCTAGCAG
 CATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAGGCCCGT
 TGCTGGCGTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAT
 CGACGCTCAAGTCAGAGGTGGCAAACCCGACAGGACTATAAAGATCCA
 GGCCTTCCCCCTGGAAGCTCCCTCGCGCTCTCTGTTCCGACCCCTGC
 CGCTTACCGATACTGTCCGCCCTTCCTCCCTCGGGAAAGCTGGCGCTT
 TCTCATAGCTCACGCTGTAGGTATCTCAGTCCGTAGTGTGCTCGCTC
 CAAGCTGGCTGTGACGACGACCCCCCGTCAGCCGACCGCTGCGCCT
 TATCCGTAACTATCGCTTGAGTCCAACCCGTAAGACACGACTTATCG
 CCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGG
 CGGTGCTACAGAGTTCTGAAAGTGGTGGCCTAACTACGGCTACACTAGAA
 GAACAGTATTGGTATCTGCGCTCTGCTGAAGGCCATTACCTCGGAAAA
 AGAGTTGGTAGCTCTGATCCGCAAACAAACACCCTGGTAGCGGTGG
 TTTTTTGTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAG
 AAGATCTTGTATCTTCTACGGGCTGACGCTCAGTGGAACGAAAAC
 TCACGTTAAGGGATTTGGTCATGAGATTCAAAAGGATCTCACCTA
 GATCCTTTAAATTAAAATGAAGTTAAATCAATCTAAAGTATATATG
 AGTAAACTTGGCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATC
 TCAGCGATCTGTCTATTCTGTCATCCATAGTGCCTGACTCCCCGTCG
 GTAGATAACTACGATACTGGGAGGGCTTACCATCTGGCCCCAGTGTGCAA
 TGATACCGCGAGACCCACGCTCACCGCTCCAGATTATCAGCAATAAAC
 CAGCCAGCCGAAAGGGCGAGCGCAGAAGTGGTCCGCAACTTATCCG
 CTCCATCCAGTCTATTAAATTGTGCGGGAAAGCTAGAGTAAGTAGTCG
 CAGTTAATAGTTGCGAACGTTGTCATTGCTACAGGCATCGTGGT
 TCACGCTCGTCTGGTATGGCTTACAGCTCCGTTCCAAAGATC
 AAGGCAGTTACATGATCCCCATGTTGTGCAAAAAGCGGTTAGCTCCT
 TCGGTCTCCGATCGTGTAGAAGTAAGTGGCCAGTGTATCACTC
 ATGGTTATGGCAGCACTGCATAATTCTTACTGTCTGAGTCAAG
 ATGCTTTCTGTGACTGGTAGACTCAACCAAGTCATTCTGAGAATAGT
 GTATGCGCGACCGAGTTGCTCTGCCCCGCTCAATACGGATAATACC
 GCGCCACATAGCAGAACTTTAAAGTGCTCATCTGGAAAACGTTCTC
 GGGCGAAAATCTCAAGGATCTTACCGCTGTGAGATCCAGTTGATGT
 AACCCACTCGTCACCCAACTGATCTTCAGCATCTTACTTCAACCAGC
 GTTCTGGGTGAGCAAAACAGGAAGGCAAAATGCCGAAAAAGGGAAT

48

- continued

AAGGGCGACACGGAAATGTTGAATACTCATACTCTTCTTTCAATATT
 ATTGAAGCATTATCAGGGTTATTGTCATGAGCGGATAACATATTGAA
 5 TGTATTAGAAAATAAACAAATAGGGTTCCGCGCACATTCCCGAAA
 AGTGCCACCTGAC

LB2 comprising the FLIP cassette with the miR30 targeting $\alpha 4$ integrin in the antisense orientation was constructed, with a sequence as follows:

(SEQ ID NO: 8)

GTCGACGGATCGGGAGATCTCCGATCCCCTATGGTGCACCTCAGTACA
 15 ATCTGCTCTGATGCCGATAGTTAAGCCAGTATCTGCTCCCTGCTTGTG
 GTTGGAGGTGCGTAGTGTGCGAGCAAATTAAGCTACAAACAAGGC
 AAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTT
 20 GCCTGCTCGCGATGTACGGCCAGATATACGCGTTGACATTGATTATT
 GACTAGTcatgttctttctgttgttattccctgatctgtggataaccgt
 attaccgccttttgtgactgtgataccgcctgcccgcacccgaaacccg
 25 ggcgcaggcagtcagtgcggaggaaagccggaaagccggaaacccgaaac
 cgcctctcccccgcgcgttgccgattattaatgcagctggcacgcagg
 tttcccgactggaaagccggcagtgcggcaacgcgcaattatgtgagtt
 30 gtcactcattaggcaccaggctttacactttatgttccggctcgta
 tgggtgtggattgtgagcgataacaatttcacacaggaaacagcttat
 gaccatgattacgcacccgcgcaattaccctagcttaatgtgatctta
 35 tgcaatacttctgttgttgcacatggtaacgcgttgttgcacatcg
 ctttacaaggagagaaaaagcaccgtgcgtgcgcattttggtaagg
 tggtagcgtgccttatttaggaaggcaacacggctgtgacatggat
 40 tggacgaaccactgaattgccgcattgcagagatattgtatggcc
 tagctcgatataaaacgggtctctgttgttagaccagatctgacgcctg
 ggagctctggctaactagggacccactgcattaaagctcaataaagct
 45 tgccttgcgttgtcaactgtgtgtgtgtgtactctgt
 aactagagatccctcagacccttttgtcagtgtggaaaatctctagcag
 tGGGCCGAAACAGGGACTTGAAGCGAAAGGGAAACAGAGGGCTC
 TCGACGAGACTCGGCTGCTGAAGCGCGACGGCAAGAGGGAGGGC
 50 GGCAGCTGGTAGTACGCCAAATTTGACTAGCGGAGGCTAGAAGGAG
 AGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGAGAATTAGATCG
 ATGGGAAAAAAATCGGTTAAGGCCAGGGGGAAAGAAAAAAATAAATTAA
 55 AACATATAGTATGGCAAGCAGGGAGCTAGAACGATTGCACTTAACCT
 GGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCT
 ACCATCCCTCAGACAGGATCAGAAGAACCTAGATCATTATATAACAG
 60 TAGCAACCCCTATTGTGTCATCAAAGGATAGAGATAAAAGACACCAAG
 GAAGCTTAGACAAGATAGAGGAAGGCAAAACAAAGTAAGACCACCGC
 ACAGCAAGCGGGCGCCGCGCTGATCTCAGACCTGGAGGAGGAGATAG
 65 AGGGACAATTGGAGAAGTGAATTATAAAATAAAGTAGTAAAAATTGA

US 9,043,994 B2

49

-Continued

ACCATTAGGAGTAGCACCCACCACAGCAAAGAGAAGAGATGGTGCAGAGAG
 AAAAAAGAGCAGTGGGAATAGGAGCTTGTCCCTGGTTCTGGGAGCA
 GCAGGAAGCACTATGGCGCAGCGTCATGACGCTGACGGTACAGGCCAG
 ACAATTATTGTCTGGTATAGTGACAGCAGACAACATTGCTGAGGGCTA
 TTGAGGCACACAGCATCTGTGCAACTCACAGTCTGGGCATCAAGCAG
 CTCCAGGCAAGAACCTGGCTGTGGAAAGATAACCTAAAGGATCAACAGCT
 CCTGGGATTGGGTTGCTCTGGAAAACATTTGACCCACTGCTGTGC
 CTTGGATGCTAGTTGGAGTAATAAATCTGGAAACAGATTTGAATCAC
 ACGACCTGGATGGAGTGGGACAGAGAAATTACAATTACACAAGCTTAAT
 ACACCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG
 ATTATTGGAAATTAGATAAAATGGCAGTTGTGAAATTGGTTAACATA
 ACAAAATTGGCTGGTATATAAAATTATTCAATAATGATAGTAGGAGGCTT
 GGTAGGTTAAGAATAGTTTGCTGTACTTCTATAGTGAATAGAGTTA
 GGCAGGGATATTCAACCATTATCGTTTACAGACCCACCTCCAACCCCGAGG
 GGACCCGACAGGCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGAC
 AGAGACAGATCCATTGATTAGTGAACGGATCGGCACTGCGTGCACCAAT
 TCTGCAGACAAATGGCAGTATTCCACAAATTAAAAGAAAAGGGGG
 ATTGGGGGTACAGTGCAGGGAAAGAATAGTAGACATAATAGCAACAGA
 CATACAAACTAAAGAATTACAAAACAAATTACAAAATTCAAAATTTC
 GGGTTTATTACAGGGACAGCAGAGATCCAGTTGGTTAGTACCGGGCCG
 GTGCTTGCTCTGAGCCAGCCCACAGTTGGAATGACTCCTTTTATGA
 CTTGAATTTCAGTATAAAGTCTAGTGCTAAATTAAATTGAAACAACGT
 TATAGTTTTGCTGGTGGGGAAAGGAAAAAAATGGTGGCAGTTTT
 TTCAGAATTAGAAGTGAATGAAAATTGTTGTGTGAGGATTCTAAT
 GACATGTGGTGGTGCATACTGAGTGAAGCGGTGAGCATTCTGCATGT
 CACCCCTCGTGCCTAGTAATGACTTACAGAAATCTAAACTCAAAAG
 ATTGATATAAACATGCTTCTTGTATATCCGTCTTCTCTGGTAG
 TCTCACTCAGCCTGCATTCTGCCAGGGCCGCTCTAGATCTAGACGGTT
 GATCTggccctccgcgcgggttttggcgtcccgccggcccccctcc
 tcaacggcgagcgctgccccgtcagacgaaggcgccaggagcggttcgt
 cttccggccggacgtcaggacagcgccggctgtcataagactcgcc
 cttagaaccccgatcagcagaaggacattttagacggacttgggt
 actctagggactggtttcttccagagagcggaaacaggcgaggaaaag
 tagtcccttcggcgattctggggatctccgtggggccgggtgaacg
 ccgatgattataaggacgccccgggtggcacagctgttcgtc
 agccgggattgggtcgccgtttgtggatcgctgtgategtcac
 ttggtagttggggctgtgggtggccggggtttctgtggccgggg
 ccgcteggtggacggaagcggtggagagaccccaaggcgtagtct
 gggcccgacgatgggtggccctgaactgggggtggggggcgccaca
 aatggcggtgttcccgagtctgaatggaaagacgcttggatgggg
 gtgagggtcgtaaaacaagggtggggcatggtgccggcaagaaccca
 aa

50

-continued

ggcttggggccctcgtaatgcggaaagcttattcggtgagatgg
 gctggggccatctggggaccctgcacgtgaagttgtcactgactgg
 5 aactcggttgcgtctgggtgcggggccggcagttatgcggtgccgt
 gggcagtcacccgtacctttggagcgcgcgcctcgctgtcgacg
 tcacccgtctgtggctataatgcagggtggggccacctgcccgtagg
 10 tgcggtaggttttccgtcgaggacgcagggttcggcccttaggt
 aggctctctgaatcgacaggcgccggacctctggtagggggaggataa
 gtggggcgtcgtttttgttgcgggttatgtacctatctttaagta
 15 gctgaagctccgggtttgaactatgcgtcggggtggcagtggttt
 gtgaagtttttaggcacctttgaatgtaatcattgggtcaatatgt
 aatttcagtgtagacttagtaattgtccctaaattctggcgtttt
 20 ggctttttgttagacGAAGTACGCGTAGCCGTTAATAAGCCTCGATGC
 ggatccataacttcgtataggataccttatacgaagttatctcaggacc
 gccaccatgaccgagtcacagccacccgtcgccctcgccaccggcga
 25 cgtccccaggccgtacgcaccctcgccgcgcgttcggcactacc
 ccacgcgcacaccgtcgatccggaccggccacatcgacgggttcacc
 ctgcaagaactttccctacgcgcgtcggtcgacatcgcaagggt
 30 ggtcgcggacgcaggccgcgtggggctggacacgcggagacgc
 tcgaaggccccgggtttcgccagatcgccgcgtcgccgagtt
 aggggttcccgctggccgcagcaacagatggaaaggctctggcc
 35 gcacccggcccaaggagcccggtgggtctggccaccgtcggttc
 cccgaccaccaggcgaagggtctggcagcgcgtcggtcccgaggt
 gaggccggcggcgcgcgggtgccccttctggagacctccgc
 cccgacacccccccttacgcggcgtcggttcaccgtcacc
 40 tcgaggtccccgaaggacccgcacccgtcgatgaccgc
 gccctgtacaagaaacagaaaattggcaccaggtaaaacagactt
 gtttgccttcgtcaaggtaggtggggagacgtcgagtc
 tgaaccaccatcagcgctcgcttcgtcgttcagggt
 45 cgaggccagggtcccgccatgagaataacccaaaggataact
 tcgcctggactccgcgtcgatggggccatggccatggcc
 atgagttcagccatcaccggagaaaggaaacgtcgatc
 50 ctcggataccggcgcacacgtaccgtcccggtcacc
 gccctatatacggtccctaccctagccaaacttcacc
 accaaggatgg
 55 ggcactactttgttaggtcgactcggtccggccgat
 aataaaagtatcgtgtatagagacaactggta
 aacccgtcggttcaaaacacatccgtcgatgt
 60 tctcccttcgtcaaggccctggacttcattctgt
 aacttcgtatagtacacattatacgaaggat
 tttATGCATACCTGGAG
 GAAAAAAAAAGGGGAGAGTCAGGGgtttaacgcatt
 65 gaaaaaaagtgttataattaccatttaattcagctt
 gaaaaatgt

US 9,043,994 B2

51

-Continued

atcaaagagatagaaggattcgttttagtaaacaagataattgtcc
 taaaatggcccttgaATCCGAGGCAGTAGGCATGGCATCATGTGATCA
 CCAAACATCTGTGGCTTCACTATTGGTGAATCAGATGCCCGCCT
 CACTGTCAACAGCAATATACCTTctcgagcctctgttggttaaccta
 agaagttaatcccagcaagtgttccaagatgtgcaggcaacgattctga
 aagtactgaagccttcatcaaaatagtagtatatgtctggcaagcgagca
 cttaacaaggcttcggccgcCCACTCACCTGCAATTGGGCCGtacttg
 tacagctcgccatgccgagagtgtatccggccggcgatcacgaaactccag
 caggaccatgtatcgcttcgttgggtcttgctcaggcggact
 ggggtctcgatggtagtggtagtggccggcagcagcacggccgtcgccgatg
 gtgtggccgatcttgaagttcaccttgcgttgcgttgcgttgcgt
 ccatgatatacgttgtggctgttagtgtactccagctgtgtcccc
 agatgttgcgtcccttgcgttgcgttgcgttgcgttgcgttgcgt
 caccagggtgtccctcgaaacctcacctcgccgggtttgttagttgc
 cgtcgcttgcgttgcgttgcgttgcgttgcgttgcgttgcgt
 ggggacttgcgttgcgttgcgttgcgttgcgttgcgttgcgt
 gactgcacgcgttaggtcagggtggtcacgagggtggccaggcacgg
 geagcttgcgttgcgttgcgttgcgttgcgttgcgttgcgt
 geatcgccctcgccctcgccggacacgcgttgcgttgcgttgcgt
 gccgtccagtcgaccaggatggcaccaccccggttgcgttgcgt
 cttgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt
 acgaaggatccattcaggctgtgttgcgttgcgttgcgttgcgt
 ttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt
 GGTTCCGGTTCACAGGTACAATTGATATCAAGCTTATCGATAATCA
 ACCTCTGGATTACAAAATTGTGAAAGATTGACTGGTATTCTTAACATATG
 TTGCTCCTTTACGCTATGTGGATAACGCTGCTTAAATGCCCTTGATCAT
 GCTATTGCTCCGTATGGCTTCATTTCTCCTCTGTATAAACCTG
 GTTGCTGTCTCTTATGAGGAGTTGTCAGGCCGTTGTCAGGCAACGTGGCG
 TGGTGTGCACTGTGTTGCTGACGCAACCCCCACTGGTGGGCATTGCC
 ACCACCTGTCAGCTCTTCCGGACTTCGCTTCCCTCCCTATTG
 CACGGCGGAACCTCATGCCCGCTGCCCTGCCCCGCTGCTGGACAGGGCTC
 GGCTGTTGGCACTGACAATTCCGTGGTGTGTCGGGAAATCATCGTCC
 TTGCTTGCTGCTGCCCTGTGTTGCCACCTGGATTCTGCGCGGACGTC
 CTTCTGCTACGTCCTCGGCCCTCAATCCAGCGGACCTTCCCTCCGCG
 GCCTGCTGCCGCTCTGCCCTCTCCGCTTCCGCTTCCGCTCAG
 ACGAGTCGGATCCTCCCTTGGGCCCTCCCCGATCGATACCGTCGACC
 TCGATCGAGACCTAGAAAAACATGGAGCAATCACAAGTAGCAATACAGCA
 GCTACCAATGCTGATTGTGCGCTGGCTAGAAGCACAAGAGGAGGAGGAGT
 GGGTTTCCAGTCACACCTCAGGTACCAAGCATGGGTAAGTACTGTT
 TCATCACATCATATCAAGGTTATACCATCAATATTGCCACAGATGTTA

52

-continued

CTTAGCCTTTAATATTCTCAATTAGTGTATATGCAATGATAGTTCT
 CTGATTCTGAGATTGAGTTCTCATGTAATGATTATTTAGAGTTCT
 5 CTTCATCTGTCAAATTTTGCTAGTTTATTTTACTGATTGTA
 GACTCTTTATAATCTGCATATTACAATTCTTACTGGGTGTGC
 AAATATTTCTGTCATCTATGCCCTGACTTTCTTAATGGTTTTAA
 10 TTTAAAATAAGCTTAATATTATGCAATCTAATTAACAATCTTCTT
 TGTTGTTAGGACTTGAGTCATAAGAAATTTCTACACTGAAGTCAT
 GATGGCATGCTCTATATTATTTCTAAAGATTTAGTTGCCTCT
 15 CCATTTAGACTTATAATTCACTGGAATTTTTGTTGTTGATGGTATGACA
 TATGGGTTCCCTTTATTTTACATATAAATATTTCCCTGTTTCT
 AAAAAGAAAAGATCATCATTCCATTGTAATGCCATATTTTT
 20 CATAGGTCACTTACATATCAATGGCTGTTCTGAGCTACTCTAT
 TTTATCACCTCACTGCTATCCCCACACATCTCATGCTTGTCTAAAT
 CTTGATATTAGGAAACCTTCCATTGTTCTACAGAAATATT
 25 TTGTTATTGCTTTGGCTCTATACATTTAGAATGAGGTTGCAA
 GGTACCTTAAGACCAATGACTTACAAGGCAAGCTGAGATCTTAGCCACT
 TTTTAAAAGAAAAGGGGGACTGGAAGGGCTAATTCACTCCCAGCTGCTT
 30 TTGCTGTACTGGCTCTCTGGTTAGACCACTGAGCTGGCTGGGAGCT
 CTCTGGCTAACTAGGAAACCACTGCTTAAGCCTATAAGCTCGACTGT
 GCCTCTAGTGCCAGGCATCTGTTGCTTGCCTCCCCGTGCCTTCT
 35 TGACCCCTGAAAGGTGCCACTCCACTGCTCTTCTAAATAAATGAGGAA
 ATTGCATCGCATTGTCGTAGTGTCTAGTGTCTTCTGGGGGGGG
 GGGGCAGGACAGCAAGGGGGAGGATTGGAAGACAATAGCAGGCATCTG
 GGATGCGGTCCGGACTGACTGGTCTCTGGTTAGACCACTGAGCTGAG
 40 CCTGGGAGCTCTGGCTAACTAGGAAACCACTGCTTAAGCCTCAATAA
 AGCTTGGCTTGAGTGTCTCAAGTAGTGTGCCCCGTGTTGTTGACTC
 TGTTAAGAGATCCCTCAGACCTTTAGTCAGTGTGAAAATCTCTA
 45 GCAGCATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAAGGCC
 GCCTGGCTGGCTTTCCATAGGCTCGCCCCCTGACGAGCATCACAA
 AAATCGACGCTCAAGTCAGAGGTGGCAAACCCGACAGGACTATAAAGAT
 50 ACCAGGCCTTCCCCCTGAAAGCTCCCTCGTGCCTCTGTTCCGACC
 CTGCGCTTACCGATACTGTCGCCCTTCTCCCTGGAAAGCGTGGC
 GCTTCTCATAGCTACGCTGTAGGTATCTCAGTTCGGTGTAGGTGTT
 55 GCTCCAAGCTGGCTGTGTCAGCAACCCCCCTGTCAGCCGACCGCTG
 GCCTTATCCGGTAACATCGTCTTGAGTCCAACCCGTAAGACACGACTT
 ATCGCCACTGGCAGCAGCACTGGTAACAGGATTAGCAGAGCAGGATAG
 60 TAGGCGGTGCTACAGAGTCTTGAAGTGGCTAACTACGGCTACACT
 AGAAGAACAGTATTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTCGG
 AAAAAGAGTGGTAGCTTGTGATCCGGAAACAAACCCACCGCTGGTAGCG
 65 GTGGTTTTGTTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCT

US 9,043,994 B2

53

-Continued

CAAGAAGATCCTTGATTTCTACGGGCTCGACGTCAGTGGAACGA
 AAACTCACGTTAAGGGATTGGTCATGAGATTATCAAAAAGGATCTTC
 CCTAGATCCTTAAATTAAAAATGAAGTTTAAATCAATCTAAAGTATA
 TATGAGTAAACTGGCTGACAGTTACCAATGTTAATCAGTGAGGCACC
 TATCTCAGCGATCTGTCTATTCTGTCATCCATAGTTGCCTGACTCCCCG
 TCGTGTAGATAACTACGATAACGGGAGGGCTTACCATCTGGCCCCAGTGT
 GCAATGATAACCGCGAGACCCACGCTCACCGGCTCCAGATTATCAGCAAT
 AAACACGCCAGCGGAAGGGCCGAGCGCAGAAGTGGTCTGCACACTTTAT
 CCGCCTCCATCCAGTCTATTATTGTCGGGAAGCTAGAGTAAGTAGT
 TCGCCAGTTAATAGTTGCGCAACGTTGTCATTGTCACAGGCATCGT
 GGTCACGCTCGTGTGATGGCTTCATCGCTCCGGTCCCAAC
 GATCAAGGCGAGTTACATGATCCCCATGTTGCAAAAAAGCGGTTAGC
 TCCTTCGGTCTCCGATCGTTGTCAGAAGTAAAGTTGGCGCAGTGTATC
 ACTCATGGTTATGGCAGCACTGCATAATTCTTACTGTCATGCCATCCG
 TAAGATGCTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAA
 TAGTGTATGCGCGACCGAGTTGCTCTGCCCCGCTCAATACGGGATAA
 TACCGCGCCACATAGCAGAACTTAAAGTGCCTCATCATTGAAAACGTT
 CTTCGGGGCAGAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCG
 ATGTAACCCACTGTCACCCAACGTATCTCAGCATTTTACTTCAC
 CAGCGTTCTGGGTGAGCAAAACAGGAAGGCAAATGCCGAAAAAGG
 GAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTCCCTTTCAA
 TATTATTGAAGCATTTCAGGGTTATTGTCATGAGCGGATACATATT
 TGAATGTATTAGAAAATAACAAATAGGGGTTCCCGCGCACATTCCCC
 GAAAAGTGCCACCTGAC.

The MSCV FLIPi Puro2ATHy1.1/human c-Myc-miR-p53 vector (SEQ ID NO: 21) comprised a sequence as follows:

TGAAAGACCCCACCTGTAGGTTGGCAAGCTAGCTTAAGTAAAGCCATT
 TGCAAGGCATGGAAAATACATAACTGAGAATAGAGAAGTTCAGATCAAGG
 TTAGAACAGAGAGACAGCAGAATATGGGCAACAGGATATCTGTTG
 AGCAGTTCTGCCCGCTAGGGCAAGAACAGATGGTCCCGATGCG
 GTCCCGCCTCAGCAGTTCTAGAGAACATCAGATGTTCCAGGGTGC
 CCAAGGACTGAAAATGACCTGTGCCTTATTGAACTAACCAATCAGTT
 CGCTTCTCGTTCTGTCGCGCCTCTGTCCTCCGAGCTCAATAAAAGA
 GCCCACACCCCTCACTCGCGCGCAGTCCTCGATAGACTGCGTCGCC
 CGGGTACCCGTATCCAAATAAGCCTTGTGTCAGATTGACTGCCACC
 GGACTCGCTGATCCTGGGAGGGTCTCTCAGATTGATTGACTGCCACC
 TCGGGGTCTTCATTGGAGGGTCCACCGAGATTGGAGACCCCTGCCT
 AGGGACCACCGACCCCCCGCCGGAGGTAAGCTGGCCAGCGGTGTTTC
 GTGTCTGTCCTGCTTGTGCGTGTGTCAGCTGAGGAAACCGT
 CCTGCGTCTGTACTAGTTAGCTAACTAGCTCTGATCTGGCGGACCCGTG

54

-Continued

GTGGAAC TGACGAGTTCTGAACACCCGCCGCAACCTGGGAGACGTCCC
 AGGGACTTGGGGCCGTTTGTGGCCGACCTGAGGAAGGGAGTCGAT
 5 GTGGAATCGACCCCGTCAGGATATGTGGTCCTGGTAGGAGACGAGAAC
 TAAACAGTCTCCGCTCCGTCTGAATTGGCTTCGGTTGGAACCGA
 AGCGCGCGTCTGTCAGCGCTGCAGCATCGTCTGTGTTCT
 10 CTGCTGACTGTGTTCTGTATTGTCGAAAATTAGGGCCGACAGTCTTA
 CCACTCCCTTAAGTTGACCTTAGGTACTGGAAAGATGTCGAGCGGATC
 GCTCACACCACTCGGTAGATGTCAGAAGAGAGACGTTGGTTACCTCTG
 15 CTCTGCAGAATGCCAACCTTAACGTCGGATGGCCCGAGACGGCACCT
 TTAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTTCACCTGGC
 CCGCATGGACACCCAGACCCAGGTCCTACATCGTACCTGGGAAGCCTT
 20 GGCTTTGACCCCCCTCCCTGGTCAAGCCCTTGACACCTAAGCCTC
 CGCCTCCCTTCCATCCGCCCGTCTCTCCCTGAAACCTCCTCGT
 TCGACCCCGCCTCGATCCTCCCTTATCCAGCCCTACTCCTCTCTAGG
 CGCCGGAATTAGAtccataacttcgtataggataccctatacgaatttat
 25 ctcaggtaccgcacatgaccgagtaaagcccacgggtgcgcctcgcca
 cccgcgacgacgtccccaggggcgtacgcacccctgcgcgcgcgcgcgc
 gactacccgcacgcgcacaccgtcgatccggaccgcacatcgacgc
 30 ggtcaccgagctgcaagaactttcctacgcgcgtcggtcgacatcg
 gcaagggtgggtcgccgacgcggcgcgcgcgtggaccacgc
 ccggagacgacgtcgaaagccccgggttgcgcgcgcgcgcgcgcgc
 35 ggcgcagttgacggttcccgctggccgcgcgcgcgcgcgcgcgc
 tccctggccgcacccgcacaggagccgcgcgcgcgcgcgcgcgc
 gggttcgcgcgcacccaccaggcaagggttgcgcgcgcgcgcgc
 40 cccggagtgaggcgccgcgcgcgcgcgcgcgcgcgcgcgcgc
 ctcggccgcgcgcgcaccccttcacgcacccgcgcgcgcgc
 accggccacgtcgagggtgcgcgcgcgcgcgcgcgcgc
 45 caagcccggtccctgtacaagaacacaaaattgtggcaccagtgaac
 agactttgaatttgcaccccttcacgcacccgcgcgcgc
 cctggcccatgaacccagccatcagcgtcgcttcctgcctcagtc
 50 gcaggtgtcccgaggcgcagggtgcacccgcgcgcgcgcgc
 accaaaaacccctgcctggactgcgcgcacccgcgcgcgc
 tccatcccgatcgatgcgtccgcgcgcgcgcgcgc
 55 ctcaaggccacccctcgggatacccgagcacacgtaccgcgcgc
 tctccaaaccaggccatatacaggcccttaccctagccaaacttc
 aaggatgaggcgactactttgtgagcttcgacttc
 catgagctccaataaaagtatcagtgatagagacaaactggtc
 60 gtggccgatagaacccctgcgtggatcagaacacatcc
 ctgcgtttccctccctccctccatcaaggcccttaccct
 tagaaggccataacttcgtatagtagacacattatacga
 65 atacctggaggaaaaaaaaaaaaaggggagagtcagggtt
 AACGCATTAG

US 9,043,994 B2

55

- continued

TCTTCCAATTGAAAAAAAGTGAATTAATTATACCATTTAATTCAAGCTT
 GTAAAAATGTATCAAAGAGATAGCAAGGTATTCAAGTTAGTAAACAAGA
 TAATTGCTCCTAAAGTAGCCCCCTGAATTCCGAGGCAGTAGGCATCCACT
 ACAAGTACATGTGAATAACATCTGTGGCTTCACTATTACACATGTACTTG
 TAGTGGCGCTCACTGTCAACACGAATATAACCTCTCGAGCCTCTGTTG
 GGTTAACCTGAAGAAGTAATCCCAGCAAGTGTTCAGTAAAGATGTGCAGGCA
 ACGATTCTGTAAAGTACTGAAGCCTATTCAAACATAGTATATGTGCTGC
 CGAAGCGAGCACTTAAACAAAGGCTCGGCCGCCACTCACCTGAATTGT
 CACGCACAAGAGTTCCGTAGCTGTTCAAGTTGTGTTCAACTGTTCTG
 TCGTTTCCGACAAGTCTCTTCAGAAAATGAGCTTTGCTCTGCTT
 GGACGGACAGGATGTATGCTGTGGCTTTTAAGGATAACTACCTGGGG
 GCCTTTTCAATTGTTTCCAACCTCGGGATCTGGTACCGCAGGGCAAAAAA
 GCTCCGTTTAACTCGTTCTCTCGGCGCTCCAAGACGTTGTGTT
 GCCTCTTGACATTCTCTCGGTGTCAGGACCTGGGCTGGTGATT
 CGGTTGTTGCTGATCTGTCAGGACTCTGACACTGTCCAACTTGACCCT
 CTTGGCAGCAGGATAGTCCTCCGAGTGGAGGGAGGGCCTGGTAGTTG
 GCTGATGTGTGGAGACGTGGCACCTTGAGGACCAAGTGGCTGTGAGGA
 GGTTTGTGTGGCCTCCAGCAGAAAGGTGATCCAGACTCTGACCTTTGCC
 AGGAGCCTGCCTTTCCACAGAAACACATCGATTCTCCTCATCTT
 CTTGTTCTCCTCAGAGTCGCTGCTGGTGGTGGCGGTGTCCTCATGG
 AGCACCAAGGGCTCGGGCTGCCCTCGGGGAGGACTCGTCAGGAGAG
 CAGAGAATCCGAGGACGGAGAGAAGGGCCTGGAGTCTGCGAGGCGCAGG
 ACTTGGCGAGCTGCTGTCGTTGAGAGGGTAGGGGAAGACCACCGAGGG
 TCAGTGCACTCTGAGGCGGGCGTCAGATCTCGCAGGTACAAGCTGGA
 GGTGGAGCAGACGCTGTGGCGGGGGTTGGCTGCCGTGCTT
 TGCGCGCAGCTGGTAGGAGGCCAGCTCTGAGACGAGCTGGCGCG
 GCCGAGAAGCCCTCCACATACAGTCCTGGATGATGATGTTGATGAAG
 GTCTCGTCGTCGGGTCGAGATGAAACTCTGTTACCATGTCCTCC
 CAGCAGTCGTCACCATCTCAGTGGTCGGCGTGGAGAACGCTCCGC
 CACCGCCGTCGTTGTCCTCCCGAAGGGAGAAGGGTGTGACCGCAAGCT
 GAGGGCGAGCAGAGCCGGAGCGGCGTAGGGGACAGGGGGGGGGGG
 CAGCAGTCGAATTCTCCAGATACCTCGCTGGCGCCGGGGCTGCA
 GCTCGCTCTGCTGCTGCTGGTAGAAGTCTCCCTCGTCGAGTAG
 AAATAACGGCTGACCGAGTCGAGTCAGGTCATGTTCTGTTGGTGA
 GCTAACGTTGAGGGTCTAGACATCAGCATCAGGCTGGCATAGTCAGGCA
 CGTCATAAGGATAGCTCATCAGCATCAGGCTGGCATAGTCAGGCACGTCA
 TAAGGATAGCTCATCAGCATCAGGCTGGCATAGTCAGGCACGTCAAGG
 ATAGCTATCCATggggcaccggataacttcgtataaggatccata
 cgaagttatccattcaggctgtgtacatggcatcaatggcatggcaca
 tagccataacttcgtataatgtgtactatacgaagttatcccggttAAA

56

- continued

CGACCTGCAGCCAAGCTTATCGATAAAATAAAAGATTATTTAGTCTCC
 AGAAAAAGGGGGATGAAAGACCCCACCTGTAGGTTGGCAAGCTAGCT
 5 TAAGTAACGCCATTGCAAGGCATGGAAAATACATAACTGAGAATAGAG
 AAGTCAGATCAAGGTTAGGAACAGAGAGACAGCAGAATATGGGCCAAC
 AGGATATCTGTGGTAAGCAGTTCTGCCCGGCTAGGGCAAGAACAGA
 10 TGGTCCCCAGATGCGGCCGCCCTCAGCAGTTCTAGAGAACCATCAGA
 TGTTCCAGGGTCCCCAAGGACCTGAAAATGACCTGTGCCTTATTG
 ACTAACCAATCAGTCGCTCTCGCTCTGTTCGCGCCTCTGCTCCCC
 15 GAGCTCAATAAAAGAGCCCACAACCCCTCACTCGGCCGCCAGTCCTCCG
 ATAGACTGCGTCGCCCGGGTACCCGTATCCAATAACCCCTTGCAGT
 TGCGATCCGACTTGTGGTCTCGCTGTTGGGAGGGCTCCCTGAGTG
 ATTGACTACCCGTCAAGGGGGCTTTATGGTAACAGTTCTTGAAGT
 20 TGGAGAACACATTCTGAGGGTAGGAGTCGAATATTAGTAATCCTGACT
 CAATTAGCCACTGTTGAATCCACATACTCCAATACTCCTGAAATAGTT
 CATTATGGACAGCGCAGAAGAGCTGGGAGAATTAATCGTAATCATGGT
 25 CATAGCTGTTCTGTGAAATTGTTATCCGCTCACATTCCACACAAAC
 ATACGAGCCGAAGCATAAAAGTAAAGCCTGGGTGCGCTAATGAGTGAG
 CTAACTCACATTAATTGCGTTGCGCTACTGCCGCTTCCAGTCGGAA
 30 ACCTGTCGTGCCAGCTGCAATTGAATCGGCAACGCCGGGGAGGC
 GGTTTGCATTGGCGCTTCCGCTTCCTCGCTACTGACTCGCTGCG
 CTGGTCTGGCTGCCGGCGAGCGGTATCAGCTACTCAAAGGGGTA
 35 TACGGTTATCCACAGAAATCAGGGATAACGCAGGAAGAACATGTGAGCA
 AAAGGCCAGAAAGGCCAGGAACCGTAAAGGCCCGTTGCTGGCGTT
 TTCCATAGGCTCCGCCCCCTGACGAGCATCACAAATCGACGCTCAA
 40 GTCAGAGGTGGCAACCCGACAGGACTATAAGATACCAGCGTTCCC
 CCTGGAAGCTCCCTCGCGCTCTCCCTGGAAAGCGTGGCGTTCTCATAGCT
 ATACCTGTCGCTTCCCTCGCGCTCTCCCTGGAAAGCGTGGCGTTCTCATAGCT
 45 CACGCTGTAGGTATCTCAGTCGGTAGGTCGTTGCTCAAGCTGGC
 TGTCGACGAACCCCGTTAGCCGACCGCTGCCCTTACCGGTA
 CTATCGCTTGAGTCCAACCCGTAAGACACGACTATCGCACTGGCAG
 50 CAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTCTACA
 GAGTTCTGAAGTGGTGGCTAACCTACGGCTACACTAGAAGGACAGTATT
 TGGTATCTCGCTCTGCTGAAGCCAGTACCTCGGAAAGAGTTGGTA
 55 GCTCTGATCCGCAAAACACCCGCTGGTAGCGGTGGTTTTGTT
 TGCAAGCAGCAGATTACCGCAGAAAAAAAGGATCTCAAGAAGATCCTT
 GATCTTTCTACGGGCTGACGCTAGTGGAACGAAACTCACGTTAAG
 GGATTTGGTCAAGGATTATCAAAAGGATCTTCACCTAGATCCTTTA
 60 AATTAAAAATGAAGTTAAATCAATCTAAAGTATATGAGTAAACTG
 GTCTGACAGTTACCAATGCTTAATCAGTGAGGACCTATCTCAGCGATCT
 GTCTATTGCTCATCCATAGTGCCTGACTCCCGCTGAGATAACT
 65 ACGATACGGGAGGGTTACCATCTGGCCCCAGTGCCTGCAATGATAACCGCG

US 9,043,994 B2

57

- continued

AGACCCACGCTACCGGCTCCAGATTTATCAGCAATAAACGCCAGCCG
 GAAGGGCGAGGCAGAAGTGGCTCGCAACTTATCCGCCATTCCAG
 TCTATTAATTGTGCCGGAAAGCTAGAGTAAGTAGTCGCCAGTTAATAG
 TTGCGAACGTTGCGCATTCAGGATCGTGGTCACGCTCGT
 CGTTGGTATGGCTTATTCAAGCTCCGGTCCCAACGATCAAGGGAGTT
 ACATGATCCCCATGGTGTGCAAAAAGCGGTAGCTCCTCGGTCTCC
 GATCGTTGTCAGAAGTAAGTTGCCGCAGTGTATCACTCATGGTTATGG
 CAGCACTGCATAATTCTTACTGTATGCCATCCGTAAGATGCTTTCT
 GTGACTGGTAGACTCAACCAAGTCATTCTGAGAATAGTGTATGCCGC
 ACCGAGTTGCTTGGCCGGCGCAATACGGATAATACCGGCCACATA
 GCAGAACTTAAAGTGTCTCATGGAAAACGTTCTCGGGCGAAAA
 CTCTCAAGGATTTACCGCTGTGAGATCCAGGTCATGTAACCCACTCG
 TGCACCCAACGTATCTCAGCATCTTTACTTCAACCAGCTTCTGGGT
 GAGCAAAACAGGAAGGCAAATGCCGCAAAAAGGGATAAGGGCGACA
 CGGAAATGTTGAATACTCATACTCTCCTTTCAATATTATTGAAGCAT
 TTATCAGGGTTATTGTCATGAGCGGATAACATATTGAATGTTAGA
 AAAATAACAAATAGGGTTCCCGCACATTCCCGAAAAGTGCACCT
 GACGTCTAAAGAACCATTTATCATGACATTAACCTATAAAATAGGCG
 TATCACGAGGCCCTTCGTCTCGCGTTCGTGTGACGGTGAAACC
 TCTGACACATGCAGCTCCGGAGACGGTCACAGCTGTCTGTAAGCGGAT
 GCCGGAGCAGACAAGCCGTCAGGGCGCTCAGCGGTCTGGGGTG
 TCGGGCTGGCTTAACATGCGCATCAGAGCAGATTGACTGAGAGTGC
 ACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAATACCGC
 ATCAGGGGCCATTGCCATTCAAGGCTGCGCAACTGTTGGGAGGGCGATC
 GGTGCGGGCTTCGCTATTACGCCAGCTGGCGAAAGGGGATGTGCTG
 CAAGGGCATTAAGTTGGTAAACGCCAGGGTTCCAGTCACGACGTTG
 AAAACGACGGCGAAGGAAGCAGCCCAGTAGTAGTTGAGGCCGTTGAGC
 ACCGCCGCCAGGAATGGTCATGCAAGGAGATGGCGCCAACAGTCC
 CCCGGCCACGGGCCACCATACCCACGCCGAAACAAGCGCTCATGA
 GCCCGAAGTGGAGGCCGATTCCTCCATCGTGTGTCGGCGATATAG
 GCGCCAGCAACCGCACCTGTGGCGCCGGTGTGCGGCCACGATGCGTCC
 GCGTAGAGGGCATTAGTCCAATTGTTAAAGACAGGATATCAGTGGTCC
 AGGCTCTAGTTGACTCAACAAATACCCAGCTGAAGCCTATAGAGTAC
 GAGCCATAGATAAAATAAGATTATTTAGTCTCCAGAAAAGGGGG
 AA

The MSCV FLIP-p53 sequence was as follows (SEQ ID NO: 22):

TGAAAGACCCACCTGTAGGTTGGCAAGCTAGCTTAAGTAACGCCATT
 TGCAAGGCATGGAAAATACATACTGAGAATAGAGAAGTTCAGATCAAGG
 TTAGGAACAGAGAGACAGCAGAATATGGCCAAACAGGATATCTGTGGTA

58

- continued

AGCAGTTCTGCCCGCTCAGGGCAAGAACAGATGGTCCCCAGATGCG
 GTCCCGCCCTCAGCAGTTCTAGAGAACCATCAGATGTTCCAGGGTGC
 5 CCAAGGACCTGAAATGACCCCTGCGCTTATTGAACTAACCAATCAGTT
 CGCTCTCGCTCTGTCGCGCTCTGCTCCCGAGCTCAATAAAAAGA
 GCCCACAAACCCCTCACTCGGCCGCCAGTCCTCGATAGACTCGCTGCC
 10 CGGGTACCGTATTCCAATAAGCCTCTGCTGTTGCATCCGAATCGT
 GGACTCGCTGATCCTGGAGGGTCTCCTCAGATTGATTGACTGCCACC
 TCGGGGGCTTTCTATTGGAGGTTCCACCGAGATTGGAGACCCCTGCC
 15 AGGGACCAACGCCACCCCCCGCCGGAGGTAAGCTGGCCAGCGGTGTTTC
 GTGCTGTCCTGTCGTTGTGCGTGTGCGGATCTAATGTTGCG
 CCTGCGCTGTAAGTTAGCTAACTAGCTCTGATCTGGGGACCCGTG
 20 GTGAACTGACGAGTTCTGAAACACCCCGCGCAACCCCTGGGAGACGTCCC
 AGGGACTTGGGGGCCGTTTGTCGCCCCGACCTGAGGAAGGGAGTCGAT
 GTGGAATCCGACCCCGTCAGGATATGTTGCTGGTAGGAGACGAGAAC
 25 TAAACAGTTCCGCCCTCGTCTGAATTTCGTTGGTTGGAACCGA
 AGCCGCCGCTCTGTCGTCGAGCGCTGAGCATCGTCTGTTGCT
 CTGTCGACTGTGTTCTGATTTGCTGAAATTAGGGCAGACTGTTA
 30 CCACTCCCTTAAGTTGACCTTAGGTAAGTGTGAGCGGATC
 GCTCACAAACAGTCGGTAGATGTCAGAACAGAGACGTTGGTTACCTCTG
 CTCTGCGAGATGCCAACCTTAAACGTCGGATGCCGAGACGGCACCT
 35 TAAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTTTTACCTGGC
 CCGCATGGACACCCAGACCAGGTCCTACATCGTGACTGGGAAGCCTT
 GGCTTTGACCCCTCCCTGGTCAAGCCCTTGACACCTTAAGCTC
 CGCTCCTCTTCCTCCATCCGCCCGCTCTCCCCCTGAAACCTCCTCGT
 40 TCGACCCCGCCTCGATCTCCCTTATCCAGCCCTACTCCTCTAGG
 CGCCGGAAATTAGAtccataactcgtagatggataccctatacgaaggat
 ctcaaggtagccaccatgaccgagtacaagcccacgggtgcgcctegcca
 45 cccgcgcacgtccccaggccgtacgcacccctgcgcgcgcgttcgc
 gactaccgcacccgcgcacccgtcgatccggaccgcacatcgacgc
 ggtcaccgagctgcaagaactttccctacgcgcgtcggtcgacatcg
 gcaagggtgtgggtcgccgacgacggccgcgtgggtctggaccacgc
 ccggagagcgtcgaagccggccgggttgcgcgagatcgccgcgcgc
 50 ggccgaggttgcgggtcccggtcgccgcgcacagatggaaaggcc
 55 tcctggccgcaccggcccaaggaggccgcgtgggttcctggccaccgtc
 ggcgtctcgccgaccaccaggcaagggttgcggccgcgcgcgc
 ccccgagtgaggccggccgacgcgcgcgggtgcggcccttcctggaga
 60 cctccgcgcgcgcacccctcccttctacgcgcggctggctcaccgc
 accgcgcacgtcgagggtgcggcaaggaccgcgcacccgtgcacatcg
 caagcccggtgcgcctgtacaagaaaacagaaaattgtggcaccagt
 65 agacttgaatttgcaccccttcgtcaagttggccggagacgtcgact
 cccac

US 9,043,994 B2

59

-Continued

cctgggcccataaccaggcatcagcgccgtctctgtctcagtctt
 gcagggttcccgaggccagaaggtagccacgcctgcctgggtga
 accaaaacccctcgccctggactggccatgagaataacaccaaggataac
 tccatccagcatgagttcagccgtacccggagagaagaggaagcacgtgt
 ctcaggcacccctcgggatacccgagcacacgtaccgcctccgcgtcccc
 tcctccaaccagccctataatcaaggcttaccctacccaacttaccacc
 aaggatgagggcgactactttgttagctcgactctggcgcaatcc
 catgagctccaaataaaagatcagtgtatagagacaaactggtaagt
 gtggcgccataaggctgtggttcagaacacatcctggatgtgtgt
 ctgtttcccttcctccctccaaagccctggacttctgtgtate
 tagaaggccataacttcgtatagtagacacattatacgaagttatgtttaaac
 GCATTAGTCTTCAATTGAAAAAGTAGTTAATTATACCATTTAATT
 CAGCTTGTAATAATGTATCAAAGAGATAGCAAGGTATTCAGTTTAGTA
 AACAAAGATAATTGCTCTAAAGTAGCCCTGAAATCCGAGGCAGTAGGC
 ATCCACTACAAGTACATGTGAATAACATCTGTGGCTTCACTATTACACAT
 GTACTTGTAGTGGCGCTCACTGTCAACAGCAATAACCTCTCGAGCCT
 TCTGTTGGTTAACCTGAAGAGTAATCCCAGCAAGTGTTCAGATGTT
 GCAGGCAACGATTCTGTAAAGTACTGAAGCCTCATTCAAACATAGTATAT
 GTGCTGCCGAAGCGAGCACTTAACAAGGCTTGGCGCCGtacttgtacag
 ctcgtccatgcccggaggtgatccggccggccgtacgaactccagcagga
 ccatgtatcgccgttctcggtgggtcttgctcaggccggactgggt
 ctcaaggtagtgggtgtcgccggcagcagcacggggccgtcgccgtgggg
 gttctgtggtagtgtgtcgccggaggtgcacgcgtccgtctcgatgttgt
 ggccggatcttgaagttcaccttgatgccgtttctgtgtcgcccatg
 atatagacgttgggttgttagtgtactccagttgtgtccccaggat
 gttccgtcccttgaagtcgtatgcgtccctcagctcgatgcgggttacca
 ggggtcgccctcgaaacttacacctggccgggtcttgtagtgtccgtcg
 tccttgaagaagatggtgccgtctggacgttagccttcggccatggccga
 ctgttgaagaagatgtgtgtgtgtactccagttgtgtccccaggat
 gcaacgcgttaggtcagggtggtacgagggtggccaggccacggccagc
 ttggccgggtgtcgatgaaacttcagggtcagttggccgttaggtggcata
 gcccctggccctcgccggacacgctgaacttggccgtttacgtccgt
 ccagctcgaccaggatggccaccaccccggtgaacagctccgtcccttg
 ctcaccatggtgccgaccggataacttcgtataaggatccatacgaa
 gttatccattcaggctgtgttagcatcaatggcatggcacaaggatc
 cataacttcgtataatgtgtactatacgaagttatccgggttAAACGAC
 CTGCAGCCAAGCTTATCGATAAAAAGATTTATTAGTCTCCAGAA
 AAAGGGGGAAATGAAAGACCCACCTGTAGGTTGGCAAGCTAGCTTAAG
 TAACGCCATTGCAAGGCATGGAAAATACATAACTGAGAATAGAGAAGT
 TCAGATCAAGGTTAGGAACAGAGAGACAGCAGAAATGGGCCAAACAGGA
 TATCTGTGGTAAGCAGTTCTGCCCGGCTCAGGGCCAAGAACAGATGGT

60

-continued

CCCCAGATGCGGCCGCTCAGCAGTTCTAGAGAACCATCAGATGTT
 TCCAGGGTGCCCAAGGACCTGAAAATGACCTGTGCCTTATTGAACTA
 5 ACCAATCAGTCGCTCTCGCTCTGTTCGCGCTCTGCTCCCGAGC
 TCAATAAAAGAGGCCACAACCCCTCACTCGGCGCCAGTCCTCCGATAG
 ACTGCGTCGCCCCGGTACCCGTATCCAATAAACCTCTTGCAGTTGCA
 10 TCCGACTGTGGTCTCGCTGTTCTGGAGGGTCTCTGAGTGTATTG
 ACTACCCGTCAAGCGGGGTCTTCATGGTAACAGTTCTGAAGTTGGA
 GAACAAACATTCTGAGGGTAGGAGTCGAATATAAGTAATCCTGACTCAAT
 15 TAGCCACTGTTTGAATCCACATACTCCAATACTCCTGAAATAGTTCAATT
 ATGGACAGCGCAGAAGAGCTGGGGAGAATTATCGTAATCATGGTCATA
 GCTGTTCTGTGTGAAATTGTTATCCGCTCACAAATCCACACAAACATAC
 20 GAGCCGGAAGCATAAAGTGTAAAGCCTGGGTGCTTAATGAGTGAGCTAA
 CTCACATTAATTGCGTTCGCTCACTGCCGTTTCAGTCGGAAACCT
 GTGCGCCAGCTGCATTAATGAATCGCCAACCGCAGGGAGAGGCGGTT
 25 TCGTATTGGCGCTCTCCGCTTCCTCGCTACTGACTCGCTGCCTCG
 GTCGTCCGGCTCGCCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACG
 GTTATCCACAGAATCAGGGATAACCGCAGGAAAGAACATGTGAGCAAAG
 30 GCCAGCAAAGGCCAGAACCGTAAAGGCCGCTGCTGGCGTTTTC
 CATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCA
 GAGGTGGCAGACGGACTATAAGATAACCAGGCCTTCCCCCTG
 35 GAAAGCTCCCTCGTGCCTCTCTGTTCCGACCTGCCCTTACCGGATAC
 CTGTCGCCCTTCTCCCTCGGAAAGCGTGGCGCTTCTCATAGCTCACG
 CTGTAGGTATCTCAGTTGGTGTAGGTCGCTCCAAGCTGGCTGTG
 TGACGAAACCCCGTTCAGCCGACCGCTGCCCTTACCGGTAATCT
 40 CGTCTTGAGTCCAACCCGTAAGACACGACTTATGCCACTGGCAGCAGC
 CACTGGTAACAGGATTAGCAGAGCAGGGTATGTAGGGGTGCTACAGAGT
 TCTTGAAGTGGTGGCTAACTACGGCTACACTAGAAGGACAGTATTG
 45 ATCTGCGCTCTGCTGAAGCCAGTTACCTCGGAAAAAGAGTTGGTAGCTC
 TTGATCCGCAAACAAACCCACCGCTGGTAGCGTGGTTTTGTTGCA
 AGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTGATC
 50 TTTTCTACGGGTCTGACGCTCAGTGGAAACGAAAACCTACGTTAAGGGAT
 TTTGGTCATGAGATTATCAAAAGGATCTCACCTAGATCCTTTAAATT
 AAAAATGAAGTTTAAATCAATCTAAAGTATATGAGTAAACTTGGTCT
 55 GACAGTTACCAATGCTTAATCAGTGGAGGCACCTATCAGCGATCTGCT
 ATTCGTTACATCCATAGTGCCTGACTCCCCGTCGTAGATAACTACGA
 TACGGGAGGGCTTACCATCTGGCCCCAGTGTGCAATGATAACCGCAGAC
 60 CCACGCTCACCGCTCCAGATTATCAGCAATAAACCCAGCCAGCCGAG
 GGCCGAGCGCAGAAGTGGCCTGCACTTATCGCCCTCATCCAGTCTA
 TTAATTGTTGCCGGAAAGCTAGAGTAAGTAGTTGCGCCAGTTAATGTTG
 65 CGCAACGTTGTTGCCATTGCTACAGGCATCGGGTGTACGCTCGTCTT

US 9,043,994 B2

61

-Continued

TGGTATGGCTTCATTAGCTCCGGTCCAACGATCAAGGCAGTTACAT
GATCCCCATGTGTGCAAAAAGCGGTTAGCTCCTCGCTCCGATC
GTGTAGAAGTAAGTGGCCGAGTGTATCACTCATGGTTATGGCAGC
ACTGCATAATTCTCTACTGTGATGCCATCGTAAGATGCTTCTGTGA
CTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCCGACCG
AGTTGCTCTGCCCGCGTCAACAGGATAATACCGCACATAGCAG
AACTTTAAAGTGTCTCATTTGAAAACGTTCTCGGGCGAAACTCT
CAAGGATCTTACCGCTGTTGAGATCAGTTGATGTAACCCACTGTGCA
CCCAACTGATCTCAGCATCTTACTTACCGCTTCTGGTGAGC
AAAAACAGGAAGGCAAATGCCGAAAAAGGAATAAGGGCACACGGA
ATAGTTGAATACTCATACTCTCCCTTTCAATATTATTGAAGCATTTAT
CAGGGTTATTGTCTCATGAGCGGATACATATTGAATGATTAGAAAAA
TAAACAAATAGGGTTCGCGCACATTCGGAAAGTGCCACCTGACG
CTAAGAAACCATTATTATCATGACATTAACCTATAAAATAGCGTATCA
CGAGGCCCTTCGTCTCGCGTTTGGTGTGACGGTGAACCCCTCTGA
CACATGCAGCTCCGGAGACGGTCAAGCTTGTCTGTAAGCGATGCCG
GAGCAGACAAGCCGTCAGGGCGTCAGCGGGTGTGGGGTGTGGG
GCTGGCTTAACTATGCGGCATCAGAGCAGATTGACTGAGAGTGCACCAT
ATCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAG
GCGCATTGCCATTAGGCTGCGCAACTGTTGGAAAGGGGATCGGTG
GGGCTCTCGTATTACGCCAGCTGGCAAGGGGGATGCGTGCAGG
CGATTAAGTGGTAACGCCAGGGTTCCAGTCAGACGTTGAAAC
GACGGCGAAGGAAGCAGCCAGTAGTAGGTTGAGGCCGTGAGCACGC
CCCGCGAAGGAATGGTCATGCAAGGAGATGCCGCCAACAGTCCCCGG
CCACGGGCCTGCCACCATAACCCACGCCAACAGCGCTCATGAGCCG
AAGTGGCGAGCCGATCTCCCCATCGGTGTGCGGATATAGGC
AGCAACCGCACCTGTGGCGCGGTGATGCCGCCACGATGCGCCGG
AGAGGCATTAGTCCAATTGTTAAAGACAGGATATCAGTGGCCAGGCT
CTAGTTGACTCAACAATATCACCAGCTGAAGCCTATAGAGTACGAGCC
ATAGATAAAATAAAAGATTATTTAGTCTCCAGAAAAGGGGGAA.

The MSCV FLIP-PTEN construct comprises a sequence as follows (SEQ ID NO: 23):

TGAAAGACCCCACCTGTAGGTTGGCAAGCTAGCTTAAGTAAAGCCATT
TCCAAGGCATGAAAATACATAACTGAGAATAGAGAAGTTAGATCAAGG
TTAGAACAGAGAGACAGCAGAATAGGGCAACAGGATATGTGGTA
AGCAGTTCTGCCCGGCTAGGGCAAGAACAGATGGCCCCAGATGCG
GTCCCGCCCTAGCAGTTCTAGAGAACATCAGATGTTCCAGGGGCC
CCAAGGACCTGAAAATGACCTGTGCTTATTGAACTAACCAATCAGTT
CGTTCTCGTTCTGTTGCGCGCTCTGCTCCCGAGCTCAATAAGA
GCCCAACCCCTCACTGGCGGCCAGTCCTCGATAGACTGCGTCGCC

62

-Continued

CGGGTACCGTATTCCCAAAGCCTTGTGTTGCATCGAATCGT
GGACTCGCTGATCCTGGGAGGGTCTCCTCAGATTGATTGACTGCCACC
5 TCGGGGCTTCTATTGGAGGTTCCACCGAGATTGGAGACCCCTGCCT
AGGGACCAACGACCCCCCGCCGGGAGGTAAGCTGGCAGCGTGTTC
GTGTCTGCTCTGTCTTGCGTGTGCGGATCTAATGTTGCG
10 CCTGCGCTGTACTAGTAGCTAACTAGCTCTGTATCTGGCGAACCGTG
GTGGAACGTGACGAGTCTGAACACCCGGCGAACCTGGAGACGTC
AGGGACTTGGGGCGTTTGTGGCCGACCTGAGGAAGGGAGTC
15 GTGGAATCCGACCCCGTCAGGATATGTGGTCTGGTAGGAGACGAGAAC
TAAACAGTTCCGCCTCGTCTGAATTTCGTTGGTTGAAACCGA
AGCCGCGCTCTGTCTGCGAGCGTGCAGCATCGTCTGTGTTCT
20 CTGCTGACTGTGTTCTGTATTGCTGAAATTAGGGCCAGACTGTTA
CCACTCCCTTAAGTTGACCTTAGTCACTGGAAAGATGTCAGCGGATC
GCTCACAAACAGTCGGTAGATGTCAGAACAGAGACGTTGGTACCTCTG
CTCTGCGAAATGCCAACCTTAACTGGATGGCCGAGACGGCACCT
25 TTAACCGAGACCTCATACCCAGGTTAGATCAAGGTCTTACCTGGC
CCGCATGGACACCCAGACCAGGTCCTACATGTGACCTGGGAAGCCTT
GGCTTTGACCCCCCTCCCTGGGTCAGCCCTTGTACACCTAAGCCTC
30 CGCCCTCTTCCCTCCATCGGCCCGTCTCTCCCTGAAACCTCCTCGT
TCGACCCCGCCTCGATCCTCCCTTATCCAGCCCTACTCCTCTCTAGG
CGCCGAAATTAGAtccataacttcgtataggataccttatacgaaagtat
35 ctcaggtagccaccatgaccgagtaaagcccacggtgccctcgcca
cccgcgacgactccccaggccgtacgcacccctcgcccgccgttcgccc
gactaccccgccacggccacaccgtcgatccggaccggccacatcgacg
40 ggtcaccgagctgcaagaactttcctcactcgccgtcggtcgacatcg
gcaagggtgggtcgccgacgacggccgcggcggtcgacac
ccggagacgctgaaagccggggccgttcccggtggcccgagatcgcccgcc
45 ggccgagttgagcggttcccggtggcccgccgacgcaacagatggaaaggcc
tcctggcccgaccggcccaaggagcccgccgtggttctggccaccgc
ggcgctcgcccgaccaccaggcaagggtctggcagccgctgtgt
50 ccccgagttggaggccggccgagccggccgggggtgcccgccttcctggaga
ccctccggcccccaacccctcccttacgagccgctggcttccacgc
accggccacgtcgagggtcccgccgacggccgcacccctggcatgacc
55 caagcccggtccctgtacaagaaacagaaaattgtggcaccagtgaac
agactttgaatttgcacccatcaagggtggccggagacgtcgacttca
cctggggccatgaacccagccatcagcgctcgtctctcgt
60 gcagggttcccgaggccgagaagggtggcccgacccctggcatgacc
acccaaaccttcgcctggactgcccgcacccatgagaataacccaaggata
tccatcccgatcgatgcgttgcaccgcggagagaaggaaac
ctcaggccaccctcggttgcaccgcggacacgtaccgcctcccgct
65 tctccaaaccagccatatcaaggcttaccctagccaacttcaccacc

US 9,043,994 B2

63

-continued

aaggatgagggcactactttgtgagctcgagtcgggcgaatcc
catgagctccaataaaaatcatgtgtatagagacaaactggtaagt
gtggcggcataaggctgtggtcagaacacatcctggatgtgtgt
ctgtttccctccctcccaagccctggacttcatctgtgtatc
tagaaggccataacttcgtatagtagacacattatacgaagttatgtttaaac
GCATTAGTCTCCAATTGAAAAAAGTGTATTTAATTATACCATTTAATT
CAGCTTGTAATAATGTATCAAAGAGATAGCAAGGTATTCAAGTTAGTA
ACAAGATAATTGCTCTAAAGTAGCCCTGTGAACTCCGAGGGCAGTAGGC
AAGGTAAAATATACTTTACAATACATCTGTGGCTTCACTATTTGTAAA
GTATAGTTCACCGCGTCACTGTCAACAGCAATATACCTTCGAGCCT
TCTGTTGGGTTAACCTGAAGAAGTAATCCCAGCAAGTGTGTTCAAGATGT
GCAGGCAACGATTCTGTAAAGTACTGAAGCCTCATCAGCAATAGTATAT
GTGCTGCCGAAGCGAGCACTTAACAAGGCTTGCGGCCGtacttgtacag
ctcgccatgecgagagtgtatccggggggcgtacgaaactccagcagga
ccatgtatcgccgttctgtgggtcttgctcaggcggactgggt
ctcaggtagtgttgcggcagcagcacggggcgtcggcgtatgggggt
gttctgtgttagtgtcggcagctgcacgctccgttctcgatgttgt
ggcggatcttgaagttcacccatgtccgttctgtgttgcggccatg
atatacgttgcgttgttagtgtactccagttgtgcggccaggat
gttgcgttcccttgaagtcgtatgcgttccgtatgtgttgcgttgc
gggtgtccctcgaaacttcacccgggggttgcgttgtgcgt
tccttgcgttgttgcgttgttgcgttgttgcgttgttgcgttgt
ttgttgttgttgttgttgttgttgttgttgttgttgttgttgttgt
gcacgcgttaggtcagggtgttgcgttgttgttgttgttgttgttgt
ttgcgttgttgttgttgttgttgttgttgttgttgttgttgttgttgt
gcctcgccctcgccggacacgtgttgttgttgttgttgttgttgt
ccagctcgaccaggatgggcaccacccgggtgaacagctccgccttgc
ctcaccatggcgttgttgttgttgttgttgttgttgttgttgttgt
gttgcgttgttgttgttgttgttgttgttgttgttgttgttgttgttgt
cataactcgatgttgtactatacgaagtatccgggttAAACGAC
CTGCAGCCAAGCTTATCGATAAAATAAAAGATTTATTTAGTCTCAGAA
AAAGGGGAAATGAAAGACCCACCTGTAGGTTGGCAAGCTAGCTTAAG
TAACGCCATTGCAAGGCATGGAAAATACATAACTGAGAATAGAGAAGT
TCAGATCAAGGTAGGAACAGAGAGACAGCAGAAATATGGCCAAACAGGA
TATCTGTGGTAAGCAGTTCTGCCCGGCTCAGGGCCAAGAACAGATGGT
CCCCAGATGCGGTCCGCCCTCAGCAGTTCTAGAGAACCATCAGATGTT
TCCAGGGTGCCCAAGGACCTGAAATGACCTGTGCTTATTGAACTA
ACCAATCAGTTGCTTCTCGCTCTGTCGCGCCTCTGCTCCCGAGC
TCAATAAAAGAGGCCACACCCCTACTCGGCGGCCAGTCCTCCGATAG
ACTGCGTCGCCGGTACCGTGTATCCAATAACCCCTTGTGAGTTGCA

64

-continued

TCCGACTTGTGGTCTCGCTGTTCTGGAGGGTCTCTGTAGTGATTG
ACTACCCGTAGCGGGGGTCTTCATGGTAACAGTTCTGAAGTTGGA
5 GAACAACATTCTGAGGGTAGGGTCAAGTAATTAAGTAATCCTGACTCAAT
TAGCCACTGTTGAACTCACATCTCAATACTCCTGAAATAGTTTATT
ATGGACAGCGCAGAAGAGCTGGGAGAATTAATCGTAATCATGGTCATA
10 GCTGTTCTGTGTGAAATTGTTATCCGCTCACAAATTCCACACAACATAC
GAGCCGGAAGCATAAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAA
CTCACATTAATTGCGTTCGCTCACTGCCGCTTCCAGTCGGAAACCT
15 GTCGTGCCAGCTGCATTAATGAATGCCAACGCGGGGGAGAGGCGGTT
TGCCTATTGGCGCTCTCCGCTCCTCGCTACTGACTCGCTGCCTCG
GTCGTTGCCGTCGGCGAGCGGTATCGCTCACTCAAAGGCGTAATACG
20 GTTATCCACAGAATCAGGGATAACGAGAAAGAACATGTGAGCAAAG
GCCAGCAAAGGCCAGGAACCGTAAAAGGCCGTTGCTGGCGTTTTC
CATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCA
GAGGTGGCAGACCGAGGACTATAAGATAACCAGGCCTTCCCCCTG
25 GAAGCTCCCTCGCGCTCTCCGTTGTTGCGACCCCTGCCCTTACGGATAC
CTGTCGCCCTTCTCCCTCGGGAAAGCGTGGCGCTTCTCATAGCTCACG
CTGTAGGTATCTCAGTTGGTGTAGGTCGCTCCAGCTGGCTGTG
30 TGACGAAACCCCGTTAGCCGACCGCTGCCCTTACGGTAACTAT
CGTCTTGAGTCAAACCCGTAAGACAGACTTATGCCACTGGCAGCAGC
CACTGGTAACAGGATTAGCAGAGCAGGGTATGAGGCGGTGCTACAGAGT
35 TCTTGAAGTGGTGGCTAACTACGGTACACTAGAAGGACAGTATTG
ATCTGCCCTGCTGAAGCCAGTTACCTCGGAAAAGAGTTGGTAGCTC
TTGATCCGAAACAAACCACCCGCTGGTAGCGTGGTTTTGTTGCA
40 AGCAGCAGATTACGCGAGAAAAAAGGATCTCAAGAAGATCCTTGATC
TTTCTACGGGTCTGACGCTCAGTGGAACGAAAACCTACGTTAAGGGAT
TTGGTCATGAGATTATCAAAAGGATCTTACCTAGATCCTTTAAATT
45 AAAATGAAGTTAAATCAATCTAAAGTATATGAGTAAACTTGGTCT
GACAGTTACCAATGCTTACAGTGGACCCATCTCAGCGATCTGCT
ATTTCGTTACCCATAGTTGCTGACTCCCGTCGTAGATAACTACGA
50 TACGGGAGGGCTTACCATCTGGCCCGAGTGTGCTGCAATGATACCGCGAC
CCACGCTACCCGCTCAGATTATCAGCAATAACAGCCAGCCAGCGAAG
GGCCGAGCGCAGAAGTGGTCTGCAACTTATCCGCTCCATCCAGTCTA
55 TTAATTGTCGCCGGAAAGCTAGAGTAAGTAGTTGCCAGTTAATAGTTG
CGCAACCTGTTGCCATTGCTACAGGATCGTGGTGTACGCTCGTGT
TGGTATGGCTTACCTAGCTCCGGTCCACGATCAAGGCGAGTTACAT
GATCCCCCATGTTGCAAAAAAGCGGTTAGCTCCTCGGTCTCCGATC
60 GTTGTCAAGTAAGTGGCGCAGTGTATCACTCATGGTTATGGCAGC
ACTGCATAATTCTCTACTGTCATGCCATCGTAAGATGCTTGTG
CTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCACCG
65 AGTTGCTTGTGCCGGCTCAATACGGATAATACCGCGCCACATAGCAG

US 9,043,994 B2

65

- continued

AACTTTAAAAGTGCTCATTTGGAAAACGTTCTCGGGCGAAAAACTCT
 CAAGGATCTTACCGCTGTTGAGATCAGTCATGTAACCCACTCGTCA
 CCCAAGTGTCTCAGCATCTTACTTCACCAGCTTCTGGTGAGC
 AAAAACAGGAAGGCATAATGCCCAAAAAGGAATAAGGGCACCGGA
 ATATGTTGAATACTCATACTCTTCCTTTCAATATTATTGAAGCATTAT
 CAGGGTTATTGCTCATGAGCGATAACATATTGAATGTATTAGAAAAA
 TAAACAAATAGGGTTCCGCGCACATTCCCCGAAAAGTGCCACCTGACG
 TCTAAGAACCAATTATCATGACATTAACCTATAAAATAGGGTATC
 ACAGAGGCCCTTCGCTCGCGTTCGGTATGACGGTAAAAACCTCTG
 ACACATGCGAGCTCCCGAGACGGTACAGCTTGTCTGTAAGCGGATGCC
 GGAGCAGACAAGCCCGTCAGGGCGCTCAGCGGTGTTGGCGGGTGTGG
 GGCTGGCTTAACATATGCGGCATCAGAGCAGATTGACTGAGAGTGCACCA
 TATGCGGTGTAAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCA
 GGCGCCATTGCCATTAGGCTCGCAACTGTGGGAAGGGGATCGGT
 CGGGCCTTCGCTATTACGCCAGCTGGCAAAGGGGATGTGCTGCAAG
 GCGATTAAGTGGGTAACGCCAGGGTTTCCCAGTCAGCAGCTGTTAAA
 CGACGGCGCAAGGAAGCAGCCCAGTAGTAGGTTGAGGCCGTTGAGCACCG
 CGGCCGCAAGGAATGGTGCATGCAAGGAGATGCCCAACAGTCCCCG
 GCCACGGGCCTGCCACCATAACCAACGCCAACAGCGCTCATGAGCCC
 GAAGTGGCGAGGCCATCTCCCTACGGTATGTCGGCATAAGGCGC
 CAGCAACCGCACCTGTGGCGCCGGTATGCCGCCACGATCGTCCGGCG
 TAGAGGCGATTAGTCCAATTGTTAAAGACAGGATATCAGTGGTCAGGC
 TCTAGTTTGACTCAACAATACCAAGCTGAAGCTATAGAGTACGAC
 CATAGATAAAATAAAAGATTATTAGTCTCAGAAAAGGGGGAA

The MSCV FLIPi Puro2AGFP/Thy1.1-miR-FF construct comprises a sequence as follows (SEQ ID NO: 24):

TGAAAGACCCCACCTGTAGGTTGGCAAGCTAGCTTAAGTAACGCCATT
 TGCAAGGATGAAAATACATAACTGAGAATAGAGAAGTTCAGATCAAGG
 TTAGGAACAGAGAGACAGCAGAATATGGCCAAACAGGATATCTGTGGTA
 AGCAGTTCTGCCCGCTAGGGCCAAGAACAGATGGTCCCCAGATGCG
 GTCCCGCCCTAGCAGTTCTAGAGAACCATCAGATGTTCCAGGGTGC
 CCAAGGACCTGAAAATGACCCCTGCGCTTATTGAACTAACCAATCAGTT
 CGCTTCTCGCTTGTGCGCGCTCTGCTCCCCGAGCTCAATAAGA
 GCCCACAACCCCACTCGCGCGCAGTCCTCCGATAGACTCGTCGCC
 CGGGTACCGTATTCCAATAAGCTTGTGATCCGATCGTCTGCG
 GGAACCGCTGATCCTGGGAGGGTCTCTCAGATTGACTGCCACC
 TCGGGGGTCTTCATTGGAGGTTCCACCGAGATTGGAGACCCCTGCCT
 AGGGACCACCGACCCCCCGCCGGAGGTAAGCTGGCCAGCGTCGTT
 GTGTCTGCTCTGTCTTGCGTGTGCGCATCTAATGTTGCG
 CCTCGCTGTACTAGTGTACTAGCTAAGCTGTATCTGGCGAACCGTG

66

- continued

GTTGAACTGACGAGTTCTGAACACCCGGCGCAACCTGGGAGACGTCCC
 AGGGACTTGGGGCCGTTTGTGGCCGACCTGAGGAAGGGAGTCGAT
 5 GTGGAATCCGACCCGTCAAGGATATGTGGTCTGGTAGGAGACGAGAAC
 TAAACAGTCCCGCCTCGTCTGATTTCGTTGGTTGGAACCGAA
 GCGCGCGCTTGCTCGCTGCAGCGCTGCAGCATCGTCTGTGTTGCTC
 10 TGCTGACTGTTCTGTATTGCTGAAATTAGGGCAGACTGTTAC
 CACTCCCTTAAGTTGACCTAGGTCACTGGAAAGATGTCGAGCGGATCG
 CTCACAAACCAGTCGGTAGATGTCAGAAGAGAGACGTTGGTTACCTTC
 15 TCTGCAGAATGCCAACCTTAACGTCGGATGGCCGAGACGGCACCTT
 TAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTACCTG
 CGCATGGACACCCAGACCAGGTCCTACATCGTACCTGGGAAGCCTG
 20 GCTTTGACCCCCCTCCCTGGGTAAGCCCTTGTACACCTTAAGCCTCC
 GCCTCCCTTCCTCCATCCGCCCGTCTCTCCCCCTGAAACCTCCTCGTT
 CGACCCCGCCTCGATCCTCCCTTATCCAGCCCTCACTCCTCTAGGC
 25 GCGGAATTAGAtccataacttcgtataaggataccttatacgaaattat
 ctcaggataccGCCACCATGGTGGAGTACAAGCCCACGGTGCCTCGCCA
 CCCGCGACGTCCTCCAGGGCGTACGCACCCCTGCCGCCGTTGCC
 30 GACTACCCGCCACGCCACCCGTCGATCCGGACGCCACATCGAGCG
 GGTACCGAGCTGCAAGAACTCTCCTACGCGCTCGGGCTCGACATCG
 GCAAGGTGTGGGTCGCCAGCAGGCCCGCGTGGGGTCTGGACACAG
 35 CCGGAGAGCGTCAAGGGGGGGTGTTCGCGAGATCGGCCGCGCAT
 GGCGAGGTTGAGCGTTCCCGCTGGCGCGCAGCAACAGATGGAAGGCC
 TCCTGGCGCCGACCGGCCCAAGGAGGCCGCGTGGTTCTGGCACC
 GCGTCTGCCCGACCCACAGGCAAGGGTCTGGGAGCGCCGCTGTGCT
 40 CCCGGAGTGGAGGCGCCGAGCGGCCGGGTGCCCGCTTCCTGGAGA
 CCTCCCGCCCGCAACCTCCCTCTACGAGCGCTCGGCTTCACCGC
 ACCGCCGACGTCGAGGTGCCGAAGGACCGCGCACCTGGTGCATGCC
 45 CAAGCCCGTGCCAAACAGAAAATTGTCGACAGTCAAACAGACTTGA
 ATTTTGACCTTCAGTTGGGGAGACGTCGAGTCAAACCTGGGCC
 GGCCCGGTCGCCACCATGGTGCAGCAAGGGCGAGGAGCTGTT
 50 GGTGCCCATCCTGGTCGAGCTGGACGGCAGTAAACGCCACAAGTCA
 GCGTGTCCGGCAGGGCGAGGGGAGCTGCCACCTACGCAAGCTGAC
 AAGTCATCTGCACCAACGGCAAGCTGCCGTGCCCTGGCCACCG
 55 GACCACCTGACCTACGGCGTCAAGTCTTCAGCCGATGCCGTA
 TGAAGCAGCAGACTCTCAAGTCCGCATGCCGAAGGCTACGTCAG
 GAGCGCACCATCTCTCAAGGACGACGGCAACTACAAGACCCGCC
 60 GGTGAAGTTCGAGGGCGACCCCTGGTGAACCGCATCGAGCTGA
 TCGACTTCAAGGAGGACGGCAACATCCTGGGCACAAGCTGGAGTAC
 TACAACGCCACAACGCTATATCATGCCGACAAGCAGAAGAACGG
 65 CAAGGTGAACCTCAAGATCCGCCACACATCGAGGACGGCAGCGTGCAGC

US 9,043,994 B2

67

-Continued

TCGCCGACCACTACCAGCAGAACACCCCATCGGCACGGCCCCGTGCTG
 CTGCCGACAACCACTACCTGAGCACCCAGTCGCCCTGAGCAAAGACCC
 CAACGAGAAGGCCGATCACATGGCTCTGGAGTCGTGACGCCCG
 GATCACTCTGGCATGGACGACTGACAAGTAGTctagaagccataact
 tcgtatagtacacattatacgaatTTTATGCATACCTGGAGGAAAAAAA
 AAGGGGAGAGTCAGGGtttaacgcattagtcattcaatgaaaaagtg
 attaatttataccatttaattcagcttgtaaaatgtatcaaagaga
 tagcaaggtattcagtttagtaaacaagataattgtctaaagtagcc
 cttgaattcCGAGGCAGTAGGCAGGCTCCCCTGAATTGGAATCCTACA
 TCTGTGGCTTCACTAGGATTCCAATTCACGGAGCTCGCTACTGTCAAC
 AGCAATACCTCtcgagcctctgttggttaacctgaagaagtaatc
 ccagcaagtgttccaagatgtcgaggcaacgattctgtaaagtaactgaa
 gcctcattcaaacatagtatatgtctggcaagcgagcaacttaacaagg
 ctgcggccgtacttgtacagctgtccatgccagagtgtatccggcg
 ggcgCCACTCACCTGCAATTGGCCGCTCACAGAGAAATGAAGTCCAGGGC
 TTGGAGGAGGGAGGGAAAGCAGCAGCAGCAGCAGCATCCAGGATGTCT
 GAACCAGCAGGTTATGCCAACACTTGACCAGTTGTCTCATACACA
 CTGATACTTTATTGGAGCTCATGGATTGCGCCCGAGACTCGAAGCTC
 ACAAAAGTAGTCGCCCTCATCCTGGTGAAGTTGGCTAGGGTAAGGA
 CCTTGATATAGGGCTGGTTGGAGAGGGTGACGCCGGAGCGGTACGTG
 TCGGGTATCCCGAGGGTGCCTGAGGACACGTGCTTCTCTCGGGT
 CAGGCTGAACTCATGCTGGATGGAGTTATCCTGGTTATTCTCATGGC
 GGCAGTCCAGGCGAAGGTTGGTACCGAGCAGGCTGTGAGGTGGT
 ACCTCTGCCCTCGGACACCTGAAGACTGAGAGCAGGAGGGACGCT
 GATGGCTGGTTCATggtgccgaccggtaacttcgtataaggtatcct
 atacgaagttatccattcaggctgtgttagcatcaatggcatggcacaaa
 gettagccataacttcgtataatgtgtactatacgaagttatccgggtt
 AACAGACCTGCAGCCAAGCTTATCGATAAAATAAGATTTATTAGTC
 TCCAGAAAAGGGGGAATGAAAGACCCCACCTGTAGGTTGGCAAGCTA
 GCTTAAGTAACGCCATTTGCAAGGCATGGAAAATACATAACTGAGAATA
 GAGAAGTTCAAGGTTAGGAACAGAGAGACAGCAGAATATGGGCCA
 AACAGGATATCTGTGTAAGCAGTTCTGCCCGGCTCAGGCCAAGAAC
 AGATGGTCCCGAGTCGGTCCGCCCTCAGCAGTTCTAGAGAACCATC
 AGATGTTCCAGGGTCCCCAAGGACCTGAAATGACCTGTGCCCTATT
 TGAACTAACCACTACGGCTCTCGCTCTGGCTCGCGCCTGCT
 CCCGAGCTCAATAAGAGCCCACAACCCCTCACTCGCGCGCAGTCCT
 CCGATAGACTGCCTGCCGGTACCGTGTATCCAATAACCCCTTGTG
 AGTTGCATCCGACTTGTGGTCTCGCTGTTGGAGGGTCTCTGTA
 GTGATTGACTACCCGTCAGGGGGCTTCTGGTAAACAGTTCTGTA
 AGTTGGAGAACACATTCTGAGGGTAGGAGTCGAATATTAAGTAATCCTG
 ACTCAATTAGCCACTGTTGAATCCACATACTCCAATACTCCTGAAATA

68

-continued

GTTCATATTGGACAGCGCAGAAGAGCTGGGAGAATTAACTCGTAATCAT
 GGTACATGCTGTTCTGTGAAATTGTTATCGCTCACATTCCACAC
 AACATACGAGCCGAAGCATAAAAGTGTAAAGCCTGGGTGCTAATGAGT
 GAGCTAACTCACATTAATTGCGTGCCTACTGCCCTTCCAGTCGG
 GAAACCTGCGTGCAGCTGCATTAATGAATCGGCCAACGCCGGGAGA
 GCGGTTTGCCTATTGGCGCTTCCGCTTCCGCTACTGACTCGCT
 GCGCTCGGTGTTGGCTGCCGAGCGGTACGCTACTCAAAGCGG
 TAATACGGTTATCCACAGAATCAGGGATAACGAGAAACATGTGA
 GCAGGAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAGGCCGCTGCTGG
 GTTTCCATAGGCTCCGCCCTGACGAGCATCACAAATCGACGCTC
 AAGTCAGAGGTGGCGAAACCGACAGGACTATAAGATAACCAGGCTT
 CCCCTGGAAGCTCCCTCGCCTCTCTGGTACCCGACCCCTGCCCTTAC
 GGATACCTGTCGCCCTTCTCCCTCGGAAGCGTGGCTTCTCATAG
 CTCACGCTGTAGGTATCTCAGTTCGGTGTAGGCTCGCTCAAGCTGG
 GCTGTGTCACGAACCCCCGGTTCAGCCGACCGCTGCCCTATCCGGT
 AACTATCGTCTTGAGTCCAACCCGTAAGACGACTATCGCCACTGGC
 AGCAGCCACTGGTAACAGGATTAGCAGAGCAGGTATGAGGCGGTGCTA
 CAGAGTTCTGAAAGTGGCTTAACACTGGCTACACTAGAAGGACAGTA
 TTTGGTATCTGCCTCTGCTGAAGCCAGTTACCTCGGAAAAGAGTTGG
 TAGCTCTGATCGGCCAACAAACCACCGCTGGTAGCGGTGGTTTTTG
 TTGCAAGCAGCAGATTACGCCAGAAAAAGGATCTAAGAAGATCCT
 TTGATCTTCTACGGGCTGACGCTCAGTGGAAACAAACTCACGTTA
 AGGGATTTGGTATGAGATTATCAAAAGGATCTCACCTAGATCCTTT
 TAAATTAAAATGAAGTTAAATCAATCTAAAGTATATGAGTAAACT
 TGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTAGCGAT
 CTGCTCTTCTGTTCATCCATAGTGGCTGACTCCCGCTGTGAGATAA
 CTACGATACGGGAGGGTTACCATCTGCCAGTGTGCAATGATACCG
 CGAGACCCACGCTCACCGCTCCAGATTACGCAATAAACAGCCAGC
 CGGAAGGCCGAGCGCAGAAGTGGCTCGCAACTTATCCGCTCCATCC
 AGTCTATTAAATTGTCGGGGAGCTAGAGTAAGTAGTTCGCCAGTTA
 AGTTTGCACGTTGGCTCATTCAGCTGGTCCCAACGATCAAGGCAG
 GTCTGGTATGGCTTCTGCTCAGTCCGGTCCAGTGGCTACAGGATCG
 TTACATGATCCCCATGGTGTGCAAAAAGCGGTTAGCTCCTCGGTCT
 CCGATCGTGTAGAAGTAAGTGGCCAGTGTATCACTCATGGTTAT
 GGCAGCACTGCTAACCTTACTGTCTGCTACAGGATCGTGGTGTAC
 CTGTGACTGGTAGACTCAACCAAGTCATTCTGAGAATAGTGTATCGGG
 CGACCGAGTTGCTCTGCCGGCTCAATACGGATAATACCGGCCACA
 TAGTAGAACCTTAAAGTGTCTCATCTGGAAAACGTTCTCGGGCGAA
 AACTCTAAGGATCTTACCGCTGTTGAGATCCAGTTGATGTAACCCACT
 CGTGCACCCAACTGATCTTCAGCATCTTACTTTTACCCGCTTCTGG

US 9,043,994 B2

69

-Continued
 GTGAGAAAAACAGGAAGGAAATGCCGAAAAAGGAATAAGGGCGA
 CACGGAAATGTTGAATACTCATACTCTTCCTTTCAATATTATTGAAGC
 ATTATCAGGGTATTGTCATGAGCGGATACATATTGAATGTATTGA
 GAAAAATAAACAAATAGGGGTTCCGCGCACATTCCCCGAAAAGTGCAC
 CTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAATAGG
 CGTATCACGAGGCCCTTCGTCGCGCTTCGGTGATGACGGTAAAAA
 CCTCTGACACATGCAGCTCCGGAGACGGTACAGCTTGTCTGTAAGCGG
 ATGCCGGGAGCAGACAAGCCGTCAGGGCGCTACGGGTGTTGGCGG
 TGTCGGGCTGGCTTAACATGCGGCATCAGAGCAGATTGACTGAGAGT
 GCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACC
 GCATCAGCGCCATTGCCATTAGCCTGCGCAACTGTTGGAAAGGGCGA
 TCGGTGCGGGCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGATGTG
 TCCAAGGCAGATAAGTGGTAACGCCAGGGTTTCCCAGTCACGACGTT
 GTAAACAGCGCGCAAGGAAGCAGCCAGTAGTAGGTTGAGGCCGTTGA
 GCACCGCGCGCAAGGAATGGTCATGCAAGGAGATGGCGCCAACAGT
 CCCCCGCCACGGGCCTGCCACCATAACCCACGCCAACAGCCTCAT
 GAGCCCGAAGTGGCGAGCCGATCTCCCCATGGTGATGCGCGATAT
 AGGCGCCAGCAACCGCACCTGTCGGCGCCGGTATGCCGCCACGATGCGT
 CCGCGTAGAGCGATTAGTCAAATTGTTAAAGACAGGATATCAGTGGT
 CCAGGCTCTAGTTTGACTCAACAAATACCCAGCTGAAGCTATAGAGT
 ACAGGCCATAGAAAAAAGGATTTTATAGCTCCAGAAAAAGGG
 GGAA

The MSCV FLIPi Puro2AGFP/Thy1.1-miR-p53 construct comprises a sequence as follows (SEQ ID NO: 25):

TGAAAGACCCACCTGTAGGTTGGCAAGCTAGCTTAAGTAACGCCATT
 TGCAAGGCATGAAAATACATAACTGAGAATAGAGAAGATTGAGATCAAGG
 TTAGGAACAGAGAGACAGCAGAATATGGCCAAACAGGATATCTGTTG
 AGCAGTTCTGCCCGGCTCAGGGCAAGAACAGATGGTCCCAGATGCG
 GTCCCGCCTCAGCAGTTCTAGAGAACATCAGATGTTCCAGGGTGC
 CCAAGGACCTGAAAATGACCTGTGCTTATTGAACTAACCAATCAGTT
 CGCTTCTCGCTCTGTTGCGCGCTCTGCTCCCCGAGCTAACATAAAAGA
 GCCCACAACCCCTCACTCGCGGCCAGTCCTCGATAGACTCGCTCGC
 CGGGTACCGTATTCCAATAAACGCTTCTGCTGTTGCAATCGAACG
 GGACTCGCTGATCTGGAGGGTCTCTCAGATTGATTGACTGCCACC
 TCGGGGTCTTCATTGGAGGGTCCACCGAGATTGGAGACCCCTGCCT
 AGGGACCACGACCCCCCGCCGGAGGTAAGCTGGCCAGCGGTGTTTC
 GTGTCTGCTCTGCTTGTGCGTGGTGTGCGCATCTAATGTTGCG
 CCTGCGTCTGACTAGTTAGCTAACTAGCTCTGATCTGGCGACCCGTG
 GTGGAACGTGAGCTTGACACCCGGCCGCAACCTGGGGAGACGTCCC
 AGGGACTTTGGGGCGTTTGTGGCCGACCTGAGGAAGGGAGTCGAT

70

-Continued
 GTGGAATCCGACCCCGTCAGGATATGTTGCTGGTAGGAGACGAGAAC
 TAAACAGTCCCGCCTCGTGAATTGCTTCGGTTGGAACCGA
 5 AGCCGCGCTCTGCTGCTGAGCGCTGCAGCATCGTCTGTTCT
 CTGCTGACTGTTCTGATTTGCTGAAAATTAGGGCCAGACTGTTA
 CCACTCCCTTAAGTTGACCTTAGGTACTGGAAAGATGTCGAGCGATC
 10 GCTCACAAACAGTCGGTAGATGTCAGAAGAGACGTTGGTTACCTCTG
 CTCTGAGAATGCCAACCTTAACGTCGGATGGCCCGAGACGGCACCT
 TTAACCGAGACCTCATACCCAGGTTAAGATCAAGGTCTTTCACCTGGC
 15 CCGCATGGACACCCAGACCAGGTCCTACATCGTACGGAAAGCCTT
 GGCTTTGACCCCCCTCCCTGGGTAAGCCCTTGACACCCTAACGCTC
 CGCTCCCTCTCCCTCACCGCCCGTCTCTCCCTGAACCTCCTCGT
 20 TCGACCCCGCTCGATCTCCCTTATCCAGCCCTACTCCTCTCTAGG
 CGCCGAAATTAGAtccataacttcgtataggataccttatacgaagtat
 ctcaggattaccGCCACCATGGTGGAGTACAAGCCCACGGTGCCTCGCC
 CCCCGACGACGCTCCAGGGCGTACGCACCCCTGCCGCCGCGTCCG
 25 GACTACCCGCCACGCCACACCGTGTATCCGGACGCCACATCGAGCG
 GGTACCGAGCTGCAAGAACCTTCCCTACGCGCCTGGGCTCGACATCG
 GCAAGGTGTGGTCGGGACGACGGGCCCGCGTGGCGTCTGGACCACG
 30 CCGGAGAGCGTGAAGGGGGCGGTTCGCGAGATCGGCCCGCAT
 GGCGAGTTGAGCCGGTCCCGCTGGCGCGCAGAACAGATGGAAGGC
 CTCTGGCGCCGACCCGCCAACAGGAGCCCGTGGTCTGGCCACCGT
 35 CGCGTCTGCCCGACCACAGGGCAAGGGTCTGGCAGCGCCGTCGTG
 TCCCCGGAGTGGAGGGCCCGAGCGCCCGGGGTGCCGCTTCTGGAG
 ACCTCCCGCCCCCGAACCTCCCTTACGACGGCTCGCTTACCGT
 40 CACCGCCGACGTCGAGGTGCCCAGGACCGCGCACCTGGTGCATGACCC
 GCAAGCCGGTGCCAAACAGAAAATTGTCGACCGAGTGAACAGACTTG
 AATTGACCTCTCAAGTGGCGGGAGACGTCGAGTCAACCCCTGGGC
 45 CGGCCCCGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTTACCGGG
 TGGTGCCTACCTGGTCAGGCTGGACGGGAGCTAACGGCCACAAGTTC
 AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCC
 50 GAAGTTCATCTGCACCAACCGGCAAGCTGCCGTGCCCTGGCCACCC
 TGACCAACCTGACCTACGGCGTGCAGTCCTCAGCCCTACCCGACCA
 ATGAAGCAGCACGACTCTCAAGTCCGCATGCCGAAGGCTACGTC
 55 GGAGCGCACCATCTCTCAAGGACGACGGCAACTACAAGACCCGCC
 AGGTGAAGTCGAGGGCGACACCTGGTAACCGCAGTCAGGCTGAAGGGC
 ATCGACTTCAAGGAGGACGGCAACATCTGGGCACAAGCTGGAGTACAA
 CTACAACAGCCACAACGCTATATCATGGCGACAAGCAGAAGAACGG
 60 TCAAGGTGAACCTCAAGATCCGCCAACACATCGAGGACGGCAGCGTGCAG
 CTCGCCGACCACTACCGCAGAACACCCCCATGGCGACGGCCCGTGC
 GCTGCCGACAAACCAACTACCTGAGCACCCAGTCGCCCTGAGCAAAGAC
 65 CCAACGAGAAGCGCGATCACATGGCTGCTGGAGTTGCGTACCGCCGCC

US 9,043,994 B2

71

- continued

GGGATCACTCTCGGCATGGACGAGCTGTACAAGTAGtctagaaggcataa
 ctccgtatagtagacacattatacggaaGTTTATGCCATACCTGGAGGAAAAAA
 AAAAGGGAGAGTCAGGGTTAACGCATTAGTCTCCAATTGAAAAAA
 GTGATTTAATTATACCATTTAATTCACTAGCTTGAAATGTATCAAAG
 AGATAGCAAGGTATTCAAGTTAGTAACAAAGATAATTGCTCTAAAGTA
 GCCCCTGAATTCGAGGCAGTAGGCATCCACTACAAGTACATGTGTAAT
 ACATCTGTGGCTCACTATTACACATGTACTTGAGTGGCGCTCACTGT
 CAACAGCAATATACTTCTCGAGCCTCTGGTTAACCTGAAGAAGT
 AATCCCAGCAAGTGTTCAGATGTGCAGGCAACGATTCTGTAAAGTAC
 TGAAGCCTCATTCAAACATAGTATATGTGCTGCCAAGCGAGCACTTAAAC
 AAGGCTTGCAGGCCACTCACCTGCAATTGGCCGCTCACAGAGAAAT
 GAAGTCCAGGGCTTGGAGGAGGGAGAGGAAAGCAGCAGCAGCAGCATCC
 AGGATGTGTTCTGAACCAGCAGGCTTATGCCGCCACACTTGACCAAGTTG
 TCTCTATACACACTGATACTTTTATGGAGCTCATGGGATTCCGCCCGA
 GACTCGAAGCTCACAAAGTAGTCGCCCTCATCCTGGTGGTAAGTTGG
 CTAGGGTAAGGACCTGATATAGGGCTGGTGGAGAGGGTGACGCCGGAG
 CGGTACGTGTGCTCGGTATCCGAGGGTGCTGAGAGCACGTGCTTCC
 CTTCTCGGGTCAAGCTGAACTCATGCTGGATGGAGTTACCTTGGTGT
 TATTCTCATGGGGCAGTCCAGGCGAAGGTTGGTCACCAGGCAAGGCT
 GTCAAGCTGGTACCTCTGCCCTGGGACACCTGCAAGACTGAGAGCAG
 GAGAGCGACGCTGATGGCTGGGTCATggggcgaccggataacttcgt
 ataaggatccatatacgaagttatccattcaggctgtctagcatcaatg
 gcatggcacaaagcttagccataacttcgtataatgtgtactatacgaag
 ttatccgggttAAACGACCTGCAAGCTTATCGATAAAAATAAAAGA
 TTTTATTTAGTCTCCAGAAAAAGGGGGAAATGAAAGACCCCACCTGTAGG
 TTGGCAAGCTAGCTTAAGTAACGCCATTGCAAGGCATGGAAAATACA
 TAATGAGAATAGAGAAGTTAGATCAAGGTTAGAACAGAGAGCAGCAG
 AATATGGGCAAACAGGATATCTGTGGTAAGCAGTTCTGCCCGCTCA
 GGCCAAAGAACAGATGGTCCCAGATGCGGCCGCCCCCTCAGCAGTTCT
 AGAGAACCATCAGATGTTCCAGGGTCCCCAAGGACCTGAAAATGACCC
 TGTCCTTATTGAACTAACCAATCAGTCGCTTCTCGCTCTGTCGCG
 CGCTCTGCTCCCGAGCTCAAAAAAGAGCCACACCCCTACTCGGC
 GCGCCAGTCCCGAGACTGCGTCCGGTACCCGTATCCAATA
 AACCCCTTGCAGTTGCATCCAGCTTGTGGTCTCGCTTCTGGGAGG
 GTCTCTCTGAGTGATTGACTACCCGTACGGGGGTCTTCATGGTAA
 CAGTTCTGAAGTTGGAGAACACATTCTGAGGGTAGGAGTCGAATATT
 AAGTAATCCTGACTCAATTAGCCACTGTTTGAATCCACATACTCCAATA
 CTCCGTAAATAGTCATTATGGACAGCGCAGAACAGAGCTGGGAGAATTAA
 TTGCAATCATGGTCAAGCTGTTCTGTGTAAGGTTATCCGCTCA
 CAATTCCACACAAACATACGAGCCGAAGCATAAAAGTGTAAAGCCTGGGT

72

- continued

GCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCGC
 TTTCCAGCTGGAAACCTGTCGTGCCAGCTGCATTAAATGAATCGGCCAAC
 5 GCGCGGGAGAGGCAGGGTTCGCTATTGGCGCTCTCCGCTCCCTCGCTC
 ACTGACTCGCTCGCTCGTCGCTGCCGAGCGGTATCAGCTCA
 CTCAAAGGCAGGTAATACGGTATCCACAGAATCAGGGATAACGCAGGAA
 10 AGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAGGCC
 GCGTTGCTGGCTTTCCATAGGCTCGCCCCCTGACGAGCATCACAA
 AAATCGACGCTCAAGTCAGAGGTGGGAAACCCGACAGGACTATAAAGAT
 15 ACCAGGCAGTTCCCCCTGGAAGCTCCCTCGTCGCTCTCCGACC
 CTGCCGTTACCGATACTGTCCGCTTCTCCCTCGGGAAAGCGTGGC
 GCTTCTCATAGCTCACGCTGTAGGTATCTCAGTTGGTGTAGGTGTC
 20 GCTCCAAGCTGGCTGTGTCAGCAAGCCCCCTGTCAGCCGACCGCTGC
 GCCTTATCGGTAACTATCGCTTGAGTCCAACCCGTAAGACACGACTT
 ATCGCCACTGGCAGCAGCACTGGTAACAGGATTAGCAGAGCAGGATAG
 TAGGCGGTGCTACAGAGTTCTGAAGTGGTGGCTAACTACGGCTACACT
 25 AGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTCG
 AAAAAGATGGTAGCTTGTGATCCGGAAACAAACCCACCGCTGGTAGCG
 GTGGTTTTTGTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCT
 30 CAAGAAGATCCTTGATCTTCTACGGGCTGACGCTCAGTGGAAAGA
 AAACTCACGTTAAGGGATTTGGTCATGAGATTATCAAAAGGATCTCA
 CCTAGATCCTTAAATTAAATGAAGTTAAATCAATCTAAAGTATA
 35 TATGAGTAAACTGGCTGACAGTTACCAATGCTTAATCAGTGAGGACCC
 TATCTCAGCAGTCTGCTATTGCTCATCCATAGTTGCTGACTCCCC
 TCGTGTAGATAACTACGATAACGGAGGGCTTACCATCTGCCCTAGTGT
 40 GCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTATCAGCAAT
 AAACCGCCAGCCGGAAAGGGCGAGCGCAGAAGTGGCTGCAACTTAT
 CCGCCTCCATCCAGTCTATTAAATTGTCGGGAGCTAGAGTAAGTAGT
 45 TCGCCAGTTAATAGTTGCGAACGTTGCTGCTACAGGATCGT
 GGTGTCAGCTCGCTGGTATGGCTCATCAGCTCCGGTCCAAAC
 GATCAAGGCAGTTACATGATCCCCATGTTGCAAAAAGCGTTAGC
 50 TCCTTCGGTCTCCGATCGTTGTCAGAAGTAAGTGGCCGAGTGTATC
 ACTCATGGTTATGGCAGCACTGCATAATTCTTACTGTCATGCCATCCG
 TAAGATGCTTCTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAA
 55 TAGTGTATGCGCGACCGAGTTGCTCTGCCGGCGTCAATACGGGATAA
 TACCGGCCACATAGCAGAACTTTAAAGTGCTCATTTGAAAACGTT
 CTTCGGGGGAGAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTG
 ATGTAACCCACTCGTGCACCCAACGTCTTCAGCATCTTACTTTCA
 60 CAGCGTTCTGGTGAGCAGAACAGGAAGGAAATGCCGAAAAAGG
 GAATAAGGGCGACCGAAATGTTGAATACTCATACTCTCTTTTCAA
 TATTATGAGCATTATCAGGGTTATGTCATGAGCGGATACATATT
 65 TGAATGTATTAGAAAAATAACAAATAGGGTCCCGCAGATTTCCC

US 9,043,994 B2

73

- continued

GAAAAGTGCCACCTGACGTCAAGAACCATATTATCATGACATTAACC
 TATAAAAATAGCGTATCACGAGGCCCTTCGCTCGCGCTTCCGGTGA
 TGACGGTAAAAACCTCTGACACATGCAGCTCCGGAGACGGTACAGCTT
 GTCTGTAAGCGGATGCCGGAGCAGACAAGCCGTCAGGGCGCTCAGCG
 GGTGTTGGCGGGTGTGGGCTGGCTTAACTATGGGGCATCAGAGCAGAT
 TGTACTGAGAGTGCACCATATGGGTGAAATACCGCACAGATCGTAA
 GGAGAAAATACCGCATCAGGCCATTGCCATTAGGCTGCCAATGT
 TGGGAAGGGCGATCGGTGCGGGCTTCGCTATTAGCCAGCTGGCAA
 AGGGGGATGTGCTGCAAGGCATTAAGTTGGTAACGCCAGGGTTTCCC
 AGTCACGACGTTGAAACGACGGCGCAAGGAAGCAGCCCAGTAGTAGGT
 TGAGGCCGTTGAGCACCGCCCGCAAGGAATGGTCATGCAAGGAGATG
 GCGCCAACAGTCCCCCGGCCACGGGCGCTGCCACCATACCCACGCCAA
 ACAAGCGCTCATGAGCCGAAAGTGGGAGGCCGATCTCCCCATGGTGA
 TGCGGCCGATATAGGCCGAGCACCGCACCTGTGGCGCCGGTGTGCGC
 GCCACGATGCGTCCGGCTAGAGGCATTAGTCAATTGTTAAAGACAG
 GATATCAGTGGTCCAGGCTCTAGTTGACTCAACAATATCACCAGCTGA
 AGCCTATAGAGTACGAGCCATAGATAAAAGATTATTAGTCTC
 CAGAAAAAGGGGGAA

The MSCV FLIPi Puro2AGFP/Thy1.1-miR-PTEN construct comprises a sequence as follows (seq id no: 26):

TGAAAGACCCCACCTGTAGGTTGGCAAGCTAGCTTAAGTAACGCCATT
 TCGAAGGCATGGAAAATACATAACTGAGAATAGAGAAGTTAGATCAAGG
 TTAGAACAGAGAGACAGCAGAATATGGCCAAACAGGATATCTGTGGTA
 AGCAGTTCCTGCCCGGCTAGGGCAAGAACAGATGGTCCCCAGATGCG
 GTCCCGCCCTCAGCAGTTCTAGAGAACCATCAGATGTTCCAGGGTGCC
 CCAAGGACCTGAAAATGACCCCTGTGCCATTGAACTAACCAATCAGTT
 CGCTTCTCGCTCTGTCGCGCTCTGCTCCCCGAGCTCAATAAAAGA
 GCCCACAACCCCTCACTCGCGCGCAGTCCTCCGATAGACTCGTCGCC
 CGGGTACCGTATTCCAATAAGCTTGTGCTGAGCTCAATAAAAGA
 GGACTCGCTGATCCTGGGAGGGTCTCTCAGATTGACTGCCAAC
 TCGGGGCTTTCTGGAGGTTCCACCGAGATTGGAGACCCCTGCC
 AGGGACCAACGACCCCCCGGGAGGTAAGCTGCCAGCGGCTTGTG
 TCTGTCTCTGCTTGTGCGTGTGCGGCTCATCTAATGTTGCC
 GCGTCTGACTAGTTAGCTAACAGCTCTGTATCTGGCGGACCCGTGGT
 GAACGTACGAGTTCTGAACACCCGGCGAACCTGGGAGACGTCCAGG
 GACTTGGGGCGTTTGTGGCCGACCTGAGGAAGGGAGTCGATGTG
 GAATCCGACCCGTCAAGGATATGTGGTTCTGGTAGGAGACGAGAAC
 AACAGTTCCCGCCTCGTCTGAATTGTTGCTTGGTTGGAACCGAAGC
 CGCGCGCTTGTGCTGCCAGCAGCATCGTCTGTGTTCTG
 TCTGACTGTGTTCTGTATTGCTGAAAATTAGGGCCAGACTGTTACCA

74

- continued

CTCCCTTAAGTTGACCTAGGTCACTGGAAAGATGTCGAGCGGATCGCT
 5 CACAACCAGTCGGTAGATGTCAGAAGAGAGCCTGGGTTACCTTCGCTC
 TGCAGAAATGCCAACCTTAACGTCGGATGCCCGAGACGGCACCTTA
 ACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTACCTGGCC
 CATGGACACCCAGACCCAGGTCCTACATCGTACCTGGAAAGCCTGGC
 10 TTTTGACCCCCCTCCCTGGGTAAGCCCTTGTACACCTTAAGCCTCCG
 CTCCCTCCCTCCATCCGCCCGTCTCTCCCCCTGAAACCTCCTCGTTG
 ACCCGCCTCGATCCTCCCTTATCCAGCCCTACTCCTCTAGGCGC
 15 CGGAATTAGAtccataacttcgtataggataccttatacgaaagtatetc
 aggtaccGCCACCAGTGGGAGTACAAGGCCACGGTGCCTGCCACCC
 GCGACGACGTCcccAGGGCGTACGACCCCTGCCCGCGTCCGCGA
 20 CTACCCGCCACCGCCACACCGTCGATCCGGACCGCCACATCGAGCGG
 TCACCGAGCTGCAAGAACTCTCTCACGCCGTCGGGCTGACATCGG
 AAGGTGTTGGGTCGGGACGACGGCGCCGGTGGCGGCTGGACCACGCC
 25 GGAGAGCGTCAAGCGGGGGCGGTGTCGCCAGATCGGCCCGCATGG
 CCGAGTTGAGCGTTCCCGCTGGCCCGCAGCAACAGATGAAAGGCTC
 CTGGCGCCGACCGGCCAAGGAGCCCGTGGTCTGGCCACCCTCGG
 30 CGTCTCGCCCGACCACCCAGGGCAAGGGCTGGGAGCGCCGTCGTC
 CCGGAGTGGAGGGCGCCAGCGCCGGGGTGCCCGCCTCTGGAGACC
 TCCCGCCCCCGAACCTCCCTCTACAGCGCTCGGCTTACCGTCAC
 35 CGCCGACGTCGAGGTGCCGAAGGACCGCGCACCTGGTGCATGACCGCA
 AGCCCGGTGCCAACAGAAAATTGTCGACCCAGTGAACACAGACTTGAAT
 TTTGACCTCTCAAGTTGGGGAGACGTCGAGTCCAACCTGGGCC
 40 CCCGGTCCGACCATGGTGGAGCAAGGGCGAGGAGCTTACCGGGTGG
 TGCCCACCTGGTCGAGCTGGACGGCACGTAACGCCAACAGTTCA
 GTGTCCCGGAGGGCGAGGGCAGTGCACCTACGGCAAGCTGACCC
 GTTCATCTGCACCAACGGCAAGCTGCCGTGCCCTGCCACCC
 45 CCACCCCTGACCTACGGCGTCAGTGCCTCAGCCGCTACCCGACCAC
 AAGCAGCACGACTCTCAAGTCGCCATGCCGAAGGCTACGTCCAGGA
 GCGCACCATCTCTCAAGGAGCACGCCACTACAAGACCCCGCCAGG
 50 TGAAGTTGAGGGCGACCCCTGGTAACCGCATCGAGCTGAAGGGCATC
 GACTTCAGGAGGACGGCAACATCCTGGGACAAGCTGGAGTACA
 CAACAGCCACAACGTCTATATCATGGCGACAAGCAGAAAGACGG
 55 AGGTGAACCTCAAGATGCCACAACATCGAGGAGCGCAGCGTGCAGCTC
 GCGGACCACTACCGAGCAACACCCCCATGGCGACGGCCCGTGC
 GCGCACCAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGAC
 60 ACGAGAACGCGCATCACATGGCTCTGCTGGAGTTCGTCAGCGGCC
 ATCACTCTGGCATGGACGAGCTGTACAAGTAGtctagaagccataact
 cgtatagtagacacattatcgaaGTTTATGCACTGAGGAGGAAAA
 65 AGGGAGAGTCAGGGTTAAACGCATTAGTCTTCAATTGAAAAAGTG

75

-Continued

ATTTAATTATACCATTAAATTCAGCTTGTAAAAATGTATCAAAGAGA
 TAGCAAGGTATTCACTTAAAGATAATTGCTCCTAAAGTAGCC
 CCTTGAATTCCGAGGCAGTAGGCACAGGTAAAACACTAATCTACAAATACA
 TCTGTGGCTTCACTATTGTAAAGTATAGTTCACCGCGTCACTGTCAA
 CAGCAATATAACCTCTCGAGCCTCTGTTGGGTAACCTGAAGAAGTAAT
 CCCAGCAAGTGTTCAGGCAACGATTCTGTAAAGTACTGA
 AGCCTATTCAAACATAGTATATGTGCTGCCAACGCGACCTAACAG
 GCTTGCGGCCCAACTCACCTCAATTGGCCGTCACAGAGAAATGAA
 GTCCAGGGCTTGGAGGGAGAGGGAAAGCAGCAGCAGCAGCATCCAGG
 ATGTGTTCTGAACCAGCAGGCTTATGCCAACACTTGACCAGTTGTCT
 CTATACACACTGATACTTTATTGGAGCTCATGGGATTGCGCCCCAGAC
 TCGAAGCTCACAAAGTAGTCGCCCATCTTGGTGTAAAGTTGGCTA
 GGGTAAGGACCTTGATATAGGGCTGGTTGGAGAGGGTACGCCGGAGCG
 TACGTGTGCTCGGTATCCGGGGTGCCTGAGAGCACGTGCTTCTCTT
 CTCTCGGGTCAGGCTGAACCTATGCTGGATGGAGTTATCCTGGTGTAT
 TCTCATGGCGCAGTCCAGGCAAGGTTGGTACCCAGGAGGTGTC
 AGGCTGGTCACCTCTGCCCTGGACACCTGCAAGACTGAGAGCAGGAG
 AGCGACGCTGATGGCTGGGTCATggtgccgaccggtaacttcgtata
 aggtatccatacgaagttatccattcaggctgtctagcataatggca
 tggcacaaagcttagccataacttcgtataatgttactatacgaagtt
 tcccggttAAACGACCTGCAAGCCAAGCTATCGATAAAATAAGATT
 TATTAGTCTCCAGAAAAGGGGGAAATGAAAGACCCCACCTGTAGGTT
 GGCAAGCTAGCTTAAGTAAACGCCATTGCAAGGCATGGAAATACATAA
 CTGAGAATAGAGAAGTTCAGATCAAGGTTAGAACAGAGAGACAGCAGAA
 TATGGGCAACAGGATATCTGTTGAAAGCAGTTCTGCCCGGTCAGG
 GCCAAGAACAGATGGTCCCCAGATCGGTCCGCCCTCAGCAGTTCTAG
 AGAACCATCAGATGTTCCAGGGTCCAGGAAAGGACCTGAAATGACCTG
 TGCTTATTGAACTAACCAATCAGTCGCTCTCGCTCTGTCGCGCG
 CTTCTGCCCCGAGCTCAAAAAAGGCCACAACCCCTACTCGGCGC
 GCCAGTCCTCGATAGACTCGTCGCCGGTACCGTGTATCCAATAAA
 CCTCTTGAGTGCATCCGACTTGTGGTCTCGCTGTTCTGGGAGGGT
 CTCCCTGAGTGAATGACTACCCGTAGCGGGGGTCTTCATGGTAACA
 GTTTCTGAAGTGGAGAACACATTCTGAGGGTAGGAGTCGAATATTAA
 GTAATCCTGACTCAATTAGCCACTGTTGAATCCACATACTCCAATACT
 CCTGAAATAGTCATTATGGACAGCGCAGAACAGAGCTGGGAGAAATTAA
 CGTAATCATGGTCATAGCTGTTCTGTTGAAATTGTTATCCGTCACA
 ATTCCACACAAACATCAGAGCGGAAGCATAAAAGTGTAAAGCCTGGGTG
 CTAATGAGTGAAGCTAACACATTAATTGCGTTGCGCTCACTGCCGCTT
 TCCAGTCGGGAAACCTGTCGCGCAGCTGCATTAATGAATCGGCCAACGC
 GCAGGGAGAGGGGTTGCGTATTGGCGCTTCCGCTTCGCTCAC
 TGACTCGCTCGCCTCGGTGCGCTCGGCTCGGGAGCGGTATCAGCTCACT

76

-continued

CAAAGGCGTAATACGGTATCCACAGAATCAGGGATAACGCAGGAAAG
 AACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAGGCCGC
 5 GTTGCTGGCTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAA
 ATCGACGCTCAAGTCAGAGGTGGCAGAACCCGACAGGACTATAAAGATAC
 CAGGCGTTCCCGTGGAGCTCCCTCGTGCCTCTCTGTTCCGACCC
 10 GCGCTTACCGATACTGTCCGCCTTCTCCCTCGGAAGCGTGGCG
 TTTCTCATAGCTACGCTGTAGGTATCTCAGTTGGTAGGTGTTCGC
 TCCAAGCTGGCTGTGTCAGCAACCCCCCGTCAGCCGACCGCTGCGC
 15 CTTATCCGTAACTATCGTCTTGAGTCCAACCCGTAAGACACGACTTAT
 CGCCACTGGCAGCAGCAGCTGGTAACAGGATTAGCAGAGCAGGGTATGTA
 GCGGGTCTACAGAGTTCTGAAGTGGCTTAACACTGGCTACACTAG
 20 AAGGACAGTATTGGTATCTGCGCTCTGCTGAAGCCATTACCTCGGA
 AAAGAGTTGGTAGCTCTGATCCGGAAACAAACACCCTGGTAGCGG
 GGTTTTTTGTTGCAAGCAGATTACGCGCAGAAAAAAAGGATCTCA
 25 AGAAGATCTTGTATCTTCTACGGGTCTGACGCTCAGTGGAACGAA
 ACTCACGTTAAGGATTGGTATGAGATTCAAAAGGATCTTACCC
 TAGATCCTTTAAATTAAAGTAAAGTTAAATCAATCTAAAGTATATA
 30 TGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGACACTA
 TCTCAGCGATCTGTCTTCTGTCATCCATAGTGCCTGACTCCCCGTC
 GTGTAGATAACTACGATAACGGAGGGTACCATCTGCCCGAGTGTG
 35 AATGATAACCGCAGACCCACGCTCACCGCTCAGATTATCAGCAATAA
 ACCAGCCAGCCGAAGGGCGAGCGCAGAAGTGGTCTGCAACCTTAC
 GCCTCCATCCAGTCTATTAAATTGTCGGAGCTAGAGTAAGTAGTTC
 40 GCGAGTTAATAGTTGCGAACGTTGTCATTGCTACAGGATCTG
 TGTCACGCTCGTGTGGTATGGCTTACAGCTCCGGTCCAACGA
 TCAAGGGAGTTACATGATCCCCATGTTGTGCAAAAGCGGTTAGCTC
 CTCGGCTCCGATCGTGTAGAAGTAAGTGGCCAGTGTATCAC
 45 TCATGGTTATGGCAGCAGTCATAATTCTTACTGTCATGCCATCCGTA
 AGATGCTTTCTGACTGGTAGACTCAACCAAGTCATTCTGAGAATA
 GTGTATGCGCGACCGAGTTGCTCTGCCGGGTCAATACGGATAATA
 50 CGCGCCACATGCAGAACCTTAAAGTGTCTCATATTGAAAACGTTCT
 TCGGGCGAAAACCTCAAGGATCTACCGCTGTTGAGATCCAGTTG
 GTAACCCACTCGTCAGCCAACTGATCTCAGCATCTTACTTTACCA
 55 GCGTTTGGGTGAGCAAAACAGGAAGGAAAATGCCAAAAAGGGA
 ATAAGGGCAGACGGAAATGTTGAATACTCATACTCTCCTTTCAATA
 TTATTGAAGCATTATCAGGGTATTGTCATGAGCGGATACATATTG
 60 AATGTTAGAAAATAACAAATAGGGTTCGCGCACATTCCCCGA
 AAAGTGCCACCTGACGCTAAGAAACCAATTATCATGACATTAACCTA
 TAAAAATAGCGTATCAGGCGCTTCGTCGCGTTCGGTAGT
 65 ACGGTGAAAACCTCTGACACATGCAGCTCCGGAGACGGTACAGCTGT

77

78

-Continued

-continued

CTGTAAGCGGATGCCGGAGCAGACAAAGCCGTCAGGGCGCTCAGCGGG
 TGTGGCGGGTGTGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTG
 TACTGAGAGTCACCATATGCGGTGAAATACCGCACAGATGCGTAAGG
 AGAAAATACCGCATCAGGCCATTGCCATTAGCGCTGCCAAGCTGGTGA
 GGAAGGGCGATCGGTGCGGGCTCTCGCTATTAGCCAGCTGGCGAAAG
 GGGGATGTGCGCAAGCGATTAAGTTGGTAACGCCAGGGTTTCCCAG
 TCACGACGTTGAAACGACGGCGCAAGGAAGCAGCCCAGTAGTAGGTTG
 AGGCCGTTGAGCACCGCCGCCAAGGAATGGCATGCAAGGAGATGGC
 GCCAACAGTCCCCGGCCACGGGCCTGCCACCATAACCCACGCCAAC
 AAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTCCCCATCGGTGATG
 TCGCGATATAGCGCCAGCACCGCACCTGGGCCGGTGATGCCGC
 CACGATCGCTCCGGCTAGAGCGATTAGTCCAATTGTTAAAGACAGGA
 TATCAGTGGTCAGGCTCTAGTTTACTAACATAATCACCAGCTGAAG
 CCTATAGAGTACGAGCCATAGATAAAAATAAAAGATTTATTTAGTCTCA
 GAAAAAGGGGGAA

The MSCV FLIPi Puro2AGFP/Thy1.1-miR-Dbl (p53 & PTEN) construct comprises a sequence as follows (seq id no: 27):

TGAAAGACCCACCTGTAGGTTGGCAAGCTAGCTTAAGTAACGCCATT
 TGCAAGGCATGGAAAATACATAACTGAGAATAGAGAAGTTAGATCAAGG
 TTAGAACAGAGAGACAGCAGAATATGGGCAACAGGATATCTGTTGTA
 AGCAGTTCTGCCCGCTCAGGGCAAGAACAGATGGTCCCCAGATGCG
 GTCCCGCCCTCAGCGATTCTAGAGAACATCAGATGTTCCAGGGTGC
 CCAAGGACCTGAAAATGACCTGTGCCATTGAACTAACCAATCAGTT
 CGCTTCTCGCTCTGTTGCGCCTCTGCTCCCCAGCTCAATAAAAGA
 GCCCACAACCCCTCACTCGCGCGCAGTCCTCGATAGACTCGCTGCC
 CGGGTACCGTATTCCAATAAGCCTTGTGTTGATCCGAATCGT
 GGACTCGCTGATCCTTGGAGGGTCTCTCAGATTGATTGACTGCCACC
 TCGGGGGCTTTCATTGGAGGGTCCACCGAGATTGGAGACCCCTGCC
 AGGGACCACCGACCCCCCGCCGGAGGTAAAGCTGGCCAGCGCTGTT
 GTGTCTGCTCTGTCTTGTGCGTGGTGTGGCGCATCTAATGTTGCG
 CCTGCGCTGACTAGTTAGCTAAGCTGCTGTATCTGGCGACCCGTG
 GTGGAACTGACGAGTTCTGAAACACCCGGCGCAACCCCTGGAGACGT
 AGGGACTTTGGGGCGTTTGTGGCCGACCTGAGGAAGGGAGTCGAT
 GTGGAACTCGACCCCGTCAAGGATATGTGGTTCTGGTAGGAGACGAG
 TAAAACAGTTCCCGCTCCGCTGAAATTGCTTGGTTGGAAACCGA
 AGCCGCGCTCTGCTGCTGAGCGCTGCAGCATCGTTCTGTTGCT
 CTGCTGACTGTGTTCTGTATTGCTGAAATTAGGGCAGACTGTTA
 CCACTCCCTAACGTTGACCTAGGTCACTGGAAAGATGTCGAGCGGATC
 GCTCACAAACAGTCGGTAGATGTCAGAAGAGACGTTGGGTTACCTCTG
 CTCTGAGAACGCCAACCTTAACGTCGGATGGCGCGAGACGGCACCT

TTAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTTCACCTGGC
 CCGCATGGACACCCAGCAGCAGGCTCCATACCGTGAACCTGGAGCCT
 5 GGCTTTGACCCCCCTCCCTGGGTAAGCCCTTGACACCCCTAACGCTC
 CGCCCTCCTCTCCATCCGCCCGCTCTCCCCCTGAAACCTCCTCGT
 TCGACCCCGCTCGATCTCCCTTATCCAGCCCTCACTCCTCTCTAGG
 10 CGCCGGAATTAGAtccataacttcgtataggataccctatacgaagtat
 ctcaaggtaaccGCCACCATGGTGGAGTACAAGCCCACGGTGCCTCGCA
 CCCCGACGACGCTCCAGGGCGTACGCCACCCCTGCCCGCGCTCGCC
 15 GACTACCCGCCACGCCACACCGTCGATCCGGACGCCACATCGAGCG
 GGTCACCAGCTGCAAGAACACTTCTCTCACGCCGTCGGCTCGACATCG
 GCAAGGTGTGGTCGCGGACGACGGCCCGCGTGGCGTCTGGACCACG
 20 CCGGAGAGCGTCAAGGGGGCGGTGTTGCCAGATCGGCCCGCAT
 GGCGAGGTTGAGCGTTCCCGCTGGCCGCGCAGCAACAGATGGAAGGCC
 TCCCTGGCCCGCACGCCCAAGGAGCCCGCTGGTTCTGGCCACCGTC
 25 GCGTCTCGCCGACCCAGGGCAAGGGCTGGGAGCGCCGCTCGTGC
 CCCGGAGTGGAGGGCGCCAGCGCGCCGGGTGCCCGCTTCTGGAGA
 CCTCCCGCCCGCAACCTCCCTCTACGAGCGCTCGCTTACCGTC
 30 ACCGCCGACGTCGAGGTGCCGAAGGACCGCGCACCTGGTGCATGACCG
 CAAGCCGGTGCAAACAGAAAATTGTCGACCAAGTGAAACAGACTTGA
 ATTTGACCTCTCAAGTTGGCGGAGACGTCGAGTCCAACCTGGGCC
 35 GCGCCGGTGCACCATGGTGGCAAGGGCGAGGAGCTGTTACCCGGGT
 GGTGCCCATCTGGTGGAGCTGGACGGCGACGTAAACGGCCACAAGTCA
 GCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGCAAGCTGACCTG
 AAGTTCATCTGACCAACCGCAAGCTGCCGTGCCCTGGCCACCCCTCGT
 40 GACCACCTGACCTACGGCGTGCAGTGCTTCAGCCGTAACCCGACCACA
 TGAAGCAGCAGACTTCTCAAGTCCCATGCCGAAGGCTACGTCAG
 GAGCGCACCATCTCAAGGACGACGGCAACTACAAGACCCGCGCA
 45 GGTGAAGTTGAGGGCGACACCCCTGGTAACCGCATCGAGCTGAAGGCCA
 TCGACTTCAAGGAGGACGGCAACATCTGGGGACAAGCTGGAGTACAAAC
 TACAACAGCCACAACGCTATATCATGGCGACAAGCAGAAGAACGGCAT
 50 CAAGGTGAACCTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGC
 TCGCCGACCACTACCGCAGAACACCCCATGGCGACGGCCCGTGTG
 CTGCCCCACAACCACTACCTGAGCACCCAGTCGCCCTGAGCAAAGACCC
 55 CAACGAGAAGCGCGATCACATGGCTCTGCTGGAGTTGCTGACCGCCCG
 GGATCACTCTCGCATGGACGAGCTGACAAGTAGtctagaagccataac
 ttcgatagatcacattatacgaaGTTTATGCATACCTGGAGGAAAAAAA
 60 AAAGGGAGAGTCAGGGTTAACGCAAGCTGTTCAATTGAAAAAG
 TGATTTAATTATACCATTTAATTGCTGAAAGATGTATCAAAGA
 GATAGCAAGGTATTCAGTTAGTAAACAAGATAATTGCTCCTAAAGTAG
 65 CCCCTGAATTCCGAGGCAGTAGGCAAGGTGAAACTATACTTTACAATA

US 9,043,994 B2

79

80

-continued

-continued

CATCTGGCTTCACTATTGTAAAGTATGTTACCGCGCTCACTGTC
 AACAGCAATATACTTCGAGCCTCTGTTGGTTAACCTGAAGAAGTA
 ATCCCAGCAAGTGTTCAGATGTGCAGGAACGATTCTGTAAAGTACT
 GAAGCCTCATCAAACATAGTATATGTGCTGCCGAAGCGAGCACTTAACA
 AGGCTTGCAATTAAACGCATTAGTCTTCAATTGAAAAAGTGAATTAAAT
 TTATACCATTAACTTCAAGCTTGTAAAATGTATCAAAGAGATAGCAAG
 GTATTCAAGTTTAGTAAACAAGATAATTGCTCTAAAGTAGCCCTTGAA
 TTCCGAGGCAGTAGGCATCCACTACAAGTACATGTGAATACATCTGTGG
 CTTCACTATTACACATGTAATTGTAGTGGCGCTACTGTCAACAGCAAT
 ATACCTTCTCGAGCCTCTGTTGGTTAACCTGAAGAAGTAATCCCAGCA
 AGTGTTCAGATGTGCAGGAACGATTCTGTAAAGTACTGAAGCCTCA
 TTCAAAACATAGTATATGTGCTGCCGAAGCGAGCACTTAAACAAGGCTTGCG
 GCCGCCACTCACCTGCAATTGGCGCTCACAGAGAAATGAAGTCCAGG
 GCTTGGAGGAGGGAGAGGGAAAGCAGCAGCAGCAGCATCCAGGATGTGTT
 CTGAACCAGCAGGCTTATGCCCAACACTTGGCAGTGTCTCTATACA
 CACTGATACTTTTATTGGAGCTATGGATTGCGCCGAGACTCGAAGC
 TCACAAAAGTAGTCGCCCTCATCCTTGGTGAAGTTGGCTAGGGTAAG
 GACCTTGATATAGGGCTGGTGGAGAGGGTGACGCCGGAGCGGTACGTGT
 GCTCGGGTATCCGAGGGTGCCTGAGAGCACGTGCTCTCTCTCGG
 GTCAGGCTGAACTCATGCTGGATGGAGTTACCTTGGTGTATTCTCATG
 GCGGCACTCCAGGCAGGGTTGGTCAACAGGCCAGGCTGTCAGGCTGG
 TCACCTCTGCCCTGGGACACCTGCAAGACTGAGAGCAGGAGAGCGACG
 CTGATGGCTGGGTCATggggcaccggataacttcgtataaggatc
 ctatacgaagttatccattcaggctgtgtactatacgaagttatccggg
 aagcttagccataacttcgtataatgtgtactatacgaagttatccggg
 ttAAACGACCTGCAGCCAAGCTTATCGATAAAAAGATTTTATTAG
 TCTCCAGAAAAGGGGGGAATGAAAGACCCACCTGAGGTTGGCAAGC
 TAGCTTAAGTAACGCCATTGCAAGGCATGGAAAATACATAACTGAGAA
 TAGAGAAGTTAGATCAAGGTTAGAACAGAGAGACAGCAGAATATGGGC
 CAAACAGGATATCTGGTAAGCAGTTCTGCCCGCTCAGGGCAAGA
 ACAGATGGCCCCAGATGCCCTGCCCTCAGCAGTTCTAGAGAACCA
 TCAGATTTCAAGGTGCCCTGAGGACCTGAAAATGACCTGTCCTTA
 TTTGAACTAACCAATCAGTTGCTCTCGCTTCTGTCGCGCCTCTGC
 TCCCCGAGCTCAATAAGAGCCCACAACCCCTCACTCGCCGCCAGTC
 CTCGATAGACTGCCAGGGTACCGCTATCCAATAAACCCCTT
 GCAGTTGCATCCGACTTGTGGCTCGCTGTTCTGGAGGGCTCCCT
 GAGTGATTGACTACCCGTCAAGGGGGTCTTCATGGTAACAGTTCTT
 GAAGTTGGAGAACACATTCTGAGGGTAGGAGTCGAATATTAAGTAATCC
 TGACTCAATTAGCCACTGTTGAATCCACATACTCCAATACTCTGTAAA
 TAGTTCAATTATGGACAGCGCAGAAGAGCTGGGAGAATTATCGTAATC
 ATGGTCATAGCTGTTCTGTGAAATTGTTATCGCTCACAAATTCCAC

5 5
 10 10
 15 15
 20 20
 25 25
 30 30
 35 35
 40 40
 45 45
 50 50
 55 55
 60 60
 65 65

- continued

```

AGCATTATCAGGGTATTGTCATGAGCGATACTATTTGAATGTAT
TTAGAAAATAAACAAATAGGGTCCGCGCACATTCGGAAAAGTGC
CACCTGACGCTAAGAACCATTTATCATGACATTAACCTATAAAAT
AGCGTATCACGAGGCCCTTCGTCTCGCGCTTCGGTATGACGGTGA
AACCTCTGACACATGCAGCTCCGGAGACGGTCACAGCTGCTGTAAG
CGGATGCCGGAGCAGACAAGCCGTCAGGGCGCTCAGCGGTGTTGGC
GGGTGTCGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAG
AGTGCACCATATGCGGTGTAAGAACCGCACAGATGCGTAAGGAGAAAAT
ACCGCATCAGGCCATTGCCATTAGGCTGCGCAACTGTTGGGAGGG
CGATCGGTGCGGCCTTCGTATTACGCCAGCTGGCAAAGGGGGATG
TCTGCAAGCGATTAAGTGGTAACGCCAGGGTTCCAGTCACGAC
GTTGAAACAGCGCAAGGAAGCAGCCCAGTAGTAGGTTGAGCCGT
TGAGCACGCCGCCGAAGGAATGGTCATGCAAGGAGATGGCGCCAAAC
AGTCCCCGGCACGGGCCTGCCACCATAACCGCGAAACAGCGCT
CATGAGCCGAAGTGGCAGGCCGATCTCCCCATCGGTATGTCGGCGA
TATAGGCCACCAACCGCACCTGTGGCGCCGTATGCCGCCACGATG
CGTCCGGCGTAGAGGCAGTTGCAATTGTTAAAGACAGGATATCAGT
GGTCCAGGCTCTAGTTGACTCAACAATATCACCAGCTGAAGCCTATAG
AGTACGAGCCATAGATAAAATAAAAGATTATTAGTCTCAGAAAAAG
GGGGAA.

```

The Tie2-Cre construct was as described in Kisanuki, Y.Y., et al. (2001) Dev Biol 230, 230-42. The CD19-Cre construct was as described in Rickert, R. C., Roes, J. & Rajewsky, K. (1997) Nucleic Acids Res 25, 1317-8. The Mox-Cre construct was as described in Tallquist M D; Soriano P. 2000. Genesis 26(2):113-5.

Reagents

Anti p53 antibody was provided by Andrea Ventura. Doxo-rubicin and doxycycline were obtained from Sigma.

Verification of Reporter Expression:

Reverse transcriptase-PCR assays were conducted, probing for efficient intron splicing from the FLIP vector and compared to PCR of genomic DNA. Primers were as follows:

Reverse primer (in vector): (SEQ ID NO: 9)
CCA GGA TTT ATA CAA GGA GGA GAA AAT GAA AGC

Forward primer (in GFP): (SEQ ID NO: 10)
CTG AGC AAA GAC CCC AAC GAG AAG C

The PCR amplified only the transcript derived from FLIP vectors reversed by Cre activity.

Lewis Lung carcinoma cells (LL2) were transduced with pFLIP and probed for Thy 1.1 expression by FACS analysis following puromycin selection. Selected cells were also probed for GFP expression, prior to and following infection with MCSV-Cre.

Infectious viral particles were produced through standard lab methods. 293FT cells were transiently transfected with retroviral gag/pol and VSVg envelopes plasmids along with the viral vector. The supernatants were harvested at 48 hours and used to infect target cells in the presence of 4 ug/ml polybrene.

Northern Blot Analysis:

HEK293 cells were infected with retrovirus expressing an miR30 targeting firefly luciferase (FF), PTEN, p53, two tandem miR30 constructs targeting p53 and PTEN, or FLIP vector (Lanes 5-7). The FLIP vector contained the miR30 targeting PTEN or p53 in the antisense that was reversed by Cre expression. The intron pair contained the miR30 targeting PTEN or p53 flanked by synthetic consensus splice donor and splice acceptor sites. The blots were hybridized with a probe specific for the guide strand (sense probe) that mediates RNAi, or the antisense probe that is non-functional. The functional guide strand was only produced when the vector was flipped to the sense orientation.

HEK293 cells infected with FLIP retrovirus expressing miR-181a or miR-15b in the antisense that is reversed to the sense orientation by Cre expression were similarly evaluated. The intron vectors contained the miRNAs between consensus synthetic splice sites. The blots were hybridized with probes specific for miR181a or miR15b. The miRNA was only processed to the mature form when expressed in the sense orientation.

Probes utilized were as follows:

p53 sense probe (hybridizes to guide strand)
(SEQ ID NO: 15)
5'-CCA CTA CAA GTA CAT GTG TA-3'.

p53 anti-sense probe
(SEQ ID NO: 16)
5'-TAC ACA TGT ACT TGT AGT GG-3'.

PTEN sense probe
(SEQ ID NO: 17)
5'-GGT GAA ACT ATA CTT TAC AA-3'.

PTEN anti-sense probe
(SEQ ID NO: 18)
5'-TTG TAA AGT ATA GTT TCA CC-3'.

Mir-181a probe
(SEQ ID NO: 19)
5'-ACT CAC CGA CAG CGT TGA ATG TT-3'.

Mir-15b probe
(SEQ ID NO: 20)
5'-TGT AAA CCA TGA TGT GCT GCT A-3'.

In Vitro Knockdown Studies

The DC2.4 cell line was transduced with the pLB2 construct expressing a miR30 targeting alpha-4 integrin expression (SEQ ID NO: 2), with and without MCSV-Cre. Integrin expression was assessed by FACS analysis probing with anti-integrin alpha-4 conjugated to PE (Becton-Dickinson).

In Vivo Knockdown Studies

Murine embryonic stem cells that express Cre from the VEGF-R2 (Flk1) locus, which turns on Cre expression about embryonic day 8 were infected with the pLB2 constructs, and selected with puromycin. Using tetraploid complementation, FLIP-infected ES cells were injected and embryos were generated, which were derived exclusively from pLB2-expressing ES cells.

Adult pLB2-FLIP males were also subsequently crossed with Mox-Cre females and embryos were removed at stage e9.5. Mox-Cre expressed very early in embryo (e2 or e3).

Bone marrow stem were purified by lineage depletion of marker positive cells and cultured for 8 days in STIF medium and angiopoietin-like-2 (Zhang et al.) On days 1 and 2, bone marrow stem cells were infected with FLIP retroviral supernatants and cultured for 4 days in the presence of puromycin.

83

Recipient mice were lethally irradiated and reconstituted with infected bone marrow stem cells and additional supporting cells derived from the spleen.

Bone marrow stem cells were also obtained from Cre-ERT2 mice (see Hayashi S, and McMahon A P. Dev Biol. 2002 Apr. 15; 244(2):305-18). Eight weeks after reconstitution, mice were treated with 2 mg/mouse tamoxifen to induce recombination of the vector. Five days later spleens were minced and sorted by MACS for Thy1.1+ cells. Purified cells were cultured for 4 hours in 5 ug/ml doxorubicin and lysed for SDS-PAGE.

Bone marrow stem cells were obtained from CD19-Cre mice, as well. After three months, mice appeared lethargic and were sacrificed, spleens obtained and analyzed (see Zhang C C, et al. Nat. Med. 2006 February; 12(2):240-5).

Example 1

Construction of Stable, Cre-lox Based Knockdown Constructs

A pFLIP cassette was constructed as schematically depicted in FIG. 1A. The construct may be expressed by a constitutive, tissue-specific, or inducible promoter. The mRNA expressed puromycin resistance and the surface marker Thy1.1 or GFP. The puromycin-Thy1.1, or -GFP construct, respectively, was translated as a fusion protein but generated two distinct polypeptides by virtue of the 2A peptide at the C-terminus of the puromycin resistance or GFP cassette, which resulted in the translation of two distinct polypeptide species from a single cistron.

As depicted in FIG. 1A, the green fluorescent protein (GFP) and a miR30 microRNA-based, RNAi construct were present in the anti-sense orientation in the 3' untranslated region of the mRNA. Upon addition of Cre recombinase, the puro-Thy1.1 cassette was deleted and the GFP-microRNA construct was reversed to the sense orientation, allowing expression of GFP and RNAi.

The vector expressed two markers, a drug selection and a surface marker. When Cre was introduced, the markers were deleted and expression of GFP and RNAi was induced. GFP and the RNAi were in antisense orientation until Cre-recombinase was active, at which point there was a "flip" to the sense orientation.

The vector containing the pFLIP cassette was referred to as pLB. The vector comprised a CMV promoter driving the RNA genome, a packaging signal (Psi), central polypurine tract (cPPT), antirepressor (Element #40) and scaffold attached region (SAR), an internal U6 and CMV promoter driving the FLIP cassette, with the GFP-miR30 in antisense orientation. The 3'LTR comprised a deletion of U3, and HIV U5 polyadenylation signal. For example, the pLB vector expressing a miR30 targeting firefly luciferase (SEQ ID NO: 7).

In one embodiment of this invention, a modified pLB vector was constructed, resulting in greater expression, the vector being schematically depicted in FIG. 1B, and referred to herein as pLB2.

In this embodiment of the modified vector (pLB2), the promoter driving the RNA genome was derived from RSV, as opposed to the former CMV. The packaging signal (Psi), central polypurine tract (cPPT), antirepressor (Element #40) and scaffold attached region (SAR) were unchanged.

84

The internal CMV promoter was replaced by Ubiquitin-C. The U6 promoter was removed and replaced with the FLIP cassette. The FLIP cassette maintained GFP-miR30 in the antisense orientation until reversed by Cre activity.

The 3'LTR was modified, as well: Deletions of the U3 resulted in self-inactivating vectors (SIN). The U3 in pLB has ~200 nucleotide deletion. The U3 in pLB2 has a 420 nucleotide deletion. The remaining nucleotides in U3 were the minimum required for integration (~25 nt) and another 20 nt that significantly improved polyadenylation of the integrated viral transcript. The HIV U5 was replaced by a Bovine Growth Hormone Polyadenylation signal.

FIG. 1C schematically highlights differences between the MScV and pLB2 vectors.

In addition, the FLIP cassette was modified as well, in order to include a splice donor and splice acceptor flanking the miR30, such that the miR30 is contained within an artificial intron (FIG. 2A). By placing the miR30 in an intron, miRNA processing was uncoupled from reporter expression, such that the miR30 was spliced out of the transcript. FIG. 2B schematically depicts the FLIP vector comprising the miRNA in an intron.

The GFP-intron-miR30 is maintained in the antisense until reversed by Cre action on flanking loxP sites (purple and orange arrows). The intron cannot be maintained in the sense orientation of retro/lentiviruses, as the genome is RNA.

The intron follows the GFP (or other marker gene) within 30 nucleotides of the STOP codon so as to avoid nonsense-mediated decay of the transcript.

Example 2

pLB2 Constructs Demonstrate Enhanced Expression Following Cre-Mediated Recombination

In order to determine whether efficient intron splicing from the FLIP vector occurred, cellular mRNA was assayed by reverse transcription PCR, and expression was compared to PCR of genomic DNA. PCR amplification of only the transcript derived from FLIP vectors occurred, which had been reversed by Cre activity (FIG. 3). Whereas constructs without an intron produced similarly sized products, PCR of mRNA derived from the intron-containing sample produced a significantly smaller fragment.

FACS analysis of marker expression was conducted on cells transduced with the pLB2 constructs and compared to pLB construct-mediated expression. FIG. 4 demonstrates that inclusion of the intron enhanced expression of reporter. While all the constructs, when exposed to Cre, and assayed by FACS produced GFP+ cells, inclusion in an intron increased expression.

Similarly, FIG. 5 demonstrates that placement of miR30 in an intron maintains its ability to "knock down" or diminish target gene expression. miR30 targeting integrin alpha-4 (surface protein) and assayed by FACS, following Cre expression (green plot), lowered surface alpha-4 expression by about 6-fold as compared to the FLIP vector without Cre (orange plot).

The miR30 constructs when placed in an intron produced greater expression of the miRNA, and enhanced targeted knockdown in vitro.

Functionally, placing the miR30 in an intron increased reporter expression. Such enhanced expression may be attributable to splicing being coupled to mRNA export from the

85

nucleus to the cytoplasm and/or miR30 processing (cleavage and excision of the hairpin) and translation being mutually exclusive, as miR30 processing results in transcript destruction. By placing miR30 in an intron, the processing is uncoupled from translation.

Example 3

In Vivo pLB2 Expression

A scheme for generating mice transgenic for pLB2 expression is presented in FIG. 6. Embryonic stem cells (ESC) that express Cre from the VEGF-R2 (Flk1) locus, which turns on Cre expression at about embryonic day 8 were infected with pLB2 containing the FLIP cassette, and transduced cells were selected with puromycin. Using tetraploid complementation, the pLB2-infected ES cells were injected to blastocysts, and generated embryos derived exclusively from the pLB2-infected ES cells.

FIG. 7 demonstrates GFP expression in the yolk sacs of e8.5 embryos thus derived. As evident from the figure, cells that are “blood islands” represent the endothelial precursor cells, the only that express Flk1 (and hence Cre) about 1 day prior to embryo removal, and thus are “stained” by specific GFP expression.

Similarly, FIG. 8 demonstrates embryos derived at stage e9.5 from adult pLB2-FLIP transgenic males crossed to Mox-Cre females. Mox-Cre is expressed very early in embryos (e2 or e3). Embryos inheriting both the pLB2 vector and Cre exhibited GFP+ throughout, as compared to embryos lacking Cre.

The microRNA in antisense orientation was not processed to generate effective RNAi intermediates, nor did the anti-sense disrupt marker gene translation or virus production, indicating that the constructs provide for specific, controlled regulation of gene expression.

Example 4

Multiple Knockdowns with pLB2

FIG. 9A presents a scheme for multiple gene knockdowns. The miR30s can be concatamerized to knockdown more than 1 gene with a single vector. FIG. 9B demonstrates targeted knockdown of p53 and PTEN tumor suppressors using the scheme of FIG. 9A. In this aspect, cooperative knockdown of related or suspected related gene products can be obtained.

FIGS. 9C and 9D demonstrates targeted knockdown of p53 and PTEN tumor suppressors using the scheme of FIG. 9A respectively, as well, including comparative expression profiles of expression in an intron, or not.

FIGS. 9E and F demonstrates a pFLIP construct in which GFP was replaced with the oncogene c-Myc. The immunoblot showed Cre-regulated expression of a c-Myc transgene incorporating an HA tag. Such a construct provided for the ability to combine c-Myc expression with targeted knockdown of p53, or PTEN expression, or p53/PTEN expression in an intron, which in turn allowed for the examination of oncogene-tumor suppressor interactions. The miRNAs expressed from the construct are endogenous (from the mouse genome), and mediate cellular differentiation by suppressing a set of genes. FIG. 9E further demonstrates, in one embodiment of the invention, the ability to regulate miRNA expression by flipping sense to antisense, a generally applicable method for gene regulation.

86

These constructs represent embodiments of the invention, whereby cooperative and/or antagonistic relationships can be instituted, evaluated, and/or used for therapy in complex diseases and/or conditions.

5

Example 5

Regulated Gene Expression in Hematopoietic Cells

10

In order to determine whether regulated expression could be accomplished in adult animals, bone marrow reconstitutions were conducted, using Cre-ER donor marrow infected with FLIP vector puro2AGFP/Thy1.1+miRNA(s). Three months post-transfer of infected bone marrow, mice were treated with tamoxifen (TMX). Peripheral blood leukocytes were collected 1 week after tamoxifen treatment and analyzed by fluorescent activated cell sorting (FACS) for changes 20 in marker expression.

Immunoblots of spleens of mice subjected to bone marrow reconstitution with Cre-ER donor marrow infected with FLIP vector puro2AGFP/Thy1.1+miRNA(s) were probed for the expression of the knocked down gene product as a measure of the ability to regulate expression. Three months post-transfer of infected bone marrow, mice were treated with tamoxifen and 1 week later spleens were harvested and sorted for Thy1.1+ cells (FIG. 10B). Each construct effectively resulted 30 in reduced expression of the indicated gene product.

Regulated expression was further evaluated in vivo, as well, via methods similar to those described in Example 4. Lenti FLIP-p53 transgenic mice were crossed to Mox-Cre males (FIG. 10C). Tails of the siblings were visualized, with animals expressing Cre failing to exhibit fluorescence. Similarly (FIG. 10D) lenti FLIP-p53 transgenic mice crossed to Tie2-Cre (hematopoietic Cre). B cells isolated, stimulated and cultured with or without Doxorubicin were evaluated for fluorescence. GFP+ cells expressed the p53 knockdown and exhibited a significant growth advantage in the presence of Doxorubicin.

35

Example 6

Tissue Specific Oncogene Expression

In order to determine whether tissue specific oncogene expression could be accomplished, mouse bone marrow reconstitutions with CD19-Cre (B cell Cre) donor marrow infected with FLIP vector puro2AGFP/c-Myc+miR-p53 was accomplished. Fourteen weeks post-transfer, spleens and 50 lymph nodes of moribund mice were analyzed by FACS for marker expression (FIG. 11A). Spleen cells were cultured in vitro for 9 days prior to analysis by FACS. Similarly, spleen and lymph nodes were assessed for c-Myc expression by immunoblot (FIG. 11B), with both organs showing good 55 expression of the oncogene.

Immunoblots of spleens of mice subjected to bone marrow reconstitution with Cre-ER It will be appreciated by persons skilled in the art that the present invention is not limited by what has been particularly shown and described herein above and that numerous modifications, all of which fall within the 60 scope of

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 28

<210> SEQ ID NO 1
<211> LENGTH: 466
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: GFP-miR30 flanked by NotI-PmeI and splice donor and acceptor sequences

<400> SEQUENCE: 1

agttagcgcc	caattgcagg	tgagtggcgc	gcccgaagcc	ttgttaagtg	ctcgcttcgg	60
cagcacat	actatgtttg	aatgaggcctt	cagtaactta	cagaatcggt	gcctgcacat	120
cttggaaaca	cttgcgtggga	ttacttcttc	aggttaacc	aacagaaggc	tcgagaaggt	180
atattgtgt	tgacagttag	cgagctccc	tgaattggaa	tccttagtgaa	gccacagatg	240
taggattcca	attcagcggg	agcctgccta	ctgcctcgaa	attcaagggg	ctactttagg	300
agcaattata	ttgtttacta	aaaactgaata	ccttgctatc	tctttgatac	attttacaa	360
agctgaatta	aaatggata	aattaaatca	ctttttcaa	ttggaaagact	aatgegtta	420
aaccctgac	tctccccctt	ttttttcct	ccaggtatgc	ataaac		466

<210> SEQ ID NO 2
<211> LENGTH: 467
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: GFP-miR30 flanked by NotI-PmeI and splice donor and acceptor sequences

<400> SEQUENCE: 2

agttagcgcc	caattgcagg	tgagtggcgc	gcccgaagcc	ttgttaagtg	ctcgcttcgg	60
cagcacat	actatgtttg	aatgaggcctt	cagtaactta	cagaatcggt	gcctgcacat	120
cttggaaaca	cttgcgtggga	ttacttcttc	aggttaacc	aacagaaggc	tcgagaaggt	180
atattgtgt	tgacagttag	cgccgacatt	tcaccatcat	tattnatgt	agccacagat	240
gtaaataatg	atggtaaat	gtcggtgcct	actgcctcg	aattcaagg	gctactttag	300
gagcaattat	tttggttact	aaaactgaat	accttgctat	ctctttgata	cattttacaa	360
aagctgaatt	aaaatggat	aaattaaatc	actttttca	attgaaagac	taatgcgtt	420
aaaccctgac	tctccccctt	ttttttcct	tccaggtatgc	cataaac		467

<210> SEQ ID NO 3
<211> LENGTH: 10849
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pLB2 construct comprising the FLIP cassette containing miR30 targeting FireFly luciferase

<400> SEQUENCE: 3

gtcgacggat	cgggagatct	cccgatcccc	tatggtgac	tctcagtaca	atctgctctg	60
atgcccata	gttaagccag	tatctgctcc	ctgcttgtt	gttggaggc	gctgagtagt	120
gcgcgagcaa	aatttaagct	acaacaaggc	aaggcttgc	cgacaattgc	atgaagaatc	180
tgttttaggtt	taggcgtttt	gctgcgttcc	gcgtatgtac	ggccagatat	acgcgttgac	240
attgatttatt	gactagtcat	gttcttctt	gcgttatccc	ctgattctgt	ggataaccgt	300
attaccgcct	ttgagtgagc	tgataaccgt	cgccgcagcc	gaacgaccga	gcccgcgcg	360

-continued

tcaagttagcg aggaagcggg agagcgccca atacgcaaac cgccttcggc cgcggttgg	420
ccgattcatt aatgcagactg gcacgacagg ttcccggact ggaaagcggg cagtgagcgc	480
aacgcaatta atgtgagttt gctcaactcat taggcacccc aggcttaca ctatgttt	540
ccggctcgta tggtgtgtgg aatttgagc ggataacaat ttcacacagg aaacagctat	600
gaccatgatt acgccaagcg cgcaattaac cctagctta tgtagtcta tgcaataactc	660
tttgtatctt gcaacatggt aacgatgagt tagcaacatg ctttacaagg agagaaaaag	720
caccgtgcat gccgattggg ggaagtaagg tggtagcgtc gtgccttatt aggaaggcaa	780
cagacgggtc tgacatggat tggacgaacc actgaattgc cgcattgcag agatattgtt	840
tttaagtgcc tagctcgata caataaacgg gtctctctgg ttagaccaga tctgagctg	900
ggagctctctt ggcttaacttag ggaacccact gcttaagctt caataaaagct tgccttgagt	960
gtttcaagta gtgtgtgccc gtctgttggt tgactctggt aacttagat ccctcagacc	1020
cttttagtca gtgtggaaaaa tctctagcag tggcgccccg acagggactt gaaagcgaaa	1080
gggaaaccagg aggagctctc tcgacgcagg actcggttg ctgaagcgcg cacggcaaga	1140
ggcgaggggc ggcgactggg gtagtacgcca aaaattttga cttagcggagg cttagaaggag	1200
agagatgggt gcgagagcgt cagtattaa cggggggagaa ttagatcgcg atggggaaaaa	1260
attcgggttaa ggccagggggg aaagaaaaaaa tataaattaa aacatatagt atgggcaagc	1320
agggagcttag aacgattcgc agttaatctt ggcctgttag aaacatcaga aggctgtaga	1380
caaataactgg gacagctaca accatccctt cagacaggat cagaagaact tagatcatta	1440
tataatacag tagcaaccctt ctattgttg catcaaaggaa tagagataaa agacaccaag	1500
gaagcttttag acaagataga ggaagagcaa aacaaaagta agaccaccgc acagcaagcg	1560
gcggccgcg ctgatcttca gacctggagg aggagatatg agggacaattt ggagaagtga	1620
attatataaa tataaagtag taattaaatttga accatttagga ttagcacccca ccaaggcaaa	1680
gagaagagtg gtgcagagag aaaaaagacg agtgggataa ggagcttgc tccctgggtt	1740
cttgggagca gcaggaagca ctatggcgc agcgtcaatg acgctgacgg tacaggccag	1800
acaattatttg tctggatag tgcagcagca gaacaatttg ctgaggccca ttgaggcgc	1860
acagcatctg ttgcaactca cagttttttt catcaagcag ctccaggcaa gaattctggc	1920
tgtggaaaga tacctaaagg atcaacagct cctggggattt tgggggttgc tggaaaact	1980
catttgacc actgtgtgc cttggaatgc tagttggatg aataaaatctc tggAACAGAT	2040
tttggaaatcac acgacacttgg tggagtggga cagagaaattt aacaatttaca caagcttaat	2100
acactcccttta attgaagaat cgcaaaaacca gcaagaaaag aatgaacaag aattatttgg	2160
attagataaa tggcaagtt tggaaattt gtttacata acaaatttggc tggatgttat	2220
aaaattttttt ataatgtatg taggaggctt ggttagtttta agaatagttt ttgtgtact	2280
ttctatagtg aatagatgtt ggcagggtata ttccacattttt tgggttttccca cccacccccc	2340
aaccccgagg ggacccgaca ggcccggagg aatagaagaa gaaggtggag agagagacag	2400
agacagatcc attcgatttgc tgaacggatc ggcactgcgt ggcaccaatc tgcagacaaa	2460
tggcagtattt catccacaat tttaaaagaa aaggggggat tgggggggtac agtgcagggg	2520
aaagaatagt agacataata gcaacagaca tacaaactaa agaatttaca aaacaaatttta	2580
caaaaattca aattttcgg gtttattaca gggacacggc agatccagtt tggtttagtac	2640
cgggcccggt gctttgtctt gagecagccc accagttgg aatgactctt tttttatgtact	2700
tgaattttca agtataaaagt ctatgtctaa atttaatttg aacaactgtt tagtttttgc	2760

-continued

tggttggggg aaggaaaaaa aatggtggca gtgtttttt cagaattaga agtgaatga 2820
 aaacttggt tgggtgagga ttctaatga catgtgggg ttgcatactg agtgaagccg 2880
 gtgagcattc tgccatgtca cccccctcg 3000
 ctcaaaaat tggatataaac catgtttttt gtgtatatcc ggttctttt ctgggtagtc 2940
 tcactcagcc tgcatttctg ccagggcccg ctctagatct agacgggtta tctggctcc 3060
 gcccgggtt ttggggcctc ccggggccgc cccccctctc acggcgagcg ctgccacgtc 3120
 agacgaaggg cgaggagcg ttctgtatcc ttccggccgg acgctcagga cagggcccg 3180
 ctgctcataa gactcggcct tagaacccca gtatcagcag aaggacattt taggacggga 3240
 ctgggtgac tctagggcac tggttttttt tccagagagc ggaacaggcg aggaaaagta 3300
 gtcccttctc ggcgattctg cggagggatc tccgtggggc ggtgaacgcc gatgattata 3360
 taaggacgcg ccgggtgtgg cacagctagt tccgtcgcag cggggatttg ggtcgccgtt 3420
 ctgtttgtg gatcgctgtg atcgtcaattt ggtgagttgc gggctgtgg gctggccggg 3480
 gtttctgtgg ccggccggcc gctcggtggg acggaagcggt gtggagagac cgccaaggcc 3540
 ttagtctgg gtcccgagc aagggtgccc tgaactgggg gttggggggg ggcacaaaaa 3600
 tggccgtgt tcccgagttc tgaatggaa acgcttgc tgggggggtgt gaggtcggtt 3660
 aaacaagggtt gggggcatgg tggggcccaa gaacccaaagg tcttggggcc ttcgtataatg 3720
 cgggaaagct ttattcggg tgagatgggc tggggcacca tctggggacc ctgaegtgaa 3780
 gtttctgtact gactggagaa ctcgggtttt tctgtctggg gggggggcccg cagttatgcg 3840
 gtgcccgtgg gcagtgcacc cgtacctttt ggagcgccgc ctcgtcgtg tcgtgacgtc 3900
 acccgttctc ttggcttata atcgagggtt gggccaccc cccgttaggtg tgccgttaggc 3960
 ttttctccgt cgcaaggacgc agggttcggg cctagggttag gctctctga atcgacaggc 4020
 gccggaccc tgggtggggg agggataagt gaggcgttag tttctttgtt cggtttatg 4080
 tacctatctt cttaaatgtgc tgaagctccg gttttgaact atgcgtccg ggttggcgag 4140
 tgggttttgtt gaagttttt aggacccctt tgaatgttaa tcaatgggtt caaatgtaa 4200
 ttttcagtgt tagacttagta aattgtccgc taaattctgg ccgtttttgg ctttttgtt 4260
 agacgaagta cgcgtatgc gttataaagc ctcgtccgg atccataact tcgtatagga 4320
 taccttatac gaagtttatct caggtaccgc caccatgacc gagtacaagc ccacgggtgc 4380
 ctcgcacc cgcgacgcg tccccaggcc cgtacgcacc ctcgcggccg cgttgcgcga 4440
 ctacccgcac acgcgcacaca ccgtcgatcc ggaccgcac atcgagcggg tcaccgagct 4500
 gcaagaactc ttccctacgc gcgctgggtt cgcacatccg aagggtgtgg tcgcggacga 4560
 cggcgccgcg gtggcggtt ggaccacgcg ggagagcgcc gaagcggggg cgggtttcgc 4620
 cgagatccgc cgcgcacatgg ccgtgttgcg cgggtccggg ctggccgcgc agcaacagat 4680
 ggaaggccctc ctggcgccgc accggcccaa ggagccgcg tgggttctgg ccaccgtcgg 4740
 cgtctcgccc gaccaccagg gcaagggtct gggcagcgcg ctcgtgtcc cccggatgg 4800
 ggccggccgag cgcgcggggg tgcccgccctt cctggagacc tccgcgcaccc gcaacccccc 4860
 cttctacgag cggctcggtt tcaccgtcac cgcgcacgtc gaggtgcggc aaggaccgcg 4920
 cacctgggtgc atgaccgcgca agccgggtgc cctgtacaag aaacagaaaa ttgtggcacc 4980
 agtgaacacag actttgaatt ttgacccctt caagttggcg ggagacgtcg agtccaaccc 5040
 tggggccatg aaccctggccca tcagcgatgc tctccgtatcc tcagtttgc aggtgtcccg 5100

-continued

aggcgagaag	gtgaccagcc	tgacagcctg	cctggtaac	caaaaccttc	gcctggactg	5160
ccgccatgag	aataaacacca	aggataactc	catccagcat	gagttcagcc	tgaccggaga	5220
gaagaggaag	cacgtgctct	caggcaccc	cgggataccc	gagcacacgt	accgetcccg	5280
cgtcaccctc	tccaaccagc	cctatatcaa	ggtccttacc	ctagccaact	tcaccaccaa	5340
ggatgagggc	gactacttt	gtgagcttcg	agtctcgcc	gogaatccca	tgagetc当地	5400
taaaagtatac	agtgtgtata	gagacaaact	ggtaaagtgt	ggccgcataa	gcctgctgg	5460
tcagaacaca	tcctggatgc	tgctgctgt	gcttccttc	tccttcctcc	aagccctgg	5520
cttcatttct	ctgtgtatcta	gaagccataa	cttcgtatag	tacacattat	acgaagtat	5580
gtttaaacgc	attagtcttc	caattgaaaa	aagtgattta	atttataccca	ttttaatca	5640
gctttgtaaa	aatgtatcaa	agagatagca	agttatttag	tttttagtaaa	caagataatt	5700
gctcctaaag	tagccccctt	aattccgagg	cagtaggcag	gctcccgctg	aatttggatc	5760
ctacatctgt	ggcttcacta	ggattccat	tcacgggagc	tcgcteactg	tcaacagcaa	5820
tataccttct	cgagcccttct	gttgggtaa	cctgaagaag	taatccacgc	aagtgttcc	5880
aagatgtgc	ggcaacgcatt	ctgttaagta	ctgaagccct	attcaaaacat	agtatatgt	5940
ctgccgaagc	gagcacttaa	caaggcttgc	ggccgcatact	tgtacagctc	gtccatgccc	6000
agagtgtatcc	cgccggcggt	cacgaactcc	agcaggacca	tgtatcgcg	cttctcggt	6060
gggtctttgc	tcagggcgga	ctgggtgtct	aggtatgtt	tgtcgccag	cagcacgggg	6120
ccgtcgccga	tgggggtgtt	ctgctggtag	tggtcggcga	gctgcacgc	gccgtccctg	6180
atgttgtggc	ggatcttgaa	gttcacccctt	atgcgttct	tctgtgtc	ggccatgata	6240
tagacgttgt	ggctgttgta	gttgtactcc	agcttgtgcc	ccaggatgtt	gccgtccctc	6300
ttgaagtgc	tgcccttcag	ctcgatgcgg	ttcaccagg	tgtcgccctc	gaacttcacc	6360
tcggcgccgg	tcttgttagt	gcccgtgtcc	ttgaagaaga	tgtcgccctc	ctggacgtag	6420
ccttcgggca	tggcgactt	gaagaagtcg	tgctgcttca	tgtggcgccc	gtagcggtg	6480
aagcactgca	cgccgttagt	cagggtggc	acgagggtgg	gccaggccac	ggccagcttgc	6540
ccgggtgtgc	agatgaactt	cagggtcage	ttgcccgtagg	tggcatgc	ctgccttcg	6600
ccggacacgc	tgaacttgc	gccgtttacg	tcgcccgtca	gtcgaccag	gatgggcacc	6660
accccggtga	acagctcc	gccctgtctc	accatggtgg	cgaccggat	aacttcgtat	6720
aaggatccat	atacgaagtt	atccattcag	gctgtgtact	catcaatggc	atggcaca	6780
gtttagccat	aacttcgtat	aatgtgtact	atacgaagt	atccctgtt	aagggttccg	6840
gttccactag	gtacaattcg	atatacgat	tatcgataat	caacctctgg	attacaaaat	6900
ttgtgaaaga	ttgactggta	ttcttaacta	tgttgctct	tttacgtat	gtggatacgc	6960
tgcttaatg	cttttgtatc	atgtatattgc	ttcccgatag	gtttcattt	tctccctc	7020
gtataaatcc	tgggtgtct	ctctttatga	ggaggtgtgg	cccggtgtca	ggcaacgtgg	7080
ctgtgggtgc	actgtgttttgc	ctgacgcac	ccccactgg	tggggcat	ccaccac	7140
tca	ccggacttcc	tcgggactt	cctcccttcc	cctcccttcc	gccacggcc	7200
cgccctgcctt	ccccgtgtct	ggacaggggc	tcggctgttg	ggcactgaca	attccgtgg	7260
gttgcgggg	aaatcatcgt	ccttccttg	gctgtcgcc	tgtgttgcca	cctggattct	7320
ggccggacgc	tccttctgt	acgtcccttc	ggccctcaat	ccagcgacc	ttccctcccg	7380
cgccctgcgt	ccggctctgc	ggcccttc	gctgtcgcc	ttccgcctc	agacgagtc	7440
gatccctt	tggccgcct	ccccgcac	ataccgtcg	cctcgatcg	gacctagaaa	7500

-continued

aacatggagc aatcacaagt agcaatacag cagctaccaa tgctgattgt gcctggctag	7560
aaggcacaaga ggaggaggag gtgggttttc cagtcacacc tcaggtacca agcatgggt	7620
aaagtactgt tctcatcaca tcataatcaag gttatatacc atcaatattg ccacagatgt	7680
tacttagcct ttaatattt ctctaattta gtgtatgc aatgatagtt ctctgatttc	7740
tgagattgag tttctcatgt gtaatgatta ttttagagttt ctctttcatc tggtaaatt	7800
tttgtctagt ttatTTTTT actgatTTT aagacttctt ttataatct gcataattaca	7860
attctttta ctgggtgtt gcaaattttt tctgtcatc tatggctga ctTTTCTAA	7920
tggTTTTTA attttaaaaa taagtcttaa tattcatgca atctaattaa caatCTTTC	7980
tttgtggta ggactttgag tcataagaaa ttttctcta cactgaagtc atgatggcat	8040
gtttctatat tattttctaa aagattttaa gttttgcctt ctccatTTT acttataatt	8100
cactggaatt ttttgtgtg tatggatgaa catatgggtt ccTTTTATT ttttacatAT	8160
aaatataattt ccctgttttt ctaaaaaaaga aaaagatcat cattttccca ttgtaaaatg	8220
ccatattttt ttcataggTC acttacatAT atcaatgggt ctgtttctGA gctctactCT	8280
atTTTATCAG CCTCACTGTC tatecccaca catctcatGC ttgctctaa atCTTGATAT	8340
ttagtggAAC attctttccc attttgttAC acaagaataAT ttttgttATT gtctttGGG	8400
cttctatATA cattttAGAA tgaggTTGC aaggTACCTT taagaccaAT gacttACAAG	8460
gcagctgtAG atcttagCCA ctTTTTAAA gaaaaggGGG gactggAAgg gctaattcac	8520
tcCcAGCTGc ttttgcctG tactggGTct ctctggTTAG accAGATCTG agcCTGGAG	8580
ctctctggCT aactaggGAA cccACTGCTT aAGCCTCATC aAGCTEGACT GTGCCttCTA	8640
gttggCCAGCC atctgttGTT tgccccCTCC CGTGCCTTC CTGACCCTG gaaggTGCcA	8700
ctccccACTGt ccttctAA taaaatgagg aaattgcATC gCATTGTCtG agtaggtGTC	8760
attctattCT ggggggtggg gtggggcagg acagcaagg ggaggattgg gaagacaata	8820
gcaggcatGC tggggatGCG gtccggactG tactggGTct ctctggTTAG accAGATCTG	8880
agcCTGGAG CTCTCTGGCT aactaggGAA cccACTGCTT aAGCCTCAAT AAAGCTTGCC	8940
ttgagtgCTT caagtagtGT gtccccGTCT gttgtgtGAC tctggtaACT agagatCCt	9000
cagacccTTT tagtcAGtGT ggAAAATCTC tagcAGCATG tgAGCAAAG GCCAGAAAA	9060
ggccAGGAAC CgtaaaaAGG CCcgTTGCTT GGCgtTTTC catAGGCTCC GCCCCCTGA	9120
cgagcatCAC AAAATCGAC GCTCAAGTC GAGGTGGCGA AACCCGACAG GACTATAAAG	9180
ataccaggCG tttccccCTG gaagCTCCt CGTGCCTCT CctgttCCGA CCCTGCCGCT	9240
tacCCGataC CTGTCGCTT ttctccCTC gggAAGCgtG gCgtTTCTC atAGCTCACG	9300
ctgttaggtat CTCAGTTCGG TGTAGGTGT TCGCTCCAAG CTGGGTGtG TGcacGAACC	9360
ccccGTTCAg CCCGACCGCT GCGCCTTATC CGGTAACtAT CGTCTTGTAGT CCAACCCGGT	9420
aagacacgAC ttatCGCCAC TGGCAGCAGC CACTGGTAAC aggattAGCA gagCGAGGTA	9480
tgtaggcGGT gCTACAGAGT CTCTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGAAC	9540
agtatTTGgt ATCTGCGCTC TGTGAAAGCC AGTtACCTTC GGAAAAGAG TTGGTAGCTC	9600
ttgatCCGC aaacAAACCA CCgCTGGTAG CGGTGGTTT TTTGTTGCA AGCAGCAGAT	9660
tacGCGCAGA AAAAAGGAT CTCAAGAAGA TCCTTGTATC TTTCTACGG GGTCTGACGC	9720
tcaGtggAAC gaaaactCAC GTTAAGGGAT TTGGTCTATG AGATTATCAA AAAGGATCTT	9780
cacctagATC CTTTAAATT AAAAATGAAG TTTAAATCA ATCTAAAGTA TATATGAGTA	9840

-continued

```

aacttggctc gacagttacc aatgcttaat cagtgggca cctatctcg cgatctgtct 9900
atttcgttca tccatagttg cctgactccc cgtcgtgttag ataactacga tacggggagg 9960
cttaccatct ggccccagtg ctgcaatgt accgcgagac ccacgtcac cggtccaga 10020
tttatcagca ataaaccagc cagccggaag ggccgagcgc agaagtggtc ctgcaactt 10080
atccgctcc atccagtcta ttaattgttg cccggaaagct agagtaagta gttcgccagt 10140
taatagttt cgcaacgttg ttgcattgc tacaggcatc gtgggtgtcac gctcgctt 10200
tggtatggct tcattcagct ccggttccca acgatcaagg cgagttacat gatccccat 10260
gttgtgcaaa aaagcggtt gctccctcg tccctcgatc gttgtcagaa gtaagttggc 10320
cgcagtgtta tcactcatgg ttatggcagc actgcataat tctcttactg tcatgccatc 10380
cgtaagatgc ttttctgtga ctggtagta ctcaaccaag tcattctgag aatagtgtat 10440
gccccgaccc agttgtctt gcccggcgtc aatacgggat aataccgcgc cacatagcag 10500
aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg cgaaaaactct caaggatctt 10560
accgctgttg agatccagtt cgatgttaacc cactcgtgca cccaaactgtat cttcagcatc 10620
ttttacttcc accagcggtt ctgggtgagc aaaaacagga aggcaaaaatg ccgcaaaaaa 10680
ggaataagg gcgacacggc aatgttgaat actcatactc ttcccttttc aatattattg 10740
aagcatttat cagggtttatt gtctcatgag cggtacatac tttgaatgta ttttagaaaa 10800
taaacaaata ggggttccgc gcacatttcc cgaaaaatgt ccacctgac 10849

```

<210> SEQ_ID NO 4
<211> LENGTH: 2530
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pFLIP insert comprising an RNAi to p53

<400> SEQUENCE: 4

```

tccataacctt cgtataggat accttatacg aagttatctc aggtaccggcc accatgaccc 60
agtacaagcc cacgggtgcgc ctgcaccc cgcacgtcgt ccccaaggcc gtacgcaccc 120
tcgcgcgcgc gttcgccgac taccggccca cgcgcacac cgtcgatccg gaccgcacaca 180
tcgagcggtt caccgagctg caagaactct tccacgcgc cgtcgggtctc gacatcgca 240
aggtgtgggt cgccggcgcac ggcgcggcg tggcggtctg gaccacgcgc gagagcgctc 300
aagcgggggc ggtgttcgccc gagatcgcc cgcgcacggc cgagttgagc ggttccggc 360
tggccgcgcga gcaacagatg gaaggccctcc tggcgccgcga cccggccaag gagcccgctg 420
ggttcctggc caccgtcgcc gtctcgcccg accaccaggc caagggtctg ggcagcgccg 480
tcgtgttccc cggagtgagc gggccggcgc ggcgggggtt gcccgccttc ctggagaccc 540
ccgcgcggccg caacccccc ttctacgagc gggtcggtttt caccgtcacc gccgacgtcg 600
aggtgccccgaa aggacccgcgc acctgggtca tgaccggcaaa gcccgggtgcc ctgtacaaga 660
aacagaaaaat tgtggcacca gtgaaacaga ctttgaattt tgaccccttc aagttggcg 720
gagacgtcgta gtccaaacctt gggcccatga acccagccat cagcgtcgct ctccgtct 780
cagtcctgca ggtgtcccgaa gggcagaagg tgaccagcct gacagcctgc ctggtaacc 840
aaaacccctcg cctggactgc cgccatgaga ataacaccaa ggataactcc atccagcatg 900
agttcagctt gaccggagag aagaggaagc acgtgctctc aggcacccctc gggatacccg 960
agcacacgtaa cccgtcccgcc gtcaccctct ccaaccagcc ctatataag gtccttaccc 1020
tagccaaacctt caccaccaag gatgagggcg actacttttg tgagcttcga gtctcgccgc 1080

```

US 9,043,994 B2

99**100**

-continued

cgaatccat gagctccaat aaaagtatca gtgtgtatag agacaaaactg gtcaagtgtg	1140
ggggcataag cctgctggtt cagaacacat cctggatget gctgctgtc cttccctct	1200
ccctcctcca agccctggac ttcatcttc tgtgatctag aagccataac ttcgtatagt	1260
acacattata cgaagttatg tttaaacgc ttagtcttcc aattgaaaaa agtgattaa	1320
tttataccat tttaattcag ctttgtaaaa atgtatcaa gagatagcaa ggtattcagt	1380
ttagttaaac aagataattt ctcctaaagt agcccttga attccgaggc agttaggcattc	1440
cactacaagt acatgtgtaa tacatctgtg gtttcaactat tacacatgtt cttgtatgg	1500
gcttcactg tcaacagcaa tataccttctt cgagcccttctt gttgggttaa cctgaagaag	1560
taatcccagc aagtgtttcc aagatgtgca ggcaacgatt ctgtaaagta ctgaagcctc	1620
attcaaaat agtatatgtt ctgcgcgaagc gagcaacttta caaggcttgc ggccgcact	1680
tgtacagctc gtccatgccg agagtgtatcc cggcgccggt cacgaactcc agcaggacca	1740
tgtgatcgcc otctcggtt gggctttgc tcagggcgga ctgggtgtc aggttagtgg	1800
tgtcgcccgag cagcacgggg ccgtcgccga tgggggtgtt ctgctggtag tggcgccga	1860
gtgcacgctt gccgtctcg atgttgcgcg ggatcttgcg gttcacctt atgcgttct	1920
tctgcttgcg gccccatgata tagacgttgcg ggtgttgcg gttgtactcc agcttgcgc	1980
ccaggatgtt gccgtctcc ttgaagtcga tggcccttgcg ctgcgtgcg ttcaccagg	2040
tgtcgccctc gaacttcacc tggcgccggg tcttgcgtt ggcgttgtcc ttgaagaaga	2100
tggtgegctc ctggacgttgc cttccggca tggcgactt gaagaacttgc tgctgttca	2160
tgtggcgccgg gtagccggctg aagcaacttgcg cggccgttgcg cagggtggc acgagggtgg	2220
ggccaggccac gggcagcttgc cccggccggc agatgaactt cagggttgcg ttgcgttgc	2280
tggcatcgcc ctgcgcctcg ccggacacgc tgaacttgcg ggcgttgcg tgcgttca	2340
gttcgaccat gatggccacc accccggcga acagctctc gcccgttgc accatgggtgg	2400
cgaccggat aacttcgtat aaggatctt atacgaagt atccatttgc gctgtgttgc	2460
catcaatggc atggcacaaa gcttagccat aacttcgtat aatgtgtact atacgaagtt	2520
atccccgggtt	2530

<210> SEQ ID NO 5
<211> LENGTH: 1205
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: GFP-miR30 flanked by a single loxP site

<400> SEQUENCE: 5

atggataact tcgtatagga taccttatac gaagttatac cggtcgcac catggtagc	60
aaggggcgagg agctgttac cgggggtgggtt cccatctgg tcgagctggc cggcgacgtt	120
aacggccaca agttcagcgt gtccggcgag ggcgaggccgc atgccaccta cggcaagctg	180
accctgaagt tcatctgcac caccggcaag ctggccgtgc cctggccac cctcgatgg	240
accctgaccc acggcggtca gtgtttcgcg cgttaccggc accatgttgc gcaacacgc	300
ttcttcaagt ccgcattgcg cgaaggctac gtccaggagc gcaccatctt cttcaaggac	360
gacggcaact acaagaccccg cgccgagggtt aagttcgagg ggcacaccctt ggtgttgc	420
atcgagctga agggcatcga cttcaaggag gacggcaaca tccctggggca caagctggag	480
tacaactaca acagccacaa cgtctatatac atggccgaca agcagaagaa cggcatcaag	540

US 9,043,994 B2

101

102

-continued

gtgaacttca agatccggca caacatcgag gacggcagcg tgcagctcg cggaccactac	600
cagcagaaca cccccatcggt cgacggcccc gtgctgtcgcc cgcacaacca ctacctgagc	660
acccagtccg ccctgagcaa agacccaaac gagaagecgat atcacatggt cctgtggag	720
ttcgtgaccc cgccggat cactctcgcc atggacgagc tgtacaagta gcccgcgaa	780
gccttgtttaa gtgctcgctt cgccagcaca tatactatgt ttgaatgagg cttagtact	840
ttacagaatc gttgcgtca catcttgaa acacttgcgt ggattacttc ttcaaggtaa	900
cccaacagaa ggctcgagaa ggttatattgc tggtgacagt gagcgcac tacaagtaca	960
tgtgtaatag tgaaggcaca gatgttattac acatgtactt gtatgtggatg cctactgcct	1020
cggaattcaa ggggtactt taggagcaat tatcttggtt actaaaactg aataacctgc	1080
tatctctttt atacattttt acaaagctga attaaaatgg tataaattaa atcaattttt	1140
tcaattggaa gactaatgcg tttaaacata acttcgtata atgtgtacta tacgaagtt	1200
tggtt	1205

<210> SEQ_ID NO 6
<211> LENGTH: 10570
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pLB2 comprising the FLIP cassette

<400> SEQUENCE: 6

gtcgacggat cgggagatct cccgatcccc tatggtgac tctcagtaca atctgctctg	60
atgccgcata gttaagccag tatctgctcc ctgcttgtgt gttggaggc gctgagtatgt	120
gccccggccaa aatttaagct acaacaaggc aaggcttgac cgacaattgc atgaagaatc	180
tgcgttgggt taggcgtttt ggcgtgcctt gcgtatgtacg ggccagatat acgcgttgac	240
attgatttatt gactagtcat gtttttctt gcgttatccc ctgattctgt ggataaccgt	300
attaccgcct ttgagtggc tgataccgtt cggccgcggc gaacgaccgc gcccggcgg	360
tcaatgtggcg aggaagcgga agagcgccca atacgcaaac cgcctctccc cgcgcgttgg	420
ccgatttattt aatgcggctg gcacgacagg tttcccgact ggaaagcgccc cagtggcgc	480
aacgcatttta atgtggatgtt gctcaactcat taggcacccccc aggcttaca ctttatgttt	540
ccggctcgta tgggtgtgg aattgtggc ggataacaat ttccacacagg aaacagcttat	600
gaccatgatt acgccaaggc cgcaatttac cctagcttaa tggatgttca tgcaataactc	660
tggatgttca gcaacatggt aacgtatgtt tagcaacatgtt ctttacaagg agagaaaaag	720
caccgtgcattt ggcgttgggt ggaagtaagg tggatgtatgc gtgccttattt aggaaggcaa	780
cacacgggttgc tgacatggat tggacggacc actgaattgc cgcattgcag agatattgtt	840
tttaagtggcc tagctcgata caataaacgg gtctctctgg ttagaccaga tctgagcctg	900
ggagatctctt ggcttaacttag ggaacccactt gcttaagccat caataaaatgtt tgccttgagt	960
gtttcaagttt gttgtgtggcc gtctgttgtgt tgactctgtt aacttagatgtt ccctcagacc	1020
cttttagtca gtgtggaaaaa tctcttagcag tggccggccca acagggactt gaaagcgaaa	1080
gggaaaccagg aggagctctc tcgacggcagg actcggtttt ctgaaggcgcg cacggcaaga	1140
ggcgaggggc ggcgttgggt ggttacggcc aaaattttgc ctagcggagg cttagaaggag	1200
agagatgggtt ggcgttgggtt cgttataatgg cggggggagaa ttagatgttgcg atggggaaaa	1260
atccgtttaa ggcgttgggg aaagaaaaaa tataaattaa aacatataatgtt atggggcaagc	1320
aggagatgtt aacgatttcgc agttaatcctt ggcctgttagt aaacatcaga aggctgtttaga	1380

-continued

caaaatactgg gacagactaca accatccctt cagacaggat cagaagaact tagatcatta 1440
 tataatacag tagcaaccct ctattgtgtg catcaaaggaa tagagataaa agacaccaag 1500
 gaagctttag acaagataga ggaagagcaa aacaaaagta agaccaccgc acagcaagcg 1560
 gccggccgcg ctgatcttca gacctggagg aggagatatg agggacaatt ggagaagtga 1620
 attatataaa tataaagtag taaaaattga accattagga gtagcaccca ccaaggcaaa 1680
 gagaagatg gtgcagagag aaaaaagacg agtgggata ggagcttgt tccttgggtt 1740
 ctggggagca gcaggaagca ctatggcgc agcgtcaatg acgctgacgg tacaggcag 1800
 acaattatttgc tctggatag tgccggcgc gaacaatttg ctgaggcgtt ttgaggcgc 1860
 acagcatctg ttgcaactca cagtcgtggg catcaagcag ctccaggcaa gaatcctggc 1920
 tgtggaaaga tacctaaagg atcaacagct cctggggatt tgggggtgt ctggaaaact 1980
 catttgcacc actgctgtgc cttggaatgc tagttggagt aataaatctc ttggAACAGAT 2040
 ttggaaatcac acgacactgga tggagtggga cagagaaatt aacaattaca caagcttaat 2100
 acactcotta attgaagaat cgcaaaacca gcaagaaaag aatgaacaag aattattgga 2160
 attagataaa tggcaagtt tggaaatgg gtttaacata acaaattggc tgggttat 2220
 aaaatttttc ataatgatag taggaggctt ggttaggttta agaatagttt ttgctgtact 2280
 ttctatagtg aataatgatag ggcaggata ttcaccatta tgggttccaga cccacccccc 2340
 aaccccgagg ggacccgaca ggcccgaaagg aatagaagaa gaagggtggag agagagacag 2400
 agacagatcc attcgattag tgaacggatc ggcactgcgt ggcacccatc tgcagacaaa 2460
 tggcagtatt catccacaat tttaaaagaa aaggggggat tgggggttac agtgcagggg 2520
 aaagaatagt agacataata gcaacagaca tacaaactaa agaattacaa aaacaattta 2580
 caaaaattca aaatttcgg gtttattaca gggacagcag agatccagg tggtagtac 2640
 cggccccgt gctttctct gagecagccc accagttgg aatgactcct ttttatgact 2700
 tgaattttca agtataaagt ctatgtctaa attaatttg aacaactgtt tagttttgc 2760
 tgggtgggg aaggaaaaaa aatggtggca gtgtttttt cagaattaga agtgaatga 2820
 aaacttggtg tgggtgagga ttctaatga catgtgggtt ttgcatactg agtgaaggcg 2880
 gtgagcatc tgccatgtca cccctcggt ctcagtaatg tactttacag aaatcctaaa 2940
 ctcaaaaatg tgatataaac catgctttt gtgtatcc ggtcttttct ctgggtagtc 3000
 tcactcagcc tgcatttctg ccaggccccg ctctagatct agacgggttga tctggccctcc 3060
 ggcgggggtt ttggcgctc ccggggccgc cccctcttc acggcgagcg ctgccacgtc 3120
 agacgaaggc cgcaaggagcg ttccctgatcc ttccggcccg acgctcagga cagcggcccg 3180
 ctgctctaa gactcggcct tagaaccctca gtatcagcag aaggacattt taggacggga 3240
 ctgggtgac tctaggcgcac tggttttttt tccagagagc ggaacaggcg aggaaaagta 3300
 gtcccttctc ggcgattctg cggagggtatc tccgtggggc ggtgaacgcc gatgattata 3360
 taaggacgcg ccgggtgtgg cacagctagt tccgtcgca gccggatttg ggtcgccgtt 3420
 ctgtttgtg gatcgctgtg atcgtcaattt ggtgagttgc gggctgtgg gctggccggg 3480
 gctttcggtt ccggccggcc gctcggtggg acggaagcgt gtggagagac cgccaaaggc 3540
 tggtagtctgg gtcccgagc aagggtggcc tgaactgggg gttggggggc ggcacaaaaa 3600
 tggcggtgt tcccgagtc tgaatggaa acgcttgc tgggggtgtt gaggtcggtt 3660
 aaacaaggtg gggggcatgg tggcgccaa gaacccaagg tcttgaggcc ttcgctaattg 3720

-continued

cgggaaagct cttattcggg tgagatggc tggggcacca tctggggacc ctgaegtcaa	3780
gtttgtcaact gactggagaa ctcgggtttg tctgtctgggt gggggggcccg cagttatgcg	3840
gtgccgttgg gcagtgcacc cgtaccttg ggagcgccgcg cctcgctgt tcgtgacgtc	3900
acccgttctg ttgggtata atgcagggtg gggccacctg ccggtaggtg tgccgttaggc	3960
ttttctccgt cgcaaggacgc agggttccggg cctaggtagt gctctctgta atcgacaggc	4020
gcgggacctc tggtgagggg agggataagt gaggcgtagt tttcttttgtt cggtttatg	4080
tacctatctt cttaaatgtac tgaagctccg gttttgaact atgcgtccg ggttggcgag	4140
tgtgttttgtt gaagttttt aggacacccc taaaatgtaa tcatttttgtt caaatatgtaa	4200
ttttcagtgt tagacttagt aattgtccgc taaattctgg ccgttttttgtt cttttttgtt	4260
agacgaagta cgcgcctagcc gttataatgc ctcgcgtccg atccataact tcgtatagga	4320
taccttatac gaagtttatct caggtaccgc caccatgacc gagtacaagc ccacgggtcg	4380
cctcgccacc cgcgacgcgcg tccccaggcc cgtacgcacc ctcggccgcg cggtcgccga	4440
ctaccccccc acgcgcgcaca ccgtcgatcc ggaccgcaccc atcgagcgccg tcaccgagct	4500
gcaagaactc ttccctcacgc gcgtcggtctt cgacatecgcc aaggtgtggg tcgcggacga	4560
cggcgcgcgcg gtggcggtctt ggaccacgcg ggagagcgccg gaagcggggg cggtgttcgc	4620
cgagatcgcc cgcgcatgg ccgagtttagt cggttcccg ccgtccgcg agcaacagat	4680
ggaaggccctc ctggcgccgc accggcccaa ggagcccgccg tgggttctgg ccaccgtcgg	4740
cgtctcgccc gaccaccagg gcaagggtctt gggcagcgccg tcgtgtctcc ccggagtgga	4800
ggcggccgag cgcgccgggg tgcccgccctt cctggagacc tccgcgcccc gcaacctccc	4860
cttctacgag cggctcggtct tcaccgtcac cgcgcacgtc gaggtgccc aaggaccgcg	4920
cacctgggtgc atgaccgcgca agcccggtgc cctgtacaag aaacagaaaa ttgtggcacc	4980
agtgaaacag actttgaatt ttgacaccc taaaatgtggccg ggagacgtcg agtccaacccc	5040
tgggcccattt aacccagccca tcagcgctgc tctcctgtctc tcagtttgc aggtgtcccg	5100
agggcagaag gtgaccagcc tgacagcctg cctggtaaac caaaaccttc gcctggactg	5160
ccgccccatgaa aataacacca aggataactc catccagcat gagttcagcc tgaccggaga	5220
gaagaggaag cacgtgtctt caggcaccc cgggataacc gggcacacgt accgtccc	5280
cgtcacccctc tccaaaccaggc cctatatcaa ggtccttacc ctagccaaact tcaccaccaa	5340
ggatgaggggc gactactttt gtgagcttcg agtctcgccg gcaatccca tgagctccaa	5400
taaaagtatac agtgtgtata gagacaaact ggtcaagtgtt ggcggcataa gcctgtctgg	5460
tcagaacaca tcctggatgc tgctgtctgtc gctttccctc tccctctcc aagccctggaa	5520
cttcattttctt ctgtgtatcta gaaggccataa cttcgatatac tacacattat acgaagttat	5580
gtttatgtcat acctggagga aaaaaaaaaaaggggaggtca ggggtttaaa cctggaaatga	5640
aagggtcaagg tggacgtca gcttggccgg ccgcggccactc acctgcattt gggccgcata	5700
ttgtacagct cgtccatgcc gagagtgtac ccggccggccg tcacgaactc cagcaggacc	5760
atgtgtatgcg ctttctcggtt ggggttttttgc ctcaggccgg actgggtgtctt caggttagtgg	5820
ttgtcgccgcgca gcagcacccggg gcccgtccgcg atgggggtgt tctgtgttgc tggtcgccgcg	5880
agctgcacgc tgccgtccctc gatgttgtgg cggatcttgc agttcaccc tgcgtccgttc	5940
ttctgtttgtt cggccatgtat atagacgttg tggctgttgtt agttgtactc cagttgtgc	6000
cccaaggatgtt tgccgtccctc cttgaagtcg atgccttcac gtcgtatgcg gttcaccagg	6060
gtgtcgccctt cgaacttcac ctcggccggg gtcttgcgtt tgccgtccgtc cttgaagaag	6120

-continued

atgggtgcgtc octggacgta gccttcgggc atggcgact tgaagaagtc gtgctgctc 6180
atgtggtcgg ggttagccgtc gaagcaactgc acggccgtagg tcagggttgt caccgggtg 6240
ggccaggcga cgggcagctt gcccgtggc cagatgaact tcagggttag cttgccgtag 6300
gtggcatcgc cctcgccctc gcccggacacg ctgaacttgtt ggccgtttac gtcggcgctc 6360
agctcgacca ggatgggcac cacccggtg aacagctctt cgcccttgctt caccatggtg 6420
gcgaccggta taacttcgta taagggtatcc tatacgaagt tatccattca ggctgtgcta 6480
gcataatgg catggcacaa agcttagcca taacttcgta taatgtgtac tatacgaagt 6540
tatccctgtt taagggttcc gggttccacta ggtacaattc gatatacgtt ttatcgataa 6600
tcaacctctg gattacaaaaa tttgtgaaag attgactggt attcttaact atgttgcctc 6660
ttttacgcta tggatatacg ctgctttaat gcctttgtat catgctattt cttcccgat 6720
ggcttcatt ttcttccttct tggatataatc ctgggttgtg tctctttatg aggagttgtg 6780
gcccgttgtc aggcaacgtg gctgggtgtg cactgtgtttt gctgacgcaa cccccactgg 6840
ttggggcatt gccaccaccc gtcagctctt ttccgggact ttgcgtttcc ccctccctat 6900
tgccacggcg gaactcatcg ccgcgtgcct tgcccgctgc tggacagggg ctgggtgtt 6960
gggcactgac aatccgtgg tggatccggg gaaatcatcg tcttttctt ggctgtcgc 7020
ctgtgttgc acctggatcc tgccgggac gtccttcgtc tacgttccctt cggccctcaa 7080
tccageggac ttcccttccc gccggctgtc gccggctctt cggcccttcc cgggttccg 7140
ccttcgcctt cagacggatc ggtatccctt ttggccgcctt tcccccgcata gataccgtcg 7200
acctcgatcg agacctagaa aaacatggag caatcacaag tagcaataca gcagetacca 7260
atgctgttgc tgcctggctt gaaacccaaag aggaggaggaa ggtgggtttt ccagtccac 7320
ctcaggtaacc aagcatgggg taaagtactg ttctcatcac atcatatcaa ggttatatac 7380
catcaatattt gccacagatg ttacttagcc tttaatattt tctctaattt agtgtatatg 7440
caatgatagt tctctgattt ctgagattt gtttctcatg tggatattt atttagagtt 7500
tctcttcattt ctgttcaat ttttgcgtt ttttatttt tactgttgc tggatattt 7560
ttttataatc tgcatttttcc aattctttt actgggggtt tgcaaatattt ttctgtcatt 7620
ctatggcctt acctttctt atgggtttt aattttaaaataatctt atattcatgc 7680
aatctaatta acaatctttt ctttgcgtt aggacttgc gtcataagaa attttctct 7740
acactgaagt catgtggca tgcttctata ttatcttctt aagatttaa agtttgcct 7800
tctccatttta gacttataat tcactggat tttttgtgt gtatggatg acatatgggt 7860
tccctttat tttttacata taaaatattt tccctgtttt tctaaaaaag aaaaagatca 7920
tcatatccctt attgtttttt gccatattttttt tttccataggat cacttacata tatcaatggg 7980
tctgtttctt agctctactc tattttatca gcttcactgt ctatccccac acatctcatg 8040
ctttgtctta aatcttgcata ttttagtggaa cattcttcc cattttgttc tacaagaata 8100
ttttgttat tggatccat ttttgcgtt acatcttgc tggatattt atgggttgg caaggttac 8160
ttaagaccaa tgacttacaa ggcagctgtt gatcttagcc acctttaaa agaaaagggg 8220
ggactggaaag ggcttaattca ctcccagctg cttttgcctt gtactgggtc tctctggta 8280
gaccagatct gaggccggaa gcttcgttgc taacttagggaa accccactgtt taagcctcat 8340
aaagctcgac tggatccat ttttagtggaa cattcttcc cattttgttc tacaagaata 8400
ccttgaccctt ggaagggtgcc actccactg tccttcata ataaaatgag gaaattgcat 8460

-continued

cgcattgtct gagtaggtgt cattcttattc tgggggggtgg ggtggggcag gacagcaagg	8520
gggaggaggatg ggaagacaat agcaggcatg ctggggatgc ggtccggact gtactgggtc	8580
tctctggtaa gaccagatct gagectggga gctctctggc taactaggaa acccactgct	8640
taaggctcaa taaagttgc cttgagtgtc tcaagtagtg tggcccgctc tggtgtgtga	8700
ctctggtaac tagagatccc tcagaccctt tttagtcgtg tggaaaatct ctgcgcgt	8760
gtgagcaaaa ggccagcaaa aggcaggaa ccgtaaaaag gccgcgttgc tggcggtttt	8820
ccataggctc cgccccctg acgagcatca caaaaatcga cgctcaagtc agagggtggcg	8880
aaacccgaca ggactataaa gataccaggc gtttccccctt ggaagtc tgcgtgcgtc	8940
tcctgttccg accctgccc ttagccgata cctgtccgccc tttctccctt cgggaagcgt	9000
ggcgctttct catagtcac gctgttagta ttcgttgcgt gttgttaggtcg ttgcgtccaa	9060
gttgggtgt gtgcacgaac ccccggttca gcccggaccgc tgcgccttat ccggtaacta	9120
tcgtcttgcg tccaacccgg taagacacga cttatcgcca ctggcagcag ccactggtaa	9180
caggatttgc agagcggagg atgttagggcg tgctacagag ttcttgaagt ggtggctaa	9240
ctacggctac actagaagaa cagtattttg tatctgcgtc tgcgtgaagc cagttacctt	9300
cgaaaaaaga gttggtagct cttgatccgg caaacaaacc accgctggta gccgggtttt	9360
ttttgttgc aagcagcaga ttacgcgcag aaaaaaagga tctcaagaag atcctttgat	9420
cttttctacg gggctgtacg ctcagtggaa cggaaactca cgttaaggga ttttgtcat	9480
gagattatca aaaaggatct tcaccttagat cttttttat taaaaatgaa gttttaaatc	9540
aatctaaagt atatatgagt aaacttggtc tgacagttaa caatgtttaa tcagtggaggc	9600
acctatctca gcgatctgtc tatttcgttc atccatagtt gcctgactcc ccgtcgtgt	9660
gataactacg atacggggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga	9720
cccacgctca ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg	9780
cagaagtggt cctgcaactt tatccgcctc catccagtct attaattgtt gccgggaagc	9840
tagagtaagt agttcgccag ttaatagttt ggcacacgtt gttgccattg ctacaggcat	9900
cgtgggtgtca cgctcgctgt ttggatggc ttcatcgcc tccgggtccc aacgtcaag	9960
ggaggttaca tgatccccca tgggttgcaaa aaaaagggtt agtccttcg gtcctccgat	10020
cgttgcaga agtaagttgg ccgcgtgtt atcactcgat gttatggcag cactgcataa	10080
ttctcttact gtcatgccat ccgttaagatc ctttctgtg actggtgagt actcaaccaa	10140
gtcattctga gaatagtgtc tgccgcgacc gagttgtct tgccggcgt caatacggga	10200
taataccgcg ccacatagca gaactttaaa agtgctcatc attggaaaac gttttcggg	10260
ggaaaaaaactc tcaaggatct taccgctgtt gagatccagt tgcgtgttcc ccaactcggt	10320
acccaaactga ttttcagcat ctttacttt caccagcggtt tctgggtgag caaaaacagg	10380
aaggcaaaa gccgcaaaaa agggataaag ggccgcacgg aaatgttggaa tactcataact	10440
tttcctttt caatattttt gaagcattt tcaagggttat tgtctcatga gccgatacat	10500
atttgaatgt atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaatg	10560
gccacctgac	10570

<210> SEQ ID NO 7
 <211> LENGTH: 10912
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: pLB2 comprising the FLIP cassette with the

-continued

miR30 targeting FireFly luciferase

<400> SEQUENCE: 7

```

gtcgacggat cgggagatct cccgatcccc tatggtcac tctcagtaca atctgctctg      60
atgccgcata gttaagccag tatctgcctc ctgcttgtgt gttggaggc gctgagtagt     120
gcgcgagcaa aatttaagct acaacaaggc aaggcttgc acacaattgc atgaagaatc     180
tgcttagggt taggegtttt gcgcgtcttc gegatgtacg ggccagatat acgcgttgac    240
attgattatt gactagtcat gttcttctt gcgttatccc ctgattctgt ggataaccgt    300
attaccgcct ttgagtgagc tgataccgt cgccgcagcc gaacgaccga ggcgcagcag     360
tcagtgagcg aggaagcgga agagcgccca atacgcaaac cgcctctccc cgcgcgttgg   420
ccgattcatt aatcgagctg gcacgacagg tttcccgact ggaaagcggg cagtgagcgc   480
aacgcaatta atgtgagttt gctcactcat taggcaccccc aggcttaca ctttatgttt  540
ccggctcgta tgttgtgtgg aatttgtgagc ggataacaat ttcacacagg aaacagctat  600
gaccatgatt acgccaagcg cgcaattaac cctagcttaa tgcataactc tgcaataactc  660
tttgtgtctt gcaacatgggt aacgatgagt tagcaacatg ccttacaagg agagaaaaag  720
caccgtgtcat gccgattgggt ggaagtaagg tggcacgatc gtgccttatt aggaaggcaa  780
cagacgggtc tgacatggat tggacgaacc actgaattgc cgcattgcag agatattgtta 840
tttaagtggcc tagctcgata caataaacgg gtctctctgg ttagaccaga tctgagcctg  900
ggagctctct ggctaacttag ggaacccact gcttaagccct caataaaagct tgccttgagt 960
gcttcaagta gtgtgtgccc gtctgttgg ttagactctgg aacttagagat ccctcagacc 1020
cttttagtca gtgtggaaaaa tctcttagcag tggcgcccgaa acagggactt gaaagcgaaa 1080
gggaaaccag aggagctctc tcgacgcagg actcggcttgc ctgaagcgcc cacggcaaga 1140
ggcgaggggc ggcgactgggt gtagtacgcca aaaatttga ctagcggagg cttagaaggag 1200
agagatgggt gcgagagcgt cagtattaa cgggggagaa ttagatcgatc atggggaaaaaa 1260
attcggtaa ggccagggggg aaagaaaaaa tataaaattaa aacatatagt atgggcaagc 1320
agggagctag aacgattcgc agttaatctt ggcctgttag aaacatcaga aggctgtaga 1380
caaatactgg gacagctaca accatccctt cagacaggat cagaagaact tagatcatta 1440
tataatacag tagcaaccct ctattgtgtg catcaaaggaa tagagataaa agacaccaag 1500
gaagcttag acaagataga ggaagagcaa aacaaaagta agaccaccgc acagcaagcg 1560
gcggccgcgc ctgatcttca gacctggagg aggagatatg agggacaattt ggagaagtga 1620
attatataaa tataaaagtag taaaattaa accattagga gtagcacccca ccaaggcaaa 1680
gagaagatgt gtgcagagag aaaaaagacg agtgggataa ggagcttgc ttcttgggtt 1740
cttgggagca gcaggaagca ctatggcgc agcgtcaatg acgctgacgg tacaggccag 1800
acaattatttgc tctggatag tgcagcagca gaacaatttgc ctgaggccata ttgaggcga 1860
acagcatctg ttgcaactca cagtctgggg catcaaggcag ctccaggccaa gaatcttgc 1920
tgtggaaaga tacctaaagg atcaacagct cctggggatt tggggttgt ctggaaaact 1980
catttgcacc actgctgtgc cttggaatgc tagttggagt aataaatctc tggaaacagat 2040
ttggaatcac acgacaccttggaa tggagtggga cagagaaattt aacaattaca caagcttaat 2100
acactccata attgaagaat cgccaaacca gcaagaaaag aatgaacaag aattatttggaa 2160
attagataaa tggcaagtt tggcaattt gtttaacata acaaatttgc tgggtatata 2220
aaaattatttca ataatgtatag taggaggctt ggttagtttta agaatagttt ttgctgtact 2280

```

-continued

ttctatagtg aatagagtta ggcagggata ttcaccatta tcgttcaaga cccacctccc	2340
aaccccgagg ggacccgaca ggccccgaagg aatagaagaa gaaggtggag agagagacag	2400
agacagatcc attcgattag tgaacggatc ggcactgcgt ggcaccaattc tgcaaaaaaaa	2460
tggcagtatt catccacaat tttaaaagaa aaggggggat tggggggtagt acgtcagggg	2520
aaagaatagt agacataata gcaacagaca tacaaactaa agaattacaa aaacaaatta	2580
caaaaaattca aaatttcgg gtttattaca gggacagcag agatccagtt tggtttagtac	2640
cggggccgggt gctttgcctc gagccagccc accagtttg aatgactctt ttttatgact	2700
tgaatttca agtataaaat ctatgtctaa atttatgg aacaactgtt tagttttgc	2760
tggttggggg aaggaaaaaa aatggtggtca gtgtttttt cagaattaga agtgaatgt	2820
aaacttggt tgggtgagga tttctaatgtt catgtgggtt ttgcataactg agtgaagccg	2880
gtgagcatcc tgccatgtca ccccccctcgctc ctcagtaatg tactttacag aaatccctaaa	2940
ctcaaaaatgt tggatataaac catgtttttt gtgtatatcc ggtctttttt ctgggttagtc	3000
taactcagcc tgcattttctg ccagggcccg ctctagatct agacgggttga tctggctcc	3060
gcccgggggtt ttggggccctc ccggggggccccc ccccccctctc acggcgagcg ctgccacgtc	3120
agacgaaggg ogcaggagcg ttctgtatcc ttccggccgg acgctcagga cagcggcccg	3180
ctgctcataa gacttggccct tagaacccttta gtatcagcag aaggacattt tagggacggg	3240
cttgggtgac tctagggcac tggttttttt tccagagac ggaacaggcg aggaaaagta	3300
gtcccttctc ggccattctg cggagggttcc tccgtggggc ggtgaacgcc gatgattata	3360
taaggacgcg ccgggtgtgg cacagctgt tccgtcgcag ccgggatttg ggtcgccgtt	3420
cttgggtgtt gatcgctgtt atcgctactt ggtgagttgc gggctgtgg gctggccggg	3480
gttttgtgg ccgcggggcc gctcggtggg acggaagcggt gtggagagac cgccaagggc	3540
tgttgtctgg gtcccgagac aagggtggcc tgaactgggg gttggggggc ggcacaaaaaa	3600
tggccgtgt tccccgggttctt tgaatggaaac acgcttgcattt ggcgggtgtt gagggtcggtt	3660
aaacaagggtt gggggcatgg tggggggcaaa gaacccaaagg tcttggggcc ttcgatataatg	3720
ccggaaagctt cttattcggg tgagatgggc tggggcacca tctggggacc ctgaegtgaa	3780
gtttgtcaact gacttggagaa ctcgggtttt tgggtttttt gggggggccgg cagttatgcg	3840
gtggccgttgg gcagtcacc cgtacctttt ggagcgcggc cctcgatgtt tcgtgacgtc	3900
accggatcttctc ttgggttata atcgagggtt gggccaccc cccggtaggtt tgccgttaggc	3960
ttttctccgtt cgcaggacgc agggttcggtt cctagggttgc gtttgccttgc atcgacaggc	4020
gccggacccctc tgggtggggg agggataagt gaggcgttgc tttttttttt cggttttatg	4080
tacctatctt cttaaatgttgc tgaagcttgc gtttgcactt atgcgttgcgg gtttggcgag	4140
tgtgtttttt gaaatttttt aggcacccctt tgaatgttgc tcaatgggtt caatatgtt	4200
ttttcagtgt tagacttagt aattgtccgc taaattctgg ccgtttttttt cttttttttt	4260
agacgaagta cgcgttgcgc gtttgcactt atccataact tcgtatagga	4320
tacccatatac gaagtttatctt caggttccgc caccatgacc gaggataacgc ccacgggtgc	4380
cctcgccacc cgcgcgcgc tccccggggc cgtacgcacc ctcggccgcg cgttgcgcga	4440
ctaccccgcc accgcgcaca ccgtcgatcc ggaccgcaccc atcgagcggg tcaccggatct	4500
gcaagaactc ttccctacgc gctcggttgc cgcacatggc aagggtgtggg tcggcggacga	4560
ccggccggccg gttgggggttgc ggaccacgcg ggagagcggtc gaagcgggggg cgggttgc	4620

-continued

cggatcgcc cgccgcgtgg ccgagtttag cggttccgg ctggccgcgc agcaacagat	4680
ggaggcctc ctggggccgc accggcccaa ggagccccgg tggttctgg ccacccgtgg	4740
cgtctegccc gaccaccagg gcaagggtct gggcagegccc gtcgtgtcc ccggagtgga	4800
ggcgcccgag cgccgcgggg tgccgcctt cctggagacc tccgcgcccc gcaacccccc	4860
cttctacgag cggctcggt tcaccgtcac cgccgacgtc gaggtgcccg aaggaccgcg	4920
cacctgggtc atgaccgcgca agcccggtgc cctgtacaag aaacagaaaa ttgtggcacc	4980
agtgaaacag actttgaatt ttgaccttct caagttggcg ggagacgtcg agtccaaccc	5040
tggcccatatg aaccaggcca tcacgtcgcc tctcctgtcc tcagtttgc aggtgtccga	5100
gggcagaagg tgaccagcct gacagcctgc ctggtaacc aaaacccctcg cctggactgc	5160
cgccatgaga ataacaccaa ggataactcc atccagcatg agttcagcct gacccgagag	5220
aagaggaagc acgtgtctc aggacccctc gggatacccg agcacacgta ccgcctccgc	5280
gtcaccctct ccaaccagcc ctatatacg gtcccttaccc tagccaaactt caccaccaag	5340
gtgaggccgc actactttt tgagcttgcgt gtctcgccgc cgaatccat gagctccat	5400
aaaagtatca gtgtgtatag agacaaactg gtcaagtgtg gcggcataag cctgtggtt	5460
cagaacacat cctggatgtc gctgtgtcg cttccctct ccctccctca agccctggac	5520
ttcatttctc tgtgtatct aagccataac ttcgtatagt acacattata cgaagttatg	5580
tttatgcata cctggaggaa aaaaaaaaaagg ggagagtcag gggtttaaac gcattagtct	5640
tccaattgaa aaaagtgatt taatttatac cattttaaat cagtttgcgaaa aaaatgtatc	5700
aaagagatag caaggtattc agttttagta aacaagataa ttgctctaa agtagccct	5760
tgaattccga ggcagtaggc aggctccgc tgaattggaa tcctacatct gtggcttac	5820
taggattcca attcacggga gctcgctcac tgtcaacagc aatataccctt ctcgagcctt	5880
ctgtgggtt aacctgaaga agtaatccca gcaagtgttt ccaagatgtg caggcaacga	5940
ttctgtaaag tactgaagcc tcattcaaac atagttatgt tgctgtccaa gcgagactt	6000
aacaaggctt gggccgcgc actcacctgc aattggcccg ctacttgtac agctcgatcca	6060
tgcgcagagt gatccggcgcc gccgtcacga actccagcag gaccatgtga tcgcgttct	6120
cgttgggtc tttgtcagg gcccgtggg tgctcaggta gtgggtgtcg ggcagcagca	6180
cggggccgtc gccatgggg tggttctgtc ggttagtggc ggcagactgc acgctgcgt	6240
cctcgatgtt gtggggatc ttgaagttca ctttgatgcc gttttctgc ttgtggcca	6300
tgatatacgt gttgtggctg ttgttagttgt actccagttt gtgcggccagg atgttgcgt	6360
cctcattgaa gtcgatgccc ttcaagtcga tgccgttcac cagggtgtcg ccctcgaaact	6420
teacctcgcc gcccgttgc tagttgtcg cgtccattaa gaagatgtg cgcctctgg	6480
cgtageccctc gggcatggcg gacttgaaga agtcgtgtcg ctcatgtgg tcggggtagc	6540
ggctgaagca ctgcaccccg taggtcaggg tggtcacag ggtggccag ggcacgggca	6600
cttgcgggt ggtcagatg aacttcaggg tcagcttgcgt gtaggtggca tcgcctcgc	6660
cctcgccgga cacgtcgaaac ttgtggccgt ttacgtcgcc gtccagctcg accaggatgg	6720
gcaccacccc ggtgaacagc tcctcgccct tgctcattat ggtggccacc ggtataactt	6780
cgtataaggat atcctatacg aagttatcca ttcaaggctgt gtagtgcata atggcatggc	6840
acaaagtttca gccataactt cgatataatgt gtactatacg aagttatccc tggttaagg	6900
ttccgggttcc actaggatatac aagcttacgtc aataatcaacc tctggattac	6960
aaaatttgcgaa aagatttgcgttgcgtt aactatgttg ctcccttac gctatgtgg	7020

tacgctgctt taatgccttt gtatcatgct attgctccc gatatggcttt cattttctcc 7080
 tccttgata aatcctggtt gctgtcttt tatgaggagt tggggccgt tgcaggcaa 7140
 cgtggcgctgg tggactgtgt gtttgcac gcaaccccca ctggggggg cattgccacc 7200
 acctgtcagc tccttcggg gactttcgct ttccccctcc ctattgccac ggccggaaatc 7260
 atcgccgcct gccttgcgg ggggctcgcc tggggcac tgacaattcc 7320
 gtgggttgtt cggggaaatc atcgctctt ctttgcac tggctgtgt tgccacctgg 7380
 atttgcgcg ggaegtccctt ctgtacgtc ctttgcggcc tcaatccagc ggaccttcc 7440
 tccccggggc tgctgcggc tctggggct cttccggc ttcgccttcg ccctcagacg 7500
 agtcggatct cccttgggc gctccccgc atcgataccg tggaccccg tggagaccta 7560
 gaaaaacatg gagcaatcac aagtagcaat acaggageta ccaatgctga ttgtgcctgg 7620
 ctagaagcac aagaggagga ggaggtgggt ttccactca cacctcaggt accaaggatg 7680
 gggtaaagtc tggcttcatac acatcatatc aaggttatata accatcaata ttggccacaga 7740
 tgttacttag octttaata tttctctaat tttagtgata tgcaatgata gttctctgat 7800
 ttctgagatt gagtttctca tggtaatga ttattttagt tttctcttc atctgttcaa 7860
 atttttgtct agtttattt ttactgatt tgtaagactt cttttataa tctgcattt 7920
 acaattctct ttactggggt gttgaaata tttctgtca ttctatggcc tgactttct 7980
 taatggttt ttaattttaa aaataagtct taatattcat gcaatctaata taacaatctt 8040
 ttctttgtgg ttaggacttt gagtcataag aaattttctt ctacactgaa gtcatgtgg 8100
 catgcttcta tattttttc taaaagattt aaagtttgc cttcttcatt tagacttata 8160
 attcaactggaa atttttgtt gtttatggta tgacatatgg gttccctttt atttttaca 8220
 tataaatata ttccctgtt ttctaaaaa agaaaaagat catcatttc ccattgtaaa 8280
 atgcccattt ttttcatacg gtcacttaca tatataatg ggtctgttc tgagctctac 8340
 tctattttat cagcctact gtcataccccc acacatctca tgctttgc taaatctga 8400
 tattttatgg aacattctttt cccatttgt tctacaagaa tattttgtt attgtcttt 8460
 gggcttctat atacatttta gaatgagggtt ggcaaggatc cttaagacc aatgacttac 8520
 aaggcagctg tagatcttag ccactttta aaagaaaagg ggggactgga agggtataatt 8580
 cactcccagc tgcttttgc ctgtactggg tctctctgg tagaccagat ctgagcctgg 8640
 gagctctctg gctaactagg gaaacctgg cttaaagcctc ataaagctcg actgtgcctt 8700
 ctagttgcca gccatctgtt gtttgcctt ccccggtgcc ttcccttgacc ctggaaagggt 8760
 ccactccac tggcttcata taataaaatg agggaaattgc atcgattgt ctgagtaggt 8820
 gtcattctat tctgggggtt ggggtggggc aggacagca gggggaggat tggaaagaca 8880
 atagcaggca tgctggggat ggggtccggta ctgtactggg tctctctgg tagaccagat 8940
 ctgagcctgg gagctctctg gctaactagg gaaacctgg cttaaagcctc ataaagctt 9000
 gccttgagtg cttcaagtag tggatggcccg tctgtgtgt gactctggta actagagatc 9060
 cctcagaccc ttttagtcag tggaaaat ctctagcgc atgtgagca aaggccagca 9120
 aaggccagg aaccgtaaaa aggccgcgtt gctggcggtt ttccataggc tccgcgggg 9180
 tgacgagcat cacaaaaatc gacgctcaag tcaaggggtt gaaaccccgaa caggactata 9240
 aagataccag gctttccccctt ctggaaagtc cttcggtgcgc ttcctgttc cgaccctgccc 9300
 gtttaccggaa tacctgtccg ctttctccc ttggggaaagc gtggcgctt ctcatacgctc 9360

US 9,043,994 B2

119

120

-continued

acgctgttagg tatctcagtt cgggttaggt cgttcgctcc aagctgggct gtgtgcacga	9420
accccccgtt cagcccgacc gctgcgcctt atccggtaac tatacgcttg agtccaaccc	9480
ggtaagacac gacttatcgc cactggcagc agccactggt aacaggattt gcagagcag	9540
gtatgttaggc ggtgtacag agttttgaa gtggggccct aactacggct acactagaag	9600
aacagtatcc ggtatctgcg ctctgctgaa gccagttacc ttccggaaaaa gagttggtag	9660
ctcttgatcc ggcaaaacaaa ccaccgctgg tagccgtggg tttttgttt gcaagcagca	9720
gattacgcgc agaaaaaaag gatctcaaga agatccttgc atctttctt cggggctgt	9780
cgcctcgaa aacgaaaact cacgttaagg gatccggatc atgagattat caaaaaggat	9840
cttcacccatg atccctttaa attaaaaatg aagtttaaa tcaatctaaa gtatatatga	9900
gtaaacttgg tctgacagtt accaatgctt aatcagttag gcacccatct cagcgatct	9960
tctatttcgt tcataccatag ttgcctgact ccccgtegtg tagataacta cgatacggg	10020
gggcttacca tctggccccca gtgctgcaat gataccgcg gacccacgct caccggctcc	10080
agatTTTatca gcaataaaacc agccagccgg aaggggccgag cgccagaatgt gtcctgcaac	10140
tttatccgcg tccatccagt ctattaatttgg ttcggggaa gctagatgaa gtagttcgcc	10200
agttaatatgt ttgcgcaacg ttgttgccat tgctacaggc atcgtgggtg cactctcg	10260
gtttggatgt gcttcattca gctccgggtc ccaacgtatca aggcgagttt catgtcccc	10320
catgttgtgc aaaaagcgg tttagctcctt cgggtccctcg atcgttgtca gaagtaatgt	10380
ggccgcagtg ttatcactca tggttatggc agcactgcatt aattctctt ctgtcatgcc	10440
atccgtaaaga tgctttctt tgactgggtgta gtactcaacc aagtcttctt gagaatagt	10500
tatgcggcga ccgagttgtc cttggccggc gtcaataacgg gataataccg cgccacatag	10560
cagaacttta aaagtgtctca tcattggaaa acgttctcg gggcgaaaaac tctcaaggat	10620
cttaccgcgt tttagatcca gttcgatgtt acccactcgat gcacccaaact gatcttcagc	10680
atcttttact ttcaccagcg ttctgggtg agcaaaaaca ggaaggcaaa atgcccggaaa	10740
aaaggaaata agggcgacac ggaaatgttg aataactcata ctcttcctt ttcaatattt	10800
ttgaagcatt tatcagggtt attgtctcat gagccgatac atatttgaat gtatgttagaa	10860
aaataaaacaa ataggggttc cgccacatt tccccggaaaa gttccacccgtt ac	10912

<210> SEQ ID NO 8
 <211> LENGTH: 10915
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: pLB2 comprising the FLIP cassette with the
 miR30 targeting 4 integrin

<400> SEQUENCE: 8	
gtcgacggat cggggatct cccgatcccc tatgggtcac tctcgttacata atctgtctg	60
atgcccgcata gttaagccag tatctgctcc ctgcttgggt gttggagggtc gctgatgt	120
gccccggcaa aatctaagct acaacaaggc aaggcttgcac cgacaattgc atgaagaatc	180
tgcgttaggtt taggggtttt gcgctgcttc gcgatgtacgc ggccagatata acgcgttgac	240
attgattttt gacttagtcat gttcttcctt gcgttattccc ctgattctgtt ggataaccgt	300
attaccgcct ttgagttggc tgcataccgtt cggccgcggc gaacgaccga ggcgcggcag	360
tcaatgtggc aggaaggcggc agagcgccca atacgcaaaac cgcctctccc cgcgcgttgg	420
ccgatttcatt aatgcgatgtt gcacgacagg tttccggact ggaaagcggc cagtggcg	480

gtgagcattc tgccatgtca cccccctcgta ctcagtaatg tactttacag aaatcctaaa 2940
 ctcaaaaat tggatataaac catgtttttt gtgtatatacc ggttctttctt ctgggttagtc 3000
 tcactcagcc tgcatttctg ccaggggcccg ctctagatct agacgggtta tctggctcc 3060
 gcccgggtt ttggcgccctc ccggggggcgc cccccctctc acggcgagcg ctgccacgtc 3120
 agacgaaggc cgccaggagcg ttccctgatcc ttccgccccgg acgctcagga cagcggcccg 3180
 ctgctcataa gactcgccct tagaacccca gtatcagcag aaggacattt taggacggga 3240
 ctgggtgac tctagggcac tggttttttt tccagagcgc ggaacaggcg aggaaaagta 3300
 gtccttcctc ggccattctg ccggagggttc tccgtggggc ggtgaacgcc gatgattata 3360
 taaggacgcg ccgggtgtgg cacagctagt tccgtcgcag ccgggatttg ggtcgccgtt 3420
 ctgtttgtg gatecgctgtg atcgtcaattt ggtgagttgc gggctgtgg gctggccggg 3480
 gtttctgtgg ccggggggcc gctcggtggg acggaagcgt gtggagagac cgccaaggcc 3540
 ttagtctgg gtcccgagac aagggtggcc tgaactgggg gttggggggg ggcacaaaaaa 3600
 tggccgtgt tcccgagtct tgaatggaa acgcttgtaa ggccgggttgt gaggtcggtt 3660
 aaacaaggtt gggggcatgg tggggcgcaa gaacccaagg ttttggggcc ttgcgtataatg 3720
 cgggaaagct ottattcggg tgagatgggc tggggcacca ttttggggacc ctgacgtgaa 3780
 gtttgcact gactggagaa ctcgggtttt tctgtctggg gggggggcccg cagttatgcg 3840
 gtgccgttgg gcagtgcacc cgtacctttt ggagcgcccg ctcgtcgtg tcgtgacgtc 3900
 acccgttctg ttgggttata atcgagggtt gggccacctt cccgttaggt tgccgttaggc 3960
 ttttctcgtt cgcaggacgc agggttcggg cctagggttag gtttctctga atcgacaggc 4020
 gccggaccc tggtaggggg agggataagt gaggcgttag tttttttgtt cggttttatg 4080
 tacatatctt cttaagttagc tgaagctccg gtttgaact atgcgtcgg gggtggcgag 4140
 tttgtttttttaa aggcacccctt taaaatctgg ccgtttttgg ctttttgtt 4200
 ttttcgtgt tagacttaga aattgtccgc taaaattctgg ccgtttttgg ctttttgtt 4260
 agacgaagta cgcgetagcc gttataaagc ctcgatgcgg atccataact tcgtatagga 4320
 tacatataac gaagtttatct caggtaaccgc caccatgacc gagtacaagc ccacgggtcg 4380
 ctcgecacc cgcgacgacg tccccaggcc cgtacgcacc ctgcggcccg cgttgcgcga 4440
 ctacccggcc acgcgccaca ccgtcgatcc ggaccgcac atcgagcggg tcaccgagct 4500
 gcaagaacactt ttccctacgc gcgccgggtt cgcacatggc aagggtgtgg tcgcggacga 4560
 cggccgcgcg gtggcggtct ggaccacgcg ggagagcgctc gaagcggggg cgggtttcgc 4620
 cgagatcgcc cgcgcacatgg ccgcgtttagt cggttccggg ctggccgcgc agcaacagat 4680
 ggaaggccctc ctggcgccgc accggcccaa ggagcccgcg tgggttctgg ccaccgtcg 4740
 cgtctcgccc gaccaccagg gcaagggtctt gggcagecgcc gtcgtgtcc ccggagtgaa 4800
 ggccggccgag cgcgcggggg tgcccgccctt cctggagacc tccgcggccc gcaacccccc 4860
 cttctacgag cggctcggttc tcaaccgtcac cggccacgtc gaggtgcggc aaggaccgcg 4920
 cacctgtgtc atgacccgcgca agcccggtgc cctgtacaag aaacagaaaa ttgtggcacc 4980
 agtgaacacag actttaattt ttgcacccctt caagttggcg ggagacgtcg agtccaaccc 5040
 tggggccatgta aacccagccca tcagcgtcgcc tctcctgtcc tcagtttgc aggtgtcccg 5100
 agggcagaag gtgaccagcc tgacagccctg cctgggtgaac caaaaccttc gcctggactg 5160
 cccgcacatgaa aataacacca aggataactc catccagcat gagttcagcc tgacccgaga 5220

-continued

gaagaggaag cacgtgctct caggcaccct cgggataccg gagcacacgt accgctccc	5280
cgtcaccctc tccaaccaggc cctatatcaa ggtccttacc ctagccaact tcaccaccaa	5340
ggatgagggc gactacttt gtgagctcg agtctcgcc gcaatccca tgagetccaa	5400
taaaagtatac agtgtgtata gagacaaact ggtcaagtgt ggccgcataa gcctgctgg	5460
tcagaacaca tcctggatgc tgctgctgtc gcttcctc tccctctcc aagccctgg	5520
cttcattct ctgtgtatca gaaggccataa cttcgtatag tacacattat acgaagtat	5580
gtttatgcat acctggagga aaaaaaaaaaag gggagagtc ggggttaaa cgcattagtc	5640
ttccaattga aaaaagtgtat ttaatttata ccattttatc tcaagcttgc aaaaatgtat	5700
caaagagata gcaaggattt cagttttagt aaacaagata attgctccca aagtagcccc	5760
ttgaatccga ggcagtaggc atgggcatca tgtgatcacc aaatacatct gtggcttcac	5820
tatgggtga tcacatgtat cccgcgtca ctgtcaacag caatatacct tctcgagcct	5880
tctgtgggt taacctgaag aagtaatccc agcaagtgtt tccaagatgt gcaggcaacg	5940
attctgtaaa gtactgaagc ctcattcaaa catagtatat gtgctgccga agcgagcact	6000
taacaaggct tgcggccgccc cactcacctg caattggcc gctacttgta cagctcgcc	6060
atgcccggag tgatccccggc ggcggtcacg aactccagca ggaccatgtg atcgcgcctc	6120
tcgtgggggt ctggctcag ggcggactgg gtgctcagg agtgggtgtc gggcagcagc	6180
acggggccgt cgccgatggg ggttctgc ttggtaggtt cggcgagctg cacgctggcc	6240
tcctcgatgt tggcgccat cttgaagttc acctgtatgc cgttcttcg cttgtcgcc	6300
atgatataga cttttgtggc gttgtatgt tactccagct tggcccccag gatgttgc	6360
tcctccttga agtcgtatgcc ctccagctcg atgcggttca ccagggtgtc gccctcgaa	6420
ttcacctcgg cgggggtctt gtatggccg tgccttgcg agaagatgtt ggcgtccctgg	6480
acgttagcctt cgggcattggc ggacttgaag aagtcgtgtc gttcatgtg gtcggggtag	6540
cggctgaagc actgcacgccc gtatggtcagg gtggtcacca gggtggccca gggcacgggc	6600
agtttgcggg tggtagcagat gaacttcagg gtcagcttc ctttttttttgc atcgcctcg	6660
ccctcgccgg acacgctgaa cttgtggccg tttacgtcg cgtccagctc gaccaggatg	6720
ggcaccaccc cggtaaacag ctctcgccc ttgttcacca ttgtggccac cggtaact	6780
tctgtataagg tatcctatac gaagttatcc attcaggctg tgcgtatgtc aatggcatgg	6840
cacaaagctt agccataact tcgtataatg tggactatac gaagttatcc ctgtttaagg	6900
gttccgggttc cactaggtac aattcgatatac caagcttatac gataatcaac ctctggatta	6960
caaaatttgtt gaaagattga ctggatttttta taactatgtt gtcctttta cgctatgtgg	7020
atacgctgtc ttaatgcctt tggatcatgc tattgtttcc cgtatggctt tcatttttc	7080
ctccctgtat aaatccgtgt tgcgtctct ttatggaggag ttgtggcccg ttgtcaggca	7140
acgtggcggtg gtgtgcactg tggggctgtca cggaccccccc actgggtggc gcatggccac	7200
cacctgtcag ctcccttcgg ggactttcgc ttcccccctc cttatgcac cggccggact	7260
catcgccccc tgccttgcggc gctgtggac agggggctgg cttttggccca ctgacaattc	7320
cgtgggtgttgc tggggaaat catcgccctt tccctggctg ctcgcctgtt ttggccac	7380
gattctgcgc gggacgttcc tctgtacgt cccttcggcc ctcaatccag cggacccctcc	7440
ttcccgccggc ctgtgcggcc ctctgcggcc tttccggctg ctgcgttcc gccctcagac	7500
gagtcggatc tccctttggg ccgcctcccc gcatcgatac cgtcgaccc gatcgagacc	7560
tagaaaaaca tggagcaatc acaagtagca atacagcagc taccaatgtt gattgtgcct	7620

ggctagaagc acaagaggag gaggaggtgg gtttccagt cacacccatg gtaccaagca 7680
 tggggtaaag tactgttctc atcacatcat atcaaggtaa tataccatca atattgccac 7740
 agatgttact tagccttta atatttctct aattttgtt atatgcaatg atagttctct 7800
 gatttctgag atttagtttc tcatgtgtaa tgattattta gagtttctct ttcatctgtt 7860
 caaatttttg tctagttta tttttactg atttgaaga cttctttta taatctgcat 7920
 attacaattc tctttactgg ggtgtgcaa atatttctg tcattctatg gcctgacttt 7980
 tcttaatggt ttttaattt taaaataag tcttaatatt catgcaatct aattaacaat 8040
 cttttcttg tggtaggac tttgagtc aaaaaattttt tctctacta gaagtcatga 8100
 tggcatgctt ctatattatt ttctaaaaga tttaaagttt tgccctctcc atttagactt 8160
 ataattcaact ggaattttt tgggtgtatg gtatgacata tgggttccct tttattttt 8220
 acatataaaat atattccctt gttttctaa aaaagaaaaa gatcatcatt ttccccatgt 8280
 aaaaatgcccattttttca taggtcaattt acatataatca atgggtctgt ttctgagctc 8340
 tactctatattt tatcagccctc actgtctatc cccacacatc tcatgctttg ctctaaatct 8400
 tgatatttag tggAACATTC ttcccccattt tggtagtacaa gaatattttt gttattgtct 8460
 ttggggottc tatatacatt tttagaatgag gttggcaagg taccttaag accaatgact 8520
 tacaaggcag ctgttagatct tagccactttt taaaagaaaa aaaaaaaaaa ggaagggcta 8580
 attcaactccc agctgctttt tgccctgtact gggctctct ggttagacca gatctgagcc 8640
 tgggagctct ctggtaact agggAACCCCA ctgcttaagc ctcataaagc tcgactgtgc 8700
 ctcttagttt ccagecatct gttgtttgcc cctccccgt gccttcttg accctggaaag 8760
 gtgccactcc cactgtccctt tcctaataaa atgaggaaat tgcatecgat tgcgtgagta 8820
 ggtgtcatcc tattctgggg ggtgggggtgg ggcaggacag caagggggag gattggaaag 8880
 acaatagcag gcatgctggg gatcgccgtcc ggactgtact gggctctct ggttagacca 8940
 gatctgagcc tgggagctct ctggtaact agggAACCCCA ctgcttaagc ctcataaag 9000
 ctgccttga gtgcttcaag tagtgtgtgc cctgttgc tgcactctg gtaactagag 9060
 atccctcaga cccttttagt cagtgtggaa aatctctagc agcatgtgag caaaaggcca 9120
 gaaaaaggccc aggaaccgta aaaaggccgc gttgctggc ttttccata ggctccggcc 9180
 ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact 9240
 ataaagatac caggcgtttc cccctggaaat ctccctcgat cgctctccgtt ttccgaccc 9300
 gccgcttacc ggatacctgt ccgcctttctt cccttcggga agcgtggcgc tttctcatag 9360
 ctcacgctgt aggtatctca gttcggtgta ggtcggtcgcc tccaaagctgg gctgtgtgca 9420
 cggaaaaaccggccctt gttcagcccg accgctgcgc cttatccggta aactatcgatc ttgagtc 9480
 cccggtaaga cacgacttat cgccactggc agcagccact ggtaaacagga ttagcagagc 9540
 gaggtatgta ggcggtgcta cagagttttt gaaatgggtgg cctaaactacg gctacactag 9600
 aagaacagta tttggtatct gcgctctgtc gaagccagttt accttcggaa aaagagttgg 9660
 tagctcttgc tccggcaaaac aaaccaccgc tggtagcggtt ggttttttgc tttgcagca 9720
 gcagattacg cgcagaaaaa aaggatctca agaagatccctt ttgatctttt ctacgggtc 9780
 tgacgctcgat tggaaacggaa actcacgtta agggattttgc tcatgagat tatcaaaaag 9840
 gatcttaccat tagatccctt taaataaaaa atgaagttttaaaatcaatct aatgtatata 9900
 ttagttaact tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat 9960

-continued

```

ctgtctatccatgtttttt cgttcatcca tagttgcctg actccccgtc gtgttagataa ctacgatacc 10020
ggagggctta ccatctggcc ccagtgcgtgc aatgataccg cgagaccac gctcacccgc 10080
tccagattta tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc 10140
aactttatcc gcctccatcc agtctattaa ttgttgcgg gaagcttagag taagtagttc 10200
gcagttaat agtttgcgca acgttgttgc cattgtaca ggcacatcggtt tgtaacgcgc 10260
gtcggttggat atgggttcat tcagtcggg ttcccaacgc tcaaggcgag ttacatgtatc 10320
ccccatgttg tgcaaaaaag cggttagtc ctccgggtcc cccatcggttgc tcagaagtaa 10380
gttggccgca gtgttatcac tcattgttat ggcacgttgc cataattctc ttactgttcat 10440
gcacatccgta agatgtttt ctgtgactgg tgagttactca accaagtcat tctgagaata 10500
gtgtatgcgg cgaccgagtt gctttgtccc ggcgtcaata cgggataata ccgcgcacaca 10560
tagcagaact taaaagggtc tcattcattgg aaaacgttct tcggggcgaa aactctcaag 10620
gatcttaccg ctgtttagat ccagttcgat gtaacccact cgtgcaccca actgtatctc 10680
agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgcgc 10740
aaaaaaaggga ataaggcgca cacggaaatgg ttgaataactc atactttcc ttttcaata 10800
ttattgaagc atttatcagg gttattgtct catgagcgga tacatatttgc aatgtatcca 10860
aaaaaaataaaa caaatagggg ttccgcgcac atttcccgaa aaagtgcac ctgac 10915

```

<210> SEQ ID NO 9
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Reverse primer

<400> SEQUENCE: 9

```
ccaggattta tacaaggagg agaaaatgaa agc 33
```

<210> SEQ ID NO 10
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Forward primer

<400> SEQUENCE: 10

```
ctgagcaaag accccaacgaa gaagc 25
```

<210> SEQ ID NO 11
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: loxP WT

<400> SEQUENCE: 11

```
ataacttcgt atagcataca ttatacgaag ttat 34
```

<210> SEQ ID NO 12
<211> LENGTH: 9
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: ras splice donor sequence

<400> SEQUENCE: 12

```
gacgtaagt 9
```

-continued

<210> SEQ ID NO 13
<211> LENGTH: 8
<212> TYPE: RNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 5' splice donor site
<400> SEQUENCE: 13

agguaagu

8

<210> SEQ ID NO 14
<211> LENGTH: 4
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 3' splice acceptor site
<400> SEQUENCE: 14

cagg

4

<210> SEQ ID NO 15
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: p53 sense probe
<400> SEQUENCE: 15

ccactacaag tacatgtgta

20

<210> SEQ ID NO 16
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: p53 anti-sense probe
<400> SEQUENCE: 16

tacacatgta cttgttagtgaa

20

<210> SEQ ID NO 17
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PTEN sense probe
<400> SEQUENCE: 17

ggtgaaacta tactttacaa

20

<210> SEQ ID NO 18
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PTEN anti-sense probe
<400> SEQUENCE: 18

ttgtaaagta tagttcacc

20

<210> SEQ ID NO 19
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Mir-181a probe

<400> SEQUENCE: 19

actcacccgac agcggttgaat gtt 23

<210> SEQ ID NO 20

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Mir-15b probe

<400> SEQUENCE: 20

tgtaaacat gatgtgctgc t 21

<210> SEQ ID NO 21

<211> LENGTH: 8503

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: MSCV FLIPi Puro2ATHy1.1/human c-Myc-miR-p53 vector

<400> SEQUENCE: 21

tcaaagaccc cacctgttagg ttggcaagg tagcttaagt aacgccatt tgcaaggcat 60

ggaaaataaca taactgagaa tagagaagtt cagatcaagg ttaggaacag agagacagca 120

gaatatgggc caaacaggat atctgtggta agcagttcct gcccccggctc agggccaaga 180

acagatggc cccagatgcg gtcccgccct cagcagtttc tagagaacca tcagatgtt 240

ccagggtgcc ccaaggacct gaaaatgacc ctgtgccta tttgaactaa ccaatcagtt 300

cgcttcgc ttctgtcgc gcgttctgc tccccgagct caataaaaga gcccacaaacc 360

cctcaactcg cgccgcagtc ctccgataga ctgcgtcgcc cgggtacccg tattccaat 420

aaagcctctt gctgtttgca tccgaatctgt ggactcgctg atccttggga gggctctc 480

agattgattt actgeccacc tcgggggtct ttcattttga ggttccaccc agatttggag 540

accctgcctt agggaccacc gaccccccgg cggggaggtt agctggccag cggctgttc 600

gtgtctgtct ctgtctttgt gcgtgtttgt gccggcatct aatgtttgcg cctgegtctg 660

tactagttt ctaacttagct ctgttatctgg cggaccegtt gtggacttga cgagttctga 720

acacccggcc gcaaccctgg gagacgtccc agggactttt gggccgttt ttgtggccgg 780

acctgaggaa gggagtcgtat gtggatccg accccgtcag gatatgttgt tctggtagga 840

gacgagaacc taaaacagtt cccgcctccg tctgaatttt tgctttcggt ttggaccga 900

agccgcgcgtt ctgtctgtct gcagcgctgc agcatcgttc tgtgttgtct ctgtctgact 960

gtgtttctgt atttgtctga aaatttagggc cagactgtta ccactccctt aagttgacc 1020

ttaggtcaact ggaaagatgt cgagcggatc gctcacaacc agtcggtaga tgtcaagaag 1080

agacgttggg ttaccttctg ctctgcagaa tggccaaacct ttaacgtcgg atggccgcga 1140

gacggcacct ttaaccgaga cctcatcacc caggttaaga tcaaggctt ttcacctggc 1200

cgcgcattggac acccagacca ggtcccccac atcgtgaccc gggaaacccctt ggctttgac 1260

ccccctccctt gggtaagcc ctgttgcac cctaagcctc cgcctccctt tcctccatcc 1320

ccccctgtctc tcccccttgc acctcctctgt tcgaccccccgc ctgcgtccctc cctttatcca 1380

ccccctcactc cttctcttagg cgccggaaatt agatccataaa cttcgatatacgatacccttat 1440

acgaagttat ctcaggttacc gccaccatga ccgagttacaa gcccacggtg cgcctcgcca 1500

-continued

cccgcgacga cgtccccagg gccgtacgca ccctcgccgc cgcggtcgcc gactacccc	1560
ccacggegccca caccgtcgat ccggaccgccc acatcgagcg ggtcacccgag ctgcaagaac	1620
ttttctcac gcgcgtcgaa ctcgacatcg gcaagggtgtg ggtcgccggac gacggcgccg	1680
cggtgtgggt ctggaccacg ccggagagcg tcgaageggg ggccgtgttc gccgagatcg	1740
gcccggccat ggccgagttg agcggttccc ggctggccgc gcagcaacag atggaaaggcc	1800
tcttggccgc gcacccggcc aaggagcccg cgtggttctt ggccacccgc ggcgtctcg	1860
ccgaccacca gggcaagggt ctgggcagcg ccgtcgtgtc ccccgagtg gaggcgccg	1920
agcgcgccgg ggtggccgc ttccctggaga cctccgcgc cgcacccctc cccttctacg	1980
agcggtcggtt cttcaccgtc accgcccacg tcgaggtgcc cgaaggaccc cgacactgg	2040
gcacgtccgg caagcccggt gcccgtaca agaaacacaa aattgtggca ccagtgaac	2100
agactttgaa ttttgcacctt ctcaagttgg cggagacgt cgagtccaaac cctggggcca	2160
tgaacccagc catcagcgtc gctctcctgc tctcagtctt gcaggtgtcc cgagggcaga	2220
agggtgaccag cctgacagcc tgccctggta accaaaaacct tcgcctggac tgccggcatg	2280
agaataaacac caaggataac tccatccagc atgagttcg cctgacccga gagaagagga	2340
agcacgtgct ctcaggacc ctcgggatac ccgagcacac gtaccgtcc cggtcaccc	2400
tctccaacca gcccataatc aaggctctta ccctagccaa cttcaccacc aaggatgagg	2460
gcgactactt ttgtgagctt cgagtctcg ggcgaaatcc catgagctcc aataaaagta	2520
tcaatgtgtta tagagacaaa ctggtaaagt gtggcgccat aaggctgtcg gttcagaaca	2580
catcctggat gctgctgctg ctgctttccc tctccctctt ccaagccctg gacttcattt	2640
ctctgtgatc tagaagccat aacttcgtat agtacacatt atacgaagtt atgttatgc	2700
ataccctggag gaaaaaaaaa aggggagagt caggggttta aacgcattag tcttccatt	2760
gaaaaaaaaatg atttaattta taccattttt attcagctt gtaaaaatgt atcaaagaga	2820
tagcaaggtt ttcagtttta gtaaaacaaga taattgtcc taaagttagcc ctttgaattc	2880
cgaggcagta ggcattccact acaagtacat gtgtataaca tctgtggctt cactattaca	2940
catgtacttg tagtggcgcc tcactgtcaa cagcaatata ctttctcgag ctttctgtt	3000
ggtaaacctg aagaagtaat cccagcaagt gtttcaaga tgtgcaggca acgattctgt	3060
aaagtactga agcctcattt aaacatagta tatgtgtgc cgaagcgagc acttaacaag	3120
gcttgcggcc gcccactcac ctgcaattgt cacgcacaag agttccgtag ctgttcaagt	3180
tttgttccatc actgttctcg tcgtttccgc aacaagtctt cttcagaaat gagcttttc	3240
tctctgtctt ggacggacag gatgtatgtc gtggcttttt taaggataac taccttgggg	3300
gcctttcat tggggccaa ctccgggatc tggcacgca gggcaaaaaa gctccgtttt	3360
agctcggtcc tctctggcg ctccaagacg ttgtgtgttc gctcttgcatttctcg	3420
gtgtccgagg acctggggct ggtgcatttt cgggtgtgc tgcgtgtct caggactcg	3480
acactgtcca acttgaccctt cttggcagca ggatagtccttccgactggaa gggaggcgct	3540
gcgttagtgt gctgtgtgt ggagacgtgg caccttgc ggaccgtgg gctgtgagga	3600
ggtttgcgtgtt ggcctccagc agaagggtat ccagactcg accttttgcg aggacgtcg	3660
ctctttcca cagaaacaac atcgatttctt ctgcattttt cttgttccctc ctcagatcg	3720
ctgtgtgggg tgggggggtt ctgcattttt cgggtgtgc tgcgtgtct caggactcg	3780
gaggactccg tcgaggagag cagagaatcc gaggacggag agaaggcgct ggagtcgtc	3840
gaggcgcagg acttggccga gctgtgtcg ttgaggggtt agggaaagac caccgagggg	3900

-continued

tcgatgcact ctgaggcggc ggcgctcaga tcctgcaggta acaagctgga ggtggagcag 3960
 acgctgtggc cgccccgggg gtccgggtcg ccgctgttctt tgccgcacgc ctggtaggag 4020
 gccagttctt ctgagacgag cttggcggcg gccgagaagc cgetccacat acagtccctgg 4080
 atgatgatgt ttttgcataaa ggtctcgctg tccgggtcgcc agatgaaaact ctggttcacc 4140
 atgtcttcctc ccagcagctc ggtcaccatc tccagctggt cggccgtgga gaagctccc 4200
 ccaccggcgt cggtgtctcc ccgaaggag aagggtgtga ccgcaacgta ggaggccgag 4260
 cagagcccg agcggccggtt aggggacagg ggccgggtgg gcagcagctc gaatttcttc 4320
 cagatatacctt cgctggccgc cgggggctgc agctcgtctt gctgctgtcg ctggtagaaag 4380
 ttctcccttc ctgcgcagta gaaatacggc tgcaccgagt cgtagtcgag gtcatagttc 4440
 ctgttggta agctaaccgtt gaggggtcta gacatcagca tcaggctggc atagtcaggc 4500
 acgtcataag gatagtcatc cagcatcagg ctggcatagt caggcacgtc ataaggatag 4560
 ctcatcagca tcaggctggc atagtcaggc acgtcataag gatagtcatc catggtggcg 4620
 accggtataa ottcgtataa ggtatcctat acgaagttat ccattcaggc tgtgttagca 4680
 tcaatggcat ggcacaaggc tttagccataa cttcgtataa tgtgtactat acgaagttat 4740
 cccgggttaa acgacctgca gccaagctta tcgataaaat aaaagattt atttagtctc 4800
 cagaaaaagg ggggaatgaa agacccacc tggtaggtttt gcaagcttagc ttaagtaacg 4860
 ccattttgca aggcatggaa aatacataac tgagaataga gaagttcaga tcaaggttag 4920
 gaacagagag acagcagaat atggccaaa caggatctt gtggtaagca gttcctggcc 4980
 cggctcaggc ccaagaacag atggccccca gatgcggtcc cgcctcagc agtttctaga 5040
 gaaccatcatc atgtttccag ggtggcccaa ggacctgaaa atgaccctgt gccttatttg 5100
 aactaaccctt tcaatcgct tctcgcttctt gttcgccgc ttctgtccc ctagtcaat 5160
 aaaagagccc acaacccttc actcgccgac ccagtccctc gatagactgc gtcgeccggg 5220
 taccgggtgtt tccaataaac cctcttgcag ttgcattcgat cttgtggctc cgctgttcc 5280
 tgggggggttc tcctctgagt gattgactac ccgtcagccgg gggctttca tgggtaaacag 5340
 ttcttgcataa ttggagaaca acattcttagt ggtaggagtc gaatattaag taatcctgac 5400
 tcaataggcc actgttttga atccacatac tccaataactc ctgaaatagt tcattatgga 5460
 cagcgcagaa gagctggggaa gaattaattc gtaatcatgg tcatagctgt ttctgtgtg 5520
 aaatttgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaacg 5580
 ctgggggtgcc taatgagtga gctaactcac attaattgcg ttgcgtcac tggccgcctt 5640
 ccagtcggga aacctgtcgat gccagctgca ttaatgaatc gccaacgcg cggggagagg 5700
 cgggtttcgat attggccgtt cttccgccttc ctcgctactt gactcgctgc gtcggcgtt 5760
 tccggctcgcc cgagcggat cagctactc aaaggccgtt atacgggtt ccacagaatc 5820
 aggggataac gcagggaaaga acatgtgacg aaaaggccag caaaaggccca ggaaccgtaa 5880
 aaaggcccg ttcgtggcgat tttccatag gtcggccccc cctgacgagc atcacaaaaa 5940
 tccgacgtca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc 6000
 ccctggaaagc tccctcggtc gctctccgtt tccgaccctg ccgcttaccc gatacctgtc 6060
 ccgccttcctc cttccggaa gcgccggat ttctcatagc tcacgtgtt ggtatctc 6120
 ttccgggttag gtcgttcgtt ccaagctggg ctgtgtgcac gaacccccc ttcagccgaa 6180
 ccgctgcggcc ttatccggta actatcgatc tgagtccaaac ccggtaagac acgacttac 6240

US 9,043,994 B2

139

140

-continued

gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtctac	6300
agagttcttg aagtgggtgc ctaactacgg ctacactaga aggacagtat ttggtatctg	6360
cgctctgctg aagccagttt ccttcggaaa aagagtttgt agctcttgcgat ccggcaaaaca	6420
aaccaccgct ggttagcggtg gttttttgtt ttgcaagcag cagattacgc gcagaaaaaa	6480
aggatctcaa gaagatcctt tgatcttttc tacgggtctac gacgctcagt ggaacgaaaa	6540
ctcacgttaa gggatTTGG tcatgagatt atcaaaaagg atcttcacct agatccttt	6600
aaattaaaaa tgaagtttttta aatcaatcta aagtatataat gagtaaactt ggtctgacag	6660
ttaccaatgc ttaatcagtg aggacacctat ctcagcgtac tgcatttttc gttcatccat	6720
agttgcctga ctccccgtcg tgcataac tacgatacgg gagggttac catctggccc	6780
cagtgcgtca atgataccgc gagacccacg ctcacccggc ccagattttat cagcaataaa	6840
ccagccagcc ggaaggggccg agcgcagaag tggccctgca actttatccg cctccatcca	6900
gtcttataat tggccgggg aagcttagt aagtagttcg ccagttataa gtttgcgcaaa	6960
cgttgcgtcc attgtacacg gcatcgttgt gtcacgcgtc tcgttttgta tggcttcatt	7020
cagctccggc tcccaacgtat caaggcgagt tacatgtatcc cccatgttgt gcaaaaaagc	7080
gtttagtcc ttcggccctc cgatcgttgt cagaagtaa gttggccgcag tggccgttact	7140
catggttatgc gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgttttc	7200
tgtgacttgtt gtagtactcaa ccaagtcatt ctgagaataag tgcgtgcgc gaccgagtt	7260
ctctggccgc ggcgtcaatac gggataatac cggccacat agcagaactt taaaagtgc	7320
catcattggaa aacgttctt cggggcgaaa actctcaagg atcttaccgc tggccgttact	7380
cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatcttttta ctggccgttact	7440
cgttgcgtgg tgagcaaaaaa caggaaggca aaatgccca aaaaaggggaa taaggccgac	7500
acggaaatgt tgaataactca tactcttctt tttcaatat tattgaagca tttatcagg	7560
ttattgtctc atgagccgtt acatatttgc atgtatTTAG aaaaataaac aaatagggt	7620
tccgcgcaca ttccccgaa aagtgcacc tgacgtctaa gaaaccatata ttatcatgac	7680
attaacctat aaaaataggc gtatcacgag gcccggcgtt ctgcgcgtt tgggtatgt	7740
cggtaaaaac ctctgacaca tgcagctccc ggagacggc acagttgtc tggccgttact	7800
tgcggggagc agacaagccc gtcaggccgc gtcagccgggtt gttggccgggt gtcggggctg	7860
gtttaactat gcccgtatcag agcagattgt actgagatgt caccatgc ggtgtaaat	7920
accgcacaga tgcgtaaaggaa gaaaataccg catcaggccgc cattcccat tcaggctgc	7980
caactgttgg gaagggcgat cgggtgcggc ctettcgat ttcgcgcgc tggccaaagg	8040
gggatgtgtc gcaaggcgat taatgtgggtt aacgccagggtt tttcccaatg caccgttg	8100
taaaacgacg ggcgtaaaggaa gcaaggccagt agtaggttgc ggcgttgcg caccgcgc	8160
gcaaggaaatgt gtgcgtatcgc ggcgtggccg cccaaacgtc cccggccac gggccgtgc	8220
accataccca cggccaaaca agcgtatcgt agcccgaaatg ggcgtggccg atcttccca	8280
tccgtgtatgtt cggcgatata ggcgcgc gca accgcacgtt gggccgggtt gatgcgc	8340
acgtatgcgtc cggcgatagat ggcgtatgtc caattttttttt aagacaggat atcgtgtc	8400
caggctctag ttttgcactca acaatatac cagctgtaaac cttatagatgc cggccatag	8460
ataaaataaa agatTTTATT tagtctccatg aaaaagggggg gaa	8503

<210> SEQ ID NO 22

<211> LENGTH: 7697

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: MSCV FLIP-p53

<400> SEQUENCE: 22

tgaagaccc cacctgttagg tttggcaagg tagcttaagt aacgccattt tgcaaggcat      60
ggaaaataca taactgagaa tagagaagtt cagatcaagg ttaggaacag agagacacga     120
gaatatgggc caaacaggat atctgtggta agcagttcct gccccggctc agggccaaga     180
acagatggtc cccagatgcg gtccccccct cagcagttc tagagaacca tcagatgtt     240
ccagggtgcc ccaaggacct gaaaatgacc ctgtgcctta tttgaactaa ccaatcagtt    300
cgtttctcgc ttctgttcgc gcgcttctgc tccccgagct caataaaaga gcccacaacc    360
cctcactcg cgccgcagtc ctccgataga ctgcgtcgcc cgggttaccgg tattcccaat    420
aaagcctctt gctgtttgca tccgaatcgt ggactcgcgt atccttggga gggtctcctc    480
agattgattg actgeccacc tcgggggtct ttcatttggaa ggttccaccc agatttgag     540
acccctgcct agggaccacc gaccccccgg ccgggaggtt agctggccag cggtcgttc    600
gtgtctgtct ctgtctttgt gctgtttgtt gccggcatct aatgtttgcg cctgcgtctg    660
tactagttag ctaacttagct ctgtatctgg cggacccgtt gtggaaactga cgagttctga   720
acacccggcc gcaaccctgg gagacgtccc agggactttt gggccgttt ttgtggcccg    780
acctgaggaa gggagtcgtt gtggaaatccg accccgtcag gatatgtggt tctggtagga   840
gacgagaacc taaaacagtt cccgcctcg tctgaatttt tgctttcggt ttggaaaccga   900
agccgcgcgtt ctgtctgtc gcagcgctgc agcatcgttc tgtgttgcct ctgtctgact  960
gtgtttctgtt atttgtctga aaatttaggc cagactgtta ccactccctt aagtttgacc 1020
ttaggtcaact ggaaagatgt cgagcggatc gtcacaacc accgttgcgttgcgttgcgtt 1080
agacgttggg ttaccttctg ctctcgagaa tggccaaacct ttaacgtcggttgcgttgcgtt 1140
gacggcacct ttaaccgaga cctcatcacc caggtaaga tcaaggctt ttccatcggttgcgtt 1200
ccgcgcgcgc acccagacca ggtcccccac atcgtgaccc gggaaacccctt ggctttgac 1260
ccccctccctt gggtaagcc ctttgcaccc cctaagccctc cgcctccctt ccctccatcc 1320
cccccgcttc tcccccttgc acctccctgtt tggccatccctt ccctccatcc 1380
ccctcactc cttctctagg cgccggaaattt agatccataa cttcgatatacgatacccttat 1440
acgaagttt ctcaaggatcc gccaccatga ccggatccaa gcccacgggtt ccctccatcc 1500
cccgccacga cgtcccccagg gccgtacgca ccctcgccgc cgcgttgcgttgcgttgcgtt 1560
ccacgcgcaca caccgtcgat ccggacccgc acatcgaccc ggttccatcc ccctccatcc 1620
ttttccatcc ggcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt 1680
cggtggcggtt ctggaccacg ccggagagcgcc tggaaatccgggg gggccgttgcgttgcgtt 1740
ggccgcgcgtt ggccgagttt agccgttccggcc ggttccatcc ccctccatcc 1800
ttctggcgcc gcacccggccc aaggagcccg cgtggatccctt ggccacccgc ggcgttgcgtt 1860
ccgaccacca gggcaagggtt ctggggccgc cgcgttgcgttgcgttgcgttgcgttgcgtt 1920
agcgcgcgcgg ggttcccgcc ttcctggaga cttccgcgcgc cgcgttgcgttgcgttgcgtt 1980
agcggctccgg cttcaccgttcc accggccacg tggggatccggcc cggatccggcc ggcgttgcgtt 2040
gcatgaccggc caagcccggtt gcccgttaca agaaacacaa aattgtggca ccgttgcgttgcgtt 2100
agactttgaa ttttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt 2160

```

-continued

tgaacccagc catcagcgtc gctctcctgc tctcagtctt gcaggtgtcc cgagggcaga	2220
aggtgaccag cctgacagcc tgccctggta accaaaacct tcgcctggac tgccgccatg	2280
agaataaacac caaggataac tccatccagc atgagttcag cctgaccacg gagaagagga	2340
agcacgtgtc ctcaggcacc ctgggatac ccgagcacac gtaccgctcc cgcgctaccc	2400
tctccaacca gccctatac aaggcctta ccctagccaa ctccaccacc aaggatgagg	2460
gugactactt ttgtgagctt cgagtctegg ggcgaatcc catgagctcc aataaaagta	2520
tcaagtgtta tagagacaaa ctggtcaagt gtggcggcat aagcctgctg gttcagaaca	2580
catcctggat gctgctgtc ctgcttccc tctccctctt ccaagccctg gacttcattt	2640
ctctgtgatc tagaagccat aacttcgtat agtacacattt atacgaagtt atgtttaaac	2700
gcatttagtct tccaattgaa aaaagtgatt taatttatac cattttattt cagcttggta	2760
aaaatgtatc aaagagatag caaggtattc agtttagta aacaagataa ttgctcctaa	2820
agtagccccct tgaattccga ggcagtaggc atccactaca agtacatgtg taatacatct	2880
gtggcttcac tattacacat gtacttgttag tgggcgtca ctgtcaacag caataacctt	2940
tctcgagccct tctgttgggt taacctgaag aagtaatccc agcaagtgtt tccaagatgt	3000
gcaggcaacg attctgtaaa gtactgaacg ctcattcaaa catagttatat gtgctgcccga	3060
agcgagcaact taacaaggct tgccggccgct acttgtacag ctcgtccatg ccgagagtga	3120
tcccgccggc ggtcacgaac tccagcagga ccatgtgatc ggcgttctcg ttggggtctt	3180
tgcctcaggcc ggactgggtg ctccaggtagt ggttgcggg cagcagcacg gggccgtcgc	3240
cgtatgggggt gttctgctgg tagtggcggg cgagctgcac gctgcccgtcc tcgatgttgt	3300
ggcggatctt gaagttcacc ttgatgccgt tcttctgctt gtcggccatg atataagacgt	3360
tgtggctgtt gtagtgtac tccagcttgc gccccaggat gttgcgtcc tccttgaagt	3420
cgtatggccctt cagctcgatg cgggtccacca ggggtgcgc ctcgaacttc acctcggcgc	3480
gggtcttgcgtc gttgcgtcc tccttgaaga agatggcgcg ctccctggacg tagccttcgg	3540
gcatggcgga cttgaagaag tcgtgtgtc tcatgtggtc ggggtagcgg ctgaagcaact	3600
gcacgcccgtt ggtcagggtg gtcacgaggg tggccagggg cacggggcagc ttgcccgtgg	3660
tgcagatgaa ttccagggtc agcttgcgt aggtggcatac gcccctgc tgcgggaca	3720
cgtctgaacctt gtggccgttt acgtcgccgtt ccagctcgac caggatgggc accacccgg	3780
tgaacagctc ctgcgccttgc ctcaccatgg tggcgaccgg tataacttcg tataaggat	3840
cctatacgaa gttatccatt caggctgtgc tagcatcaat ggcattggcac aaagcttagc	3900
cataacttcg tataatgtgt actatacgaa gttatccggg gttaaacgc ctgcagccaa	3960
gettatcgat aaaataaaag attttatcta gtctccagaaa aaaggggggaa atgaaagacc	4020
ccacctgttag gtttggcaag cttagcttaag taacgcattt ttgcaaggca tggaaaatac	4080
ataactgaga atagagaagt tcagatcaag gtttaggaaca gagagacagc agaatatggg	4140
ccaaacagga tatctgtggt aagcagttcc tgcccccggct cagggccaag aacagatgg	4200
ccccagatgc ggtcccgcccc tcagcgtttt cttagagaacc atcagatgtt tccagggtgc	4260
cccaaggacc tgaaaatgac cctgtgcctt atttgaacta accaatcagt tcgcttctcg	4320
cttctgttcg cgcgttctg ctccccggac tcaataaaag agcccacaac ccctcactcg	4380
ggtcccgccatg ctcctcgatag actcgctgc cccggatccac gttatccaa taaacccctct	4440
tgcagttgca tccgacttgc ggtctcgctg ttccctggaa gggctccctc tgagtattt	4500
actacccgtc agcgggggtc tttcatgggt aacagttct tgaagttgga gaacaacatt	4560

-continued

ctgagggtag gagtcgaata ttaagtaatc ctgactcaat tagccactgt tttgaatcca 4620
 catactccaa tactcctgaa atatggcattt atggacagcg cagaagagct ggggagaatt 4680
 aattcgtaat catggtcata gctgtttctt gtgtgaaatt gttatccgct cacaattcca 4740
 cacaacatac gagccggaaag cataaaagtgt aaaggcctggg gtgcctaatacg agtgagctaa 4800
 ctcacattaa ttgcgttgcg ctcactgccc gctttccagt cgggaaacct gtcgtgccag 4860
 ctgcattaat gaatcgccca acgacggggg agaggcggtt tgcttatgg gcgctttcc 4920
 gtttcctcgc tcactgactc gctgcgtcg gtcgttccgc tgccggcggc ggtatcagct 4980
 cactcaaagg cggtaataacg gttatccaca gaatcaggggg ataacgcagg aaagaacatg 5040
 tgagcaaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgcg ggcgttttc 5100
 cataggctcc gccccctga cgagcatcac aaaaatcgac gtcgaatc gagggtggcga 5160
 aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct cgtgegtct 5220
 cctgttccga ccctgcgcgtt tacccggatac ctgtccgcct ttctccctc gggaaagcgtg 5280
 gggcttctc atagtcacg ctgttaggtat ctcaagttcg gtttaggtcg tgcgtccaaag 5340
 ctggggctgtg tgcaacgacc ccccggttcag cccgaccgcg ggcgttccatc cggtaactat 5400
 cgtcttgcgtt ccaacccgggt aagacacgcac ttatcgccac tggcagcagc cactggtaac 5460
 aggattagca gaggcgaggta tggtagggcgt gctacagagt tcttgaagtg gtggccaaac 5520
 tacggctaca ctggaaaggac agtattttgtt atctgcgttc tgctgaagcc agttaccc 5580
 gggaaaaagag ttggtagctc ttgatccggc aaacaaaccac ccgtggtagt cgggtggttt 5640
 ttgtttgcgca agcagcagat tacggcgcaga aaaaaggat ctcaagaaga tcctttgatc 5700
 ttgttgcgttccggc ttgttgcgttccggc aaaaacttcac gttaaaggat ttgttgcgttcc 5760
 agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag tttaaatca 5820
 atctaaagta tatatgagta aacttggctt gacagttacc aatgcttaat cagtggcga 5880
 cctatctcg cgatctgtct atttcgttca tccatagttt cctgactccc cgtcggttag 5940
 ataaactacgta tacggggagggtt cttaccatct ggccccagttt ctgcaatgtt accggcggac 6000
 ccacgttcac cggctccaga tttatcagca ataaaccacg cagccggaaag ggccgagcgc 6060
 agaaagtggc ctgcaactttt atccgcctcc atccagttca ttaattgtt ccggaaagct 6120
 agagtaagta gttcgccagt taatagttt cggcaacgtttt ttgttgcgttccggc tacaggc 6180
 gtgggtgtcactt gtcgtcggtt ttgttgcgttccggc tacaggc 6240
 cgagttacat gatccccat gttgtgcaaa aaagcggttta gtcgttccggc tacaggc 6300
 gttgtcagaa gtaagttggc cgcgtgttca tcactcatgg ttatggcagc actgcataat 6360
 tctcttactg tcatggccatc cgttcaatgtt ttttctgttca ctgggtggat ctcaaccaag 6420
 tcattctcg aatagtgtat gggccggaccg agttgttccgtt gcccggcgtt aatacgggat 6480
 aataccggcgc cacatagcag aactttaaaaa gtgttcatca ttggaaaacg ttcttcgggg 6540
 cggaaaactctt caaggatctt accgctgtttt agatccagttt cgtatgttacc cactcggttca 6600
 cccaaactgtt ctttacttttcc accagcggtt ctgggtggat aaaaacagga 6660
 agggcaaaatg cccggaaaaaaa gggaaaatggc ggcacacggaaatgttgaat actcataactc 6720
 ttcccttttc aatatttttgc aagtttttgc cagggttattt gtctcatgttccggatata 6780
 ttgttgcgttccggc gtcgttccggc gtcgttccggc gtcgttccggc 6840
 ccacgttgcgttccggc gtcgttccggc gtcgttccggc gtcgttccggc 6900

-continued

cgaggccctt tcgtctcgcg cgtttcggtg atgacggtaa aaacctctga cacatgcagc 6960
 tccccggagac ggtcacagct tgcgtgtaa cggatgcggg gagcagacaa gcccgtcagg 7020
 gcgctcagc ggggtgtggc ggggtgtcggg gctggctaa ctatgcggca tcagagcaga 7080
 ttgtacttag agtgcaccat atgcgggtgtg aaataccgca cagatgcgta aggagaaaaat 7140
 accgcattcg ggcatttcg ccattcaggc tgcccaactg ttggaaaggcgatcg 7200
 gggccttc gctattacgc cagctggcga aaggggatg tgctgcaggcgatcg 7260
 gggtaacgcc agggtttcc cagtcacgac gttgtaaaac gacggcgcaaa ggaagcagcc 7320
 cagtagtagg ttgaggccgt tgagcaccgc cgccgcaggaaatggtgcattgc 7380
 ggccccaac agtccccccg ccacggggcc tgccaccata cccacgcga aacaagcgct 7440
 catgagcccg aagtggcgag cccatcttc cccatcggtg atgtcgccgatcg 7500
 agcaaccgca cctgtggcgc cggtgatgcc ggccacgatg cgtccggcgatcg 7560
 agtccaattt gttaaagaca ggtatcgt ggtccaggct ctagtttgc tcacaacaata 7620
 tcaccagctg aagcctatag agtacgagcc atagataaaa taaaagattt tatttatct 7680
 ccagaaaaag gggggaa 7697

<210> SEQ_ID NO 23
 <211> LENGTH: 7698
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: MSCV FLIP-PTEN

 <400> SEQUENCE: 23

taaaaagaccc cacctgttagg tttggcaagc tagcttaagt aacgcattt tgcaaggcat 60
 ggaaaataca taactgagaa tagagaagtt cagatcaagg ttaggaacag agagacagca 120
 gaatatgggc caaacaggat atctgtggta agcagttctt gccccggctc agggccaaga 180
 acagatggtc cccagatgcg gtccggccct cagcagtttc tagagaacca tcagatgttt 240
 ccagggtgcc ccaaggacct gaaaatgacc ctgtgcctta tttgaactaa ccaatcgtt 300
 cgccatcgcc ttctgttcgc gcgccatctgc tccccggatcaataaaaga gcccacaacc 360
 ctcactcgg cgcgcaggc ctccgataga ctgcgtcgcc cgggtacccg tattccaat 420
 aaagcctctt gctgtttgca tccgaatcgt ggactcgctg atccttggga gggctcctc 480
 agattgattt actgeccacc tcgggggtct ttcatttggaa ggttccacccg agatttggag 540
 acccctgcctt agggaccacc gaccccccgg cggggaggta agctggccag cggtcgttcc 600
 gtgtctgtct ctgtctttgt gctgtttgtt gccggcatct aatgtttgcg cctgcgtctg 660
 tacttagttt ctaacttagct ctgtatctgg cggacccgtg gtggaaactga cgagttctga 720
 acacccggcc gcaaccctgg gagacgtccc agggactttg gggccgttt ttgtggcccg 780
 acctgaggaa gggagtcgtat gtggaaatccg accccgtcag gatatgttgttctgttagga 840
 gacgagaacc taaaacagt cccgcctccg tctgaatttt tgcttcgggt ttggaaacccg 900
 agccgcgcgt ctgtctgtc gcagcgtcgc agcatcgatc tgcgtttgtct ctgtctgtact 960
 gtgtttctgtt atttgcgtatcga aaatttagggc cagactgttta ccactccctt aagtttgcacc 1020
 ttaggtcaact ggaaagatgtt cgagcggatc gctcacaacc agtcggtaga tgtcaagaag 1080
 agacggtggg ttaccttctg ctctgcgaa tggccaaacctttaacgtcgatc atggccgcga 1140
 gacggcacct ttaaccgaga cctcatcacc caggttaaga tcaaggctt ttcaaccggc 1200
 ccgcgtggac acccagacca ggtccctac atcgtgaccc gggaaaggctt ggctttgac 1260

-continued

ccccctccct gggtaagcc ctttgacac cctaaggcctc cgccctccct tcctccatcc 1320
gccccgtctc tcccccttga accttcctcg tgcaccccgcc ctgcgttc cctttatcca 1380
gccctcaactc ttctcttagg cgccggattt agatccataa ctgcgtatag gatacctt 1440
acgaagttat ctgcaggtaacc gcaccatga ccgcgttacaa gcccacgggtc cgccctcgcca 1500
cccgccgacga cgtccccagg gccgtacgca ccctcgccgc cgccgttc gactaccccg 1560
ccacgcccacca caccgtcgat ccggaccgccc acatcgagcg ggtaaccggag ctgcaagaac 1620
tttctctcac gcgcgtcggg ctgcacatcg gcaagggtgtt ggtaaccggac gacggcccg 1680
cggtggccgt ctggaccacg ccggagagcg tgcgaaggggg ggccgtgttc gccgagatcg 1740
geccgcccacca ggccgagttt agccgttccc ggccgttccc gcaacacag atgaaaggcc 1800
tcctggccgc acaccggccc aaggagcccg cgtgggttc ggcacccgtc ggccgttcgc 1860
ccgaccacca gggcaagggtt ctggccgtcg ccgtcgtgtt ccggggagtg gagggggccg 1920
agcgccgcggg ggtgcggccccc ttccctggaga cctccggccg ccgcaacccctc cccttctacg 1980
agcggtcggtt otccaccgtc accggccgacg tcgagggtgcc cgaaggacccg cgccacccgtt 2040
gcgttgcgttcc caagcccggtt gcccgttaca agaaacagaa aatttgtggca ccagtgaaac 2100
agactttgaa ttttgcacctt ctcaagttgg cgggagacgtt cgagtcacac octgggccca 2160
tgaaccacgc catcagcgtc gcttccttc tctcagtctt gcaagggttcc cgaggccaga 2220
aggtgaccag octgacacgac tgccctggta accaaaacctt tgccctggac tgccgcctatg 2280
agaataaacac caaggataac tccatccagc atgagttcgat cctgacccgaa gagaagagga 2340
agcacgtgtt ctcaaggccacc ctcgggatcc cccggccacac gtaccgttcc cgccgtaccc 2400
tctccaacca gcccataatac aaggcccttta ccctagccaa ctttaccacc aaggatgagg 2460
gagactactt ttgtgagctt cgagtcgtt ccgcgtatcc catgagctcc aataaaagta 2520
tcgtgtgtt tagagacaaa ctggcaagt gtggccgcata aagcctgtcg gttcagaaca 2580
catcctggat gctgtgtcg tctgtttcc tctcccttc ccaaggccctg gacttcattt 2640
ctctgtgtatc tagaagccat aacttcgtat agtacacattt atacgttgcgtt atgtttaaac 2700
gcatttagtct tccaaattgaa aaaagtgtttaatc cattttattt cagtttgcgtt 2760
aaaatgtatc aaagagatag caaggatattt agttttgtt aacaagatata ttgtccctaa 2820
agtageccct tgaattccgaa ggcagtaggc aagggttgcata tatactttac aaatacatct 2880
gtggccgttcc tattttgtttaatc gtatgtttcc accggccgtca ctgtcaacag caataacatct 2940
tctcgacccct tctgttgggt taacctgttcc aagtaatccc agcaagggtttt tccaaaggatgt 3000
gcaggcaacgtt attctgtttaatc gtactgttcc ctcattcaaa catagttatat gtgtccgtt 3060
agcgagactt taacaagggtt tgcggccgtt acttgcgttcc ctcgttccatg ccggaggtgtt 3120
tccggccggcc ggtcaccaac tccagccgtt ccgttgcgttcc gctgttccatg ttggggccatg 3180
tgcgttccatg ggactgggtt ctgcgttccatg ggttgcgttcc cccggccgttccatg 3240
cgatgggggtt gttctgttccatg tagtgggttccatg cgagctgttcc ctcgttccatg 3300
ggccggatccatg gaagtttccatg ttgttccatg tcttctgttcc ctcgttccatg atatagacgt 3360
tgtggccgttccatg ttagtgggttccatg gcccaggat gttggccgttccatg ttggggccatg 3420
cgatggccctt cagctgttccatg ccgttccatg gggttccatg ctgcgttccatg acctcgccgtt 3480
gggttccatg tttgttccatg ttgttccatg agatgggttccatg ctcgttccatg tagtgggttccatg 3540
gcgttccatg cttgttccatg tcgttccatg tcgttccatg gggtagccgtt ccgttccatg 3600

-continued

gcacgcccgt a ggtcagggtg gtcacgaggg tggccaggg cacggcagc ttgcgggtgg	3660
tgcagatgaa cttcagggtc agcttgcgtt aggtggcata gcccgcgcc tcgcggaca	3720
cgcgtgaacctt gtggcggtt acgtcgccgtt ccagctcgac caggatggc accacccgg	3780
tgaacagctc ctgcgccttg ctcaccatgg tggcgaccgg tataacttcg tataaggat	3840
cctatacgaa gttatccatt caggctgtgc tagcatcaat ggcatggcac aaagcttagc	3900
cataactcg tataatgtgt actatacgaa gttatccgg gttaaacgac ctgcagccaa	3960
gcttatcgat aaaataaaag attttattta gtctccagaa aaagggggga atgaaagacc	4020
ccacactgttag gtttggcaag cttagcttaag taacgcccatt ttgcaaggca tggaaaatac	4080
ataactgaga atagagaagt tcagatcaag gttaggaaca gagagacagc agaatatggg	4140
ccaaacaggg a tatctgtggt aacgagttcc tgccccggc caggccaaag aacagatgg	4200
ccccagatgc ggtcccgccc tcagcagttt cttagagaacc atcagatgtt tccagggtgc	4260
cccaaggacc tgaaaatgac cctgtgcctt atttgaacta accaatcagt tcgcttcgt	4320
cttctgttcg cgcgcttcgt ctccccggc tcaataaaag agccccacaac ccctcactcg	4380
gcgcgcctgtt cctccgatag actgcgtgcg ccgggtaccc gtgtatccaa taaaccctct	4440
tgcaagttgca tccgacttgt ggtctcgctg ttccctggga gggctccctc tgagtattt	4500
actacccgtc agcgggggtc tttcatgggt aacagttct tgaagttgga gaacaacatt	4560
ctgagggttag gagtcgaata ttaagtaatc ctgactcaat tagccactgt tttgaatcca	4620
catactccaa tactcctgaa atagttcatt atggacagcg cagaagagct ggggagaatt	4680
aattcgtaat catggtcata gctgtttctt gtgtgaaatt gttatccgct cacaattcca	4740
cacaacatac gagccggaag cataaagtgt aaagcctggg gtgcctaatt agtgagctaa	4800
ctcacattaa ttgcgttgcg ctcaactgccc gctttccagt cgggaaacct gtcgtccag	4860
ctgcattaat gaatcgccca acgcgcgggg agaggcggtt tgcgtattgg gcgcttcc	4920
gcttcctcgc tcaactgactc gtcgcgtcg gtcgttcggc tgcggcgagc ggtatcagct	4980
cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaacatg	5040
tgagcaaaag gccagaaaa ggccagggac cgtaaaaagg ccgcgttgct ggcgttttc	5100
cataggctcc gccccctga cgagcatcac aaaaatcgac gtcagaatc gagggtggcga	5160
aacccgcac gactataaaag ataccaggcg tttccccctg gaagctccct cgtgcgtct	5220
cctgttccga ccctgcccgt taccggatac ctgtccgcct ttctccctc gggaaagcgtg	5280
ggcgcttcgtc atagctcacg ctgttaggtat ctgcgttcgg tgcgtatcg tgcgtccaa	5340
ctgggtgtg tgcacgaacc ccccggtcag cccgaccgct ggccttatac cggtaactat	5400
cgtctttagt ccaacccgtt aagacacgac ttatcgccac tggcagcagc cactggtaac	5460
aggatttagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtgt gtggctaac	5520
tacggctaca otagaaggac agtattttgtt atctgcgtc tgcgtaaagcc agttaccc	5580
ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cgggttttt	5640
tttgggttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc	5700
ttttctacgg ggtctgacgc tcagtggAAC gaaaactcac gttaaaggat tttggtcatg	5760
agattatcaa aaaggatctt cacctagatc ctttaaatt aaaaatgaag tttaaatca	5820
atctaaagta tataatgtgt aacttggctt gacagttacc aatgcgttaat cagtggggca	5880
cctatctcg cgtatgtctt attcgttca tccatagttt cctgactccc cgtcgtag	5940
ataactacgta tacgggagggtt cttaccatct ggccccagtg ctgcaatgat accgcgagac	6000

-continued

ccacgctcac	cggctccaga	tttatcagca	ataaaccagc	cagccggaag	ggccgagcgc	6060
agaagtggtc	ctgcaacttt	atccgcctcc	atccagtcta	ttaattgtg	ccggaaagct	6120
agagtaagta	gttcgcgcgt	taatagtttgc	cgcaacgttg	ttgccattgc	tacaggcatc	6180
gtgggtgtcac	gctcgtcggt	tggtatggct	tcattcagct	ccggttccca	acgatcaagg	6240
cgagttacat	gatccccat	gttgtgc当地	aaagcggtta	gtcccttcgg	tcctccgatc	6300
gttgtcagaa	gtaagttggc	cgcagtgtta	tcactcatgg	ttatggc当地	actgcataat	6360
tctcttactg	tcatgccatc	cgttaagatgc	tttctgtga	ctggtagagta	ctcaaccaag	6420
tcattctgag	aatagtgtat	gccccggacccg	agttgcttctt	gccccggc当地	aatacgggat	6480
aataccgcgc	cacatagcag	aactttaaaa	gtgctcatca	ttggaaaacg	ttcttcgggg	6540
cgaaaactct	caaggatctt	accgcgttgc	agatccagg	cgatgttaacc	cactcgtgca	6600
cccaactgat	cttcagcatc	ttttactttc	accagcggtt	ctgggtgagc	aaaaacagga	6660
aggccaaatg	ccgaaaaaaaa	gggataaagg	gccccggacccg	aatgttgaat	actcataactc	6720
ttcccttttc	aatattatttgc	aaggatttat	cagggttatt	gtctcatgag	cggatacata	6780
tttgaatgt	tttagaaaaaa	taaacaaata	gggggtccgc	gcacattttc	ccgaaaaatg	6840
ccacctgacg	tctaaagaaac	cattatttac	atgacattaa	cctataaaaa	taggcgtatc	6900
acgaggccct	ttcgctctgc	gcccgttgcgt	gatgacgggt	aaaacctctg	acacatgcag	6960
ctcccccggaga	cggtcacage	ttgtctgtaa	gccccggccg	ggagcagaca	agcccggtcag	7020
ggcgcgtcag	cggggttgg	cgggtgttgc	ggctggctta	actatgcggc	atcagagcag	7080
attgtactga	gagtgcacca	tatgcgggt	gaaataccgc	acagatgcgt	aaggagaaaa	7140
taccgcacatca	ggcgcattc	gccattcagg	ctgcgcacact	gttggaaagg	gccccggcgt	7200
cgggccctt	cgctattacg	ccagctggcg	aaagggggat	gtgctgcaag	gccccggat	7260
tgggtacacgc	cagggttttc	ccagtcacga	cgttgc当地	cgacggcgc当地	aggaagcagc	7320
ccagtagtag	gttggggccg	tttggccacccg	ccggccgc当地	aatgggtgc当地	tgcaaggaga	7380
tggcgeccaa	cagccccccg	gccacggggc	ctggccacat	acccacgc当地	aaacaagcgc	7440
tcatgagccc	gaagtggcga	gcccgatctt	ccccatcggt	gatgtggc当地	atataggcgc	7500
cagcaaccgc	acctgtggcg	ccgggtatgc	cgccccacat	gccccggc当地	tagaggcgc当地	7560
tagtccaatt	tgttaagac	aggatatcg	tggtccaggc	tctagtttgc	actcaacaat	7620
atcaccagct	gaagcctata	gagtacgac	catagataaa	ataaaagatt	ttttagtc	7680
tccagaaaaaa	ggggggaa					7698

<210> SEQ ID NO 24
<211> LENGTH: 7806
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: MSCV FLIPi Puro2AGFP / Thy1.1-miR-FF

<400> SEQUENCE: 24

tgaaagaccc	cacctgttagg	tttggcaagc	tagcttaagt	aacgcattt	tgcaaggcat	60
ggaaaataca	taactgagaa	tagagaagtt	cagatcaagg	ttaggaacag	agagacagca	120
gaatatgggc	caaacaggat	atctgtggta	agcagttctt	gccccggc当地	agggccaaga	180
acagatggtc	cccagatgcg	gtcccgccct	cagcagtttgc	tagagaacca	tcagatgtt	240
ccagggtgcc	ccaaggaccc	gaaaatgacc	ctgtgc当地	tttgaactaa	ccaatcagg	300

-continued

cgcttctcgc ttctgttcgc gcgtttctgc tccccgagct caataaaaga gcccacaacc	360
cctcaactcg cgcgccagtc ctccgataga ctgcgtcgcc cgggtacccg tattccaat	420
aaaggctctt gctgttgca tccgaatctg ggactcgctg atccttggga gggtctctc	480
agattgattg actgeccacc tcgggggtct ttcatattgga gtttccaccc agattggag	540
acccctgcctt agggaccacc gaccccccgg cggggaggtt agctggccag cggcggttc	600
gtgtctgtct ctgtctttgt gcgtgtttgtt gecggcatct aatgtttgcg cctgegtctg	660
tactagtttag ctaactagct ctgtatctgg cggacccgtt gtggaaactgaa cgagttctga	720
acacccggcc gcaaccctgg gagacgtccc agggactttt gggggcggtt ttgtggcccg	780
acctgaggaa gggagtctgat gtggaaatccg accccgtcag gatatgttgtt tctggtagga	840
gacgagaacc taaaacagtt cccgcctcgg tctgaatttt tgcttcggg ttggAACCGA	900
agcccgccgtt ctgtctgtct gcagcgctgc agcatcggtt tgggttgtt ctgtctgact	960
gtgtttctgtt atttgtctga aaatttagggc cagactgtta ccactccctt aagtttgacc	1020
ttaggtcaactt ggaaagatgtt cgagcggtt gctcacaacc agtgcgttgcgat tgcgtcaagaag	1080
agacgttggg ttaccttctg ctctcgagaa tggccaacctt ttaacgtcggtt atggcccgca	1140
gacggcacct ttaaccgaga cctcatcacc caggttaaga tcaaggctt ttccacctggc	1200
ccgcacatggac acccagacca ggtcccccatac atcgtgacccctt gggaaaggctt ggctttgtac	1260
ccccctccctt gggtaagcc ctgttgcacac cctaagcctc cgcctccctt tcctccatcc	1320
gccccgtctc tcccccttgc acctccctcg tgcaccccgcc ctgcacccctc cctttatcca	1380
gccctcaactc ttctcttagg cggccggattt agatccataa ctgcgtatag gataccttat	1440
acgaagttat ctcaaggtaacc gcccacccatgg tggagttacaa gcccacccgtt cgcctcgcca	1500
cccgccgacga cgtcccccagg gccgtacgc ccctcgcccgcc cgccgttgcgactaccgg	1560
ccacgcgcaca caccgtcgat ccggaccgc acatcgacgc ggtaaccggag ctgcaagaac	1620
tcttcctcac ggcgtcggtt ctgcacatcg gcaagggtgtt ggtaaccggac gacggcccg	1680
cggttggcggtt ctggaccacg ccggagagcg tcgaaggccggg ggccgttgcgatcg	1740
gccccggccat ggcccgatggt agccgggttccc ggctggcccgcc gcagcaacag atggaaaggcc	1800
tcttggccgc gcacccggccc aaggagcccg cgtgggttccctt ggccacccgtt ggcgtctcg	1860
ccgaccacca gggcaagggtt ctggcccgacg ccgtcgatgtt ccccgagggtt gaggccggcc	1920
agcgcgcgcgg ggtgeccgcctt ttccctggaga cctccgcgc ccccaacccctt cccttctacg	1980
agcggcgtcggtt ttccaccgttcc accggccgacg tcgagggtgcg cgaaggaccccgccac	2040
geatgaccccg caagecccggtt gccaaacaga aaattgtggc accagtgtaaa cagactttga	2100
attttgcactt tctcaaggatgtt tggggagacg tcgaggatcaa ccctggggccc ggccgggtcg	2160
ccaccatggt gagcaaggccggc gaggagctgt tcaccgggggtt ggtgccatc ctggcgagc	2220
tggacggcgca cgttaaacggcc cacaagttca ggtgtccggc cgaggccggag ggcgtatgc	2280
ccatcggccaa gctgaccctg aagttcatctt gcaccacccgg caagctgcggcc gtgcctggc	2340
ccaccctcgat gaccaccctg acctacccggcc tgcgtcgatctt cagccgttccatc cccgaccaca	2400
tgaaggcgcacca cgaacttcttc aagtccgcacca tgcccgaaagg ctacgtccag gagcgcacca	2460
tcttcttcaa ggacgacggc aactacaaga cccgcgcggc ggtgaaggatcc gagggcgaca	2520
ccctgggtgaa cccgcacccggccatcgatgttcaaa gggccggcc aacatccctgg	2580
ggcacaagctt ggagttacaac tacaacagcc acacgtcttatacatggcc gacaaggcaga	2640
agaacggccat caaggtaaac ttcaaggatcc gccacaacat cgaggacggc agcgtcgac	2700

-continued

tcggccacca ctaccaggcag aacaccccca tcggcgacgg ccccgtgctg ctgcccgaca	2760
accactacacct gaggcacccag tccgcgcctga gcaaagaccc caacgagaag cgcgatcaca	2820
tggtcctgtt ggagttcgtg accggccggc gatcaactctc ggcatggacg agctgtacaa	2880
gttagtctaga agccataact tcgtatagta cacattatac gaagtttatg catacctgga	2940
ggaaaaaaaaa aaggggagag tcagggggtt aaacgcatta gtcttccaat tgaaaaaagt	3000
gatttaattt ataccatttt aattcagtt tgtaaaaatg tatcaaagag atagcaaggt	3060
attcagtttt agtaacaag ataattgtct ctaaagttagc cccttgaatt ccgaggcagt	3120
aggcaggctc ccgctgaatt ggaatctac atctgtggc tcactaggat tccaattcac	3180
gggagctcgc tcactgtcaa cagcaatata cttctcgag cttctgttg ggttaacctg	3240
aagaagtaat occagcaagt gttccaaga tgtgcaggca acgattctgt aaagtactga	3300
agcctcatcc aacatagta tatgtgctgc cgaagcgagc acttaacaag gcttgccgccc	3360
gtctatgttgc cagctcgatcc atgcccggag tgatccccggc ggcccccactc acctgcaatt	3420
gggccgctca cagagaaatg aagtccaggg ctggaggag ggagagggaa agcagcagca	3480
gcagcatcca ggtatgtttc tgaaccagca ggcttatgcc gcacacttg accagttgt	3540
ctctatacac actgatactt ttattggagc tcatggatt cgcccccggag actcgaagct	3600
cacaaaaatg gtcgcctca tccttgggtt tgaagttggc tagggtaagg accttgat	3660
agggctgggtt ggagaggggtg acggggggagc ggtacgtgtg ctgggtatc ccgagggtgc	3720
ctgagagcac gtgttcctc ttctctcggtt tcaggctgaa ctcatgtgg atggagtat	3780
ccttgggtt attctcatgg cggcagtccaa ggcgaagggtt ttgggttacc aggccaggctg	3840
tcaggctggt caccttctgc cctcgccaca cctgcaagac tgagagcagg agagcgacgc	3900
tgtggctgg gttcatgggtt ggcaccggta taactcgta taaggatcc tatacgaagt	3960
tatccattca ggctgtgtca gcatcaatgg catggcacaa agcttagcca taactcgta	4020
taatgtgtac tatacgaagt tatccccgggt taaacgacct gcagccaagc ttatcgataa	4080
aataaaaatg tttttttttt ctcccgaaaaa agggggggat gaaagacccc acctgttaggt	4140
ttggcaagct agcttaagta acggcattttt gcaaggcatg gaaaatacat aactgagaat	4200
agagaagttc agatcaaggt taggaacaga gagacagcag aatatggcc aaacaggata	4260
tctgtggtaa gcagttcctg ccccggtca gggccaagaa cagatggtcc ccagatggcg	4320
tcccgccctc agcagtttct agagaaccat cagatgtttc cagggtgccc caaggactg	4380
aaaatgaccc tggcccttat ttgaactaac caatcagttc gtttctcgct tctgttcgcg	4440
cgcttcgtc ccccgagctc aataaaagag cccacaaccc ctcactcgcc ggcggcgtcc	4500
tccgatagac tgcgtcgccc gggttccgtt gtatccaata aaccctctg cagttgcattc	4560
cgacttgtgg tctcggtgtt ctttgggggg gtctcctctg agtggattgac taccggtag	4620
cggggggtttt tcatgggtaa cagtttcttgg aagttggaga acaacattct gagggtagga	4680
gtcgaatatt aagtaatcct gactcaatta gccactgttt tgaatccaca tactccaata	4740
ctcctgaaat agttcattat ggacagcgca gaagagctgg ggagaattaa ttctgtatca	4800
tggtcatagc tggccctgtt gtggaaattgtt tatccgtca caattccaca caacatacga	4860
gcgggaagca taaagtgtaa agcctggggt gcctaatgag tgagctaact cacattaatt	4920
gcgttgcgtc cactgcccgc ttccagtcg gggaaacctgt cgtggccagct gcattaatga	4980
atcgcccaac gcgcggggag aggccgggtt cgtattgggc gctttccgc ttctcgctc	5040

US 9,043,994 B2

159**160**

-continued

actgactcgc tgcgtcggt cggtcggtc cggcgagcgg tatcagctca ctcaaaggcg	5100
gtataacggt tatccacaga atcagggat aacgcaggaa agaacatgtg agcaaaaggc	5160
cagcaaaagg ccaggaaccg taaaaggcc gegtgtctgg cgttttcca taggtccgc	5220
ccccctgacg agcatcacaa aaatcgacgc tcaagtca ggtggcggaaa cccgacagga	5280
ctataaagat accaggcggt tccccctgga agtcccctcg tgcgtctcc tgttcgacc	5340
ctgccgtta ccggataacct gtccgcctt ctcccttcgg gaagcggtgc gctttctcat	5400
agctcacgct gtaggtatct cagttcggtg taggtcggtc gctccaagct gggctgtgtg	5460
cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtcc	5520
aacccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga	5580
gcgaggatgt taggcgggtc tacagagtcc ttgaagtggg ggcctaacta cggctacact	5640
agaaggacag tatttggat ctgcgtctg ctgaagccag ttaccttcgg aaaaagagtt	5700
ggtagctctt gatccggcaa acaaaccacc gctggtagcg gtggttttt tgtttgcag	5760
cagcagatta cgcgcagaaaa aaaaggatct caagaagatc ctttgcgtt ttctacgggg	5820
tctgacgctc agtggAACGA aaactcacgt taaggattt tggtcatgag attatcaaaa	5880
aggatcttca cctagatcct tttaaattaa aaatgaagtt tttaatcaat cttaagtata	5940
atgagtaaa cttggctctga cagttacaa tgcttaatca gtgaggcacc tatctcagcg	6000
atctgtctat ttcggtcatc catagttgc tgactcccg tcgtgtagat aactacgata	6060
cgggaggggct taccatctgg ccccaagtgc gcaatgatac cgcgcagaccc acgctcaccc	6120
gtcccaaggatt tatcagcaat aaaccagcca gccggaaaggc cgcgcgcag aagtggctct	6180
gcaactttat ccgcctccat ccagtctatt aattgttgcc gggaaagctag agtaagttagt	6240
tcgcccgtta atagttgcg caacgttgc gcaattgtca caggcatcgt ggtgtcacgc	6300
tcgtcggtt gtagggcttc attcagctcc gggtcccaac gatcaaggcg agttacatga	6360
tcccccattgt tggcaaaaa agcggttgc tccttcggc ctccgtatgt tggcaagtt	6420
aagttggccg cagtgttac actcatggtt atggcagcac tgcataattc tcttactgtc	6480
atgcgcattccg taagatgc ttctgtgact ggtgagttact caaccaagtc attctgagaa	6540
tagtgtatgc ggcgcaccgc ttgtcttgc cccgcgtcaa tacggataa taccgcgc	6600
catagcagaa ctttaaaagt gctcatcatt gggaaacgtt ctccggggcg aaaaactctca	6660
aggatcttac cgctgttgcg atccagttcg atgtaaacca ctgcgtgcacc caactgatct	6720
tcagcatctt ttactttcac cagcggttctt gggtgagcaaa aaacaggaa gcaaaatgcc	6780
gaaaaaaagg gaataagggc gacacggaaa tggtaatac tcataactctt ctttttcaa	6840
tattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt	6900
tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc	6960
taagaaacca ttattatcat gacattaacc tataaaaata ggcgtatcac gaggccttt	7020
cgtcgcgc gtttgggtga tgacgggtaa aacctctgac acatgcagct cccggagacg	7080
gtcacagctt gtctgtaa ggtgcccggg agcagacaag cccgtcaggc cggtgcacgc	7140
ggtgttggcg ggtgtcgggg ctggcttaac tatgcggcat cagagcagat tggactgaga	7200
gtgcaccata tgcgggtgtga aataccgcac agatgcgtaa ggagaaaata cgcgcattc	7260
cgccattcgc catcaggct ggcgcactgt tggaaaggcc gatcggtgcg ggccttcc	7320
ctattacgcc agctggcgaa agggggatgt gctgcaaggc gattaagttt ggttaacgc	7380
gggtttcccg agtcacgcacg ttgtaaaacg acggcgcaag gaagcagccc agtagtaggt	7440

-continued

tgaggccgtt gaggcaccggcc	gcccgaagga atggtgtcatg	caaggagatg	gcgcggcaaca	7500		
gtccccccggc	cacggggccct	gccaccatac	ccacgcccga	acaaggcgctc	7560	
agtggcgagc	ccgatttcc	ccatcggtga	tgtcgccgat	ataggcgcca	gcaaccgcac	7620
ctgtggcgcc	ggtgtatggcg	gccacgatgc	gtccggcgta	gaggcgattt	gtccaatttg	7680
ttaaagacag	gatatcgt	gtccaggctc	tagtttgac	tcaacaatat	caccagctga	7740
agcctataga	gtacgagcca	tagataaaat	aaaagatttt	attttagtctc	cagaaaaagg	7800
ggggaa						7806

<210> SEQ ID NO 25
<211> LENGTH: 7766
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: MSCV FLIPi Puro2AGFP / Thy1.1-miR-p53

<400> SEQUENCE: 25						
tgaaagaccc	cacctgttagg	tttggcaagc	tagcttaagt	aacgcattt	tgcaaggcat	60
ggaaaataca	taactgagaa	tagagaagtt	cagatcaagg	ttaggaacag	agagacagca	120
gaatatgggc	caaacaggat	atctgtggta	agcagttcct	gccccggctc	agggccaaga	180
acagatggtc	cccagatgcg	gtcccgccct	cagcagtttc	tagagaacca	tcagatgttt	240
ccagggtgcc	ccaaggacct	gaaaatgacc	ctgtgcctta	tttgaactaa	ccaatcagtt	300
cgcttctcgc	ttctgttcgc	gcgtttctgc	tccccgagct	caataaaaga	gccccacaacc	360
cctcaactcg	cgcgecagtc	ctccgataga	ctgcgtcgcc	cggttacccg	tattccaaat	420
aaagcctctt	gctgtttgca	tccgaatcgt	ggactcgctg	atccttggga	gggtctctc	480
agattgattt	actgeccacc	tcgggggtct	ttcatttggaa	ggttccacccg	agatttggag	540
acccctgcct	agggaccacc	gaccccccgg	ccgggaggta	agctggccag	cggtegttcc	600
gtgtctgtct	ctgtctttgt	gcgtgtttgt	gccccatct	aatgtttgcg	cctgtgtctg	660
tactagttag	ctaactagct	ctgttatctgg	cggaccccg	gtggaaactga	cgagttctga	720
acacccggcc	gcaaccctgg	gagacgtccc	agggactttt	ggggccggtt	ttgtggcccg	780
acctgaggaa	gggagtcgt	gtggaaatcg	accccgtag	gatatgtgg	tctggtagga	840
gacgagaacc	taaaacagtt	cccgccctcg	tctgaatttt	tgctttcggt	ttggaaccga	900
agccgcgcgt	cttgcgtct	gcacgcgtgc	agcatcgttc	tgtgttgc	ctgtctgact	960
gtgtttctgt	atttgtctga	aaatttaggc	cagactgtta	ccactccctt	aagtttgcacc	1020
ttaggtcact	ggaaagatgt	cgagcggtac	gctcacaacc	agtccgttgc	tgtcaagaag	1080
agacgttggg	ttaccttctg	ctctgcagaa	tggccaaacct	ttaacgttgc	atggccgcga	1140
gacggcacct	ttaaccgaga	cctcatcacc	caggttaaga	tcaaggctt	ttcacctggc	1200
ccgcatggac	acccagacca	ggtccctac	atcgtgaccc	gggaaggctt	ggctttgac	1260
ccccctccct	gggtcaagcc	ctttgtacac	cctaagcctc	cgccctctct	tcctccatcc	1320
cccccgcttc	tcccccttga	acccctctgt	tcgaccccg	ctcgatcc	cctttatcca	1380
ccccctactc	cttctcttagg	cgccggatt	agatccataa	cttcgtatag	gataccttat	1440
acgaagttat	ctcaggttacc	gccaccatgg	tggagtacaa	gccccacggtg	cgcctcgcca	1500
ccccgcacga	cgtccccagg	gccgtacgc	ccctcgccgc	cgcgttgc	gactaccccg	1560
ccacgcgcacca	caccgtcgat	ccggaccggcc	acatcgagcg	ggtcacccgag	ctgcaagaac	1620

-continued

ttttccac	gcgcgtcgaa	ctcgacatcg	gcaagggtgt	ggtcgggac	gacggcggcg	1680
cggtggcggt	ctggaccacg	ccggagagcg	tgcgaagggg	ggcggtgtc	gccgagatcg	1740
gcccgegcat	ggccgagttg	agcggttccc	ggctggccgc	gcagcaacag	atgaaaggcc	1800
tcttggcgcc	gcacccggcc	aaggagcccg	cgtggttccc	ggccaccgtc	ggcgtctcgc	1860
cgcaccacca	gggcacagggt	ctgggcacgcg	ccgtcggtct	ccccggagtg	gaggcggccg	1920
agcgccgcgg	ggtgcggcc	ttcctggaga	cctccgegac	ccgcaaccctc	cccttctacg	1980
agcggtctgg	tttcaccgtc	accggccacg	tcgagggtgcc	cgaaggacccg	cgcacctgg	2040
gcatgacccg	caagcccggt	gccaacacaga	aaattgtggc	accagtggaa	cagacttta	2100
attttgcacct	tctcaagttg	gccccggagacg	tcgagttccaa	ccctggggcc	ggccgggtcg	2160
ccaccatgg	gagcaacggc	gaggagctgt	tcaccgggg	ggtgcccatc	ctggcgagc	2220
tggacggcga	cgtaaacggc	cacaagttca	cggtgtccgg	cgagggcgag	ggcgatgcca	2280
cctacggcaa	gctgaccctg	aagttcatct	gcaccaccgg	caagctgccc	gtgcctggc	2340
ccaccctcg	gaccaccctg	acctacggcg	tcgactgtct	cagccgtcac	cccgaccaca	2400
tgaagcagca	cgacttcttc	aagtccgcca	tgccccgaa	ctacgtccag	gagcgcacca	2460
tcttcttcaa	ggacgacggc	aactacaaga	ccccgcggca	ggtgaagtcc	gagggcgaca	2520
ccctggtaa	ccgcatcgag	ctgaaggcga	tcgacttcaa	ggaggacggc	aacatctgg	2580
ggcacaagct	ggagtacaac	tacaacagcc	acaacgtcta	tatcatggcc	gacaagcaga	2640
agaacggcat	caaggtaaac	ttcaagatcc	gccacaacat	cgaggacggc	agcgtgcagc	2700
tcgcccacca	ctaccagcag	aacaccccca	tcggcgtacgg	ccccgtgtcg	ctgcccgaca	2760
accactaccc	gagcacccag	tccgcccgt	gcaaagaccc	caacgagaag	cgcgatcaca	2820
tggtcctgt	ggagttcgt	accggccggc	ggatcactct	cgccatggac	gagctgtaca	2880
agtagtctag	aagccataac	ttcgtatagt	acacattata	cgaagtttat	gcataacctgg	2940
agaaaaaaa	aaaggggaga	gtcaggggtt	taaacgcatt	agtcttccaa	ttgaaaaaag	3000
tgattnatt	tataccattt	taattcagct	ttgtaaaaat	gtatcaaaga	gatagcaagg	3060
tattcagttt	tagtaaacaa	gataattgt	cctaaagtag	ccccttgaat	tccgaggcag	3120
taggcatcca	otacaagttac	atgtgtata	catctgtggc	ttcaactatta	cacatgtact	3180
tgtatgggc	gctcaactgtc	aacagcaata	taccttctcg	agccttctgt	tgggttaacc	3240
tgaagaagta	atcccagcaa	gtgtttccaa	gatgtgcagg	caacgattct	gtaaagtact	3300
gaagcctcat	tcaaacatag	tatatgtgt	gccgaagcga	gcacttaaca	aggcttgccg	3360
ccgcccactc	acctgcaatt	ggggcgctea	cagagaaatg	aagtccaggg	cttggaggag	3420
ggagagggaa	agcagcagca	gcagcatcca	ggatgtgttc	tgaaccagca	ggcttattgcc	3480
gccccacttgc	accagttgt	ctctatacac	actgataactt	ttattggagc	tcatggatt	3540
cgccccccatc	actcgaagct	cacaaaagta	gtcgccctca	tcttgggtt	tgaagtttgc	3600
tagggtaagg	accttgat	agggtgtt	ggagaggggt	acgcgggagc	ggtaagtgt	3660
ctcggttatac	ccgagggtgc	ctgagagcac	gtgtttcttc	ttctctcggt	tcaggctgaa	3720
ctcatgttgtt	atggagttat	ccttgggtt	attctcatgg	cggcagtcc	ggcgaagg	3780
ttggtttacc	aggcaggctg	tcaggctgtt	caccttctgc	cctcggtaca	cctgcaagac	3840
tgagagcagg	agagegacgc	tgtatggctgg	gttcatgggt	gogacggta	taacttcgt	3900
taaggtatcc	tatacgaagt	tatccattca	ggctgtgtca	gcatcaatgg	catggcacaa	3960
agcttagcca	taacttcgt	taatgtgtac	tatacgaagt	tatccgggt	taaacgcact	4020

gcagccaagc ttatcgataa aataaaagat tttatTTTGT ctccagaaaa aggggggaat 4080
 gaaaAGACCC acctgttagt ttggcaagct agcttaagta acgcCATTt gcaaggcatg 4140
 gaaaatacat aactgagaat agagaagtTC agatcaaggt taggaacaga gagacagcag 4200
 aatatgggcc aaacaggata tctgtggtaa gcagttcctg ccccggtca gggcaagaa 4260
 cagatggtcc ccagatgcgg tcccgcctc agcagTTTCT agagaaccat cagatgttc 4320
 cagggtGCC caaggacCTG aaaatgacCC tGTGCCTTAT ttGAactAAC caATCAGTTC 4380
 gtttctcgct tctgttcgcg cgTTTCTGCT ccccgagCTC aataaaAGAG CCCACAACCC 4440
 cTCactCGGC GCGCCAGTCC TCCGATAGAC TGCGTCGCC GGGTACCCGT GTATCCAATA 4500
 aacccttTG cAGTTGCAcC CGACTTGTGG TCTCGCTGTT CCTTGGGAGG GTCTCTCTG 4560
 agtgattgac taccCGTCAG CGGGGGTCTT TCTGGGtaa CAGTTTCTG AAGTTGGAGA 4620
 acaacattCT gagggtAGGA GTCGAATATT AAGTAATCCT GACTCAATTa GCCACTGTT 4680
 tGAATCCACA TACTCCAATA CTCCtGAAAT AGTTCAATTa GGACAGCGCA GAAGAGCTGG 4740
 ggagaattaa ttCGTAATCA TGGTCATAGC TGTTCCTGT GTGAAATTGT TATCCGCTCA 4800
 caattCCACA CAACATACGA GCGGAAgCA TAAAGTGTAA AGCCTGGGGT GCCTAATGAG 4860
 tgAGCTAAct CACATTAATT GCGTTGCGCT CACTGCCGc TTCCAGTCG GGAAACCTGT 4920
 CGTGCCAGCT GCTTAATGA ATCGGCCAAC GCGGGGGAG AGGCGGTTG CGTATTGGC 4980
 GCTCTTCCGC TTCCtCGCTC ACTGACTCGC TGCGCTCGGT CGTCCGGCTG CGGCGAGCGG 5040
 tatcAGCTCA CTCAAAGGCg GtaatacCGT TATCCACAGA ATCAGGGGAT AACGcAGGAA 5100
 agAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG 5160
 CGTTTtCCCA TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAAGA 5220
 ggtggcggAAA CCCGACAGGA CtataAAAGAT ACCAGGEGTT TCCCCCTGGA AGCTCCCTG 5280
 TGCGCTCTCC TGTTCGACC CTGCGCTTA CGGATAACCT GTCCGECTT CTCCCTCGG 5340
 gaAGCGTGGC GCTTCTCAT AGTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCTTC 5400
 GCTCCAAGCT GGGCTGTGTG CACGAACCC CGTTCAGCC CGACCGCTGC GCCTTATCCG 5460
 GtaACTATCG TCTTGAGTCC AACCCGGtaa GACACGACTT ATCGCCACTG GCAGCAGCCA 5520
 CTGGTAACAG GATTAGCAGA GCGAGGATG TAGGCGGTG TACAGAGTTC TTGAAGTGGT 5580
 GGCCTAACTA CGGCTACACT AGAAGGACAG TATTGgtAT CTGCGCTCTG CTGAAGCAG 5640
 TTACCTTCGG AAAAAGAGTT GGTAGCTTT GATCCGGCAAA ACAAAACCAAC GCTGGTAGCG 5700
 GTGGTTTTT TGTtGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC 5760
 CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACtCACGT TAAGGGATT 5820
 TGGTCTAGAG ATTATCAAAA AGGATCTCA CCTAGATCTT TTAAATTAA AAATGAAGTT 5880
 TtAAATCAAT CTAAGATATA TATGAGTAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA 5940
 GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTCACTC CATAGTTGCC TGACTCCCCG 6000
 TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGT GCAATGATAc 6060
 CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCGAGCCA GCGGGAAGGG 6120
 CGAGCGCAG AAGTGGTCTT GCAACTTTAT CCGCCTCCAT CGAGTCTATT ATTGTTGCC 6180
 GGGAAAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTGCG CAACGTTGTT GCCATTGCTA 6240
 CAGGCACTCGT GGTGTCACGC TCGTCGTTG GTATGGCTTC ATTCACTCC GGTCCCCAAC 6300
 GATCAAGGCg AGTTACATGA TCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCCTCGGTc 6360

-continued

ctccgatcgt tgcagaagt aagttggcg cagtgttatac actcatggtt atggcagcac	6420
tgcataattc tcttactgtc atgecatccg taagatgctt ttctgtgact ggtgagta	6480
caaccaagtc attctgagaa tagtgtatgc ggccacccag ttgctttgc ccggcgtaa	6540
tacgggataa taccgcgcca cataggcaga cttaaaagt gtcatcatt ggaaaacgtt	6600
cttcggggcg aaaactctca aggatcttac cgctgtttag atccagttcg atgtaaccca	6660
ctcgtgcacc caactgatct tcagcatctt ttactttc acgcgtttct gggtgagcaa	6720
aaacaggaag gcaaaatgcc gcaaaaaagg gaataaggc gacacggaaa tggtgaatac	6780
tcatactctt ccttttcaa tattattgaa gcatttatca gggttattgt ctcatgagcg	6840
gatacatatt tgaatgtatt tagaaaaata aacaaatagg ggttccgcgc acatttcccc	6900
aaaaagtgcc acctgacgac taagaaacca ttattatcat gacattaacc tataaaaata	6960
ggcgtatcac gagggccctt cgttcgcgc gttcggtga tgacggtaaa aacctctgac	7020
acatgcagct cccggagacg gtcacagctt gtctgtaaacg ggatgcgggg agcagacaag	7080
cccggtcaggg cgcgtcagcg ggtgttggcg ggtgtcgggg ctggcttaac tatgcggcat	7140
cagagcagat tgcgtactgaga gtgcaccata tgccgtgtga aataccgcac agatgcgtaa	7200
ggagaaaata ccgcattcagg cgccatccgc cattcaggct ggcgcactgt tggtggcgc	7260
gatcggtgcg ggcctttcg ctattacgccc agctggcgaa agggggatgt gctgcaaggc	7320
gattaaatgg ggttaacgc gggtttccc agtcacgc gttgtaaaacg acggcgcaag	7380
gaagcagccc agtagtaggt tgaggccgtt gagcaccgc gccgcgaaggaa atggtgcatg	7440
caaggagatg ggcgcacaca gtcggccgc cacggggcct gccaccatac ccacgcgaa	7500
acaaggcgtc atgagcccga agtggcgacg ccgatcttcc ccatcggtga tgtcgccgt	7560
ataggcgcca gcaaccgcac ctgtggcgcc ggtgatgcgc gccacgcgc gtcggcgta	7620
gaggcgattt gtcccaattt gtaaagacag gatatcgtt gtccaggctc tagtttgac	7680
tcaacaatat caccagctga agcctataga gtacgagcca tagataaaat aaaagatttt	7740
atttagtctc cagaaaaagg ggggaa	7766

<210> SEQ ID NO 26
 <211> LENGTH: 7766
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: MSCV FLIPi Puro2AGFP / Thy1.1-miR-PTEN

<400> SEQUENCE: 26

tgaaagaccc cacctgttagg tttggcaagc tagcttaagt aacgcattt tgcaaggcat	60
ggaaaaataca taactgagaa tagagaagtt cagatcaagg ttaggaacag agagacagca	120
gaatatgggc caaacaggat atctgtggta agcagttcctt gccccggcgc agggccaaga	180
acagatggtc cccagatgcg gtcggccctt cagcagtttca tagagaacca tcagatgttt	240
ccagggtgcc ccaaggacct gaaaatgacc ctgtgcctt tttgaactaa ccaatcagtt	300
cgcttcgcg ttctgttcgc gcgcttcgc tccccgagctt caataaaaga gcccacaacc	360
cctcactcgcc cgcgcaggc tcggataga ctgcgtcgcc cgggtacccg tattccaat	420
aaaggcctt gctgtttgca tccgaatcgt ggactcgctg atccttggga gggtctcctc	480
agattgttttgc actgeccacc tcgggggtctt tcattttggaa ggttccaccc agattttggag	540
accctgcctt agggaccacc gaccccccgg ccgggaggtt agctggccag cggtegttcc	600
gtgtctgtct ctgtctttgtt gctgtttgtt gccggcatctt aatgtttggcg cctgcgtctg	660

tactagttag ctaactagct ctgttatctgg cgAACCCGTG gtggaaactga cgagttctga 720
 acacccggcc gcaaccctgg gagacgtccc agggacttgc gggggccgttt ttgtggcccg 780
 acctgaggaa gggagtcgtat gtggaatccg accccgtcag gatatgttgt tctggtagga 840
 gacgagaacc taaaacagtt cccgcctccg tctgaatttt tgctttcggt ttggaaaccga 900
 agcccgccgtt cttgtctgtc gcagcgctgc agcatcgttc tgtgttgtct ctgtctgact 960
 gtgtttctgtt atttgcgtat aaatttagggc cagactgtta ccactccctt aagtttgacc 1020
 ttaggtcaact ggaaagatgt cgagcggtac gtcacaacc agtcggtaga tgtcaagaag 1080
 agacgttggg ttaccttctg ctctgcgaa tggccaaacct ttaacgtcgg atggccggcga 1140
 gacggcacct ttaaccgaga cctcatcacc caggttaaga tcaaggctt ttcacctggc 1200
 cccgcattggac acccagacca ggtccccctac atcgtgaccc gggaaagccctt ggctttgac 1260
 cccctccctt gggtaagcc ctttgcacac cctaaggccctc cgcctccctt tcctccatcc 1320
 gccccgtctc tcccccttga acctccctgtc tgcaccccgcc ctcgatccctc cctttatcca 1380
 gcccctcaatc ottctcttagg cgccggaaatt agatccataa cttcgtatag gataccctt 1440
 acgaagttat otcaggttacc gccaccatgg tggagtacaa gcccacgggtc cgccctcgcca 1500
 cccgcgacga cgtccccagg gccgtacgca cccctcgccgc cgcgttgcgc gactaccccg 1560
 ccacggegccca caccgtcgat ccggaccggcc acatcgagcc ggtcaccggag ctgcaagaac 1620
 ttttcctcac ggcgcgtcggg ctcgacatcg gcaagggtgtt ggtcggggac gacggcccg 1680
 cgggtggcggtt ctggaccacg ccggagagcg tgcgggggggg ggcgggtgtc gccggatcg 1740
 gcccgegcat ggccgagttt agcgggttccc ggctggccgc gcaagcaacag atggaaaggcc 1800
 tcctggccgc gCACCGGCC aaggagcccg cgtgggttccc ggccaccggc ggcgtctcg 1860
 cccgaccacca gggcaagggtt ctgggcageg cgcgtgtgtt cccggagtg gagggggccg 1920
 agcgcgcggg ggtgeccggcc ttccctggaga cccctcgccgc cgcacaaccctc cccttctacg 1980
 agcggctcggtt ttccaccgtc accggccgacg tgcgggtgtc cgaaggacccg cgcacccgtt 2040
 gcatgaccggc caagcccggtt gccaaacaga aaattgtggc accagtgtaaa cagactttga 2100
 attttgcacct ttcgtatgtt gcccggggacg tgcgttccaa ccctggggccc ggccgggtcg 2160
 ccaccatggt ggcggccggc gaggagctgt tccaccgggtt ggtgccecatc ctggcgtggc 2220
 tggacggcga cgtaaacggc cacaagttca ggtgtccgg cgagggccgag ggcgtatgcca 2280
 cctacggcaa gtcgtaccctg aagttcatctt gcaaccggccg caagctgccc gtggccctggc 2340
 ccaccctcggtt gaccaccctg acctacggcg tgcgtgtttt cagccgttac cccgaccacca 2400
 tgaagcagca cgacttcttc aagtccggca tggccggaaatg ctacgtccag gagcgcacca 2460
 ttttcttcaa ggacgacggc aactacaaga cccggccggc ggtgaagtgc gaggccgaca 2520
 ccctgggtt ggcgtatcgag ctggggggca tgcgttccaa ggaggacggc aacatccctgg 2580
 ggcacaagctt ggagtacaac tacaacagcc acaacgtcta tatcatggcc gacaaggcaga 2640
 agaacggcat caaggtgaac ttcaagatcc gccaacacat cgaggacggc agcgtgcagc 2700
 tgcggccatc ctaccatcgag aacacccca tccggccggc ccccggtgtt ctggcccgaca 2760
 accactacccat gaggccctgtt gcaaaagccca caacgagaag cgccgtatcaca 2820
 tgggtctgtt ggagtccgtt accggccggccg ggatcactctt cggcatggac gagctgtaca 2880
 agtagtcttag aaggccataac ttgttatgtt acacattata cgaaggtttat gcatactgg 2940
 agggaaaaaaa aaagggggaga gtcagggtt taaacgcattt agtcttccaa ttggaaaaaaag 3000

-continued

tgatttaatt tataccattt taattcagct ttgtaaaaat gatatcaaaga gatagcaagg	3060
tattcagttt tagtaaacaa gataattgct cctaaatggtag ccccttgaat tccggaggcag	3120
taggc当地 gaaactatac tttacaata catctgtggc ttcactatatt gt当地gtata	3180
gtttcacccg gctcactgtc aacagcaata taccttctcg agccttctgt tgggtaacc	3240
tgaagaagta atcccagcaa gtgttccaa gatgtcagg caacgattct gt当地gtact	3300
gaaggcctcat tcaaacatag tatatgtgtc gccaagcga gcacttaaca aggcttgcgg	3360
ccgccccactc acctgcaatt gggccgc当地ca cagagaaatg aagtccaggc ct当地ggaggag	3420
ggagagggaa agcagcagca gcagcatcca ggatgtgttc tgaaccagca ggcttatgcc	3480
gccacacttgc accagttgt ctctatacac actgatactt ttattggagc tcatggatt	3540
c当地gccccggactcgaagct cacaaaagta gtc当地ccctca tc当地ttgggg tgaagttggc	3600
tagggtaagg accttgatat agggctgggtt ggagaggggtg acgc当地ggagc ggtacgtgt	3660
ctc当地gggtatc cc当地gggggtgc ct当地gagcac gtc当地tccctc ttctctc当地ggg tcaggctgaa	3720
ctcatgctgg atggagttat ccttgggtttt attctcatgg cggcagtc当地a ggc当地aggtt	3780
ttgggtaacc aggc当地ggctg tc当地ggctggt caccttctgc cctc当地gggaca cctgcaagac	3840
t当地gagcagg agagc当地acgc tgatggctgg gttcatgggt gcgaccggta taacttc当地ta	3900
taaggtaacc tatacgaagt tatccattca ggctgtgctca gcatcaatgg catggcaca	3960
agcttagcca taacttc当地ta taatgtgtac tatacgaagt tatccgggt taaacgac	4020
gc当地gcaaggc ttatcgataa aataaaagat ttatatttagt ctccagaaaa aggggggaat	4080
gaaagagcccc acctgttagt ttggcaagct agcttaagta acgc当地atttt gcaaggc	4140
gaaaatacat aactgagaat agagaagttc agatcaagg taggaacaga gagacagcag	4200
aatatgggcc aaacaggata tctgtggtaa gcaaggcttc当地ccc当地ggctca gggccaa	4260
c当地atggtcc cc当地atgc当地gg tccccc当地tca agc当地ttt agagaaccat cagatgttc	4320
cagggtgccc caaggacctg aaaatgaccc tgc当地ctt当地ttt ttaactaaccatc当地atgttc	4380
gcttctc当地tctgtcg cgcttctgtc ccccgagctc aataaaagag cccacaaccc	4440
ctc当地actggc ggc当地cagtc当地cc tccgatagac tgc当地tgc当地cc gggtacccgt gatccaa	4500
aacccttcttgc当地tctgtcg tgc当地tgc当地cc gggtacccgt gatccaa	4560
agtgattgac taccctgtc当地cc cgggggtt当地ttt tcatggtaa cagtttctgt aagttggaga	4620
acaacattct gagggttagga gtc当地aatatt aagtaatcct gactcaatta gccactgtt	4680
tgaatccaca tactccataa ctc当地tgc当地aa agttc当地ttaatggacagc当地ca gaagagctgg	4740
ggagaattaa ttgc当地atca tggc当地atgc tgc当地tgc当地cc gggtacccgt gatccaa	4800
caattccaca caacatacga gccc当地aa gca taaatgttaa agc当地tggggt gcttaatgag	4860
tgagctaact cacattaatt gcttgc当地gtc cactgccc当地tcc tttccagtc当地gg ggaaacccgt	4920
cgtgccc当地gtc gcattaatga atcggccaaac ggc当地ggggag aggccgggtt当地tcc gcttgc当地gg	4980
gcttccgc当地tcc tccctgc当地tcc actgactgc当地tcc tgc当地tgc当地cc cgccgagc当地gg	5040
tatcagctca ct当地aaaggcg gtaatacgc当地tcc tatccacaga atcaggggat aacgc当地aggaa	5100
agaacatgtg agcaaaaaggc cagcaaaaagg ccaggaaccg taaaaggcc gcttgc当地gg	5160
cgttttccca taggctccgc cccctgacg agcatcaca aaatgc当地acgc tcaagtc当地ga	5220
gggtggggaaa cccgacagga ct当地aaagat accaggcgtt tccctgtga agctccctcg	5280
tgc当地cttcc tgc当地tgc当地cc ct当地ggccctt cc当地gatacc tgc当地tgc当地cc	5340
gaagcgtggc gcttctcat agtc当地acgc当地tcc tgc当地tgc当地cc taggtatct cagttc当地gggtg taggtatcc	5400

-continued

gctccaagct gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg	5460
gttaactatcg tctttagtcc aacccggtaa gacacgactt atcgccactg gcagcaggca	5520
ctggtaacag gattagcaga gcgaggtatg taggcggtgtc tacagagttc ttgaagtgg	5580
ggcctaacta cggctacact agaaggacag tattttggat ctgcgcctcg ctgaagccag	5640
ttaccttcgg aaaaagagtt ggttagcttt gatccggcaa acaaaccacc gctggtagcg	5700
gtgggtttttt tgtttgcag cagcagatta cgcgcagaaaa aaaaggatct caagaagatc	5760
ctttgtatctt ttctacgggg tctgacgctc agtggaaacga aaactcacgt taagggattt	5820
tggcatgag attatcaaaa aggatcttca cctagatctt tttaaattaa aatgaagtt	5880
ttaaatcaat ctaaagtata tatgagtaaa ctggctctga cagttaccaa tgcttaatca	5940
gtgaggcacc tatctcagcg atctgtctat ttctgttcattt catatgtgcc tgactccccg	6000
tctgttagat aactacgata cggggagggtc taccatctgg ccccaagtgc gcaatgatac	6060
cgcgcagaccc acgctcaccg gctccagatt tattcagcaat aaaccagccca gccggaaagg	6120
ccgagcgcag aagtggtcct gcaactttat ccgcctccat ccagtctatt aattgttgcc	6180
gggaagtag agtaagtagt tcgcagtttta atagtttgcc caacgtgtt gccattgtta	6240
caggcatcgt ggtgtcacgc tcgtcggtt gtatggcttc attcagotcc ggttccaaac	6300
gatcaaggcg agttacatga tccccatgt tgtgcaaaaa agcgggttagc tccttcggtc	6360
ctccgatcgt tgtcagaagt aagttggccg cagtgttattt actcatggtt atggcagcac	6420
tgcataattc tcttactgtc atgcatttcg taagatgtt ttctgtgact ggtgagttact	6480
caaccaagtc attctgagaa tagtgtatgc ggccgcggag ttgtcttcg ccggcgtaa	6540
tacgggataa taccgcgcata catagcagaa cttaaaatgt gtcatcatt ggaaaacgtt	6600
cttcggggcg aaaactctca aggatcttac cgctgtttagt atccagttcg atgtaccca	6660
ctcgtgcacc caactgatct tcagcatctt ttactttcattt cagcgtttctt gggtgagcaa	6720
aaacaggaag gcaaaaatgcc gcaaaaaagg gaataaggcc gacacggaaa ttttgaaatac	6780
tcatactctt ctttttcaa tattattgaa gcatttatca gggttattgt ctcatgagcg	6840
gatacatatt tgaatgtatt tagaaaaata aacaaatagg ggttccgcgc acatttcccc	6900
ggaaaagtgc acctgacgatc taagaaacca ttattatcat gacattaacc tataaaaata	6960
ggcgtatcac gagggccctt cgttcgcgc gtttcgggtga tgacgggtaa aacctctgac	7020
acatgcgact cccggagacg gtcacagttt gtctgtaaagc ggtatgcggg agcagacaag	7080
cccggtcaggc cgccgtcagcg ggtgttggcg ggtgtcggtt ctggcttaac tatgcggcat	7140
cagagcagat tgtaactgaga gtgcaccata tgccgtgtga aataccgcac agatgcgtaa	7200
ggagaaaata ccgcattcagg ccgcatttcgc cattcaggctt ggcgcactgtt tgggaaggc	7260
gatcggcgcc ggccttcgc ctattacgca agctggcgaa agggggatgt gctgcaggc	7320
gattaaatgg ggttaacgc gggtttccc agtcacgc gttttaaacg acggcgcaag	7380
gaagcagccc agtagtaggt tgaggccgtt gagcaccgc ggcgcaggaa atggcgtatg	7440
caaggagatg ggcggccaa gtcggccgc acggggccctt ggcaccatc ccacgcggaa	7500
acaaggcgtc atgagcccgatg agtggcgaccc ccgtatctcc ccattcggtga tgccggcgat	7560
ataggcgccca gcaacccgac ctgtggcgcc ggtgtcgcc gccacgatgc gtccggcgta	7620
gaggcgattt gtcacatgg ttaaagacag gatatcgatg gtccaggcgc tagtttgac	7680
tcaacaatat caccagctga agcctataga gtacgagccca tagataaaat aaaagattt	7740

-continued

attttagtctc cagaaaaagg ggggaa	7766
<210> SEQ ID NO 27	
<211> LENGTH: 8157	
<212> TYPE: DNA	
<213> ORGANISM: Artificial	
<220> FEATURE:	
<223> OTHER INFORMATION: MSCV FLIPi Puro2AGFP / Thy1.1-miR-Dbl p53 & PTEN	
<400> SEQUENCE: 27	
tgaaaagaccc cacctgttagg tttggcaagg tagcttaagt aacgcattt tgcaaggcat	60
ggaaaataaca taactgagaa tagagaagtt cagatcaagg ttaggaacag agagacagca	120
gaatatgggc caaacaggat atctgtggta agcagttctt gccccggctc agggccaaga	180
acagatggtc occagatgcg gtcccgccct cagcagtttc tagagaacca tcagatgttt	240
ccagggtgcc ccaaggacct gaaaatgacc ctgtgcctt tttgaactaa ccaatcagtt	300
cgtttctcgc ttctgttcgc gcgcttcgc tccccgagct caataaaaga gcccacaacc	360
cctcaactcggtt cgcgcagtc ctccgataga ctgcgtcgcc cgggtacccg tattccaaat	420
aaaggctctt gctgtttgca tccgaatcggtt ggactcgctt atccttggga gggcttcctc	480
agattgattt actgccccacc tcgggggtt ttcatttggaa ggttccacccg agatttggag	540
acccctgcctt agggaccacc gaccccccgg cccggaggtt agctggccag cggctcggtt	600
gtgtctgtctt ctgtttttgtt gctgtttgtt gccggcatctt aatgtttggcg cctgegtctg	660
tactagttt ctaacttagct ctgtatctgg cggacccgtt gtggaaactga cgagttctga	720
acacccggcc gcaaccctgg gagacgtccc agggactttt gggcccggtt ttgtggcccg	780
acctgaggaa gggagtcgtt gtggaaatccg accccgtcaagatgttgcgtt tctggtagga	840
gacgagaacc taaaacagtt cccgcctcgg tctgaatttt tgcttcgggtt ttggAACCGA	900
agccgcgcgtt ctgtctgtt gcagcgcttc acatcggtt tgcgttgcgtt ctgtctgtt	960
gtgtttctgtt atttgtctga aaattagggtt cagactgtttt ccactccctt aagtttggacc	1020
tttaggtcaactt ggaaagatgtt cgagcggtt gctcacaacc agtcggtaga tgtcaagaag	1080
agacgttggg ttacccctgtt ctctgcggaa tggccaaacctt ttaacgtcggtt atggccgcga	1140
gacggcacctt ttaaccgaga cctcatcacc caggttaga tcaagggtttt ttcaectggc	1200
ccgcatggac acccagacca ggtcccccac atcgtgacccctt gggaaacccctt ggctttgac	1260
ccccctccctt gggtaagcc ctttgcacccctt cctaaggccctt cgcctccctt tcctccatcc	1320
ccccctccctt tcccccgtt acctccctgtt tcgaccccgcc ctcgatccctt cctttatcca	1380
gccctcaactt cttctctagg ccggcgttattt agatccataa cttcgtatag gataccttat	1440
acgaaggatattt ctccaggatcc gcccacccatgg tggagttttt gcccacccgtt cgcctcgcca	1500
cccgccgacgca ctttcccgagg gccgtacgca ccctcgcccg cgcgttccgc gactaccccg	1560
ccacgcgcaca caccgtcgat ccggaccgc acatcgagcg ggtcaccggag ctgcaagaac	1620
tcttcctcac ggcgcgttccgc ctcgacatcg gcaagggtttt ggtcggggac gacggcccg	1680
cggtgggggtt ctggaccacg ccggagagcg tcgaaggccgg ggcgggtttt gccggatcg	1740
gccccggccat gggccggatgg agccggatcc ggcggcccg gcaagcaacag atggaaaggcc	1800
tcctggccgc gcaaccggccc aaggagcccg ctttgcgttccctt gggccaccgtt ggcgttccgc	1860
ccgaccacca gggcaagggtt ctggccggcc ctcgttccgtt ccccgagggtt gaggccggcc	1920
agccgcgcggg ggtgeccgcctt ttccctggaga ctcggccgc cccgttccatcg	1980

-continued

agcgccgtcg cttcaccgtc accggccgacg tcgagggtgc cgaaggaccg cgcaccttgtt
gcgtgacccg caagccccgt gccaacacaga aaattgtggc accagtaaa cagactttga 2100
attttgacct tctcaagtgt gcgggagacg tcgagttcaa ccctggggcc ggcccccgtcg 2160
ccaccatggt gagcaagggc gaggagctgt tcaccgggggt ggtgcccatc ctggtcgagc 2220
tggacggcga cgtaaacgcg cacaagttca gcgtgtccgg cgagggcag ggcgtatgcca 2280
cctacggcaa gctgaccctg aagttcatct gcaccacccgaa cagactgccc gtgcctggc 2340
ccaccctcggt gaccaccctg acctacggcg tgcaagtgtt cagccgtac cccgaccaca 2400
tgaagcagca cgacttcttc aagtccgcca tgcccgagg ctacgtccag gagcgcacca 2460
tcttcttcaa ggacgacggc aactacaaga cccgcggcga ggtgaagttc gagggcgcaca 2520
ccctgggtgaa ccgcacatcgag ctgaaaggca tcgacttcaa ggaggacggc aacatcttgg 2580
ggcacaagct ggagtacaac tacaacagcc acaacgtcta tatcatggcc gacaagcaga 2640
agaacggcat caaggtgaac ttcaagatcc gccacaacat cgaggacggc agcgtgcagc 2700
tcgcccacca ctaccagcag aacacccca tcggcgacgg cccctgtgt ctgcccacca 2760
accactacccgt gaggccacccag tccgcctgaa gcaaagaccc caacgagaag cgccatcaca 2820
tggtcctgtt ggagttcggt accggccggc ggatcaactt cggcatggac gagctgtaca 2880
agtagtcttag aaggccataac ttctgtatagt acacattata cgaagtttat gcataacctgg 2940
aggaaaaaaa aaaggggaga gtcaggggtt taaacgcatt agtcttccaa ttgaaaaaaag 3000
tgatttaatt tataccattt taattcgat ttgtaaaaat gtatcaaaga gatagcaagg 3060
tattcagttt tagtaaacaa gataattgtt cctaaagttag cccctgtat tccgaggcag 3120
taggcaaggt gaaactatac ttacaaata catctgtggc ttcaactatTTt gtaaagtata 3180
gtttcacccgc gctcaactgtc aacagcaata tacottctcg agccttctgt tgggttaacc 3240
tgaagaagta atcccgacaa gtgtttccaa gatgtgcagg caacgattct gtaaagtact 3300
gaaggctcat tcaaacatag tatatgtgt gcegaagega gcaacttacca aggcttgcatt 3360
ttaaacgcatt tagtcttcca attgaaaaaa gtgatttaat ttataccatt ttaattcagc 3420
tttgtaaaaaa tgtatcaaag agatagcaag gtattcagtt ttagtaaaca agataattgc 3480
tcctaaagta gcccctgaa ttccgaggca gtaggcatcc actacaagta catgtgtat 3540
acatctgtgg cttcaactt acacatgtac ttgttagtggg cgctcaactgt caacacgaaat 3600
ataccccttc gaggccctcg ttgggttaac ctgaaagaagt aatcccgacca agtgtttccaa 3660
agatgtgcag gcaacgatcc tggtaaagtac tgaagccatca ttcaaaacata gtatatgtgc 3720
tgccgaagcg agcaacttac aaggcttgcg gcccggccact cacctgtcaat tggggcgctc 3780
acagagaaaat gaagtccagg gcttggagga gggagaggggaa aagcagcagc agcagcatcc 3840
aggatgtgtt ctgaaaccaggc aggctttagtgc cgccacactt gaccagtttgc tctctataca 3900
cactgtatact ttattggag ctcatggat tcgcggccga gactcgaacg tcacaaaagt 3960
agtcgccttc atccctgggtt gtgaagttgg ctagggtaag gaccttgata tagggctgg 4020
tggagaggggt gacgcggggag cggtacgtgt gctcggtat cccgagggtt cctgagagca 4080
cgtgcttcctt cttctctcggt gtcaggctga actcatgtg gatggagtttca tccctgggtgt 4140
tattctcatg gccccgtcc aggcaaggt ttgggttac caggcaggct gtcaggctgg 4200
tcacccctcggtt ccctcgggac acctgcaaga ctgagagcag gagagcgcacg ctgatggctg 4260
ggttcatgggtt ggcgaccggtaataacttcgtt ataaggatccatc ctatacgaag ttatccattc 4320
aggctgtgttgc agcatcaatg gcatggcaca aagcttagcc ataacttcgtt ataatgtgtt 4380

-continued

ctatacgaag ttatccggg ttcaaacgacc tgcagccaag cttatcgata aaataaaaga	4440
tttttatttag tctccagaaa aaggggggaa taaaaagccc cacctgttagg tttggcaagc	4500
tagcttaagt aacgccattt tgcaaggcat gaaaaataca taactgagaa tagagaagtt	4560
cagatcaagg ttaggaacag agagacagca gaatatggc caaacaggat atctgtggta	4620
agcagttcct gccccggctc agggccaaga acagatggtc cccagatgcg gtccgcct	4680
cagcagttc tagagaacca tcagatgtt ccagggtgcc ccaaggacct gaaaatgacc	4740
ctgtgccta tttgaactaa ccaatcagtt cgcttcgc ttctgttcgc gcgttgc	4800
tccccgagct caataaaaga gccccacaacc cctcactcg cgccgcagtc ctccgataga	4860
ctgcgtcgcc cgggtacccg tgtatccaat aaaccctttt gcagttgcat ccgacttgt	4920
gtctcgctgt tccttggag ggtctctct gagtatttgc ctacccgtca gcgggggtct	4980
ttcatgggta acagtttctt gaagttggag aacaacattt tgagggttagg agtcaaat	5040
taagtaatcc tgactcaatt agccactgtt ttgaatccat atactccat actcctgaaa	5100
tagttcatta tggacagcgc agaagagctg gggagaatta attcgtatc atggcata	5160
ctgttcoctg tgtgaaattt ttatccgctc acaattccac acaacatacg agccggaa	5220
ataaaagtgtt aagcctgggg tgcctaatgtt gtgagctaac tcacattaat tgcgtgc	5280
tcactgcggc cttccagtc gggaaacctg tctgtccagc tgcattatg aatccggca	5340
cgccggggga gaggggggtt gcgtatttggg cgcttcccg ctccctcgactgactcg	5400
ctgcgtcgcc tcgttccggct gccggcagcg gtatcagctc actcaaaggc ggtaatacgg	5460
ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg ccageaaaag	5520
gccaggaacc gtaaaaaggc cgcgttgctg gcgttttcc ataggctcg cccccctgac	5580
gagcatcaca aaaatcgacg ctcaagttagt aggtggcgaa acccgacagg actataaaga	5640
taccaggcgt ttccccctgg aagtcctcgtc gtgcgtctc ctgttccgac cctgcgc	5700
accggatacc tgcgtccctt tcccccctgg ggaagcgttg cgcttctca tagctcacgc	5760
tgttaggtatc tcagttcggt gttaggtcggt cgcttcaagc tggctgtgt gcacga	5820
cccggttcagc cgcaccgtg cgccttatacc ggtaactatc gtcttgatgc caaccggta	5880
agacaegact tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggat	5940
gtaggggggtg ctacagagtt cttgaagtgg tggcttaact acggctacac tagaaggaca	6000
gtatgggta tctgcgtct gctgaagcca gttaccttgc gaaaaagagt tggtagctct	6060
tgatccggca aacaaaccac cgctggtagc ggtggtttt ttgtttgcaa gcagcagatt	6120
acgcgcagaa aaaaaggatc tcaagaagat ccttgcgtt ttctacggg gtctgacgct	6180
cagtggaaacg aaaactcacg ttaagggtt tgggtcatga gattatcaa aaggatctc	6240
accttagatcc tttaaattt aaaaatgaagt tttaaatcaa tctaaagtat atatgat	6300
acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtct	6360
tttcgttcat ccatacggtc ctgactcccc gtcgttgcata taactacgtt acggagg	6420
tttaccatctg gccccagggtc tgcaatgata ccgcgagacc cacgctcacc ggctcc	6480
ttatcagcaa taaaccagcc agccggaaagg gcccggcga gaagtggtcc tgcaactt	6540
tccgcctcca tccagtcata taattgttgc cggaaagctt gagtaagttag ttcgc	6600
aatagttgc gcaacgttgc tgccattgtt acaggcatcg tgggtgcacg ctgcgtt	6660
ggtagggctt cattcaggtc cggttccaa cgtcaaggc gagttacatg atccccatg	6720

-continued

tttgtcaaaa aagcggttag ctccttcggt cctccgatcg ttgtcagaag taagttggcc	6780
gcagtgttat cactcatggt tatggcagca ctgcataatt ctcttactgt catgcacatcc	6840
gtaagatgct tttctgtgac tggtgagta tcaaccaagt cattctgaga atagtgtatg	6900
cggcgaccga gttgetcttg cccggcgtca atacgggata ataccgcgcc acatagcaga	6960
actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta	7020
cgcgtgtga gatccagttc gatgtaaacc actcgtgcac ccaactgatc ttcaagcatct	7080
tttactttca ccagegtttc tgggtgagca aaaacaggaa ggcaaaatgc cgaaaaaaag	7140
ggataaaggg cgacacggaa atgttgaata ctctactct tccttttca atattatgt	7200
agcatttatac agggttattt tctcatgagc ggatacatat ttgaatgtat tttagaaaaat	7260
aaacaaatag gggttccgcg cacatttccc cgaaaagtgc cacctgacgt ctaagaaacc	7320
attattatca tgacattaac ctataaaaat aggctatca cgagggccctt tcgtctcgcg	7380
cgttccggtg atgacgggtga aaacctctga cacatgcagc tcccgagac ggtcacagct	7440
tgtctgtaaag cggatgcccgg gaggcagacaa gcccgtcagg gcgcgtcagc ggggttggc	7500
gggtgtcggg gctggcttaa ctagcggca tcagagcaga ttgtactgag agtgcaccat	7560
atgcgggtgtg aaataccgca cagatgcgtaa aggagaaaat accgcattcag ggcgcattcg	7620
ccattcaggc tgcccaactg ttggaaaggg cgatcgggtgc gggctcttc gctattacgc	7680
cagctggcga aagggggatg tgctgcaagg cgattaagg gggtaacgcc agggtttcc	7740
cagtacgcgac gttgtaaaac gacggcgcaa ggaagcagcc cagtagtagg ttgaggccgt	7800
tgagcaccgc cgccgcaagg aatggtgcat gcaaggagat ggcgcacaac agtcccccg	7860
ccacggggcc tgccaccata cccacgcccga aacaagcgct catgagcccg aagtggcgag	7920
cccgatcttc cccatcggtg atgtccggcga tataaggcgcgca agcaaccgca cctgtggcgc	7980
cggtgatgcc ggccacgatg cgtccggcgt agaggcgatt agtccaattt gttaaagaca	8040
ggatatcgt ggtccaggct ctatgttga ctcaacaata tcaccagctg aagcctata	8100
agtacgagcc atagataaaa taaaagattt tatttagtct ccagaaaaag gggggaa	8157

<210> SEQ ID NO 28

<211> LENGTH: 44

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: FLIP cassette with a splice donor and splice acceptor flanking the miR30

<400> SEQUENCE: 28

cagggtgatg gcccgtactc tccccctttt tttttctcc aggt

44

What is claimed is:

1. A vector comprising

- a. a first pair of loxP sequences inverted in orientation with respect to each other,
b. a nucleic acid cassette comprising a first nucleic acid encoding
(i) at least one nucleotide sequence that can form a hairpin structure comprising at least one miRNA agent, and
(ii) miRNA sequences flanking the at least one nucleotide sequence, wherein the miRNA sequences flanking the at least one nucleotide sequence are derived from endogenous miRNA sequences that flank wild-type hairpin structures, and

wherein the nucleic acid cassette is positioned in an anti-sense orientation between the first pair of loxP sequences,

- c. a second pair of loxP sequences distinct from the first pair of the loxP sequences, inverted in orientation with respect to each other, wherein the first pair of loxP sequences and the second pair of loxP sequences are configured such that flipping of the first pair results in excision of the sequences between the second pair.

2. The vector of claim 1, wherein the vector further comprises a second nucleic acid encoding a selectable marker in sense orientation, wherein the second nucleic acid is positioned between the first pair of loxP sequences.

3. The vector of claim of claim 2, wherein the nucleic acid cassette is 3' with regard to the second nucleic acid, and

55

60

65

183

wherein a first loxP sequence of the second pair of loxP sequences is positioned between the second nucleic acid and the nucleic acid cassette, and a second loxP sequence of the second pair is positioned 3' with respect to the first pair of loxP sequences.

4. The vector of claim 3, wherein the nucleic acid cassette further comprises a third nucleic acid encoding a second selectable marker, wherein the third nucleic acid is in anti-sense orientation and fused in frame to the first nucleic acid sequence.

5. The vector of claim 1, wherein the first pair of loxP sequences comprises wild-type sequence.

6. The vector of claim 1, wherein the second pair of loxP sequences comprises a mutated loxP.

7. The vector of claim 1, wherein the first pair of loxP sequences comprises a loxP 5171 sequence.

8. The vector of claim 1, wherein the second pair of loxP sequences comprises a loxP 2272 sequence.

184

9. The vector of claim 2, wherein the second nucleic acid encodes two selectable markers fused in-frame with respect to each other.

10. A method of modulating gene expression in a cell, the method comprising:

introducing into the cell the vector of claim 1; and
inducing flipping of a first pair of loxP sequences contained
within the vector thereby inverting a nucleic acid cas-
sette contained within the vector from the antisense ori-
entation to a sense orientation,

wherein the inversion of the nucleic acid cassette allows
processing of at least one nucleotide sequence encoded
by the nucleic acid cassette into at least one functional
miRNA agent.

11. The method of claim 10, further comprising:
inducing flipping of a second pair of loxP sequences con-
tained within the vector.

* * * * *